CN109925511A - 用于癌的治疗和/或预防的药物 - Google Patents

用于癌的治疗和/或预防的药物 Download PDF

Info

Publication number
CN109925511A
CN109925511A CN201910271408.5A CN201910271408A CN109925511A CN 109925511 A CN109925511 A CN 109925511A CN 201910271408 A CN201910271408 A CN 201910271408A CN 109925511 A CN109925511 A CN 109925511A
Authority
CN
China
Prior art keywords
gln
antibody
ser
glu
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201910271408.5A
Other languages
English (en)
Other versions
CN109925511B (zh
Inventor
井户隆喜
冈野文义
成田义规
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toray Industries Inc
Original Assignee
Toray Industries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries Inc filed Critical Toray Industries Inc
Priority to CN201910271408.5A priority Critical patent/CN109925511B/zh
Publication of CN109925511A publication Critical patent/CN109925511A/zh
Application granted granted Critical
Publication of CN109925511B publication Critical patent/CN109925511B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/475Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明涉及用于癌的治疗和/或预防的药物、以及其应用,所述用于癌的治疗和/或预防的药物中一起或分别组合含有针对在癌细胞的表面特异性表达的癌抗原CAPRIN-1蛋白质的抗体和抗肿瘤剂。

Description

用于癌的治疗和/或预防的药物
本申请是中国专利申请201180017233.7的分案申请,原申请的申请日是2011年2月4日,发明名称是“用于癌的治疗和/或预防的药物”。
技术领域
本发明涉及用于癌的治疗和/或预防的药物及其应用,所述用于癌的治疗和/或预防的药物的特征在于,组合有与CAPRIN-1蛋白质具有免疫反应性的抗体或其片段、和抗肿瘤剂。
背景技术
癌是占所有死亡原因的第一位的疾病,现行的治疗是以手术疗法为主、组合使用放疗法和化疗法的治疗。另外,目前的治疗对于具有相同种类、相同阶段的癌的所有患者为相同的治疗。这些患者的至少40%在第一次治疗中失败,从而进行进一步的一系列的治疗。因此如果治疗进一次失败,则癌转移,最终死亡的可能性增大。即,现有的放射线疗法和化学疗法不能与各种癌种类、各种癌患者个体相适应,现状是外科手术本身在大部分的情况下癌的完全治愈也不充分。
作为克服上述癌治疗的问题的技术,以癌细胞上的抗原蛋白质为靶的、用于治疗癌的各种抗体药物大量上市。作为具体例,作为具有转移性乳癌的患者的治疗药物,在1998年得到上市许可的、以与Her2特异性地结合的单克隆抗体为有效成分的HERCEPTIN(注册商标)对于Her2过量表达转移性乳癌患者证明有减少复发·转移乳癌患者的死亡者数量这样的临床上的实效,与现有的化学疗法药物相比,没有心毒性以外的严重的副作用,进而作为应受到注意的方面,证明了通过与化学疗法药物的并用而产生了对于乳癌的治疗效果(专利文献1-3)。但是,以Her2为代表的、作为抗体药物的靶的癌细胞上的大部分抗原蛋白质在正常细胞中也有表达,抗体施与的结果是不仅伤害到癌细胞,而且还伤害到表达抗原的正常细胞,其结果产生的副作用可能成为问题。
细胞质增殖相关蛋白1(Cytoplasmic-and proliferation-associated protein1,CAPRIN-1)是已知在休止期的正常细胞发生活化和/或细胞分裂时表达,并在细胞内与RNA形成细胞内应激颗粒而参与mRNA的运输、翻译的控制等的细胞内蛋白质。另一方面,CAPRIN-1具有各种别名,作为其例子,有GPI锚定膜蛋白1、膜组分表面标志物1蛋白(M11S1)等,有宛如已知本蛋白质是细胞膜蛋白质那样的名称。这些别名本来源自认为CAPRIN-1的基因序列具有GPI结合区、并且CAPRIN-1是在大肠癌细胞中表达的膜蛋白质(非专利文献1)的报告,但后来报告了:上述非专利文献1的报告中的CAPRIN-1的基因序列有误,现在在GenBank等中登记的CAPRIN-1的基因序列中由于1个碱基缺失而发生移码,从而80个氨基酸从C末端缺失,其结果是所产生的人为产物(74个氨基酸)是上述报告中的GPI结合部分,而且在5’侧也存在基因序列的错误,53个氨基酸从N末端缺失(非专利文献2)。另外,已经报告了现在在GenBank等中登记的CAPRIN-1的基因序列所编码的蛋白质不是细胞膜蛋白质(非专利文献2)。
并且,基于认为CAPRIN-1是细胞膜蛋白质的非专利文献1的报告,专利文献4和5以M11S1的名称记载了CAPRIN-1作为细胞膜蛋白质的一种可作为抗体药物的靶而用于癌治疗(实施例中完全没有关于使用了针对本蛋白质的抗体的治疗的记载)。但是,如非专利文献2的报告所述,从专利文献4申请时到现在,CAPRIN-1是不在细胞表面表达的蛋白质已经成为了一般说法,显然仅基于CAPRIN-1是细胞膜蛋白质这样的错误信息的专利文献4和5的内容不应当理解为本领域技术人员的技术常识。
现有技术文献
专利文献
【专利文献1】日本特开2006-316040号公报
【专利文献2】美国专利第7485302号
【专利文献3】美国专利第7449184号
【专利文献4】美国专利公开第2008/0075722号
【专利文献5】国际公开第WO2005/100998号
非专利文献
【非专利文献1】J.Biol.Chem.,270:20717-20723,1995
【非专利文献2】J.Immunol.,172:2389-2400,2004
发明内容
发明要解决的课题
本发明的目的是鉴定在癌细胞的表面特异性地表达的癌抗原蛋白质,提供通过将以该癌抗原蛋白质作为靶的抗体和抗肿瘤剂组合、来作为癌的治疗和/或预防用药物的用途。
用于解决课题的方法
本发明人等进行了努力研究,结果发现:通过使用了源于狗的睾丸组织的cDNA文库和患乳癌的狗的血清的SEREX法,获取编码与在源于荷癌生物体的血清中存在的抗体结合的蛋白质的cDNA,以获取的基因和该基因的人、牛、马、小鼠、鸡同源性基因为基础,制作了具有序列编号2-30中偶数的序列编号所示的氨基酸序列的CAPRIN-1蛋白质和针对这些CAPRIN-1蛋白质的抗体。并且发现CAPRIN-1蛋白质在乳癌、脑瘤、白血病、淋巴瘤、肺癌、宫颈癌、膀胱癌、食道癌、大肠癌、胃癌和肾癌等的癌细胞中特异性地表达,而且发现CAPRIN-1蛋白质的一部分在这些癌细胞的细胞表面特异性地表达,发现通过将针对这些CAPRIN-1的在各癌细胞的细胞表面表达的部分的抗体和特定的抗肿瘤剂组合,可以得到显著的癌治疗效果,从而完成了本发明。
并且,在本说明书中,术语“癌”可与肿瘤(瘤)或癌肿瘤互换使用。
因此,本发明具有以下特征。
(1)用于癌的治疗和/或预防的药物,其特征在于,一起或者分别组合含有:
与CAPRIN-1蛋白质具有免疫反应性的抗体或其片段、和
1种或2种以上的抗肿瘤剂。
(2)权利要求1所述的药物,其特征在于,上述与CAPRIN-1蛋白质具有免疫反应性的抗体或其片段是与在癌细胞表面上存在的CAPRIN-1蛋白质的细胞外区域特异性地结合的抗体或其片段。
(3)上述(1)或(2)所述的药物,其特征在于,上述与CAPRIN-1蛋白质具有免疫反应性的抗体或其片段是与在癌细胞表面上存在的CAPRIN-1蛋白质的细胞外区域中的下述多肽特异性地结合的抗体或其片段,所述多肽具有序列编号37所示的氨基酸序列、或与该氨基酸序列具有80%以上的序列同一性的氨基酸序列。
(4)上述(1)-(3)中任一项所述的药物,其中上述CAPRIN-1蛋白质来源于人。
(5)上述(1)-(4)中任一项所述的药物,其中上述抗肿瘤剂是在说明书中记载的抗肿瘤剂。
(6)上述(5)所述的药物,其中,上述抗肿瘤剂选自环磷酰胺、紫杉醇、多西紫杉醇、长春瑞滨以及它们的药学上可接受的盐和衍生物。
(7)上述(1)-(6)中任一项所述的药物,其中,上述癌是乳癌、脑瘤、白血病、淋巴瘤、肺癌、肥大细胞瘤、肾癌、宫颈癌、膀胱癌、食道癌、胃癌或大肠癌。
(8)上述(1)-(7)中任一项所述的药物,其中,上述抗体为单克隆抗体、多克隆抗体或重组抗体。
(9)上述(1)-(8)中任一项所述的药物,其中,上述抗体为人抗体、人源化抗体、嵌合抗体、单链抗体、或双特异性抗体。
(10)用于癌的治疗和/或预防的方法,其含有下述步骤:将上述(1)-(9)中任一项所述的药物施与被怀疑具有癌的受试者。
(11)上述(10)所述的方法,其包含下述步骤:将上述药物中含有的、抗体或其片段和抗肿瘤剂同时或分别施与上述受试者。
本说明书包含作为本申请的优先权基础的日本专利申请2010-023455号的说明书和/或附图中记载的内容。
发明的效果
根据本发明,没有检出显著的副作用,可以得到宽范围的癌的缩小和萎缩的令人惊异的协同效果。
附图的简单说明
图1是显示编码CAPRIN-1蛋白质的基因的在正常组织和肿瘤细胞株中的表达图谱的图。参照编号1显示编码CAPRIN-1蛋白质的基因的表达图谱,参照编号2显示GAPDH基因的表达图谱。
图2是显示由与癌细胞的细胞表面反应的针对CAPRIN-1的单克隆抗体(#1-#11)产生的、对表达CAPRIN-1的乳癌细胞株MDA-MB-157的细胞毒性的图。参照编号3显示添加#1的针对CAPRIN-1的单克隆抗体时的活性,参照编号4显示添加#2的针对CAPRIN-1的单克隆抗体时的活性,参照编号5显示添加#5的针对CAPRIN-1的单克隆抗体时的活性,参照编号6显示添加#4的针对CAPRIN-1的单克隆抗体时的活性,参照编号7显示添加#5的针对CAPRIN-1的单克隆抗体时的活性,参照编号8显示添加#6的针对CAPRIN-1的单克隆抗体时的活性,参照编号9显示添加#7的针对CAPRIN-1的单克隆抗体时的活性,参照编号10显示添加#8的针对CAPRIN-1的单克隆抗体时的活性,参照编号11显示添加#9的针对CAPRIN-1的单克隆抗体时的活性,参照编号12显示添加#10的针对CAPRIN-1的单克隆抗体时的活性,参照编号13显示添加#11的针对CAPRIN-1的单克隆抗体时的活性,参照编号14显示添加与CAPRIN-1蛋白质本身反应、但不与癌细胞的细胞表面反应的单克隆抗体时的活性,参照编号15显示添加PBS代替抗体时的活性。
图3显示抗肿瘤剂环磷酰胺和与癌细胞的细胞表面反应的针对CAPRIN-1的单克隆抗体并用时的、对移植了表达CAPRIN-1的乳癌细胞株MCF-7的裸鼠的抗肿瘤效果的图。参照编号16显示施与了PBS代替抗体时的小鼠的肿瘤的大小,参照编号17显示施与了环磷酰胺时的小鼠的肿瘤的大小,参照编号18显示施与了#2的针对CAPRIN-1的单克隆抗体时的小鼠的肿瘤的大小,参照编号19显示施与了环磷酰胺和抗Her2抗体时的小鼠的肿瘤的大小,参照编号20显示施与了环磷酰胺和#2的针对CAPRIN-1的单克隆抗体时的小鼠的肿瘤的大小。
图4显示抗肿瘤剂紫杉醇和与癌细胞的细胞表面反应的针对CAPRIN-1的单克隆抗体并用时的、对移植了表达CAPRIN-1的乳癌细胞株MCF-7的裸鼠的抗肿瘤效果的图。参照编号21显示施与了PBS代替抗体时的小鼠的肿瘤的大小,参照编号22显示施与了紫杉醇时的小鼠的肿瘤的大小,参照编号23显示施与了#2的针对CAPRIN-1的单克隆抗体时的小鼠的肿瘤的大小,参照编号24显示施与了紫杉醇和抗Her2抗体时的小鼠的肿瘤的大小,参照编号25显示施与了紫杉醇和#2的针对CAPRIN-1的单克隆抗体时的小鼠的肿瘤的大小。
图5显示抗肿瘤剂多西紫杉醇和与癌细胞的细胞表面反应的针对CAPRIN-1的单克隆抗体并用时的、对移植了表达CAPRIN-1的乳癌细胞株MCF-7的裸鼠的抗肿瘤效果的图。参照编号26显示施与了PBS代替抗体时的小鼠的肿瘤的大小,参照编号27显示施与了多西紫杉醇时的小鼠的肿瘤的大小,参照编号28显示施与了#2的针对CAPRIN-1的单克隆抗体时的小鼠的肿瘤的大小,参照编号29显示施与了多西紫杉醇和抗Her2抗体时的小鼠的肿瘤的大小,参照编号30显示施与了多西紫杉醇和#2的针对CAPRIN-1的单克隆抗体时的小鼠的肿瘤的大小。
图6显示抗肿瘤剂长春瑞滨和与癌细胞的细胞表面反应的针对CAPRIN-1的单克隆抗体并用时的、对移植了表达CAPRIN-1的乳癌细胞株MCF-7的裸鼠的抗肿瘤效果的图。参照编号31显示施与了PBS代替抗体时的小鼠的肿瘤的大小,参照编号32显示施与了长春瑞滨时的小鼠的肿瘤的大小,参照编号33显示施与了#2的针对CAPRIN-1的单克隆抗体时的小鼠的肿瘤的大小,参照编号34显示施与了长春瑞滨和抗Her2抗体时的小鼠的肿瘤的大小,参照编号35显示施与了长春瑞滨和#2的针对CAPRIN-1的单克隆抗体时的小鼠的肿瘤的大小。
图7显示抗肿瘤剂环磷酰胺和与癌细胞的细胞表面反应的针对CAPRIN-1的单克隆抗体并用时的、对移植了表达CAPRIN-1的乳癌细胞株MCF-7的裸鼠的抗肿瘤效果的图。参照编号36显示施与了PBS代替抗体时的小鼠的肿瘤的大小,参照编号37显示施与了环磷酰胺时的小鼠的肿瘤的大小,参照编号38显示施与了#9的针对CAPRIN-1的单克隆抗体时的小鼠的肿瘤的大小,参照编号39显示施与了环磷酰胺和抗Her2抗体时的小鼠的肿瘤的大小,参照编号40显示施与了环磷酰胺和#9的针对CAPRIN-1的单克隆抗体时的小鼠的肿瘤的大小。
图8显示抗肿瘤剂紫杉醇和与癌细胞的细胞表面反应的针对CAPRIN-1的单克隆抗体并用时的、对移植了表达CAPRIN-1的乳癌细胞株MCF-7的裸鼠的抗肿瘤效果的图。参照编号41显示施与了PBS代替抗体时的小鼠的肿瘤的大小,参照编号42显示施与了紫杉醇时的小鼠的肿瘤的大小,参照编号43显示施与了#9的针对CAPRIN-1的单克隆抗体时的小鼠的肿瘤的大小,参照编号44显示施与了紫杉醇和抗Her2抗体时的小鼠的肿瘤的大小,参照编号45显示施与了紫杉醇和#9的针对CAPRIN-1的单克隆抗体时的小鼠的肿瘤的大小。
图9显示抗肿瘤剂多西紫杉醇和与癌细胞的细胞表面反应的针对CAPRIN-1的单克隆抗体并用时的、对移植了表达CAPRIN-1的乳癌细胞株MCF-7的裸鼠的抗肿瘤效果的图。参照编号46显示施与了PBS代替抗体时的小鼠的肿瘤的大小,参照编号47显示施与了多西紫杉醇时的小鼠的肿瘤的大小,参照编号48显示施与了#9的针对CAPRIN-1的单克隆抗体时的小鼠的肿瘤的大小,参照编号49显示施与了多西紫杉醇和抗Her2抗体时的小鼠的肿瘤的大小,参照编号50显示施与了多西紫杉醇和#9的针对CAPRIN-1的单克隆抗体时的小鼠的肿瘤的大小。
图10显示抗肿瘤剂长春瑞滨和与癌细胞的细胞表面反应的针对CAPRIN-1的单克隆抗体并用时的、对移植了表达CAPRIN-1的乳癌细胞株MCF-7的裸鼠的抗肿瘤效果的图。参照编号51显示施与了PBS代替抗体时的小鼠的肿瘤的大小,参照编号52显示施与了长春瑞滨时的小鼠的肿瘤的大小,参照编号53显示施与了#9的针对CAPRIN-1的单克隆抗体时的小鼠的肿瘤的大小,参照编号54显示施与了长春瑞滨和抗Her2抗体时的小鼠的肿瘤的大小,参照编号55显示施与了长春瑞滨和#9的针对CAPRIN-1的单克隆抗体时的小鼠的肿瘤的大小。
具体实施方式
本发明中使用的针对序列编号2-30中偶数的序列编号的多肽的抗体的抗肿瘤活性,可以如下所述,通过研究在生物体内对荷癌动物的肿瘤增殖的抑制,或者通过研究对在生物体外表达该多肽的肿瘤细胞是否显示介由免疫细胞或补体的细胞毒性,来进行评价。
其中,编码包含序列编号2-30中偶数的序列编号(即,序列编号2,4,6……28,30)的氨基酸序列的蛋白质的多核苷酸的碱基序列,分别在序列编号1-29中奇数的序列编号(即,序列编号1,3,5……27,29)中显示。
本发明公开的序列表的序列编号6、8、10、12和14所示的氨基酸序列是通过使用了源于狗睾丸组织的cDNA文库和患乳癌的狗的血清的SEREX法,作为与在源于荷癌狗的血清中特异性地存在的抗体结合的多肽而被分离出的CAPRIN-1的氨基酸序列,另外,序列编号2和4所示的氨基酸序列是作为其人同源因子(同源物)而被分离出的CAPRIN-1的氨基酸序列,序列编号16所示的氨基酸序列是作为其牛同源因子而被分离出的CAPRIN-1的氨基酸序列,序列编号18所示的氨基酸序列是作为其马同源因子而被分离出的CAPRIN-1的氨基酸序列,序列编号20-28所示的氨基酸序列是作为其小鼠同源因子而被分离出的CAPRIN-1的氨基酸序列,序列编号30所示的氨基酸序列是作为其鸡同源因子而被分离出的CAPRIN-1的氨基酸序列(参照下述的实施例1)。已知CAPRIN-1在休止期的正常细胞发生活化和/或细胞分裂时表达。
已知CAPRIN-1不在细胞表面表达,但根据本研究,可以明确CAPRIN-1蛋白质的一部分在各种癌细胞的细胞表面表达。本发明中,可以优选使用与CAPRIN-1蛋白质中的、在癌细胞的细胞表面表达的部分结合的抗体。作为在癌细胞的细胞表面表达的CAPRIN-1蛋白质中的部分肽,可以列举包含序列表的序列编号2-30中除了序列编号6和序列编号18以外的偶数编号所示的氨基酸序列中的氨基酸残基编号(aa)50-98或氨基酸残基编号(aa)233-305的区域内的连续7个以上的氨基酸序列的多肽,具体可以列举例如序列编号37所示的氨基酸序列、或与该氨基酸序列具有80%以上、优选85%以上、更优选90%以上、进一步优选95%以上的序列同一性的氨基酸序列,本发明中使用的抗体包含可与这些肽(特异性)结合的(或者(特异性)识别这些肽的、或者与这些肽具有免疫反应性的)、且表现抗肿瘤活性的所有抗体。
本发明中使用的针对上述CAPRIN-1的抗体只要是可发挥抗肿瘤活性,就可以是任何种类的抗体,包含例如单克隆抗体、多克隆抗体、重组抗体例如合成抗体、多特异性抗体、人源化抗体、嵌合抗体、单链抗体(scFv)等、人抗体、它们的抗体片段例如Fab和/或F(ab’)2、Fv等。这些抗体和其片段还可以利用本领域技术人员公知的方法制备。在本发明中,期望是可与CAPRIN-1蛋白质特异性地结合的抗体,优选为单克隆抗体,但只要可稳定地生产均质的抗体,则也可以是多克隆抗体。另外,当受试者是人时,为了避免或抑制排斥反应,期望是人抗体或人源化抗体。
这里,“与CAPRIN-1蛋白质特异性地结合”是指与CAPRIN-1蛋白质特异性地结合,与CAPRIN-1蛋白质以外的蛋白质实质上不结合。
本发明中可使用的抗体的抗肿瘤活性,可以如下所述,通过研究在生物体内对荷癌动物的肿瘤增殖的抑制,或者通过研究对在生物体外表达该多肽的肿瘤细胞是否显示介由免疫细胞或补体的细胞毒活性,来进行评价。
进一步地,本发明中作为癌的治疗和/或预防的对象的受试者是人、宠物、家畜类、竞技用动物等哺乳动物,优选的受试者是人。
以下对于与本发明相关的抗原的制备、抗体的制备、以及药物进行说明。
<抗体制备用抗原的制备>
作为用于获取本发明中使用的针对CAPRIN-1的抗体的致敏抗原使用的蛋白质或其片段,可以源自人、狗、牛、马、小鼠、大鼠、鸡等,对成为其来源的动物种类没有限制。但是优选考虑与在细胞融合中使用的母细胞的适合性来选择该蛋白质或其片段,一般来说,优选源于哺乳动物的蛋白质,特别优选源于人的蛋白质。例如当CAPRIN-1是人CAPRIN-1时,可以使用人CAPRIN-1蛋白质和/或其部分肽、表达人CAPRIN-1的细胞等。
人CAPRIN-1和其同源物的碱基序列和氨基酸序列例如可以通过访问GenBank(美国NCBI),利用BLAST、FASTA等的算法(Karlin and Alts chul,Proc.Natl.Acad.Sci.USA,90:5873-5877,1993;Altschul et al.,Nucleic Acids Res.25:3389-3402,1997)来得到。
在本发明中,当以人CAPRIN-1的碱基序列(序列编号1或3)或氨基酸序列(序列编号2或4)为基准时,包含与它们的ORF或成熟部分的碱基序列或氨基酸序列具有70%-100%、优选80%-100%、更优选90%-100%、进一步优选95%-100%、例如97%-100%、98%-100%、99%-100%或99.5%-100%的序列同一性的序列的核酸或蛋白质成为靶。这里,“%序列同一性”是将2个序列在导入间隙或不导入间隙的情况下以形成最大的类似度的方式比对(对齐)时,相同氨基酸(或碱基)相对于氨基酸(或碱基)的总数的百分比(%)。
CAPRIN-1蛋白质的片段具有从作为抗体识别的最小单位的表位(抗原决定簇)的氨基酸长度、至小于该蛋白质的全长的长度。表位是指在哺乳动物、优选人中具有抗原性或免疫原性的多肽片段,其最小单位包含(连续的)约7-12个氨基酸、例如8-11个氨基酸。作为与抗体特异性地结合的CAPRIN-1蛋白质的部分序列的具体例子,可以列举在序列编号37所示的氨基酸序列、或与该氨基酸序列具有80%以上、优选85%以上、更优选90%以上、进一步优选95%以上的序列同一性的氨基酸序列中、含有至少约7-12个氨基酸的部分序列。
上述的含有人CAPRIN-1蛋白质和/或其部分肽的多肽可以按照例如Fmoc法(芴基甲基氧基羰基法)、tBoc法(叔丁基氧基羰基法)等的化学合成法进行合成(日本生化学会编、生化学实验讲座1、タンパク質の化学(蛋白质的化学)IV、化学修飾とペプチド合成(化学修饰和肽合成)、东京化学同人(日本)、1981年)。另外,也可以利用各种市售的肽合成仪通过常规方法进行合成。另外,使用公知的基因工程学方法(Sambrook等,MolecularCloning,第2版,Current Protocols in Molecular Biology(1989),Cold Spring HarborLaboratory Press、Ausubel等,Short Protocols in Molecular Biology,第3版,Acompendium of Methods from Curr ent Protocols in Molecular Biology(1995),JohnWiley&Sons等),制备编码上述多肽的多核苷酸,将该多核苷酸整合到表达载体中并导入宿主细胞,在该宿主细胞中生产多肽,由此可以得到目的多肽。
编码上述多肽的多核苷酸可以通过公知的基因工程学方法和/或使用了市售的核酸合成仪的常规方法来容易地制备。例如含有序列编号1的碱基序列的DNA可以通过使用人染色体DNA或cDNA文库作为模板、使用以可扩增序列编号1中记载的碱基序列的方式设计的一对引物进行PCR来制备。PCR的反应条件可以适当设定,可以列举例如,使用耐热性DNA聚合酶(例如Taq聚合酶等)和含有Mg2+的PCR缓冲液,将包含在94℃保持30秒(变性)、在55℃保持30秒-1分钟(退火)、在72℃保持2分钟(延伸)的反应过程作为1个循环,例如进行30个循环后,在72℃反应7分钟的条件等,但不限定于此。对于PCR的方法、条件等,例如记载于Ausubel等,Short Protocols in Molecular Biology,第3版,A compendi um of Methodsfrom Current Protocols in Molecular Biology(1995),John Wiley&Sons(特别是第15章)中。
另外,基于本说明书中的序列表的序列编号1-30所示的碱基序列和氨基酸序列的信息,制备合适的探针和/或引物,使用该探针和/或引物来对人等的cDNA文库进行筛选,由此可以分离所需的DNA。cDNA文库优选由表达序列编号2-30中偶数的序列编号的蛋白质的细胞、器官或组织来制备。这样的细胞或组织的例子是源于睾丸、白血病、乳癌、淋巴瘤、脑瘤、肺癌、大肠癌等的癌或肿瘤的细胞或组织。上述探针或引物的制备、cDNA文库的构建、cDNA文库的筛选、以及目的基因的克隆等的操作对于本领域技术人员而言是已知的,可以按照例如Sambrook等,Molecular Cloning,第2版,Current Protocols in MolecularBiology(1989)、Ausbel等(上述)等中记载的方法来进行。由这样所得的DNA,可以得到编码人CAPRIN-1蛋白质或其部分肽的DNA。
作为上述宿主细胞,只要是可表达上述多肽的细胞,就可以是任意的细胞,作为原核细胞的例子可以列举大肠杆菌等,作为真核细胞的例子可以列举猴肾脏细胞COS1、中国仓鼠卵巢细胞CHO等哺乳动物细胞、人胎儿肾脏细胞株HEK293、小鼠胚胎皮肤细胞株NIH3T3、芽殖酵母、裂殖酵母等的酵母细胞、蚕细胞、爪蟾卵细胞等,但不限于此。
当使用原核细胞作为宿主细胞时,作为表达载体,使用具有能在原核细胞中复制的起点、启动子、核糖体结合部位、多克隆位点、终止子、抗药性基因、营养缺陷型互补基因等的表达载体。作为大肠杆菌用表达载体,可以例示pUC系、pBluescriptII、pET表达系统、pGEX表达系统等。如果将编码上述多肽的DNA整合到这样的表达载体中,用该载体转化原核宿主细胞后,培养所得的转化体,则可以在原核宿主细胞中表达由上述DNA编码的多肽。此时,也可以使该多肽作为与其他蛋白质的融合蛋白质来表达。
当使用真核细胞作为宿主细胞时,作为表达载体,使用具有启动子、剪接区、多聚(A)添加部位等的真核细胞用表达载体。作为这种表达载体,可以例示pKA1、pCDM8、pSVK3、pMSG、pSVL、pBK-CMV、pBK-RSV、EBV载体、pRS、pcDNA3、pYES2等。与上述同样地,如果将编码上述多肽的DNA整合到这样的表达载体中,用该载体转化真核宿主细胞后,培养所得的转化体,则可以在真核宿主细胞中表达由上述DNA编码的多肽。当使用pIND/V5-His、pFLAG-CMV-2、pEGFP-N1、pEGFP-C1等作为表达载体时,可以作为附加了His标签(例如(His)6-(His)10)、FLAG标签、myc标签、HA标签、GFP等各种标签的融合蛋白质,而表达上述多肽。
表达载体向宿主细胞中的导入可以使用电穿孔法、磷酸钙法、脂质体法、DEAE葡聚糖法、显微注射、病毒感染、脂质体转染、与细胞膜透过性肽的结合等周知的方法。
为了从宿主细胞中分离纯化目的多肽,可以将公知的分离操作组合来进行。可以列举例如,利用了脲等的变性剂和/或表面活性剂的处理、超声波处理、酶消化、盐析或溶剂分别沉淀法、透析、离心分离、超滤、凝胶过滤、SDS-PAGE、等电点电泳、离子交换色谱法、疏水色谱法、亲和色谱法、反相色谱法等,但不限于此。
<抗体的结构>
抗体通常是至少含有2条重链和2条轻链的杂多聚体糖蛋白质。IgM是不同的,其是由2条相同的轻(L)链和2条相同的重(H)链构成的约150k Da的杂四聚体糖蛋白质。典型地,各个轻链通过1个二硫键与重链连接,但各种免疫球蛋白同种型的重链间的二硫键的数目有变化。各个重链和轻链还具有链内二硫键。各个重链在一端具有可变区(VH区),在该端部几个恒定区与其连接。各个轻链具有可变区(VL区),在其相反的端具有1个恒定区。轻链的恒定区与重链最初的恒定区对齐,且轻链可变区与重链的可变区对齐。抗体的可变区通过特定区域表现被称为互补性决定区(CDR)的特定的可变性,从而赋予抗体以结合特异性。可变区的相对保守的部分被称为框架区(FR)。完整的重链和轻链的可变区分别含有通过3个CDR连接的4个FR。3个CDR在重链中从其N末端依次被称为CDRH1、CDRH2、CDRH3,同样在轻链中被称为CDRL1、CDRL2、CDRL3。在抗体对抗原的结合特异性中,CDRH3最为重要。另外,各链的CDR通过FR区以接近的状态被保持在一起,与来自其他链的CDR一同有助于抗体的抗原结合部位的形成。恒定区不直接有助于抗体与抗原结合,但表现各种效应器功能,例如、对抗体依赖性细胞性细胞毒活性(ADCC)的参与、介由对Fcγ受体的结合而产生的吞噬作用、介由新生儿Fc受体(FcRn)的半衰期/清除速度、介由补体级联的C1q构成要素的补体依赖性细胞毒(CDC)。
<抗体的制备>
本发明的抗CAPRIN-1抗体是指与CAPRIN-1蛋白质的全长或其片段具有免疫反应性的抗体。
这里,“免疫反应性”是指在生物体内抗体与CAPRIN-1抗原结合的特性,介由这种结合可以发挥损伤(例如、杀死、抑制或缩小)肿瘤的功能。即,本发明中使用的抗体只要能够与CAPRIN-1蛋白质结合而损伤肿瘤、例如白血病、淋巴瘤、乳癌、脑瘤、肺癌、食道癌、胃癌、肾癌、大肠癌等,则不问其种类。
抗体的例子包含单克隆抗体、多克隆抗体、重组抗体,例如合成抗体、多特异性抗体、人源化抗体、嵌合抗体、单链抗体等、人抗体、它们的抗体片段(例如Fab、F(ab’)2、Fv)等。另外,抗体是免疫球蛋白分子的任意类、例如IgG、IgE、IgM、IgA、IgD和IgY,或任意亚类、例如IgG1、IgG2、IgG3、IgG4、IgA1、IgA2等。这些抗体或其片段的任一者都与在癌的细胞表面上存在的CAPRIN-1蛋白质、优选其细胞外区域的多肽具有免疫反应性(优选与该蛋白质或该多肽特异性地结合),且表现对癌的细胞毒活性。
抗体进而除了糖基化以外,也可以通过乙酰化、甲酰化、酰胺化、磷酸化、或聚乙二醇(PEG)化等被修饰。
以下显示各种抗体的制备例。
抗体为单克隆抗体时,例如将表达CAPRIN-1的乳癌细胞株SK-BR-3等施与小鼠而进行免疫,从该小鼠取出脾脏,将细胞分离,然后使该细胞与小鼠骨髓瘤细胞融合,从所得的融合细胞(杂交瘤)中选择产生具有癌细胞增殖抑制作用的抗体的克隆。将产生具有癌细胞增殖抑制作用的单克隆抗体的杂交瘤分离,培养该杂交瘤,利用普通的亲和纯化法从培养上清中纯化抗体,由此可进行制备。
产生单克隆抗体的杂交瘤例如也可以如下地制备。首先,按照公知的方法,用致敏抗原对动物进行免疫。作为一般的方法,可以通过将致敏抗原向哺乳动物的腹腔内或皮下注射来进行。具体来说,可以将致敏抗原利用PBS(磷酸盐缓冲液,Phosphate-BufferedSaline)、生理盐水等稀释成合适量、进行悬浮,在所得的的液体中根据需要适量混合通常的佐剂、例如弗氏完全佐剂,乳化后,每4-21天对哺乳动物施与数次。另外,致敏抗原免疫时也可以使用合适的载体。
这样将哺乳动物免疫,确认在血清中所需的抗体水平升高,然后从哺乳动物收集免疫细胞,进行细胞融合,作为优选的免疫细胞特别可以列举脾细胞。
作为与上述免疫细胞融合的其它母细胞,使用哺乳动物的骨髓瘤细胞。该骨髓瘤细胞可以优选使用公知的各种细胞株、例如P3U1(P3-X63Ag8U1)、P3(P3x63Ag8.653)(J.Immunol.(1979)123,1548-1550)、P3x63Ag8U.1(Current Topics in Microbiologyand Immunology(1978)81,1-7)、NS-1(Kohler.G.and Milstein,C.Eur.J.Immunol.(1976)6,511-519)、MPC-11(Margulies.D.H.et al.,Cell(1976)8,405-415)、SP2/0(Shulman,M.et al.,Nature(1978)276,269-270)、FO(deSt.Groth,S.F.et al.,J.Immunol.Methods(1980)35,1-21)、S194(Trowbridge,I.S.J.Exp.Med.(1978)148,313-323)、R210(Galfre,G.et al.,Nature(1979)277,131-133)等。
上述免疫细胞与骨髓瘤细胞的细胞融合基本上可以按照公知的方法、例如Kohler和Milstein等的方法(Kohler,G.and Milstein,C.Methods Enzymol.(1981)73,3-46)等来进行。
更具体地,上述细胞融合例如可在细胞融合促进剂的存在下、在通常的营养培养液中实施。作为融合促进剂,可以使用例如聚乙二醇(PEG)、仙台病毒(HVJ)等,进而根据需要为了提高融合效率,还可以添加使用二甲基亚砜等的助剂。
免疫细胞与骨髓瘤细胞的使用比例可以任意地设定。例如优选使免疫细胞相对于髓瘤细胞为1-10倍。作为上述细胞融合中使用的培养液,可以使用例如,对于上述骨髓瘤细胞株的增殖合适的转/分钟I1640培养液、MEM培养液,其他可以在这种细胞培养中使用的通常的培养液,进一步也可以合并使用胎牛血清(FCS)等的血清补液。
细胞融合是将规定量的上述免疫细胞和骨髓瘤细胞在上述培养液中充分混合,将预先加热至37℃左右的PEG溶液(例如平均分子量1000-6000左右)以通常30-60%(w/v)的浓度添加、混合,由此形成作为目的的杂交瘤。接着,反复进行逐渐添加合适的培养液、离心除去上清的操作,由此除去对于杂交瘤的发育不优选的细胞融合剂等。
这样得到的杂交瘤可以通过在通常的选择培养液、例如HAT培养液(含有次黄嘌呤、氨基喋呤和胸腺嘧啶脱氧核苷的培养液)中培养来选择。上述HAT培养液中的培养持续对于除了作为目的的杂交瘤以外的细胞(非融合细胞)灭绝充分的时间(通常数天-数周)。然后,实施通常的有限稀释法,进行产生目的抗体的杂交瘤的筛选和单克隆化。
另外,除了对人以外的动物免疫抗原来得到上述杂交瘤以外,还可以将人淋巴细胞、例如感染了EB病毒的人淋巴细胞在体外(in vitro)用蛋白质、蛋白质表达细胞或其溶解物致敏,使致敏淋巴细胞与来自人的具有永久分裂能力的骨髓瘤细胞、例如U266(注册编号TIB196)融合,得到产生具有所需活性(例如、细胞增殖抑制活性)的人抗体的杂交瘤。
这样制备的产生单克隆抗体的杂交瘤可以在通常的培养液中传代培养,另外,可在液氮中长期保存。
即,使用所需抗原或表达所需抗原的细胞作为致敏抗原,按照通常的免疫方法将其免疫,将所得的免疫细胞利用通常的细胞融合法与公知的母细胞融合,利用通常的筛选法通过对单克隆抗体产生细胞(杂交瘤)进行筛选来制备。
本发明中可使用的抗体的其它例子是多克隆抗体。多克隆抗体可以例如如下地得到。
用天然的CAPRIN-1蛋白质、或作为与GST等的融合蛋白质而在大肠杆菌等微生物中表达的重组CAPRIN-1蛋白质、或其部分肽对小鼠、产生人抗体的小鼠、兔等小动物进行免疫,得到血清。通过将该血清利用例如硫酸铵沉淀、蛋白质A、蛋白质G柱、DEAE离子交换色谱、偶联有CAPRIN-1蛋白质或合成肽的亲和柱等进行纯化来制备。在下述的实施例中,制作针对CAPRIN-1蛋白质的氨基酸序列中、在癌细胞的细胞表面表达的区域的一部分肽(由序列编号37表示)的兔多克隆抗体,确认了抗肿瘤效果。
这里,作为产生人抗体的小鼠,已知例如KM小鼠(キリンファーマ/Medarex)和Xeno小鼠(Amgen)(例如国际公开第WO02/43478号、国际公开第WO02/092812号等)。将这种小鼠用CAPRIN-1蛋白质或其片段进行免疫时,可以由血液得到完全人多克隆抗体。另外,可以从免疫后的小鼠中取出脾脏细胞,利用与骨髓瘤细胞的融合法制备人型单克隆抗体。
抗原的调制可以根据使用了动物细胞的方法(日本特表2007-530068)或使用了杆状病毒的方法(例如国际公开第WO98/46777号等)等来进行。当抗原的免疫原性低时,使其与白蛋白等具有免疫原性的巨大分子结合而进行免疫即可。
此外,可以使用基因重组型抗体,该基因重组型抗体通过将抗体基因由杂交瘤克隆,整合到合适的载体中,并将其导入宿主,使用基因重组技术而产生(参照例如Carl,A.K.Borrebaeck,James,W.Larrick,THERAPEUTIC MONOCLONAL ANTIBODIES,Published inthe United Kingdom by MACMILLAN PUBLISHERS LTD,1990)。具体来说,由杂交瘤的mRNA使用逆转录酶来合成抗体的可变区(V区)的cDNA。如果可得到编码目的抗体的V区的DNA,则将其与编码所需的抗体恒定区(C区)的DNA连接,将连接产物整合到表达载体中。或者也可以将编码抗体的V区的DNA整合到含有抗体C区的DNA的表达载体中。该DNA以在表达控制区域、例如增强子、启动子的控制下表达的方式整合到表达载体中。接着可以用该表达载体转化宿主细胞,使抗体表达。
本发明中使用的抗CAPRIN-1抗体优选是单克隆抗体。但也可以是多克隆抗体、重组抗体或转基因抗体(例如嵌合抗体、人源化抗体、单链抗体、双特异性抗体等)等。
单克隆抗体包含人单克隆抗体、非人的动物单克隆抗体(例如小鼠单克隆抗体、大鼠单克隆抗体、兔单克隆抗体、鸡单克隆抗体等)等。单克隆抗体可以通过培养杂交瘤来制备,所述杂交瘤通过将来自用CAPRIN-1蛋白质免疫的非人哺乳动物(例如小鼠、产生人抗体的小鼠等)的脾细胞与骨髓瘤细胞的融合来得到。在下述的实施例中,制备小鼠单克隆抗体,并确认了抗肿瘤效果。
这些单克隆抗体包含具有序列编号43、序列编号73、序列编号83、序列编号93、序列编号103、序列编号113或序列编号123的氨基酸序列的重链可变(VH)区、和具有序列编号47、序列编号53、序列编号58、序列编号63、序列编号68、序列编号77、序列编号87、序列编号97、序列编号107,序列编号117或序列编号127的氨基酸序列的轻链可变(VL)区,其中,在该VH区包含由序列编号40、序列编号70、序列编号80、序列编号90、序列编号100、序列编号110或序列编号120的氨基酸序列表示的CDR1、由序列编号41、序列编号71、序列编号81、序列编号91、序列编号101、序列编号111或序列编号121的氨基酸序列表示的CDR2和由序列编号42、序列编号72、序列编号82、序列编号92、序列编号102、序列编号112或序列编号122的氨基酸序列表示的CDR3,该VL区域包含由序列编号44、序列编号50、序列编号55、序列编号60、序列编号65、序列编号74、序列编号84、序列编号94、序列编号104,序列编号114或序列编号124的氨基酸序列表示的CDR1、由序列编号45、序列编号51、序列编号56、序列编号61、序列编号66、序列编号75、序列编号85、序列编号95、序列编号105,序列编号115或序列编号125的氨基酸序列表示的CDR2和由序列编号46、序列编号52、序列编号57、序列编号62、序列编号67、序列编号76、序列编号86、序列编号96、序列编号106、序列编号116或序列编号126的氨基酸序列表示的CDR3。
嵌合抗体是将来自不同动物的序列组合而制备的抗体,例如是包含小鼠抗体的重链、轻链的可变区和人抗体的重链、轻链的恒定区的抗体等。嵌合抗体的制备可以使用公知的方法来进行,例如嵌合抗体可以通过将编码抗体V区的DNA和编码人抗体C区的DNA连接,将其重组到表达载体中并导入宿主而产生来得到。
多克隆抗体包含对产生人抗体的动物(例如小鼠)免疫CAPRIN-1蛋白质而得到的抗体。
人源化抗体是也称为重构(reshaped)人抗体的改变抗体。人源化抗体通过将来自免疫动物的抗体的CDR移植到人抗体的互补性决定区中来构建。其一般的基因重组方法也是已知的。
具体来说,利用PCR法由以末端部具有重叠部分的方式制备的数个寡核苷酸合成DNA序列,该DNA序列是以将小鼠抗体的CDR和人抗体的框架区(framework region;FR)连结的方式设计的。将所得的DNA与编码人抗体恒定区的DNA连接,接着整合到表达载体中,将其导入宿主而使其产生,从而得到(参照欧洲专利申请公开第EP239400号、国际公开第WO96/02576号)。经由CDR连接的人抗体的FR可以选择形成互补性决定区良好的抗原结合部位的FR。根据需要,也可以替换抗体的可变区中的框架区的氨基酸,以形成重构人抗体的互补性决定区合适的抗原结合部位(Sato K.et al.,Cancer Research 1993,53:851-856)。另外,也可以替换为各种来自人抗体的框架区(参考国际公开第WO99/51743号)。
经由CDR连结的人抗体的框架区可以选择形成互补性决定区良好的抗原结合部位的框架区。根据需要,也可以替换抗体的可变区中的框架区的氨基酸,以形成重构人抗体的互补性决定区合适的抗原结合部位(Sato K.et al.,Cancer Research 1993,53:851-856)。
在制备嵌合抗体或人源化抗体后,可以将可变区(例如FR)和/或恒定区中的氨基酸用其它氨基酸替换等。
氨基酸的替换例如是小于15个、小于10个、8个以下、7个以下、6个以下、5个以下、4个以下、3个以下、或2个以下的氨基酸、优选1-5个氨基酸、更优选1或2个氨基酸的替换,替换抗体与未替换抗体应在功能上等同。期望替换是保守的氨基酸替换,这是电荷、侧链、极性、芳香族性等性质类似的氨基酸间的替换。性质类似的氨基酸例如可以分类为碱性氨基酸(精氨酸、赖氨酸、组氨酸)、酸性氨基酸(天冬氨酸、谷氨酸)、无电荷极性氨基酸(甘氨酸、天冬酰胺、谷氨酰胺、丝氨酸、苏氨酸、半胱氨酸、酪氨酸)、无极性氨基酸(亮氨酸、异亮氨酸、丙氨酸、缬氨酸、脯氨酸、苯丙氨酸、色氨酸、蛋氨酸)、支链氨基酸(苏氨酸、缬氨酸、异亮氨酸)、芳香族氨基酸(苯丙氨酸、酪氨酸、色氨酸、组氨酸)等。
抗体可以进行化学修饰,作为这样的抗体修饰物,可以列举例如与聚乙二醇(PEG)、抗肿瘤性化合物(例如,下述例示的抗肿瘤剂)等各种分子结合的抗体。在本发明的抗体修饰物中,不限定结合的物质。为了得到这样的抗体修饰物,可以通过对所得的抗体实施化学修饰来得到。这些方法在本领域已经被确立。
这里,“在功能上等同”是指成为对象的抗体与本发明的抗体具有同样的生物学或生物化学的活性,具体来说,是指具有损伤肿瘤的功能、以及在对人应用时本质上不发生排斥反应等。作为这样的活性,可以列举例如细胞增殖抑制活性、或结合活性。
作为用于调制与某多肽在功能上等同的多肽的本领域技术人员熟知的方法,已知有在多肽中导入突变的方法。例如只要是本领域技术人员,就可以使用定点诱变法(Hashimoto-Gotoh,T.et al.,(1995)Gene 152,271-275、Zoller,MJ.,and Smith,M.(1983)Methods Enzymol.100,468-500、Kramer,W.et al.,(1984)Nucleic Acids Res.12,9441-9456、Kramer,W.and Fritz,HJ.,(1987)Methods Enzymol.154,350-367、Kunkel,TA.,(1985)Proc.Natl.Acad.Sci.USA.82,488-492、Kunkel(1988)Methods Enzymol.85,2763-2766)等,在本发明的抗体中导入适当的突变,由此制备与该抗体在功能上等同的抗体。
识别由上述抗CAPRIN-1抗体所识别的CAPRIN-1蛋白质的表位的、即与该表位特异性地结合的抗体,可以利用本领域技术人员公知的方法得到。例如,可以通过下述方法等来得到:通过通常的方法(例如表位作图(epitope mapping)等)确定由抗CAPRIN-1抗体识别的CAPRIN-1蛋白质的表位,以具有该表位中所含的氨基酸序列的多肽为免疫原来制作抗体的方法;通过通常的方法确定制作的抗体的表位,选择表位与抗CAPRIN-1抗体相同的抗体的方法等。这里,“表位”是指在哺乳动物、优选人中具有抗原性或免疫原性的多肽片段,其最小单位包含约7-12个氨基酸、优选8-11个氨基酸。
本发明中使用的抗体的亲和常数Ka(kon/koff)优选至少为107M-1、至少为108M-1、至少为5×108M-1、至少为109M-1、至少为5×109M-1、至少为1010M-1、至少为5×1010M-1、至少为1011M-1、至少为5×1011M-1、至少为1012M-1、或者至少为1013M-1
本发明中使用的抗体可以与抗肿瘤剂结合。抗体与抗肿瘤剂的结合可以经由具有与氨基、羧基、羟基、硫醇基等为反应性的基团(例如、琥珀酰亚胺基、甲酰基、2-吡啶基二硫基、马来酰亚胺基、烷氧基羰基、羟基等)的间隔物来进行。
可在本发明中使用的抗肿瘤剂的例子包含文献等中记载的公知的下述抗肿瘤剂,紫杉醇、多柔比星、柔红霉素、环磷酰胺、甲氨蝶呤、5-氟尿嘧啶、噻替哌、白消安、英丙舒凡、哌泊舒凡、benzodopa、卡波醌、meturedopa、uredopa、六甲蜜胺(altretamine)、三亚乙基三聚氰胺、三亚乙基磷酰胺、三亚乙基硫代磷酰胺(triethilenethiophosphoramide)、三羟甲基三聚氰胺(trimethylolomelamine)、布拉他辛、布拉他辛酮、喜树碱、苔藓虫素、海绵多聚乙酰(callystatin)、cryptophycin1、cryptophycin8、海兔毒素(dolastatin)、倍癌霉素(duocarmycin)、艾榴塞洛素(eleutherobin)、水鬼蕉碱(pancratistatin)、匍枝珊瑚醇(sarcodictyin)、spongistatin、苯丁酸氮芥、萘氮芥(chlornaphazine)、氯磷酰胺(cholophosphamide)、雌莫司汀、异环磷酰胺、甲氮芥、盐酸甲氧氮芥、美法仑、新氮芥(novembichin)、苯芥胆甾醇(phenesterine)、泼尼莫司汀(prednimustine)、曲磷胺(trofosfamide)、乌拉莫司汀、卡莫司汀、氯乙链脲菌素(chlorozotocin)、福莫司汀(fotemustine)、洛莫司汀、尼莫司汀、雷莫司汀、卡奇霉素(calicheamicin)、达内霉素(dynemicin)、氯屈膦酸、埃斯培拉霉素(esperamicin)、阿克拉霉素、放线菌素、安曲霉素(authramycin)、重氮丝氨酸、博来霉素、放线菌素C(cactinomycin)、卡柔比星(carabicin)、洋红霉素、嗜癌菌素(carzinophilin)、色霉素、更生霉素、detorbicin、6-重氮基-5-氧代-L-正亮氨酸、阿霉素(adriamycin)、表柔比星、依索比星、伊达比星、麻西罗霉素(marcellomycin)、丝裂霉素C、霉酚酸(mycophenolic acid)、诺加霉素(nogalamycin)、橄榄霉素(olivomycins)、培洛霉素、甲基丝裂霉素(potfiromycin)、嘌呤霉素、三铁阿霉素(quelamycin)、罗多比星(rodorubicin)、链黑菌素、链佐星、杀结核菌素(tubercidin)、乌苯美司、净司他丁(zinostatin)、佐柔比星(zorubicin)、二甲叶酸(denopterin)、蝶罗呤(pteropterin)、三甲曲沙(trimetrexate)、氟达拉滨(fludarabine)、6-巯嘌呤、硫咪嘌呤、硫鸟嘌呤、安西他滨、阿扎胞苷(azacitidine)、6-氮杂尿苷(azauridine)、卡莫氟、阿糖胞苷、二脱氧尿苷、去氧氟尿苷、依诺他滨(enocitabine)、氟尿苷(floxuridine);雄激素类、例如卡普睾酮(calusterone)、屈他雄酮丙酸酯、环硫雄醇、美雄烷、睾内酮(testolactone)、氨鲁米特、米托坦、曲洛司坦、亚叶酸(frolinic acid)、醋葡醛内酯、醛磷酰胺糖苷、氨基乙酰丙酸、恩尿嘧啶(eniluracil)、安吖啶(amsacrine)、阿莫司汀(bestrabucil)、比生群(bisantrene)、依达曲沙(edatraxate)、defofamine、秋水仙胺(demecolcine)、地吖醌(diaziquone)、依氟鸟氨酸(elfornithine)、依利醋铵(elliptinium)、埃博霉素(epothilone)、依托格鲁(etoglucid)、香茹多糖、氯尼达明(lonidamine)、美登素(maytansine)、安丝菌素(ansamitocine)、米托胍腙(mitoguazone)、米托蒽醌、mopidanmol、二胺硝吖啶nitraerine、喷司他丁、蛋氨氮芥(phenamet)、吡柔比星、洛索蒽醌(losoxantrone)、足叶草酸(podophyllinic acid)、2-乙基酰肼、甲苄肼、雷佐生(razoxane)、根瘤菌素(rhizoxin)、西佐喃、锗螺胺(spirogermanium)、细交链孢菌酮酸(tenuazonic acid)、三乙撑亚胺苯醌(triaziquone)、杆孢菌素(roridine)A、蛇形菌素(anguidine)、聚氨酯、长春地辛、达卡巴嗪、甘露醇氮芥(mannomustine)、二溴甘露醇、二溴卫矛醇(mitolactol)、哌泊溴烷(pipobroman)、gacytosine、多西紫杉醇、瘤可宁、吉西他滨(gemcitabine)、6-硫鸟嘌呤、巯嘌呤、顺铂、奥沙利铂、卡波铂、长春碱、足叶乙甙、异环磷酰胺、米托葸醌、长春新碱、长春瑞滨、诺消灵(novantrone)、替尼泊苷、依达曲沙(edatrexate)、道诺霉素、氨蝶呤、希罗达(xeloda)、伊班膦酸盐(ibandronate)、伊立替康、拓扑异构酶抑制剂、二氟甲基鸟氨酸(DMFO)、视黄酸、卡培他滨(capecitabine)、以及它们的药学上可接受的(公知的)盐或(公知的)衍生物。
或者,在本发明中使用的抗体中,也可以结合文献等中公知的211At、131I、125I、90Y、186Re、188Re、153SM、212Bi、32P、175Lu、176Lu等放射性同位素。放射性同位素期望是可有效地用于治疗或诊断肿瘤的同位素。
本发明中使用的抗体是与CAPRIN-1具有免疫反应性的抗体、特异性地识别CAPRIN-1的抗体、或者与CAPRIN-1特异性地结合的抗体,并且是显示对癌的细胞毒活性例如肿瘤增殖抑制作用的抗体。该抗体应该是具有在施与该抗体的对象动物中能够几乎避免或完全避免产生排斥反应的结构的抗体。作为这样的抗体,例如在对象动物为人时,可以列举人抗体、人源化抗体、嵌合抗体(例如人-小鼠嵌合抗体)、单链抗体、双特异性抗体等。这些抗体是重链和轻链的可变区源于人抗体的抗体;或是重链和轻链的可变区包含源于非人的动物抗体的互补性决定区(CDR1、CDR2和CDR3)和源于人抗体的框架区的抗体;或是重链和轻链的可变区源于非人的动物抗体、且重链和轻链的恒定区源于人抗体的重组型抗体。优选的抗体是前2种抗体。
这些重组型抗体可以如下制备。由杂交瘤等产生抗体的细胞克隆编码针对人CAPRIN-1的单克隆抗体(例如人单克隆抗体、小鼠单克隆抗体、大鼠单克隆抗体、兔单克隆抗体、鸡单克隆抗体等)的DNA,将其作为模板利用RT-PCR法等来制备编码该抗体的轻链可变区和重链可变区的DNA,基于Kabat EU numbering system(Kabat等、Sequences ofProteins of Immunological Interest,5thEd.Public Health Service,NationalInstitute of Health,Bethesda,Md.(1991))来确定轻链和重链的各可变区的序列或各CDR1、CDR2、CDR3的序列。
进一步地,使用基因重组技术(Sambrook等,Molecular Cloning A LaboratoryManual,Cold Spring Harbor Laboratory Press(1989))或DNA合成仪来制备编码这些各可变区的DNA或编码各CDR的DNA。其中,上述产生人单克隆抗体的杂交瘤可以通过在对产生人抗体的动物(例如小鼠)免疫人CAPRIN-1后,使从该免疫动物切除的脾细胞与骨髓瘤细胞融合来制备。与此不同,根据需要使用基因重组技术或DNA合成仪来制备编码源于人抗体的轻链或重链的可变区和恒定区的DNA。
对于人源化抗体的情况,制备将编码源于人抗体的轻链或重链的可变区的DNA中的CDR编码序列替换成与它们对应的源于人以外的动物(例如小鼠、大鼠、鸡等)的抗体的CDR编码序列而得的DNA,将由此得到的DNA分别与编码源于人抗体的轻链或重链的恒定区的DNA连接,由此可以制备编码人源化抗体的DNA。
对于嵌合抗体的情况,通过将编码源于人以外的动物(例如小鼠、大鼠、鸡等)的抗体的轻链或重链的可变区的DNA,分别与编码源于人抗体的轻链或重链的恒定区的DNA连接,可以制备编码嵌合抗体的DNA。
对于单链抗体的情况,该抗体是将重链可变区和轻链可变区通过接头(linker)以直线状连接而成的抗体,通过将编码重链可变区的DNA、编码接头的DNA、和编码轻链可变区的DNA结合,可以制备编码单链抗体的DNA。其中,重链可变区和轻链可变区都源于人抗体,或者源于仅CDR被源于人以外的动物(例如小鼠、大鼠、鸡等)的抗体的CDR替换而得的人抗体。另外,接头包含12-19个氨基酸,可以列举例如15个氨基酸的(G4S)3(G.-B.Kim等,Protein Engineering Design and Selection 2007,20(9):425-432)。
对于双特异性抗体(diabody)的情况,该抗体是可与2个不同的表位特异性地结合的抗体,例如可以通过将编码重链可变区A的DNA、编码轻链可变区B的DNA、编码重链可变区B的DNA、和编码轻链可变区A的DNA以该顺序进行结合(其中编码轻链可变区B的DNA与编码重链可变区B的DNA可通过编码如上所述的接头的DNA来结合),来制备编码双特异性抗体的DNA。其中,重链可变区和轻链可变区都源于人抗体,或者源于仅CDR被源于人以外的动物(例如小鼠、大鼠、鸡等)的抗体的CDR替换而得的人抗体。
将如上所述制备的重组DNA整合到1个或多个合适的载体中,将其导入宿主细胞(例如哺乳动物细胞、酵母细胞、昆虫细胞等),进行(共)表达,由此可以制备重组型抗体(P.J.Delves.,ANTIBODY PRODUCTION ESSENTIAL TECHNIQUES.,1997WILEY、P.Shepherdand C.Dean.,Monoclonal Antibodies.,2000OXFORD UNIVERSITY PRESS;J.W.Goding.,Monoclonal Antibodies:principles and practice.,1993 ACADEMIC PRESS)。
由上述方法制备的本发明的抗体可以列举例如以下(a)-(k)的抗体。
(a)包含重链可变区CDR1-CDR3和轻链可变区CDR1-CDR3的抗体,所述重链可变区CDR1-CDR3包含序列编号40、41和42,所述轻链可变区CDR1-CDR3包含序列编号44、45和46(优选由序列编号43的重链可变区和序列编号47的轻链可变区构成的抗体)。
(b)包含重链可变区CDR1-CDR3和轻链可变区CDR1-CDR3的抗体,所述重链可变区CDR1-CDR3包含序列编号40、41和42,所述轻链可变区CDR1-CDR3包含序列编号50、51和52(优选由序列编号43的重链可变区和序列编号53的轻链可变区构成的抗体)。
(c)包含重链可变区CDR1-CDR3和轻链可变区CDR1-CDR3的抗体,所述重链可变区CDR1-CDR3包含序列编号40、41和42,所述轻链可变区CDR1-CDR3包含序列编号55、56和57(优选由序列编号43的重链可变区和序列编号58的轻链可变区构成的抗体)。
(d)包含重链可变区CDR1-CDR3和轻链可变区CDR1-CDR3的抗体,所述重链可变区CDR1-CDR3包含序列编号40、41和42,所述轻链可变区CDR1-CDR3包含序列编号60、61和62(优选由序列编号43的重链可变区和序列编号63的轻链可变区构成的抗体)。
(e)包含重链可变区CDR1-CDR3和轻链可变区CDR1-CDR3的抗体,所述重链可变区CDR1-CDR3包含序列编号40、41和42,所述轻链可变区CDR1-CDR3包含序列编号65、66和67(优选由序列编号43的重链可变区和序列编号68的轻链可变区构成的抗体)。
(f)包含重链可变区CDR1-CDR3和轻链可变区CDR1-CDR3的抗体,所述重链可变区CDR1-CDR3包含序列编号70、71和72,所述轻链可变区CDR1-CDR3包含序列编号74、75和76(优选由序列编号73的重链可变区和序列编号77的轻链可变区构成的抗体)。
(g)包含重链可变区CDR1-CDR3和轻链可变区CDR1-CDR3的抗体,所述重链可变区CDR1-CDR3包含序列编号80、81和82,所述轻链可变区CDR1-CDR3包含序列编号84、85和86(优选由序列编号83的重链可变区和序列编号87的轻链可变区构成的抗体)。
(h)包含重链可变区CDR1-CDR3和轻链可变区CDR1-CDR3的抗体,所述重链可变区CDR1-CDR3包含序列编号90、91和92,所述轻链可变区CDR1-CDR3包含序列编号94、95和96(例如由序列编号93的重链可变区和序列编号97的轻链可变区构成的抗体)。
(i)包含重链可变区CDR1-CDR3和轻链可变区CDR1-CDR3的抗体,所述重链可变区CDR1-CDR3包含序列编号100、101和102,所述轻链可变区CDR1-CDR3包含序列编号104、105和106(例如由序列编号103的重链可变区和序列编号107的轻链可变区构成的抗体)。
(j)包含重链可变区CDR1-CDR3和轻链可变区CDR1-CDR3的抗体,所述重链可变区CDR1-CDR3包含序列编号110、111和112,所述轻链可变区CDR1-CDR3包含序列编号114、115和116(例如由序列编号113的重链可变区和序列编号117的轻链可变区构成的抗体)。
(k)包含重链可变区CDR1-CDR3和轻链可变区CDR1-CDR3的抗体,所述重链可变区CDR1-CDR3包含序列编号120、121和122,所述轻链可变区CDR1-CDR3包含序列编号124、125和126(优选由序列编号123的重链可变区和序列编号127的轻链可变区构成的抗体)。
其中,序列编号40、41和42、序列编号70、71和72、序列编号80、81和82、序列编号90、91和92、序列编号100、101和102、序列编号110、111和112、序列编号120、121和122所示的氨基酸序列分别是小鼠抗体重链可变区的CDR1、CDR2和CDR3,另外,序列编号44、45和46、序列编号50、51和52、序列编号55、56和57、序列编号60、61和62、序列编号65、66和67、序列编号74、75和76、序列编号84、85和86、序列编号94、95和96、序列编号104、105和106、序列编号114、115和116、序列编号124、125和126所示的氨基酸序列分别是小鼠抗体轻链可变区的CDR1、CDR2和CDR3。另外,本发明的人源化抗体、嵌合抗体、单链抗体或双特异性抗体例如是以下的抗体(用抗体(a)例示)。
(i)重链的可变区包含序列编号40、41和42的氨基酸序列和源于人抗体的框架区的氨基酸序列,且轻链的可变区包含序列编号44、45和46的氨基酸序列和源于人抗体的框架区的氨基酸序列的抗体(例如,重链可变区中包含序列编号43的氨基酸序列、且轻链可变区中包含序列编号47的氨基酸序列的抗体)。
(ii)重链的可变区包含序列编号40、41和42的氨基酸序列和源于人抗体的框架区的氨基酸序列,且重链的恒定区包含源于人抗体的氨基酸序列,且轻链的可变区包含序列编号44、45和46的氨基酸序列和源于人抗体的框架区的氨基酸序列,且轻链的恒定区包含源于人抗体的氨基酸序列的抗体(例如,重链的可变区包含序列编号43的氨基酸序列,且重链的恒定区包含源于人抗体的氨基酸序列,以及轻链的可变区包含序列编号47的氨基酸序列,且轻链的恒定区包含源于人抗体的氨基酸序列的抗体)。
并且,人抗体重链和轻链的恒定区和可变区的序列例如可以由NCBI(美国:GenBank、UniGene等)获得,例如对于人IgG1重链恒定区,可以参照注册编号J00228的序列,对于人IgG2重链恒定区,可以参照注册编号为J00230的序列,对于人IgG3重链恒定区,可以参照注册编号为X03604的序列,对于人IgG4重链恒定区,可以参照注册编号为K01316的序列,对于人轻链κ恒定区,可以参照注册编号为V00557、X64135、X64133等的序列,对于人轻链λ恒定区,可以参照注册编号为X64132、X64134等的序列。
上述抗体优选具有细胞毒活性,由此可以发挥抗肿瘤效果。
另外,可以明确上述抗体中的重链和轻链的可变区、CDR的特定序列仅仅是用于例示,并不限于特定的序列。制备可产生针对人CAPRIN-1的其它人抗体或非人的动物抗体(例如小鼠抗体)的杂交瘤,回收由杂交瘤产生的单克隆抗体,以与人CAPRIN-1的免疫结合性和细胞毒活性作为指标,来判定是否为目的抗体。由此识别目的的产生单克隆抗体的杂交瘤后,如上所述,由该杂交瘤制备编码目的抗体的重链和轻链的可变区的DNA,进行序列确定,将该DNA用于其他抗体的制备。
进一步地,本发明的上述抗体只要具有特异性地识别CAPRIN-1这样的特异性,则上述(i)~(iv)的各抗体的特别是框架区的序列和/或恒定区的序列中可以有1个或数个(优选1或2个)氨基酸的替换、缺失或添加。其中,数个是指2-5个、优选2个或3个。
本发明中使用的抗体进而也可以利用编码本发明的上述抗体的DNA、或编码上述抗体的重链或轻链的DNA、或编码上述抗体的重链或轻链的可变区的DNA、通过基因重组技术来制造。例如在抗体(a)的情况下,这样的DNA包含:包含编码序列编号40、41和42的氨基酸序列的碱基序列的、编码重链可变区的DNA,包含编码序列编号44、45和46的氨基酸序列的碱基序列的、编码轻链可变区的DNA等。
由这些序列的DNA编码的互补决定区(CDR)是决定抗体的特异性的区域,因此编码抗体的这以外的区域(即,恒定区和框架区)的序列可以是源于其它抗体的序列。这里,其它抗体也包含源于人以外的生物的抗体,但从降低副作用的观点出发,优选源于人的抗体。即,在上述DNA中,编码重链和轻链的各框架区和各恒定区的区域优选包含编码源于人抗体的对应氨基酸序列的碱基序列。
进一步地,作为编码本发明中使用的抗体的DNA的其它例子,例如对于抗体(a)的情况,有包含编码序列编号43的氨基酸序列的碱基序列的编码重链可变区的DNA、编码轻链可变区的区域含有编码序列编号47的氨基酸序列的碱基序列的DNA等。这里,编码序列编号43的氨基酸序列的碱基序列的例子是序列编号48的碱基序列。另外,编码序列编号47的氨基酸序列的碱基序列的例子是序列编号49的碱基序列。在这些DNA中,编码重链和轻链的各恒定区的区域优选包含编码源于人抗体的对应氨基酸序列的碱基序列。
上述的DNA例如可以用上述的方法或以下的方法得到。首先,由与本发明的抗体相关的杂交瘤,使用市售的RNA提取试剂盒制备总RNA,使用随机引物等通过逆转录酶合成cDNA。接着通过使用在已知的小鼠抗体重链基因和轻链基因的各可变区中分别保存的序列的寡核苷酸作为引物的PCR法,扩增编码抗体的cDNA。对于编码恒定区的序列,可以通过利用PCR法扩增已知的序列来得到。DNA的碱基序列可以整合到序列确定用质粒或噬菌体中等通过常法来确定。
与上述抗体(a)-(k)有关的DNA的具体例子如以下所述。
(i)作为编码含有序列编号43、序列编号73、序列编号83、序列编号93、序列编号103、序列编号113、序列编号123、序列编号133、序列编号143或序列编号153的氨基酸序列的多肽的DNA,含有序列编号48、序列编号78、序列编号88、序列编号98、序列编号108、序列编号118或序列编号128的碱基序列的DNA。
(ii)作为编码含有序列编号47、序列编号53、序列编号58、序列编号63、序列编号68、序列编号77、序列编号87、序列编号97、序列编号107,序列编号117、序列编号127、序列编号137、序列编号147或序列编号157的氨基酸序列的多肽的DNA,含有序列编号49、序列编号54、序列编号59、序列编号64、序列编号69、序列编号79、序列编号89、序列编号99、序列编号109、序列编号119或序列编号129的碱基序列的DNA。
认为本发明中使用的抗CAPRIN-1抗体对表达CAPRIN-1的癌细胞的抗肿瘤效果,是由以下机理所引起的。
CAPRIN-1表达细胞的效应器细胞抗体依赖的细胞毒性(ADCC)、和CAPRIN-1表达细胞的补体依赖的细胞毒性(CDC)。
因此,本发明中使用的抗CAPRIN-1抗体的活性评价,如以下实施例中具体所示的那样,可以通过在生物体外对表达CAPRIN-1蛋白质的癌细胞测定上述ADCC活性或CDC活性来进行评价。
ADCC活性的测定可以使用例如细胞毒性检测试剂盒(Roche)等的细胞毒活性测定用的市售试剂盒来进行。根据该方法,可以通过下述步骤进行,所述步骤包括:在使靶癌细胞与抗CAPRIN-1抗体在冰上反应后,与效应器细胞(例如PBMC)一起培养4小时,对于培养上清液,测定释放到培养基中的乳酸脱氢酶(LDH)酶活性或Cr51放射活性。另外,CDC活性的测定可以通过下述步骤进行,所述步骤包括:使靶癌细胞与抗CAPRIN-1抗体在冰上反应后,与补体溶液(例如血清)一起培养4小时,对于培养上清液,测定与上述同样的酶活性或放射活性。
可以认为,本发明中使用的抗CAPRIN-1抗体,与癌细胞上的CAPRIN-1蛋白质结合,通过上述活性而表现抗肿瘤作用,因此在癌的治疗或预防中是有用的。即,本发明提供以抗CAPRIN-1抗体为有效成分的、用于癌的治疗和/或预防的药物组合物。在以将抗CAPRIN-1抗体施与人体的目的(抗体治疗)使用时,为了使免疫原性降低,优选为人抗体和/或人源化抗体。
并且,抗CAPRIN-1抗体与癌细胞表面上的CAPRIN-1蛋白质的结合亲和性越高,越可得到由抗CAPRIN-1抗体产生的更强的抗肿瘤活性。因此,如果可以获得与CAPRIN-1蛋白质具有高的结合亲和性的抗CAPRIN-1抗体,则可以期待更强的抗肿瘤效果,可以适合作为以癌的治疗和/或预防为目的的药物组合物。作为高的结合亲和性,如上所述,结合常数(亲和常数)Ka(kon/koff)优选至少为107M-1、至少108M-1、至少为5×108M-1、至少为109M-1、至少为5×109M-1、至少为1010M-1、至少为5×1010M-1、至少为1011M-1、至少为5×1011M-1、至少为1012M-1、或至少为1013M-1
<对表达抗原的细胞的结合>
抗体与CAPRIN-1蛋白质结合的能力可以利用如实施例中所述的使用了例如ELISA、蛋白质印迹法、免疫荧光和流式细胞仪分析等的结合分析来特定。
<免疫组织化学染色>
识别CAPRIN-1蛋白质的抗体,可以利用本领域技术人员公知的方法中的免疫组织化学,使用由外科手术期间从患者得到的组织、或从担载了接种有自然地或在转染后表达CAPRIN-1的细胞系的异种移植组织的动物得到的组织进行低聚甲醛或丙酮固定而得的冷冻切片或用低聚甲醛固定并进行石蜡包埋而得的组织切片,关于与CAPRIN-1的反应性进行试验。
为了进行免疫组织化学染色,可以将对CAPRIN-1具有反应性的抗体用各种方法进行染色。例如通过与辣根过氧化物酶复合山羊抗小鼠抗体或山羊抗兔抗体反应,能够可视化。
<抗肿瘤剂>
本发明的特征在于将抗CAPRIN-1抗体与以上例示的抗肿瘤剂进行组合。抗CAPRIN-1抗体和抗肿瘤剂分别具有抗肿瘤活性,但通过将它们组合并施与癌患者,可以得到实施例中所示的协同性的显著的抗肿瘤效果、即在荷癌动物模型中使肿瘤几乎完全萎缩的效果。这样的显著的抗肿瘤效果,在肿瘤的增殖经时地逐渐增加的情况下,通过将抗CAPRIN-1抗体和抗肿瘤剂并用时也是令人非常惊讶的。
在本发明中,与抗CAPRIN-1抗体组合使用的抗肿瘤剂包含在各种癌和/或肿瘤的治疗中正在使用、使用过的、或将要使用的全部化学疗法药剂。这种抗肿瘤剂是代谢抑制剂、抗生素抗癌剂、植物生物碱系抗癌剂、拓扑异构酶抑制剂、抗肿瘤烷化剂等,例如包括文献等中公知的上述例示的所有抗肿瘤剂。作为非限定性的具体例,可以列举下述实施例中使用的抗肿瘤剂、即环磷酰胺、紫杉醇、多西紫杉醇、长春瑞滨等的抗癌剂,可以确认这些显著的抗肿瘤效果。因此,在本发明中,可以使用选自环磷酰胺、紫杉醇、多西紫杉醇和长春瑞滨以及它们的药学上可接受的盐或衍生物的1种或2种以上作为抗肿瘤剂。
<用于癌的治疗和/或预防的药物>
本发明的用于癌的治疗和/或预防的药物的靶只要是表达CAPRIN-1基因的癌(细胞)即可,没有特别限定。
本说明书中使用的“肿瘤”和“癌”这样的术语是指恶性新生物,可以互换使用。
本发明的药物的特征在于,将与CAPRIN-1蛋白质具有免疫反应性的抗体或其片段、与1种或2种以上的抗肿瘤剂一起或分别组合来含有。即,在将这些有效成分一起组合的情况下,可以将上述抗体或其片段与上述抗肿瘤剂在载体(或赋形剂)中一起混合并制剂化来形成药物组合物。另一方面,在将这些有效成分分别组合的情况下,可以将含有上述抗体或其片段作为有效成分的药物组合物、与含有上述抗肿瘤剂作为有效成分的药物组合物分别制剂化后,形成药物试剂盒的方式的药物。对于药物组合物和药物试剂盒,以下具体地进行说明。
作为在本发明中成为对象的癌,是表达编码具有序列编号2-30中偶数的序列编号的氨基酸序列的CAPRIN-1蛋白质的基因的癌,优选是乳癌、脑瘤、白血病、肺癌、淋巴瘤、肥大细胞瘤、肾癌、宫颈癌、膀胱癌、食道癌、胃癌和大肠癌。
这些特定的癌中,包含例如乳腺癌、复合型乳腺癌、乳腺恶性混合肿瘤、乳管内乳头状腺癌、肺腺癌、鳞状细胞癌、小细胞癌、大细胞癌、作为神经上皮组织性肿瘤的神经胶质瘤、室管膜瘤、神经元肿瘤、胎儿型的神经外胚层肿瘤、神经鞘瘤、纤维神经瘤、脑脊膜瘤、慢性淋巴细胞白血病、淋巴瘤、消化道淋巴瘤、消化器官淋巴瘤、小-中细胞型淋巴瘤、盲肠癌、升结肠癌、降结肠癌、横结肠癌、乙状结肠癌、直肠癌,但不限于此。
另外,成为对象的优选的受试者是哺乳动物,是包含例如灵长类、宠物、家畜类、竞技用动物等的哺乳动物,特别优选是人、狗和猫。
<药物组合物>
构成本发明的癌的治疗和/或预防用药物的有效成分、即上述抗体或其片段和上述抗肿瘤剂,可以作为将它们一起混合了的药物组合物或它们各自的药物组合物,利用本领域公知的方法形成制剂。
例如,可以以与水或水以外的药学上可接受的液体的无菌性溶液、或悬浮液剂的注射剂的形式非经口地使用。例如,认为可以与药理学上可接受的载体或介质、具体来说为灭菌水和/或生理盐水、植物油、乳化剂、悬浮剂、表面活性剂、稳定剂、香味剂、赋形剂、媒介物(vehicle)、防腐剂、结合剂等适当组合,通过以一般被认可的制药实施所要求的单位用量方式混和来进行制剂化。另外,本发明的药物组合物中也可含有药理学上可接受的盐。作为药理学上可接受的盐,可以使用例如盐酸或磷酸等的无机酸、或醋酸、酒石酸、扁桃酸等的有机酸。另外,可以使用与游离羧基形成的盐,例如可以由钠、钾、铵、钙、二价铁的氢氧化物等的无机碱、和异丙胺、三甲胺、2-乙基氨基乙醇、组氨酸、普鲁卡因等的有机碱衍生。
用于注射的无菌组合物可以使用注射用蒸馏水这样的媒介物按照通常的制剂实施来处方。
作为注射用的水溶液,可以列举例如生理盐水、含有葡萄糖和/或其它辅助剂、例如D-山梨糖醇、D-甘露糖、D-甘露醇、氯化钠的等渗液,也可以与适当的溶解助剂、例如醇、具体为乙醇、多元醇例如丙二醇、聚乙二醇、非离子性表面活性剂例如聚山梨醇酯80(TM)、HCO-60合并使用。
作为油性液可以列举芝麻油、大豆油,其可以与作为溶解助剂的苯甲酸苄酯、苄醇合并使用。另外,还可以与缓冲剂例如磷酸盐缓冲液、醋酸钠缓冲液、镇痛剂例如盐酸普鲁卡因、稳定剂例如苄醇、苯酚、抗氧化剂配合。制备的注射液通常填充到合适的安瓿中。
施与为经口或非经口,优选非经口施与,具体来说,可以列举注射剂型、经鼻施与剂型、经肺施与剂型、经皮施与型等。作为注射剂型的例子,可以通过例如静脉内注射、肌内注射、腹腔内注射、皮下注射等全身或局部性地施与。另外,非经口施与时,可以进行花费时间的缓慢的输液施与。另外,可以根据患者的年龄、体重、性别、症状等选择合适的施与方法。对于含有抗体的药物组合物,优选为非经口施与,另一方面,对于含有抗肿瘤剂的药物组合物,根据抗肿瘤剂的种类、适应症,选择经口施与或非经口施与的任一者。
在本发明的用于癌的治疗和/或预防的药物组合物中,作为上述抗体的施与量,可以例如以一次每1kg体重为0.0001mg至1000mg的范围来选择。或者可以例如以每个患者0.001-100000mg/个体的范围来选择施与量,但未必限于这些数值。另外,作为上述抗肿瘤剂的施与量,可以例如选择每位患者1-1000mg/个体、优选10-500mg/个体的范围的施与量,但未必限于这些数值。施与量、施与方法根据患者的体重、年龄、性别、症状等不同而变化,只要是本领域技术人员就可以适当选择。
<施与方法>
利用本发明的癌的治疗和/或预防剂进行的癌的治疗和/或预防,除了包含作为上述的药物组合物施与的形式以外,还包含其他各种形式。例如本发明的癌的治疗和/或预防剂的各有效成分可以同时或按照順序分别施与。作为具体例,可在约3周的时间间隔内,即从刚施与第1有效成分后至约3周时施与第2有效成分。此时,即使紧接着外科处理来实施,也可以在施与第1药物和第2药物之间实施外科处理。另外,可以将本发明的癌的治疗和/或预防剂按照多个施与循环来施与。例如在实施本发明的癌的治疗和/或预防剂的各有效成分的同时施与的情况下,将含有两者的有效成分的药物组合物以约2日至约3周为1个循环进行施与。然后也可以按照主治医师的判断根据需要反复該治疗循环。在计划按照同样的顺序的处方的情况下,分别调节各药物施与期间,以达到相同的期间。循环间的间隔可以改变0-2个月。本发明的癌的治疗和/或预防剂的各有效成分的施与量可以与药物组合物中的各有效成分的施与量同样地设定。
<药物试剂盒>
本发明的癌的治疗和/或预防用的药物可以是药物试剂盒的形式。药物试剂盒是为了在治疗或预防癌的方法中,将作为有效成分的上述抗CAPRIN-1抗体或其片段和上述抗肿瘤剂以各自的药物组合物的形式使用的包装,該包装中含有用于施与各有效成分的说明书。药物试剂盒中含有的癌的治疗和/或预防用的上述药物组合物的各有效成分,可以是按照可将各有效成分一起或分别施与的方式那样,使各自如上所述形成制剂的药物组合物的形式。另外,药物试剂盒中含有对于一次或数次用量为充分量的有效成分,以使得可将各有效成分按照上述施与方法施与。
基于上述具体説明的内容,本发明进而提供包含将本发明的上述药物施与被怀疑具有癌的(包括具有癌)的受试者的、用于癌的治疗和/或预防的方法。另外,对于其实施方式,上述药物中含有的、抗体或其片段和抗肿瘤剂可以同时或分别施与上述受试者。
实施例
以下,基于实施例更为具体地说明本发明,但本发明的范围不限于这些具体例。
实施例1利用了SEREX法的新的癌抗原蛋白的鉴定
(1)cDNA文库的制作
通过酸胍-酚-氯仿方法(Acid guanidium-Phenol-Chloroform法)从健康狗的睾丸组织提取总RNA,并且使用Oligotex-dT30mRNA纯化试剂盒(宝酒造社制),按照试剂盒附带的说明书纯化多聚A RNA。
使用如此获得的mRNA(5μg)合成狗睾丸cDNA噬菌体文库。在cDNA噬菌体文库的制作中使用cDNA合成试剂盒、ZAP-cDNA合成试剂盒、ZAP-cDNA GigapackIII Gold Cloning试剂盒(STRATAGENE公司制),按照试剂盒中附带说明书制作文库。制作的cDNA噬菌体文库的大小是7.73×105pfu/ml。
(2)利用血清的cDNA文库的筛选
使用上述制作的狗睾丸cDNA噬菌体文库进行免疫筛选。具体地,感染宿主大肠杆菌(XL1-Blue MRF’)使得Φ90×15mm的NZY琼脂糖平板上形成2210个克隆,在42℃培养3-4小时,形成溶菌斑(噬斑),用渗透了IPTG(异丙基-β-D-硫代半乳糖苷)的硝酸纤维素膜(Hybond C Extra:GE Healthcare Bio-Scinece公司制)在37℃覆盖该平板4小时,由此使蛋白质诱导、表达,在该膜上转印蛋白质。然后回收该膜,并浸入到含有0.5%脱脂奶粉的TBS(10mM Tris-HCl,150mM NaCl pH值7.5)中,在4℃振摇过夜,由此抑制非特异性反应。使该滤膜与稀释了500倍的患病狗血清在室温下反应2-3小时。
作为上述患病狗的血清,使用由患有乳癌的狗中收集的血清。这些血清在-80℃保存,在即将使用前进行前处理。血清的前处理方法利用以下的方法。即,使宿主大肠杆菌(XL1-Blure MRF’)感染没有插入外来基因的λZAP表达噬菌体后,在NZY平板培养基上于37℃培养过夜。接着在平板中加入含有0.5M NaCl的0.2M NaHCO3pH值8.3的缓冲液,在4℃静置15小时后,将上清液作为大肠杆菌/噬菌体提取液回收。接着,使回收的大肠杆菌/噬菌体提取液流经NHS-柱(GE Healthcare Bio-Science公司制),将源于大肠杆菌·噬菌体的蛋白质固定化。使患病狗的血清流经固定了该蛋白质的柱进行反应,将吸附在大肠杆菌和噬菌体上的抗体从血清中除去。将直接流过该柱的血清级分用含有0.5%脱脂奶粉的TBS稀释500倍。将所得物用作免疫筛选材料。
将该处理血清和印迹了上述融合蛋白的膜用TBS-T(0.05%吐温20/TBS)洗涤4次,然后与作为二抗的已经用含有0.5%脱脂奶粉的TBS稀释5000倍的山羊抗狗IgG(Goat antiDog IgG-h+I HRP conjugated:BETHYL Laboratories公司制)在室温反应1小时,通过使用了NBT/BCIP反应液(Roche公司制)的酶显色反应来检测,从Φ90x15mm的NZY琼脂糖平板上收集与显色反应阳性部位相对应的集落,并将其溶解于500μl的SM缓冲液(100mM NaCl,10mM MgClSO4,50mM Tris-HCl,0.01%明胶,pH值7.5)中。以与上述同样的方法重复二次、三次筛选,直至显色反应阳性集落单一化,从而筛选30940个与血清中的IgG反应的噬菌体克隆,并分离了5个阳性克隆。
(3)分离的抗原基因的同一性检索
为了对通过上述方法分离的5个阳性克隆进行碱基序列分析,进行将噬菌体载体转换成质粒载体的操作。具体地,将宿主大肠杆菌(XL1-Blue MRF’)调制成吸光度OD600为1.0的溶液,将该溶液200μl与250μl纯化的噬菌体溶液、以及1μl ExAssist辅助噬菌体(STRATAGENE公司制)混合,随后在37℃反应15分钟。添加3ml LB培养基,在37℃培养2.5-3小时,立即用70℃的水浴保温20分钟,进行4℃、1000×g、15分钟的离心分离,收集上清液作为噬菌粒溶液。随后,将噬菌粒宿主大肠杆菌(SOLR)调制成吸光度OD600为1.0的溶液,将该溶液200μl与10μl纯化的噬菌体溶液混合,随后在37℃反应15分钟。将50μl接种于含有氨苄青霉素(终浓度:50μg/ml)的LB琼脂培养基,并且在37℃培养过夜。收集转换的SOLR单集落,在含有氨苄青霉素(终浓度:50μg/ml)的LB培养基中在37℃培养后,使用QIAGEN plasmidMiniprep Kit(QIAGEN)纯化具有目的插入物的质粒DNA。
使用序列编号31记载的T3引物和序列编号32记载的T7引物,通过引物步移法,对纯化的质粒进行插入物全长序列的分析。通过该序列分析,获得了序列编号5、7、9、11、13所记载的基因序列。使用该基因的碱基序列和氨基酸序列(序列编号6、8、10、12、14)来进行同源性检索程序BLAST检索(http://www.ncbi.nlm.nih.gov/BLAST/),从而进行与已知基因的同源性检索,结果判明获得的5个基因均是编码CAPRIN-1的基因。就被翻译为蛋白质的区域而言,这五个基因之间的序列同一性为碱基序列100%,氨基酸序列99%。就被翻译为蛋白质的区域而言,与编码该基因的人同源因子的基因的序列同一性为:94%的碱基序列同一性、98%的氨基酸序列同一性。人同源因子的碱基序列示于序列编号1、3,氨基酸序列示于序列编号2、4。此外,就被翻译为蛋白质的区域而言,与编码所获得的狗基因的牛同源因子的基因的序列同一性为:94%的碱基序列同一性、97%的氨基酸序列同一性。牛同源因子的碱基序列示于序列编号15,氨基酸序列显示于序列编号16。另外,就被翻译为蛋白质的区域而言,编码人同源因子的基因与编码牛同源因子的基因之间的序列同一性为:94%的碱基序列同一性、93%-97%的氨基酸序列同一性。此外,就被翻译为蛋白质的区域而言,与编码所获得的狗基因的马同源因子的基因的序列同一性为:93%的碱基序列同一性、97%的氨基酸序列同一性。马同源因子的碱基序列示于序列编号17,氨基酸序列示于序列编号18。另外,就被翻译为蛋白质的区域而言,编码人同源因子的基因与编码马同源因子的基因之间的序列同一性为:93%的碱基序列同一性、96%的氨基酸序列同一性。此外,就被翻译为蛋白质的区域而言,与编码所获得的狗基因的小鼠同源因子的基因的序列同一性为:87%-89%的碱基序列同一性、95%-97%的氨基酸序列同一性。小鼠同源因子的碱基序列示于序列编号19、21、23、25、27,氨基酸序列示于序列编号20、22、24、26、28。另外,就被翻译为蛋白质的区域而言,编码人同源因子的基因与编码小鼠同源因子的基因之间的序列同一性为:89%-91%的碱基序列同一性、95%-96%的氨基酸序列同一性。此外,就被翻译为蛋白质的区域而言,与编码所获得的狗基因的鸡同源因子的基因的序列同一性为:82%的碱基序列同一性、87%的氨基酸序列同一性。鸡同源因子的碱基序列示于序列编号29,氨基酸序列示于序列编号30。另外,就被翻译为蛋白质的区域而言,编码人同源因子的基因与编码鸡同源因子的基因之间的序列同一性为:81%-82%的核苷酸序列同一性、86%的氨基酸序列同一性。
(4)各组织中的基因表达分析
对由上述方法得到的基因,利用RT-PCR法研究狗和人的正常组织和各种细胞株中的表达。逆转录反应如下进行。即,使用TRIZOL试剂(invitrogen公司制)并按照附带的说明书从各组织5mg和各细胞株5-10×106个细胞中提取总RNA。使用该总RNA,利用Superscript First-Strand Synthesis System for RT-PCR(invitrogen公司制)按照附带的说明书合成cDNA。PCR反应使用取得的基因特异性引物(在序列编号33和34中记载)如下进行。即,以使通过逆转录反应制备的样品为0.25μl,上述引物为各2μM,dNTP为各0.2mM、ExTaq聚合酶(宝酒造社制)为0.65U的方式添加各试剂和附带的缓冲液,调节至总量25μl,使用Thermal Cycler(BIO RAD公司制),将94℃-30秒、60℃-30秒、72℃-30秒的循环重复30次。此外,上述基因特异型引物是扩增序列编号5的碱基序列(狗CAPRIN-1基因)中的第206-632位碱基的区域和序列编号1的碱基序列(人CAPRIN-1基因)中的第698-1124位碱基的区域的引物。为了进行比较对照,同时使用GAPDH特异性引物(在序列编号35和36中记载)。其结果如图1所示,在健康的狗组织中,在睾丸中发现强的表达,另一方面在狗乳癌和腺癌组织中有表达。进一步地,还一并确认了所获得的基因的人同源因子的表达,结果与狗CAPRIN-1基因同样地,在正常组织中能够确认表达的仅为睾丸,但在癌细胞的情况下,在乳癌、脑瘤、白血病、肺癌和、食道癌细胞株等多种的癌细胞株中检测到表达,尤其在大量乳癌细胞株中确认了表达。由这些结果可确认,CAPRIN-1在除睾丸之外的正常组织中观察不到表达,另一方面,在大量癌细胞中表达,尤其在乳癌细胞株中表达。
此外,在图1中,纵轴的参照编号1表示上述鉴定的基因的表达图谱,参照编号2表示作为比较对照的GAPDH基因的表达图谱。
(5)免疫组织化学染色
(5)-1小鼠和狗正常组织中的CAPRIN-1的表达
将小鼠(Balb/c,雌性)和狗(比格犬,雌性)在乙醚麻醉下和氯胺酮/异氟烷麻醉下放血,开腹后,将各器官(胃、肝、眼球、胸腺、肌肉、骨髓、子宫、小肠、食道、心脏、肾、唾液腺、大肠、乳腺、脑、肺、皮肤、肾上腺、卵巢、胰腺、脾脏和膀胱)分别转移至加入有PBS的10-cm平皿中。在PBS中切开各器官,用含有4%低聚甲醛(PFA)的0.1M磷酸盐缓冲液(pH值7.4)回流固定过夜。弃去回流液,用PBS漂洗各器官的组织表面,将含有10%蔗糖的PBS溶液添加入50ml容量的离心管中。然后将各组织置于管中,使用转子在4℃振摇2小时。替换成含有20%蔗糖的PBS溶液,在4℃静置直至组织沉降,然后替换成含有30%蔗糖的PBS溶液,在4℃静置直至组织沉降。取出组织并使用手术刀切下所需的部分。接着,加入OCT化合物(Tissue Tek公司制)使其浸润组织表面,随后将组织置于Cryomold(冷冻切片包埋模具)上。将Cryomold置于干冰上使其迅速冷冻,然后使用低温恒温器(LEICA公司制)将组织切成10-20μm薄片,并且用电吹风对每个载玻片风干30分钟,由此制备置有薄切片组织的载玻片。接着,将载玻片置于充满PBS-T(含有0.05%吐温20的生理盐水)的染色瓶,将每隔5分钟更换PBS-T的操作进行3次。使用Kimwipes擦掉切片周围的多余水分,用DAKOPEN(DAKO公司制)包围后,作为封闭液,对小鼠组织施用MOM小鼠Ig封闭试剂(VECTASTAIN公司制),对狗组织施用含有10%FBS的PBS-T溶液,置于保湿室中在室温静置1小时。接着,施加将实施例3制备的与癌细胞表面反应的、具有序列编号73的重链可变区和序列编号77的轻链可变区的针对CAPRIN-1的单克隆抗体(单克隆抗体#6)用封闭液调制成10μg/ml溶液,在保湿室中于4℃静置过夜。在用PBS-T进行10分钟3次洗涤后,施加用封闭液稀释250倍的MOM生物素标记抗IgG抗体(VECTASTAIN公司制),在保湿室中于室温静置1小时。在用PBS-T进行10分钟3次洗涤后,施加抗生物素蛋白-生物素ABC试剂(VECTASTAIN公司制),在保湿室中于室温静置5分钟。在用PBS-T进行10分钟3次洗涤后,施加DAB显色液(DAB 10mg+30%H2O2 10μl/0.05M Tris-HCl(pH值7.6),50ml),在保湿室中于室温静置30分钟。用蒸馏水淋洗,然后施加苏木精试剂(DAKO公司制),于室温静置1分钟后,用蒸馏水淋洗。载玻片依次地放入70%、80%、90%、95%和100%的各乙醇溶液中各1分钟,随后使其在二甲苯中静置过夜。取出载玻片,用Glycergel Mounting Medium(DAKO公司制)封片,随后观察。其结果是,在唾液腺、肾、结肠和胃的各组织中仅在细胞内观察到微弱程度的CAPRIN-1表达;然而在细胞表面上没有观察到CAPRIN-1表达。此外,在来自其它器官的组织中完全没有观察到表达。此外,本结果在使用具有序列编号103的重链可变区和序列编号107的轻链可变区的针对CAPRIN-1的单克隆抗体(单克隆抗体#9)时,也是同样的。
(5)-2狗乳癌组织中的CAPRIN-1的表达
使用在病理诊断中诊断为患有恶性乳癌的狗的冷冻乳癌组织108份样本,用与上述同样的方法制备冷冻切片载玻片,并进行使用了在实施例3中制备的单克隆抗体#6的免疫组织化学染色。作为其结果,在108个样本中,确认有100个样本(92.5%)表达CAPRIN-1,特别是在异型度高的癌细胞表面有强烈表达。此外,本结果在使用实施例3中制作的单克隆抗体#9时,也是同样的。
(5)-3人乳癌组织中的CAPRIN-1的表达
使用石蜡包埋的人乳癌组织阵列(BIOMAX公司制)的188个乳癌组织样本,进行免疫组织化学染色。将人乳癌组织阵列在60℃处理3小时后,放入装满了二甲苯的染色瓶中,将每隔5分钟替换二甲苯的操作进行3次。接着用乙醇和PBS-T代替二甲苯,进行同样的操作。在装满了含有0.05%Tween20的10mM柠檬酸缓冲液(pH值6.0)的染色瓶中加入人乳癌组织阵列,在125℃处理5分钟后,在室温下静置40分钟以上。将切片周围的多余水分用Kimwipes擦去,用DAKOPEN包围,适当滴加Peroxidase Block(DAKO公司制)。在室温下静置5分钟后,加入到装满了PBS-T的染色瓶中,将每隔5分钟替换PBS-T的操作进行3次。作为封闭液,加入含有10%FBS的PBS-T溶液,在保湿室内、在室温下静置1小时。接着加入将在实施例4制备的与癌细胞表面反应的单克隆抗体#6用含有5%FBS的PBS-T溶液调制成10μg/ml而得的溶液,在保湿室内、在4℃静置过夜,用PBS-T进行10分钟3次洗涤后,滴加适量的Peroxidase Labelled Polymer Conjugated(DAKO公司制),在保湿室内、在室温下静置30分钟。利用PBS-T洗涤3次每次10分钟后,加入DAB显色液(DAKO公司制),在室温下静置10分钟左右后,丢弃显色液,用PBS-T洗涤3次每次10分钟后,用蒸馏水冲洗,依次加入到70%、80%、90%、95%、100%的各乙醇溶液中各1分钟,然后在二甲苯中静置过夜。取出载玻片,用Glycergel Mounting Medium(DAKO公司制)封片后,进行观察。作为其结果,在全部188份乳癌组织样本中,确认有138份样本(73%)较强地表达CAPRIN-1。此外,本结果在使用实施例3中制作的单克隆抗体#2或#9时,也是同样的。
(5)-4人恶性脑瘤中的CAPRIN-1的表达
使用石蜡包埋的人恶性脑瘤组织阵列(BIOMAX公司制)的247份恶性脑瘤组织样本,利用与上述(5)-3同样的方法进行使用了在实施例3中制备的单克隆抗体#6的免疫组织化学染色。作为其结果,在全部247份恶性脑瘤组织样本中,227份样本(92%)观察到强烈的CAPRIN-1表达。并且,本结果在使用实施例3中制作的单克隆抗体#2或#9时,也是同样的。
(5)-5人乳癌转移淋巴结中的CAPRIN-1表达
使用石蜡包埋的人乳癌转移淋巴结组织阵列(BIOMAX)的150份人乳癌转移的淋巴结组织样本,利用与上述(5)-3同样的方法进行使用了在实施例3中制备的单克隆抗体#6的免疫组织化学染色。作为其结果,在全部150份乳癌转移淋巴结组织样本中,136份样本(90%)观察到强烈的CAPRIN-1表达。即,判定CAPRIN-1在由乳癌转移的癌组织中也强烈地表达。此外,本结果在使用实施例3中制作的单克隆抗体#2或#9时,也是同样的。
(5)-6人各种癌组织中的CAPRIN-1的表达
用与上述同样的方法使用石蜡包埋的人各种癌组织阵列(BIOMAX公司制)的样本,利用与上述同样的方法进行使用了在实施例3中制备的单克隆抗体#6的免疫组织化学染色。作为其结果,CAPRIN-1在食道癌、结肠癌、直肠癌、肺癌、肾癌、膀胱癌和宫颈癌中确认有强的表达。此外,本结果在使用单克隆抗体#2或#9时,也是同样的。
实施例2人新的癌抗原蛋白的制备
(1)重组蛋白质的制备
基于序列编号1的基因通过以下方法制备人同源基因的重组蛋白质。PCR如下进行:以乳癌组织·细胞cDNA通过RT-PCR法可以确认表达的cDNA 1μl、含有SacI和XhoI限制性酶切割序列的两种引物(序列编号38和39中记载)各0.4μM、0.2mM dNTP、1.25UPrimeSTAR HS聚合酶(宝酒造社制))的方式添加各试剂和附带的缓冲液,使总量为50μl,使用Thermal Cycler(BIO RAD公司制),将98℃-10秒、68℃-2.5分钟的循环重复30次。此外,上述2种引物是扩增编码序列编号2的氨基酸序列全长的区域的引物。PCR后,将扩增的DNA利用1%琼脂糖凝胶进行电泳,使用QIAquick Gel Extraction Kit(QIAGEN公司制)纯化约2.1kbp的DNA片段。
将纯化的DNA片段连接到克隆载体pCR-Blunt(Invitrogen)中。将其转化大肠杆菌,然后回收质粒,通过测序确认扩增的基因片段与目的序列一致。用SacI和XhoI限制性酶处理与目的序列一致的质粒,然后用QI Aquick Gel Extraction Kit纯化后,将目的基因序列插入到用SacI、XhoI限制性酶处理后的大肠杆菌用表达载体pET30a(Novagen公司制)中。通过使用该载体能够产生His标签融合型的重组蛋白质。将该质粒转化表达用大肠杆菌BL21(DE3)中,用1mM IPTG诱导表达,由此在大肠杆菌中表达目的蛋白质。
(2)重组蛋白质的纯化
将上述得到的表达序列编号1的基因的各重组大肠杆菌在含有30μg/ml卡那霉素的LB培养基中在37℃培养,直至在600nm的吸光度达到0.7左右,然后添加异丙基-β-D-1-硫代吡喃半乳糖苷至终浓度1mM,在37℃培养4小时。此后,以4800转/分钟离心10分钟收集菌体。将该菌体颗粒悬浮在磷酸缓冲生理盐水中,进一步以4800转/分钟离心10分钟,进行菌体的洗涤。
将菌体悬浮在磷酸缓冲生理盐水中,然后在冰上超声破碎。将大肠杆菌超声破碎液以6000转/分钟离心分离20分钟,将所得的上清液作为可溶性级分,将沉淀物作为不溶性级分。
将可溶级分添加至根据常规技术制备的镍螯合柱(载体:ChelateingSepharose(商标)Fast Flow(GE Health Care社);柱体积:5ml;50mM盐酸缓冲液(pH值8.0)作为平衡缓冲液)。用10倍柱体积的50mM盐酸缓冲液(pH值8.0)和含有20mM咪唑的20mM磷酸盐缓冲液(pH值8.0)洗去未吸附的级分,然后立即用含有100mM咪唑的20mM磷酸盐缓冲液(pH值8.0)溶出6个床。将通过考马斯染色法确认了目的蛋白质的溶出的含有100mM咪唑的20mM磷酸盐缓冲液(pH值8.0)溶出级分添加至强阴离子交换柱(载体:Q Sepharose(商标)Fast Flow(GE Health Care社);柱体积:5ml;以及20mM磷酸缓冲液(pH值8.0)作为平衡缓冲液)。用10倍柱体积的20mM磷酸缓冲液(pH值7.0)和含有200mM氯化钠的20mM磷酸缓冲液(pH值7.0)洗去未吸附的级分,然后立即用含有400mM氯化钠的20mM磷酸缓冲液(pH值7.0)溶出5个床,获得具有序列编号2所示氨基酸序列的各蛋白质的纯化级分。
将200μl通过上述方法获得的各纯化样品分注到1ml的反应用缓冲液(20mM Tris-HCl,50mM NaCl,2mM CaCl2,pH值7.4)中,然后添加2μl肠激酶(Novagen公司制)后,在室温静置过夜进行反应,切除His标签,使用Enterokinase Cleavage Capture Kit(Novagen公司制)按照附带的说明书进行纯化。随后,使用超滤NANOSEP 10K OMEGA(PALL社制),1.2ml由上述方法获得的纯化样品用生理用磷酸缓冲液(日水制药社制)置换,然后用0.22μm HTTuffryn Acrodisc(PALL公司制)实施无菌过滤,将所得物用于以下实验。
实施例3针对CAPRIN-1的鸡单克隆抗体的制备
将实施例2中制备的序列编号2所示抗原蛋白(人CAPRIN-1)100μg与等量的MPL+TDM佐剂(Sigma公司制)混合,将该混合物用作1只小鼠的抗原溶液。将抗原溶液施与6周龄的Balb/c小鼠(日本SLC公司制)的腹腔内,每1周施与3次,即施与24次,完成免疫。从最后免疫起3日后分别取出脾脏,然后将其在两片无菌的载玻片之间磨碎,将用PBS(-)(日水社制)洗涤并以1500转/分钟离心10分钟移除上清液的操作重复3次,获得脾脏细胞。将获得的脾脏细胞与小鼠骨髓瘤细胞SP2/0(由ATCC购入)以10∶1的比例混合,向其中添加通过使加热至37℃的200μl含有10%FBS的RPMI1640培养基与800μl PEG1500(ベーリンガー社制)混合而制得的PEG溶液,静置5分钟以进行细胞融合。以1700转/分钟离心5分钟,移除上清液后,将细胞用150ml添加了2%当量的Gibco公司制的HAT溶液的含有15%FBS的RPMI1640培养基(HAT选择培养基)悬浮,并且以每孔各100μl接种于15块96孔板(Nunc公司制)中。在37℃、5%CO2的条件下培养7天,获得因脾脏细胞与骨髓瘤细胞的融合而产生的杂交瘤。
以由制备的杂交瘤产生的抗体对CAPRIN-1蛋白的结合亲和力作为指标来筛选杂交瘤。将实施例1中制备的CAPRIN-1蛋白溶液(1μg/ml)以每孔100μl的量添加至96孔板,并使该板在4℃静置18小时。各孔用PBS-T洗涤3次后,以每孔400μl的量添加0.5%牛血清白蛋白(BSA)溶液(SIGMA公司制),使该板在室温静置3小时。移除溶液,用每孔400μl的PBS-T洗涤各孔3次后,以每孔100μl的量添加上述获得的杂交瘤的各培养上清液,使该板在室温静置2小时。用PBS-T洗涤各孔3次,然后以每孔100μl的量添加用PBS稀释5000倍的HRP标记抗小鼠IgG(H+L)抗体(インビトロジェン公司制),并且在室温静置1小时。用PBS-T洗涤孔3次后,以每孔100μl的量添加TMB底物溶液(Thermo公司制),并且静置15-30分钟,进行显色反应。在颜色显现后,以每孔100μl的量添加1N硫酸以终止该反应,使用吸光度计测定在450nm的吸光度值和在595nm的吸光度值。作为其结果,选出了数个产生吸光度值高的抗体的杂交瘤。
将选出的杂交瘤以每孔0.5个的量添加至96孔板并培养。1周后,观察到在孔中形成单个集落的杂交瘤。进一步培养这些孔中的细胞,以从克隆的杂交瘤产生的抗体对CAPRIN-1蛋白的结合亲和力作为指标,选择杂交瘤。将实施例1中制备的CAPRIN-1蛋白溶液(1μg/ml)以每孔100μl的量添加至96孔板,并在4℃静置18小时。将各孔用PBS-T洗涤3次,然后以每孔400μl的量添加0.5%BSA溶液,并在室温静置3小时。移除溶液,用每孔400μl的PBS-T洗涤孔3次后,以每孔100μl的量添加上述获得的杂交瘤的各培养上清液,并在室温静置2小时。用PBS-T洗涤各孔3次后,以每孔100μl的量添加用PBS稀释5000倍的HRP标记抗小鼠IgG(H+L)抗体(インビトロジェン公司制),并且在室温静置1小时。用PBS-T洗涤孔3次后,以每孔100μl的量添加TMB底物溶液(Thermo公司制),并且静置15-30分钟,进行显色反应。在颜色显现后,以每孔100μl的量添加1N硫酸以终止该反应,使用吸光度计测定450nm和595nm的吸光度值。作为其结果,获得了产生与CAPRIN-1蛋白显示反应性的单克隆抗体的150个杂交瘤株。
接下来,在这些单克隆抗体当中选出与表达CAPRIN-1的乳癌细胞的表面显示反应性的单克隆抗体。具体地,在1.5ml容量的微量离心管中离心分离106个人乳癌细胞株MDA-MB-231V,向其中添加上述各杂交瘤的培养上清液100μl,在冰上静置1小时。在用PBS洗涤后,添加用含有0.1%FBS的PBS稀释500倍的FITC标记山羊抗小鼠IgG抗体(インビトロジェン公司制),并在冰上静置1小时。在用PBS洗涤后,使用ベクトンディッキンソン株式会社的FACSCaliber测定荧光强度。另一方面,使用将没有任何处理的6周龄的Balb/c小鼠的血清用杂交瘤培养用培养基稀释了500倍的物质代替抗体,进行与上述同样的操作,制备对照的样品。作为其结果,选出了11个(#1-#11)与对照相比荧光强度强、即与乳癌细胞的细胞表面反应的单克隆抗体。
实施例4选出的抗体所具有的特征
(1)抗CAPRIN-1单克隆抗体的可变区基因的克隆
从分别产生实施例3中选出的11个小鼠单克隆抗体的各杂交瘤株中提取mRNA,通过使用了对于源于小鼠FR1的序列和源于小鼠FR4的序列为特异性的引物的RT-PCR法,获得全部的抗CAPRIN-1单克隆抗体的重链可变(VH)区和轻链可变(VL)区的基因。为了确定序列,将这些基因克隆到pCR2.1载体(Invitrogen公司制)中。另外,从源于产生与表达CAPRIN-1的乳癌细胞的细胞表面反应的单克隆抗体的小鼠的杂交瘤株2株中提取mRNA,通过使用了对于源于小鼠FR1的序列和源于小鼠FR4的序列为特异性的引物的RT-PCR法,获得各抗体的重链可变(VH)区和轻链可变(VL)区的基因。为了确定序列,将这些基因克隆到pCR2.1载体(Invitrogen公司制)中。
(1)-1RT-PCR
使用High Pure RNA Isolation Kit(Roche公司制)从106个的各杂交瘤株提取总RNA后,使用PrimeScriptII 1st strand cDNA Synthesis Kit(Takara公司制)合成cDNA。这些操作按照各试剂盒所附带的说明书来进行。
以合成的cDNA作为模板,使用KOD-Plus-DNA聚合酶(TOYOBO公司制),按照常规方法利用PCR法扩增小鼠抗体重链基因可变区和小鼠抗体轻链基因可变区。
为了获取小鼠抗体的VH区和VL区的基因,使用了对小鼠重链FR1序列为特异性的引物(序列编号130)、对小鼠重链FR4序列为特异性的引物(序列编号131)、对小鼠轻链FR1序列为特异性的引物(序列编号132)、和对小鼠轻链FR4序列为特异性的引物(序列编号133)。
使用上述得到的各PCR产物,利用琼脂糖凝胶进行电泳,切出VH区和VL区各自的DNA带。DNA片段使用QIAquick Gel purification kit(QIAGEN公司制)并按照附带的说明书来进行。纯化的各DNA使用TA克隆试剂盒(Invitrogen公司制)克隆到pCR2.1载体中。将连结的载体利用常规方法转化到DH5感受态细胞(TOYOBO公司制)中。将各个转化体的各10个克隆在培养基(100μg/ml氨苄青霉素)中、在37℃培养过夜后,将各质粒DNA使用QiaspinMiniprep kit(QIAGEN公司制)进行纯化。
(1)-2序列确定
上述得到的各质粒中的VH区和VL区的基因序列分析,使用M13正向引物(序列编号134)和M13反向引物(序列编号135),利用荧光测序仪(ABI公司制DNA测序仪3130XL),并使用ABI公司制的BigDye Terminat or Ver3.1循环测序试剂盒,按照其附带的说明书来进行。其结果可以确定各基因序列(在10个克隆中分别一致)。
得到的单克隆抗体的重链可变区的基因序列分别列示于序列编号48、序列编号78、序列编号88、序列编号98、序列编号108、序列编号118和序列编号128,其氨基酸序分别列示于序列编号43、序列编号73、序列编号83、序列编号93、序列编号103、序列编号113、和序列编号123,轻链可变区的基因序列分别列示于序列编号49、序列编号54、序列编号59、序列编号64、序列编号69、序列编号79、序列编号89、序列编号99、序列编号109、序列编号119和序列编号129,以其氨基酸序列分别示于序列编号47、序列编号53、序列编号58、序列编号63、序列编号68、序列编号77、序列编号87、序列编号97、序列编号107,序列编号117和序列编号127。
即,可以确认,单克隆抗体#1包含序列编号43的重链可变区和序列编号47的轻链可变区,#2包含序列编号43的重链可变区和序列编号53的轻链可变区,#3包含序列编号43的重链可变区和序列编号58的轻链可变区,#4包含序列编号43的重链可变区和序列编号63的轻链可变区,#5包含序列编号43的重链可变区和序列编号68的轻链可变区,#6包含序列编号73的重链可变区和序列编号77的轻链可变区,#7包含序列编号83的重链可变区和序列编号87的轻链可变区,#8包含序列编号93的重链可变区和序列编号97的轻链可变区,#9包含序列编号103的重链可变区和序列编号107的轻链可变区,#10包含序列编号113的重链可变区和序列编号117的轻链可变区,#11包含序列编号123的重链可变区和序列编号127的轻链可变区。
(2)使用了抗CAPRIN-1抗体#2和#9的各种癌细胞表面的CAPRIN-1的表达
接着对于确认表达CAPRIN-1基因的乳癌细胞株7种(MDA-MB-157,T47D,MRK-nu-1,MDA-MB-231V,BT20,SK-BR-3,MDA-MB-231T)和其它乳癌细胞株3种(MDA-MB-231C,MCF-7,ZR75-1)、神经胶质瘤细胞株5种(T98G,SNB19,U251,U87MG,U373)、肾癌细胞株4种(Caki-1,Caki-2,A498,ACHN)、胃癌细胞株2种(MNK28,MKN45)、大肠癌细胞株5种(HT29,LoVo,Caco2,SW480,HCT116)、肺癌细胞株3种(A549、QG56、PC8)、白血病细胞株4种(AML5,Namalwa、BDCM、RPI1788)、淋巴瘤细胞株1种(Ramos)、宫颈癌细胞株1种(SW756)、膀胱癌细胞株1种(T24)、和食道癌细胞株1种(KYSE180),使用产生实施例3所得的含有#2和#9的杂交瘤的培养上清液,研究在各细胞的细胞表面上的CAPRIN-1蛋白质的表达。在1.5ml容量的微量离心管中离心分离各细胞株分别106细胞。向其中添加产生实施例3所得的含有#2和#9的杂交瘤的培养上清液(100μl),在冰上静置1小时。在用PBS洗涤后,添加用含有0.1%FBS的PBS稀释500倍的FITC标记山羊抗人IgG(H+L)抗体(SouthernBiotech公司制)和FITC标记抗小鼠IgG(H+L)抗体(Invitrogen公司制),并在冰上静置1小时。在用PBS洗涤后,使用ベクトンディッキンソン株式会社的FACSCalibur测定荧光强度。另一方面,使用杂交瘤培养用的培养基进行与上述同样的操作,制备阴性对照。作为其结果,添加了#1和#2的抗体的细胞与对照相比,荧光强度均增强20%以上。由此可以确认,CAPRIN-1蛋白质在上述人癌细胞株的细胞膜表面上表达。并且,上述荧光强度的增强率利用各细胞的平均荧光强度(MFI值)的增加率表示,通过以下算式来算出。
平均荧光强度的增加率(荧光强度的增强率)(%)=((与抗人CAPRIN-1抗体反应的细胞的MFI值)-(对照MFI值))÷(对照MFI值)×100。
(3)针对CAPRIN-1的抗体对癌细胞的抗肿瘤效果(ADCC活性)
评价上述选出的#1-#11的针对CAPRIN-1的抗体的对癌细胞的细胞毒活性。使用杂交瘤SFM(インビトロジェン公司制)培养基培养产生#1-#11的单克隆抗体的各杂交瘤,将得到的上清液用Hitrap ProteinA SepharoseFF(GEヘルスケア社制)纯化,置换为PBS(-),将用0.22μm的过滤器(ミリポア社制)过滤而得的产物用作活性测定用的抗体。将106个人乳癌细胞株MDA-MB-157收集到50ml容量的离心管中,加入100μCi的铬(Cr)51,在37℃孵育2小时。然后用含有10%FBS的RPMI1640培养基洗涤3次,向96孔V底板中每孔添加各103个,作为靶细胞。向其中分别添加上述纯化抗体1μg,进一步地添加2×105个从小鼠脾脏分离的小鼠淋巴细胞,在37℃、5%CO2的条件下培养4小时。培养后,测定从受到损伤的肿瘤细胞中释放的培养上清液中的铬(Cr)51的量,算出抗CAPRIN-1抗体对癌细胞的ADCC活性。作为其结果,#1-#11的所有单克隆抗体对MDA-MB-157显示20%以上的ADCC活性。具体地,例如#1可以得到22.1%的细胞毒活性,#2可以得到29.1%的细胞毒活性,#6可以得到30.2%的细胞毒活性,#9可以得到32.4%的细胞毒活性(参照图1)。另一方面,使用实施例2中制作的与CAPRIN-1蛋白质本身反应、但不与癌细胞的细胞表面反应的单克隆抗体进行同样的操作时,没有细胞毒活性(参照图1)。由以上结果,表明获得的抗CAPRIN-1单克隆抗体(#1-#11)通过ADCC活性损害表达CAPRIN-1的癌细胞。同样地,算出针对作为其它人癌细胞的、神经胶质瘤细胞株T98G、U373、肺癌细胞株A549、QG56、肾癌细胞株Caki-1、ACHN、宫颈癌细胞株SW756、膀胱癌细胞株T24、食道癌细胞株KYSE180、胃癌细胞株MKN28、MKN45、大肠癌细胞株SW480、白血病细胞株AML5和淋巴瘤细胞株Ramos的抗CAPRIN-1抗体产生的对癌细胞的ADCC活性。结果#1-#11的所有单克隆抗体与同种型对照相比,显示高的ADCC活性。具体地,例如抗体#9的活性显示对T98G为12%以上(同种型对照为1.3%)、对U373为16%以上(同种型对照为3%)、对A549为24%以上(同种型对照为2.6%)、对QG56为20%以上(同种型对照为0.2%)、对Caki-1为23%以上(同种型对照为3.0%)、对ACHN为14%以上(同种型对照为1.5%)、对SW756为16%以上(同种型对照为2.5%)、对T24为18%以上(同种型对照为2.1%)、对KYSE180为22%以上(同种型对照为3.0%)的活性,显示对MNK28为15%以上(同种型对照为1.7%)、对MNK45为10%以上(同种型对照为2.3%)、对SW480为17%以上(同种型对照为1.3%)、对AML5为10%以上(同种型对照为3.0%)、对Ramos为10%以上(同种型对照为4.1%)的活性。由以上的结果表明,获得的抗CAPRIN-1抗体(#1-#11)损伤了表达CAPRIN-1的各种人癌细胞。
(4)针对CAPRIN-1的抗体对癌细胞的抗肿瘤效果(CDC活性)
评价上述选出的#1-#11的针对CAPRIN-1的抗体对癌细胞的细胞毒活性(CDC活性)。将从兔采集的血液放入Eppendorf管中,在室温静置60分钟后,以3000转/分钟离心分离5分钟,由此制备CDC活性测定用的血清。将105个作为人乳癌细胞的MDA-MB-231V收集到50ml容量的离心管中,加入100μCi的铬51,在37℃孵育2小时后,用含有10%FBS的RPMI培养基洗涤3次。然后用含有50%上述制备的兔血清的RPMI培养基悬浮,向96孔V底板中每孔添加各103个。向其中分别添加实施例3中得到的#1-#13的单克隆抗体各1μg,在37℃、5%CO2的条件下培养4小时。培养后,测定从受到损伤的肿瘤细胞中释放的培养上清液中的铬51的量,算出杂交瘤上清液中的抗CAPRIN-1单克隆抗体对MDA-MB-231V的CDC活性。作为其结果,#1-#11的所有单克隆抗体均显示30%以上的CDC活性。另一方面,使用实施例2中制作的、与CAPRIN-1蛋白质自身反应、但不与癌细胞的细胞表面反应的单克隆抗体进行同样的操作时,没有细胞毒活性。因此,可以明确针对CAPRIN-1的单克隆抗体(#1-#11)通过CDC活性,也可以损伤表达CAPRIN-1的肿瘤细胞。
实施例5与癌细胞的细胞表面反应的针对CAPRIN-1的抗体所结合的CAPRIN-1蛋白质中的肽的鉴定
使用上述获得的、与癌细胞的细胞表面反应的#1-#11的针对CAPRIN-1的单克隆抗体,进行它们识别的CAPRIN-1蛋白质中的部分序列的鉴定。
首先,向用PBS以1μg/μl的浓度溶解了重组CAPRIN-1蛋白质溶液100μl中添加DTT(Fluka公司制),以使终浓度为10mM,在95℃反应5分钟,进行CAPRIN-1蛋白质内的二硫键的还原,接着添加终浓度为20mM的碘乙酰胺(和光纯药公司制),在37℃、避光条件下进行30分钟的硫醇基的烷基化反应。在得到的还原烷基化CAPRIN-1蛋白质40μg中分别添加50μg#1-#11的针对CAPRIN-1的单克隆抗体,定容至20mM磷酸缓冲液(pH7.0)1ml,一边搅拌混合一边在4℃反应一夜。
接着,添加胰蛋白酶(プロメガ公司制),以使终浓度为0.2μg,在37℃反应1小时、2小时、4小时、12小时后,用预先含有1%BSA(Sigma公司制)的PBS封闭,在用PBS洗涤了的蛋白质A-玻璃珠(GE公司制)和1mM碳酸钙、NP-40缓冲液(20mM磷酸缓冲液(pH7.4)、5mMEDTA、150mM NaCl、1%NP-40)中混合,分别反应30分钟。
将反应液用25mM碳酸铵缓冲液(pH8.0)洗涤后,使用0.1%甲酸100μl溶出抗原抗体复合物,对于溶出液,使用Q-TOF Premier(Waters-MicroMass公司制)进行LC-MS分析。分析按照仪器附带的说明书进行。
作为其结果,作为#1-#11的针对CAPRIN-1的单克隆抗体都识别的CAPRIN-1的部分序列,鉴定为序列编号37的多肽。
实施例6抗肿瘤剂对癌细胞表面上的CAPRIN-1表达的影响
(1)抗肿瘤剂对癌细胞的50%抑制浓度的计算
为了评价抗肿瘤剂对癌细胞表面上的CAPRIN-1表达的影响,使用癌细胞(MCF-7)计算抗肿瘤剂的50%抑制浓度。对于人乳癌细胞株MCF-7,研究了作为现有乳癌治疗药使用的抗肿瘤剂4种(环磷酰胺:“エンドキサン”(注册商标、塩野義製薬株式会公司制)、紫杉醇:“タキソール”(注册商标、ブリストル·マイヤーズ公司制)、多西紫杉醇:“タキソテール”(注册商标、サノファ·アバンティス公司制)、长春瑞滨:“ナベルビン”(注册商标、協和発酵キリン株式会公司制)的50%抑制浓度。制备细胞,以使浓度为1×105cells/ml,利用6孔板在37℃、5%CO2条件下培养1天。接着,将各抗肿瘤剂以最终浓度0.001μM,0.01μM,0.1μM,1.0μM,10μM分别进行处理,在37℃、5%CO2条件下进行2天培养。除去培养液后,用PBS(-)进行2次洗涤,添加0.25%Trypsin-EDTA并剥离细胞,用PBS(-)调制成100μl后,加入0.4%台盼蓝储备溶液10μl并混合,使用血球计测定活细胞数。将各抗肿瘤剂未处理的活细胞数设为100%时的各化学疗法剂处理时的活细胞的比例,由本研究的结果,来估算50%抑制浓度,进一步地,制备该浓度附近的抗肿瘤剂,进行与上述同样的操作,由此计算具体的50%抑制浓度。
作为一例,记载使用了抗肿瘤剂环磷酰胺的研究内容。制备MCF-7,使其浓度为1×105cells/mL,在6孔板中在37℃、5%CO2条件下培养1天。接着,将环磷酰胺分别以最终浓度为1×10-1μM,5×10-2μM,2×10-2μM,1×10-2μM处理,在37℃、5%CO2条件下进行2天的培养。除去培养液后,用PBS(-)洗涤2次,添加0.25%Trypsin-EDTA,剥离细胞,用PBS(-)制成100μl,添加0.4%台盼蓝储备溶液10μl并混合,使用血球计测定活细胞数。由本研究的结果,50%抑制浓度为3×10-2μM。通过同样的操作,以下算出各癌细胞的各抗肿瘤剂的IC50(表1)。
【表1】
各抗肿瘤剂对于MCF-7的50%抑制浓度
环磷酰胺(μM) 3×10<sup>-2</sup>
紫杉醇(μM) 1×10<sup>-2</sup>
多西紫杉醇(μM) 1×10<sup>-4</sup>
长春瑞滨(μM) 2×10<sup>-2</sup>
(2)使抗肿瘤剂作用于癌细胞时的对CAPRIN-1表达的影响
对癌细胞株(MCF-7)用(1)中算出的50%抑制浓度的各抗肿瘤剂进行处理,对于其细胞表面上的CAPRIN-1蛋白质的表达行为进行研究。
对人乳癌细胞株MCF-7进行处理,对于其细胞表面上的CAPRIN-1蛋白质的表达行为进行研究。制备细胞,以使浓度为1×105cells/ml,利用6孔板在37℃、5%CO2条件下培养1天。接着分别用(1)中算出的50%抑制浓度的抗肿瘤剂和作为对照的PBS(-)进行处理,在37℃、5%CO2条件下培养2天。除去培养液后,用PBS(-)进行2次洗涤,使用细胞刮板剥离细胞。接着,将这些细胞在1.5ml的微量离心管中进行离心分离。向其中添加小鼠抗CAPRIN-1单克隆抗体#91μg(5μl),进而将95μl含有0.1%胎牛血清的PBS悬浮后,在冰上静置1小时。用PBS洗涤后,用含有5μl FITC标记山羊抗兔IgG抗体(サンタクルズ公司制)和95μl的0.1%胎牛血清(FBS)的PBS悬浮,在冰上静置1小时。用PBS洗涤后,利用ベクトンディッキンソン株式会社的FACSCaliber测定荧光强度。另一方面,使用对照抗体代替小鼠抗CAPRIN-1单克隆抗体进行与上述同样的操作,制备对照的样品。作为其结果,尽管进行了抗肿瘤剂处理,但荧光强度上并没有不同。即,在没有用抗肿瘤剂处理的MCF-7中添加抗CAPRIN-1抗体时得到的荧光强度与添加对照抗体时相比,显示增加32%。另一方面,使用用抗肿瘤剂处理的MCF-7进行同样的研究,结果显示与没有用抗肿瘤剂处理时完全相同的32%荧光强度的增强。由此判断,即使对乳癌细胞用抗肿瘤剂处理,对乳癌细胞上的CAPRIN-1的表达也没有任何影响。并且,上述荧光强度的增强率利用各细胞的平均荧光强度(MFI值)的增加率表示,由以下的计算式算出。
平均荧光强度的增加率(荧光强度的增强率)(%)=((与抗人CAPRIN-1抗体反应的细胞的MFI值)-(对照MFI值))÷(对照MFI值)×100。
实施例7in vivo的抗CAPRIN-1抗体与抗肿瘤剂的并用疗法(1)使用移植了表达CAPRIN-1的人乳癌细胞株MCF-7的荷癌小鼠,研究抗CAPRIN-1单克隆抗体与抗肿瘤剂并用所产生的抗肿瘤效果。以下记载了使用了移植MCF-7的荷癌小鼠的抗肿瘤效果的研究方法、结果。在280只裸鼠(日本SLC公司制)的背部皮下每只移植了106个MCF-7(由ATCC购入),使其生长,直至肿瘤形成直径为7mm左右的大小。
接着,按照以下的实验区1和实验区2中详述的那样,将移植了MCF-7的荷癌小鼠分成仅施与抗CAPRIN-1抗体的组、仅施与抗肿瘤剂(4种)的组、一并施与抗肿瘤剂和抗Her2抗体(小鼠抗人ErbB2单克隆抗体、同型品(アイソタイプ):IgG2b(R&D systems公司制、产品编号:MAB11291))的组、一并施与抗肿瘤剂和针对CAPRIN-1的单克隆抗体的组、最后施与对照(PBS(-))的组这5个组,进而在全部施与组中施与小鼠PBMC。
<实验区1>
(仅施与抗CAPRIN-1抗体的组)
对于5只荷癌小鼠,每只分别从试验开始第0,4,8,11,15,17天腹腔内施与#2的针对CAPRIN-1的单克隆抗体5mg/kg/shot,每只分别从试验开始第0,8,15天静脉内施与从Balb/c小鼠脾脏分离的PBMC1×107个细胞/0.2mL(RPMI1640)。
(环磷酰胺施与组)
对于5只荷癌小鼠,每只分别从试验开始第0,4天腹腔内施与环磷酰胺80mg/kg/shot,每只分别从试验开始第0,8,15天静脉内施与从Balb/c小鼠脾脏分离的PBMC 1×107个细胞/0.2mL(RPMI1640)。
(紫杉醇施与组)
对于5只荷癌小鼠,每只分别从试验开始第0,3天腹腔内施与紫杉醇15mg/kg/shot,每只分别从试验开始第0,8,15天静脉内施与从Balb/c小鼠脾脏分离的PBMC1×107个细胞/0.2mL(RPMI1640)。
(多西紫杉醇施与组)
对于5只荷癌小鼠,每只分别从试验开始第0,3天腹腔内施与多西紫杉醇10mg/kg/shot,每只分别从试验开始第0,8,15天静脉内施与从Balb/c小鼠脾脏分离的PBMC1×107个细胞/0.2mL(RPMI1640)。
(长春瑞滨施与组)
对于5只荷癌小鼠,每只分别从试验开始第0天腹腔内施与长春瑞滨1mg/kg/shot,每只分别从试验开始第0,8,15天静脉内施与从Balb/c小鼠脾脏分离的PBMC1×107个细胞/0.2mL(RPMI1640)。
(环磷酰胺和抗Her2抗体的施与组)
对于5只荷癌小鼠,每只分别从试验开始第0,4天腹腔内施与环磷酰胺80mg/kg/shot,同时,从试验开始第0、4,8,11,15,17天腹腔内施与抗Her2抗体5mg/kg/shot,每只分别从试验开始第0,8,15天静脉内施与从Balb/c小鼠脾脏分离的PBMC1×107个细胞/0.2mL(RPMI1640)。
(紫杉醇和抗Her2抗体的施与组)
对于5只荷癌小鼠,每只分别从试验开始第0,3天腹腔内施与紫杉醇15mg/kg/shot,同时,从试验开始第0、4,8,11,15,17天腹腔内施与抗Her2抗体5mg/kg/shot,每只分别从试验开始第0,8,15天静脉内施与从Balb/c小鼠脾脏分离的PBMC1×107个细胞/0.2mL(RPMI1640)。
(多西紫杉醇和抗Her2抗体的施与组)
对于5只荷癌小鼠,每只分别从试验开始第0,3天腹腔内施与多西紫杉醇10mg/kg/shot,同时,从试验开始第0、4,8,11,15,17天腹腔内施与抗Her2抗体5mg/kg/shot,每只分别从试验开始第0,8,15天静脉内施与从Balb/c小鼠脾脏分离的PBMC1×107个细胞/0.2mL(RPMI1640)。
(长春瑞滨和抗Her2的施与组)
对于5只荷癌小鼠,每只分别从试验开始第0天腹腔内施与长春瑞滨1mg/kg/shot,同时,从试验开始第0、4,8,11,15,17天腹腔内施与抗Her2抗体5mg/kg/shot,每只分别从试验开始第0,8,15天静脉内施与从Balb/c小鼠脾脏分离的PBMC1×107个细胞/0.2mL(RPMI1640)。
(环磷酰胺和抗CAPRIN-1抗体的施与组)
对于5只荷癌小鼠,每只分别从试验开始第0,4天腹腔内施与环磷酰胺80mg/kg/shot,同时,从试验开始第0、4,8,11,15,17天腹腔内施与#2的针对CAPRIN-1的单克隆抗体5mg/kg/shot,每只分别从试验开始第0,8,15天静脉内施与从Balb/c小鼠脾脏分离的PBMC1×107个细胞/0.2mL(RPMI1640)。
(紫杉醇和抗CAPRIN-1抗体的施与组)
对于5只荷癌小鼠,每只分别从试验开始第0,3天腹腔内施与紫杉醇15mg/kg/shot,同时,从试验开始第0、4,8,11,15,17天腹腔内施与#2的针对CAPRIN-1的单克隆抗体5mg/kg/shot,每只分别从试验开始第0,8,15天静脉内施与从Balb/c小鼠脾脏分离的PBMC1×107个细胞/0.2mL(RPMI1640)。
(多西紫杉醇和抗CAPRIN-1抗体的施与组)
对于5只荷癌小鼠,每只分别从试验开始第0,3天腹腔内施与多西紫杉醇10mg/kg/shot,同时,从试验开始第0、4,8,11,15,17天腹腔内施与#2的针对CAPRIN-1的单克隆抗体5mg/kg/shot,每只分别从试验开始第0,8,15天静脉内施与从Balb/c小鼠脾脏分离的PBMC1×107个细胞/0.2mL(RPMI1640)。
(长春瑞滨和抗CAPRIN-1抗体的施与组)
对于施与了长春瑞滨和抗CAPRIN-1抗体的5只荷癌小鼠,每只分别从试验开始第0天腹腔内施与长春瑞滨1mg/kg/shot,同时,从试验开始第0、4,8,11,15,17天腹腔内施与#2的针对CAPRIN-1的单克隆抗体5mg/kg/shot,每只分别从试验开始第0,8,15天静脉内施与从Balb/c小鼠脾脏分离的PBMC1×107个细胞/0.2mL(RPMI1640)。
<实验区2>
对于仅施与抗CAPRIN-1抗体的组、施与环磷酰胺和抗CAPRIN-1抗体的组、施与紫杉醇和抗CAPRIN-1抗体的组、施与多西紫杉醇和抗CAPRIN-1抗体的组以及施与长春瑞滨和抗CAPRIN-1抗体的组,除了施与#9的针对CAPRIN-1的单克隆抗体作为抗CAPRIN-1抗体以外,其他与实验区1同样地设定。
对于环磷酰胺施与组、紫杉醇施与组、多西紫杉醇施与组、长春瑞滨施与组、环磷酰胺和抗Her2抗体的施与组、紫杉醇和抗Her2抗体的施与组、多西紫杉醇和抗Her2抗体的施与组以及长春瑞滨和抗Her2抗体的施与组,与实验区1同样地设定。
对于上述各实验区的各施与组,测量每天肿瘤的大小,观察抗肿瘤效果。并且,对于5只荷癌小鼠,施与PBS(-)代替抗体来作为对照组。并且,肿瘤的大小使用长径×短径×短径×0.5的算式,算出体积。
作为抗肿瘤效果的观察结果,在实验区1中,将施与了PBS(-)的对照组的从试验开始第26天的肿瘤体积设为100%时,在各抗肿瘤剂施与组中萎缩至约79%左右,在仅施与了抗CAPRIN-1抗体的组中,萎缩至约56%左右,在各抗肿瘤剂和抗Her2抗体的施与组中,萎缩至约74%。另一方面,在各抗肿瘤剂和抗CAPRIN-1抗体的施与组中,在第14天肿瘤萎缩至数10%,在第22天以后肿瘤几乎完全萎缩。(参考图3-6)
另外,实验区2中,将施与了PBS(-)的对照组的从试验开始第26天的肿瘤体积设为100%时,在各抗肿瘤剂施与组中萎缩至约68%左右、在仅施与了抗CAPRIN-1抗体的组中萎缩至约45%左右、在各抗肿瘤剂和抗Her2抗体的施与组中萎缩至约55%。另一方面,在各抗肿瘤剂和抗CAPRIN-1抗体的施与组中,在第14天肿瘤萎缩至数10%,在第22天以后肿瘤几乎完全萎缩。(参考图7-图10)
产业可利用性
本发明可用于癌的治疗和/或预防。
将本说明书中引用的所有刊物、专利和专利申请直接作为参考引入本说明书中。
序列表自由文本
序列编号31:T3引物
序列编号32:T7引物
序列编号33、34:引物
序列编号35、36:GAPDH引物
序列编号38、39:引物
序列编号130-135:引物
序列表
<110> 东丽株式会社
<120> 用于癌的治疗和/或预防的药物
<130> PH-4658-PCT
<150> JP 2010-023455
<151> 2010-02-04
<160> 135
<170> PatentIn版本3.1
<210> 1
<211> 5562
<212> DNA
<213> 人(Homo sapiens)
<220>
<221> CDS
<222> (190)..(2319)
<223>
<400> 1
cagagggctg ctggctggct aagtccctcc cgctcccggc tctcgcctca ctaggagcgg 60
ctctcggtgc agcgggacag ggcgaagcgg cctgcgccca cggagcgcgc gacactgccc 120
ggaagggacc gccacccttg ccccctcagc tgcccactcg tgatttccag cggcctccgc 180
gcgcgcacg atg ccc tcg gcc acc agc cac agc ggg agc ggc agc aag tcg 231
Met Pro Ser Ala Thr Ser His Ser Gly Ser Gly Ser Lys Ser
1 5 10
tcc gga ccg cca ccg ccg tcg ggt tcc tcc ggg agt gag gcg gcc gcg 279
Ser Gly Pro Pro Pro Pro Ser Gly Ser Ser Gly Ser Glu Ala Ala Ala
15 20 25 30
gga gcc ggg gcc gcc gcg ccg gct tct cag cac ccc gca acc ggc acc 327
Gly Ala Gly Ala Ala Ala Pro Ala Ser Gln His Pro Ala Thr Gly Thr
35 40 45
ggc gct gtc cag acc gag gcc atg aag cag att ctc ggg gtg atc gac 375
Gly Ala Val Gln Thr Glu Ala Met Lys Gln Ile Leu Gly Val Ile Asp
50 55 60
aag aaa ctt cgg aac ctg gag aag aaa aag ggt aag ctt gat gat tac 423
Lys Lys Leu Arg Asn Leu Glu Lys Lys Lys Gly Lys Leu Asp Asp Tyr
65 70 75
cag gaa cga atg aac aaa ggg gaa agg ctt aat caa gat cag ctg gat 471
Gln Glu Arg Met Asn Lys Gly Glu Arg Leu Asn Gln Asp Gln Leu Asp
80 85 90
gcc gtt tct aag tac cag gaa gtc aca aat aat ttg gag ttt gca aaa 519
Ala Val Ser Lys Tyr Gln Glu Val Thr Asn Asn Leu Glu Phe Ala Lys
95 100 105 110
gaa tta cag agg agt ttc atg gca cta agt caa gat att cag aaa aca 567
Glu Leu Gln Arg Ser Phe Met Ala Leu Ser Gln Asp Ile Gln Lys Thr
115 120 125
ata aag aag aca gca cgt cgg gag cag ctt atg aga gaa gaa gct gaa 615
Ile Lys Lys Thr Ala Arg Arg Glu Gln Leu Met Arg Glu Glu Ala Glu
130 135 140
cag aaa cgt tta aaa act gta ctt gag cta cag tat gtt ttg gac aaa 663
Gln Lys Arg Leu Lys Thr Val Leu Glu Leu Gln Tyr Val Leu Asp Lys
145 150 155
ttg gga gat gat gaa gtg cgg act gac ctg aaa caa ggt ttg aat gga 711
Leu Gly Asp Asp Glu Val Arg Thr Asp Leu Lys Gln Gly Leu Asn Gly
160 165 170
gtg cca ata ttg tcc gaa gag gag ttg tca ttg ttg gat gaa ttc tat 759
Val Pro Ile Leu Ser Glu Glu Glu Leu Ser Leu Leu Asp Glu Phe Tyr
175 180 185 190
aag cta gta gac cct gaa cgg gac atg agc ttg agg ttg aat gaa cag 807
Lys Leu Val Asp Pro Glu Arg Asp Met Ser Leu Arg Leu Asn Glu Gln
195 200 205
tat gaa cat gcc tcc att cac ctg tgg gac ctg ctg gaa ggg aag gaa 855
Tyr Glu His Ala Ser Ile His Leu Trp Asp Leu Leu Glu Gly Lys Glu
210 215 220
aaa cct gta tgt gga acc acc tat aaa gtt cta aag gaa att gtt gag 903
Lys Pro Val Cys Gly Thr Thr Tyr Lys Val Leu Lys Glu Ile Val Glu
225 230 235
cgt gtt ttt cag tca aac tac ttt gac agc acc cac aac cac cag aat 951
Arg Val Phe Gln Ser Asn Tyr Phe Asp Ser Thr His Asn His Gln Asn
240 245 250
ggg ctg tgt gag gaa gaa gag gca gcc tca gca cct gca gtt gaa gac 999
Gly Leu Cys Glu Glu Glu Glu Ala Ala Ser Ala Pro Ala Val Glu Asp
255 260 265 270
cag gta cct gaa gct gaa cct gag cca gca gaa gag tac act gag caa 1047
Gln Val Pro Glu Ala Glu Pro Glu Pro Ala Glu Glu Tyr Thr Glu Gln
275 280 285
agt gaa gtt gaa tca aca gag tat gta aat aga cag ttc atg gca gaa 1095
Ser Glu Val Glu Ser Thr Glu Tyr Val Asn Arg Gln Phe Met Ala Glu
290 295 300
aca cag ttc acc agt ggt gaa aag gag cag gta gat gag tgg aca gtt 1143
Thr Gln Phe Thr Ser Gly Glu Lys Glu Gln Val Asp Glu Trp Thr Val
305 310 315
gaa acg gtt gag gtg gta aat tca ctc cag cag caa cct cag gct gca 1191
Glu Thr Val Glu Val Val Asn Ser Leu Gln Gln Gln Pro Gln Ala Ala
320 325 330
tcc cct tca gta cca gag ccc cac tct ttg act cca gtg gct cag gca 1239
Ser Pro Ser Val Pro Glu Pro His Ser Leu Thr Pro Val Ala Gln Ala
335 340 345 350
gat ccc ctt gtg aga aga cag cga gta caa gac ctt atg gca caa atg 1287
Asp Pro Leu Val Arg Arg Gln Arg Val Gln Asp Leu Met Ala Gln Met
355 360 365
cag ggt ccc tat aat ttc ata cag gat tca atg ctg gat ttt gaa aat 1335
Gln Gly Pro Tyr Asn Phe Ile Gln Asp Ser Met Leu Asp Phe Glu Asn
370 375 380
cag aca ctt gat cct gcc att gta tct gca cag cct atg aat cca aca 1383
Gln Thr Leu Asp Pro Ala Ile Val Ser Ala Gln Pro Met Asn Pro Thr
385 390 395
caa aac atg gac atg ccc cag ctg gtt tgc cct cca gtt cat tct gaa 1431
Gln Asn Met Asp Met Pro Gln Leu Val Cys Pro Pro Val His Ser Glu
400 405 410
tct aga ctt gct cag cct aat caa gtt cct gta caa cca gaa gcg aca 1479
Ser Arg Leu Ala Gln Pro Asn Gln Val Pro Val Gln Pro Glu Ala Thr
415 420 425 430
cag gtt cct ttg gta tca tcc aca agt gag ggg tac aca gca tct caa 1527
Gln Val Pro Leu Val Ser Ser Thr Ser Glu Gly Tyr Thr Ala Ser Gln
435 440 445
ccc ttg tac cag cct tct cat gct aca gag caa cga cca cag aag gaa 1575
Pro Leu Tyr Gln Pro Ser His Ala Thr Glu Gln Arg Pro Gln Lys Glu
450 455 460
cca att gat cag att cag gca aca atc tct tta aat aca gac cag act 1623
Pro Ile Asp Gln Ile Gln Ala Thr Ile Ser Leu Asn Thr Asp Gln Thr
465 470 475
aca gca tca tca tcc ctt cct gct gcg tct cag cct caa gta ttt cag 1671
Thr Ala Ser Ser Ser Leu Pro Ala Ala Ser Gln Pro Gln Val Phe Gln
480 485 490
gct ggg aca agc aaa cct tta cat agc agt gga atc aat gta aat gca 1719
Ala Gly Thr Ser Lys Pro Leu His Ser Ser Gly Ile Asn Val Asn Ala
495 500 505 510
gct cca ttc caa tcc atg caa acg gtg ttc aat atg aat gcc cca gtt 1767
Ala Pro Phe Gln Ser Met Gln Thr Val Phe Asn Met Asn Ala Pro Val
515 520 525
cct cct gtt aat gaa cca gaa act tta aaa cag caa aat cag tac cag 1815
Pro Pro Val Asn Glu Pro Glu Thr Leu Lys Gln Gln Asn Gln Tyr Gln
530 535 540
gcc agt tat aac cag agc ttt tct agt cag cct cac caa gta gaa caa 1863
Ala Ser Tyr Asn Gln Ser Phe Ser Ser Gln Pro His Gln Val Glu Gln
545 550 555
aca gag ctt cag caa gaa cag ctt caa aca gtg gtt ggc act tac cat 1911
Thr Glu Leu Gln Gln Glu Gln Leu Gln Thr Val Val Gly Thr Tyr His
560 565 570
ggt tcc cca gac cag tcc cat caa gtg act ggt aac cac cag cag cct 1959
Gly Ser Pro Asp Gln Ser His Gln Val Thr Gly Asn His Gln Gln Pro
575 580 585 590
cct cag cag aac act gga ttt cca cgt agc aat cag ccc tat tac aat 2007
Pro Gln Gln Asn Thr Gly Phe Pro Arg Ser Asn Gln Pro Tyr Tyr Asn
595 600 605
agt cgt ggt gtg tct cgt gga ggc tcc cgt ggt gct aga ggc ttg atg 2055
Ser Arg Gly Val Ser Arg Gly Gly Ser Arg Gly Ala Arg Gly Leu Met
610 615 620
aat gga tac cgg ggc cct gcc aat gga ttc aga gga gga tat gat ggt 2103
Asn Gly Tyr Arg Gly Pro Ala Asn Gly Phe Arg Gly Gly Tyr Asp Gly
625 630 635
tac cgc cct tca ttc tct aac act cca aac agt ggt tat aca cag tct 2151
Tyr Arg Pro Ser Phe Ser Asn Thr Pro Asn Ser Gly Tyr Thr Gln Ser
640 645 650
cag ttc agt gct ccc cgg gat tac tct ggc tat caa cgg gat gga tat 2199
Gln Phe Ser Ala Pro Arg Asp Tyr Ser Gly Tyr Gln Arg Asp Gly Tyr
655 660 665 670
cag cag aat ttc aag cga ggc tct ggg cag agt gga cca cgg gga gcc 2247
Gln Gln Asn Phe Lys Arg Gly Ser Gly Gln Ser Gly Pro Arg Gly Ala
675 680 685
cca cga ggt cgt gga ggg ccc cca aga ccc aac aga ggg atg ccg caa 2295
Pro Arg Gly Arg Gly Gly Pro Pro Arg Pro Asn Arg Gly Met Pro Gln
690 695 700
atg aac act cag caa gtg aat taa tctgattcac aggattatgt ttaatcgcca 2349
Met Asn Thr Gln Gln Val Asn
705
aaaacacact ggccagtgta ccataatatg ttaccagaag agttattatc tatttgttct 2409
ccctttcagg aaacttattg taaagggact gttttcatcc cataaagaca ggactacaat 2469
tgtcagcttt ctattacctg gatatggaag gaaactattt ttactctgca tgttctgtcc 2529
taagcgtcat cttgagcctt gcacatgata ctcagattcc tcacccttgc ttaggagtaa 2589
aacaatatac tttacagggt gataataatc tccatagtta tttgaagtgg cttgaaaaag 2649
gcaagattga cttttatgac attggataaa atctacaaat cagccctcga gttattcaat 2709
gataactgac aaactaaatt atttccctag aaaggaagat gaaaggagtg gagtgtggtt 2769
tggcagaaca actgcatttc acagcttttc cagttaaatt ggagcactga acgttcagat 2829
gcataccaaa ttatgcatgg gtcctaatca cacatataag gctggctacc agctttgaca 2889
cagcactgtt catctggcca aacaactgtg gttaaaaaca catgtaaaat gctttttaac 2949
agctgatact gtataagaca aagccaagat gcaaaattag gctttgattg gcactttttg 3009
aaaaatatgc aacaaatatg ggatgtaatc cggatggccg cttctgtact taatgtgaaa 3069
tatttagata cctttttgaa cacttaacag tttctttgag acaatgactt ttgtaaggat 3129
tggtactatc tatcattcct tatgacatgt acattgtctg tcactaatcc ttggattttg 3189
ctgtattgtc acctaaattg gtacaggtac tgatgaaaat ctctagtgga taatcataac 3249
actctcggtc acatgttttt ccttcagctt gaaagctttt ttttaaaagg aaaagatacc 3309
aaatgcctgc tgctaccacc cttttcaatt gctatctttt gaaaggcacc agtatgtgtt 3369
ttagattgat ttccctgttt cagggaaatc acggacagta gtttcagttc tgatggtata 3429
agcaaaacaa ataaaacgtt tataaaagtt gtatcttgaa acactggtgt tcaacagcta 3489
gcagcttatg tgattcaccc catgccacgt tagtgtcaca aattttatgg tttatctcca 3549
gcaacatttc tctagtactt gcacttatta tcttttgtct aatttaacct taactgaatt 3609
ctccgtttct cctggaggca tttatattca gtgataattc cttcccttag atgcataggg 3669
agagtctcta aatttgatgg aaatggacac ttgagtagtg acttagcctt atgtactctg 3729
ttggaatttg tgctagcagt ttgagcacta gttctgtgtg cctaggaagt taatgctgct 3789
tattgtctca ttctgacttc atggagaatt aatcccacct ttaagcaaag gctactaagt 3849
taatggtatt ttctgtgcag aaattaaatt ttattttcag catttagccc aggaattctt 3909
ccagtaggtg ctcagctatt taaaaacaaa actattctca aacattcatc attagacaac 3969
tggagttttt gctggttttg taacctacca aaatggatag gctgttgaac attccacatt 4029
caaaagtttt gtagggtggt gggaaatggg ggatcttcaa tgtttatttt aaaataaaat 4089
aaaataagtt cttgactttt ctcatgtgtg gttgtggtac atcatattgg aagggttaac 4149
ctgttacttt ggcaaatgag tatttttttg ctagcacctc cccttgcgtg ctttaaatga 4209
catctgcctg ggatgtacca caaccatatg ttacctgtat cttaggggaa tggataaaat 4269
atttgtggtt tactgggtaa tccctagatg atgtatgctt gcagtcctat ataaaactaa 4329
atttgctatc tgtgtagaaa ataatttcat gacatttaca atcaggactg aagtaagttc 4389
ttcacacagt gacctctgaa tcagtttcag agaagggatg ggggagaaaa tgccttctag 4449
gttttgaact tctatgcatt agtgcagatg ttgtgaatgt gtaaaggtgt tcatagtttg 4509
actgtttcta tgtatgtttt ttcaaagaat tgttcctttt tttgaactat aatttttctt 4569
tttttggtta ttttaccatc acagtttaaa tgtatatctt ttatgtctct actcagacca 4629
tatttttaaa ggggtgcctc attatggggc agagaacttt tcaataagtc tcattaagat 4689
ctgaatcttg gttctaagca ttctgtataa tatgtgattg cttgtcctag ctgcagaagg 4749
ccttttgttt ggtcaaatgc atattttagc agagtttcaa ggaaatgatt gtcacacatg 4809
tcactgtagc ctcttggtgt agcaagctca catacaaaat acttttgtat atgcataata 4869
taaatcatct catgtggata tgaaacttct tttttaaaac ttaaaaaggt agaatgttat 4929
tgattacctt gattagggca gttttatttc cagatcctaa taattcctaa aaaatatgga 4989
aaagtttttt ttcaatcatt gtaccttgat attaaaacaa atatccttta agtatttcta 5049
atcagttagc ttctacagtt cttttgtctc cttttatatg cagctcttac gtgggagact 5109
tttccactta aaggagacat agaatgtgtg cttattctca gaaggttcat taactgaggt 5169
gatgagttaa caactagttg agcagtcagc ttcctaagtg ttttaggaca tttgttcatt 5229
atattttccg tcatataact agaggaagtg gaatgcagat aagtgccgaa ttcaaaccct 5289
tcattttatg tttaagctcc tgaatctgca ttccacttgg gttgttttta agcattctaa 5349
attttagttg attataagtt agatttcaca gaatcagtat tgcccttgat cttgtccttt 5409
ttatggagtt aacggggagg aagacccctc aggaaaacga aagtaaattg ttaaggctca 5469
tcttcatacc tttttccatt ttgaatccta caaaaatact gcaaaagact agtgaatgtt 5529
taaaattaca ctagattaaa taatatgaaa gtc 5562
<210> 2
<211> 709
<212> PRT
<213> 人(Homo sapiens)
<400> 2
Met Pro Ser Ala Thr Ser His Ser Gly Ser Gly Ser Lys Ser Ser Gly
1 5 10 15
Pro Pro Pro Pro Ser Gly Ser Ser Gly Ser Glu Ala Ala Ala Gly Ala
20 25 30
Gly Ala Ala Ala Pro Ala Ser Gln His Pro Ala Thr Gly Thr Gly Ala
35 40 45
Val Gln Thr Glu Ala Met Lys Gln Ile Leu Gly Val Ile Asp Lys Lys
50 55 60
Leu Arg Asn Leu Glu Lys Lys Lys Gly Lys Leu Asp Asp Tyr Gln Glu
65 70 75 80
Arg Met Asn Lys Gly Glu Arg Leu Asn Gln Asp Gln Leu Asp Ala Val
85 90 95
Ser Lys Tyr Gln Glu Val Thr Asn Asn Leu Glu Phe Ala Lys Glu Leu
100 105 110
Gln Arg Ser Phe Met Ala Leu Ser Gln Asp Ile Gln Lys Thr Ile Lys
115 120 125
Lys Thr Ala Arg Arg Glu Gln Leu Met Arg Glu Glu Ala Glu Gln Lys
130 135 140
Arg Leu Lys Thr Val Leu Glu Leu Gln Tyr Val Leu Asp Lys Leu Gly
145 150 155 160
Asp Asp Glu Val Arg Thr Asp Leu Lys Gln Gly Leu Asn Gly Val Pro
165 170 175
Ile Leu Ser Glu Glu Glu Leu Ser Leu Leu Asp Glu Phe Tyr Lys Leu
180 185 190
Val Asp Pro Glu Arg Asp Met Ser Leu Arg Leu Asn Glu Gln Tyr Glu
195 200 205
His Ala Ser Ile His Leu Trp Asp Leu Leu Glu Gly Lys Glu Lys Pro
210 215 220
Val Cys Gly Thr Thr Tyr Lys Val Leu Lys Glu Ile Val Glu Arg Val
225 230 235 240
Phe Gln Ser Asn Tyr Phe Asp Ser Thr His Asn His Gln Asn Gly Leu
245 250 255
Cys Glu Glu Glu Glu Ala Ala Ser Ala Pro Ala Val Glu Asp Gln Val
260 265 270
Pro Glu Ala Glu Pro Glu Pro Ala Glu Glu Tyr Thr Glu Gln Ser Glu
275 280 285
Val Glu Ser Thr Glu Tyr Val Asn Arg Gln Phe Met Ala Glu Thr Gln
290 295 300
Phe Thr Ser Gly Glu Lys Glu Gln Val Asp Glu Trp Thr Val Glu Thr
305 310 315 320
Val Glu Val Val Asn Ser Leu Gln Gln Gln Pro Gln Ala Ala Ser Pro
325 330 335
Ser Val Pro Glu Pro His Ser Leu Thr Pro Val Ala Gln Ala Asp Pro
340 345 350
Leu Val Arg Arg Gln Arg Val Gln Asp Leu Met Ala Gln Met Gln Gly
355 360 365
Pro Tyr Asn Phe Ile Gln Asp Ser Met Leu Asp Phe Glu Asn Gln Thr
370 375 380
Leu Asp Pro Ala Ile Val Ser Ala Gln Pro Met Asn Pro Thr Gln Asn
385 390 395 400
Met Asp Met Pro Gln Leu Val Cys Pro Pro Val His Ser Glu Ser Arg
405 410 415
Leu Ala Gln Pro Asn Gln Val Pro Val Gln Pro Glu Ala Thr Gln Val
420 425 430
Pro Leu Val Ser Ser Thr Ser Glu Gly Tyr Thr Ala Ser Gln Pro Leu
435 440 445
Tyr Gln Pro Ser His Ala Thr Glu Gln Arg Pro Gln Lys Glu Pro Ile
450 455 460
Asp Gln Ile Gln Ala Thr Ile Ser Leu Asn Thr Asp Gln Thr Thr Ala
465 470 475 480
Ser Ser Ser Leu Pro Ala Ala Ser Gln Pro Gln Val Phe Gln Ala Gly
485 490 495
Thr Ser Lys Pro Leu His Ser Ser Gly Ile Asn Val Asn Ala Ala Pro
500 505 510
Phe Gln Ser Met Gln Thr Val Phe Asn Met Asn Ala Pro Val Pro Pro
515 520 525
Val Asn Glu Pro Glu Thr Leu Lys Gln Gln Asn Gln Tyr Gln Ala Ser
530 535 540
Tyr Asn Gln Ser Phe Ser Ser Gln Pro His Gln Val Glu Gln Thr Glu
545 550 555 560
Leu Gln Gln Glu Gln Leu Gln Thr Val Val Gly Thr Tyr His Gly Ser
565 570 575
Pro Asp Gln Ser His Gln Val Thr Gly Asn His Gln Gln Pro Pro Gln
580 585 590
Gln Asn Thr Gly Phe Pro Arg Ser Asn Gln Pro Tyr Tyr Asn Ser Arg
595 600 605
Gly Val Ser Arg Gly Gly Ser Arg Gly Ala Arg Gly Leu Met Asn Gly
610 615 620
Tyr Arg Gly Pro Ala Asn Gly Phe Arg Gly Gly Tyr Asp Gly Tyr Arg
625 630 635 640
Pro Ser Phe Ser Asn Thr Pro Asn Ser Gly Tyr Thr Gln Ser Gln Phe
645 650 655
Ser Ala Pro Arg Asp Tyr Ser Gly Tyr Gln Arg Asp Gly Tyr Gln Gln
660 665 670
Asn Phe Lys Arg Gly Ser Gly Gln Ser Gly Pro Arg Gly Ala Pro Arg
675 680 685
Gly Arg Gly Gly Pro Pro Arg Pro Asn Arg Gly Met Pro Gln Met Asn
690 695 700
Thr Gln Gln Val Asn
705
<210> 3
<211> 3553
<212> DNA
<213> 人(Homo sapiens)
<220>
<221> CDS
<222> (190)..(2274)
<223>
<400> 3
cagagggctg ctggctggct aagtccctcc cgctcccggc tctcgcctca ctaggagcgg 60
ctctcggtgc agcgggacag ggcgaagcgg cctgcgccca cggagcgcgc gacactgccc 120
ggaagggacc gccacccttg ccccctcagc tgcccactcg tgatttccag cggcctccgc 180
gcgcgcacg atg ccc tcg gcc acc agc cac agc ggg agc ggc agc aag tcg 231
Met Pro Ser Ala Thr Ser His Ser Gly Ser Gly Ser Lys Ser
1 5 10
tcc gga ccg cca ccg ccg tcg ggt tcc tcc ggg agt gag gcg gcc gcg 279
Ser Gly Pro Pro Pro Pro Ser Gly Ser Ser Gly Ser Glu Ala Ala Ala
15 20 25 30
gga gcc ggg gcc gcc gcg ccg gct tct cag cac ccc gca acc ggc acc 327
Gly Ala Gly Ala Ala Ala Pro Ala Ser Gln His Pro Ala Thr Gly Thr
35 40 45
ggc gct gtc cag acc gag gcc atg aag cag att ctc ggg gtg atc gac 375
Gly Ala Val Gln Thr Glu Ala Met Lys Gln Ile Leu Gly Val Ile Asp
50 55 60
aag aaa ctt cgg aac ctg gag aag aaa aag ggt aag ctt gat gat tac 423
Lys Lys Leu Arg Asn Leu Glu Lys Lys Lys Gly Lys Leu Asp Asp Tyr
65 70 75
cag gaa cga atg aac aaa ggg gaa agg ctt aat caa gat cag ctg gat 471
Gln Glu Arg Met Asn Lys Gly Glu Arg Leu Asn Gln Asp Gln Leu Asp
80 85 90
gcc gtt tct aag tac cag gaa gtc aca aat aat ttg gag ttt gca aaa 519
Ala Val Ser Lys Tyr Gln Glu Val Thr Asn Asn Leu Glu Phe Ala Lys
95 100 105 110
gaa tta cag agg agt ttc atg gca cta agt caa gat att cag aaa aca 567
Glu Leu Gln Arg Ser Phe Met Ala Leu Ser Gln Asp Ile Gln Lys Thr
115 120 125
ata aag aag aca gca cgt cgg gag cag ctt atg aga gaa gaa gct gaa 615
Ile Lys Lys Thr Ala Arg Arg Glu Gln Leu Met Arg Glu Glu Ala Glu
130 135 140
cag aaa cgt tta aaa act gta ctt gag cta cag tat gtt ttg gac aaa 663
Gln Lys Arg Leu Lys Thr Val Leu Glu Leu Gln Tyr Val Leu Asp Lys
145 150 155
ttg gga gat gat gaa gtg cgg act gac ctg aaa caa ggt ttg aat gga 711
Leu Gly Asp Asp Glu Val Arg Thr Asp Leu Lys Gln Gly Leu Asn Gly
160 165 170
gtg cca ata ttg tcc gaa gag gag ttg tca ttg ttg gat gaa ttc tat 759
Val Pro Ile Leu Ser Glu Glu Glu Leu Ser Leu Leu Asp Glu Phe Tyr
175 180 185 190
aag cta gta gac cct gaa cgg gac atg agc ttg agg ttg aat gaa cag 807
Lys Leu Val Asp Pro Glu Arg Asp Met Ser Leu Arg Leu Asn Glu Gln
195 200 205
tat gaa cat gcc tcc att cac ctg tgg gac ctg ctg gaa ggg aag gaa 855
Tyr Glu His Ala Ser Ile His Leu Trp Asp Leu Leu Glu Gly Lys Glu
210 215 220
aaa cct gta tgt gga acc acc tat aaa gtt cta aag gaa att gtt gag 903
Lys Pro Val Cys Gly Thr Thr Tyr Lys Val Leu Lys Glu Ile Val Glu
225 230 235
cgt gtt ttt cag tca aac tac ttt gac agc acc cac aac cac cag aat 951
Arg Val Phe Gln Ser Asn Tyr Phe Asp Ser Thr His Asn His Gln Asn
240 245 250
ggg ctg tgt gag gaa gaa gag gca gcc tca gca cct gca gtt gaa gac 999
Gly Leu Cys Glu Glu Glu Glu Ala Ala Ser Ala Pro Ala Val Glu Asp
255 260 265 270
cag gta cct gaa gct gaa cct gag cca gca gaa gag tac act gag caa 1047
Gln Val Pro Glu Ala Glu Pro Glu Pro Ala Glu Glu Tyr Thr Glu Gln
275 280 285
agt gaa gtt gaa tca aca gag tat gta aat aga cag ttc atg gca gaa 1095
Ser Glu Val Glu Ser Thr Glu Tyr Val Asn Arg Gln Phe Met Ala Glu
290 295 300
aca cag ttc acc agt ggt gaa aag gag cag gta gat gag tgg aca gtt 1143
Thr Gln Phe Thr Ser Gly Glu Lys Glu Gln Val Asp Glu Trp Thr Val
305 310 315
gaa acg gtt gag gtg gta aat tca ctc cag cag caa cct cag gct gca 1191
Glu Thr Val Glu Val Val Asn Ser Leu Gln Gln Gln Pro Gln Ala Ala
320 325 330
tcc cct tca gta cca gag ccc cac tct ttg act cca gtg gct cag gca 1239
Ser Pro Ser Val Pro Glu Pro His Ser Leu Thr Pro Val Ala Gln Ala
335 340 345 350
gat ccc ctt gtg aga aga cag cga gta caa gac ctt atg gca caa atg 1287
Asp Pro Leu Val Arg Arg Gln Arg Val Gln Asp Leu Met Ala Gln Met
355 360 365
cag ggt ccc tat aat ttc ata cag gat tca atg ctg gat ttt gaa aat 1335
Gln Gly Pro Tyr Asn Phe Ile Gln Asp Ser Met Leu Asp Phe Glu Asn
370 375 380
cag aca ctt gat cct gcc att gta tct gca cag cct atg aat cca aca 1383
Gln Thr Leu Asp Pro Ala Ile Val Ser Ala Gln Pro Met Asn Pro Thr
385 390 395
caa aac atg gac atg ccc cag ctg gtt tgc cct cca gtt cat tct gaa 1431
Gln Asn Met Asp Met Pro Gln Leu Val Cys Pro Pro Val His Ser Glu
400 405 410
tct aga ctt gct cag cct aat caa gtt cct gta caa cca gaa gcg aca 1479
Ser Arg Leu Ala Gln Pro Asn Gln Val Pro Val Gln Pro Glu Ala Thr
415 420 425 430
cag gtt cct ttg gta tca tcc aca agt gag ggg tac aca gca tct caa 1527
Gln Val Pro Leu Val Ser Ser Thr Ser Glu Gly Tyr Thr Ala Ser Gln
435 440 445
ccc ttg tac cag cct tct cat gct aca gag caa cga cca cag aag gaa 1575
Pro Leu Tyr Gln Pro Ser His Ala Thr Glu Gln Arg Pro Gln Lys Glu
450 455 460
cca att gat cag att cag gca aca atc tct tta aat aca gac cag act 1623
Pro Ile Asp Gln Ile Gln Ala Thr Ile Ser Leu Asn Thr Asp Gln Thr
465 470 475
aca gca tca tca tcc ctt cct gct gcg tct cag cct caa gta ttt cag 1671
Thr Ala Ser Ser Ser Leu Pro Ala Ala Ser Gln Pro Gln Val Phe Gln
480 485 490
gct ggg aca agc aaa cct tta cat agc agt gga atc aat gta aat gca 1719
Ala Gly Thr Ser Lys Pro Leu His Ser Ser Gly Ile Asn Val Asn Ala
495 500 505 510
gct cca ttc caa tcc atg caa acg gtg ttc aat atg aat gcc cca gtt 1767
Ala Pro Phe Gln Ser Met Gln Thr Val Phe Asn Met Asn Ala Pro Val
515 520 525
cct cct gtt aat gaa cca gaa act tta aaa cag caa aat cag tac cag 1815
Pro Pro Val Asn Glu Pro Glu Thr Leu Lys Gln Gln Asn Gln Tyr Gln
530 535 540
gcc agt tat aac cag agc ttt tct agt cag cct cac caa gta gaa caa 1863
Ala Ser Tyr Asn Gln Ser Phe Ser Ser Gln Pro His Gln Val Glu Gln
545 550 555
aca gag ctt cag caa gaa cag ctt caa aca gtg gtt ggc act tac cat 1911
Thr Glu Leu Gln Gln Glu Gln Leu Gln Thr Val Val Gly Thr Tyr His
560 565 570
ggt tcc cca gac cag tcc cat caa gtg act ggt aac cac cag cag cct 1959
Gly Ser Pro Asp Gln Ser His Gln Val Thr Gly Asn His Gln Gln Pro
575 580 585 590
cct cag cag aac act gga ttt cca cgt agc aat cag ccc tat tac aat 2007
Pro Gln Gln Asn Thr Gly Phe Pro Arg Ser Asn Gln Pro Tyr Tyr Asn
595 600 605
agt cgt ggt gtg tct cgt gga ggc tcc cgt ggt gct aga ggc ttg atg 2055
Ser Arg Gly Val Ser Arg Gly Gly Ser Arg Gly Ala Arg Gly Leu Met
610 615 620
aat gga tac cgg ggc cct gcc aat gga ttc aga gga gga tat gat ggt 2103
Asn Gly Tyr Arg Gly Pro Ala Asn Gly Phe Arg Gly Gly Tyr Asp Gly
625 630 635
tac cgc cct tca ttc tct aac act cca aac agt ggt tat aca cag tct 2151
Tyr Arg Pro Ser Phe Ser Asn Thr Pro Asn Ser Gly Tyr Thr Gln Ser
640 645 650
cag ttc agt gct ccc cgg gat tac tct ggc tat caa cgg gat gga tat 2199
Gln Phe Ser Ala Pro Arg Asp Tyr Ser Gly Tyr Gln Arg Asp Gly Tyr
655 660 665 670
cag cag aat ttc aag cga ggc tct ggg cag agt gga cca cgg gga gcc 2247
Gln Gln Asn Phe Lys Arg Gly Ser Gly Gln Ser Gly Pro Arg Gly Ala
675 680 685
cca cga ggt aat att ttg tgg tgg tga tcctagctcc taagtggagc 2294
Pro Arg Gly Asn Ile Leu Trp Trp
690
ttctgttctg gccttggaag agctgttaat agtctgcatg ttaggaatac atttatcctt 2354
tccagacttg ttgctaggga ttaaatgaaa tgctctgttt ctaaaactta atcttggacc 2414
caaattttaa tttttgaatg atttaatttt ccctgttact atataaactg tcttgaaaac 2474
tagaacatat tctcttctca gaaaaagtgt ttttccaact gaaaattatt tttcaggtcc 2534
taaaacctgc taaatgtttt taggaagtac ttactgaaac atttttgtaa gacatttttg 2594
gaatgagatt gaacatttat ataaatttat tattcctctt tcattttttt gaaacatgcc 2654
tattatattt tagggccaga caccctttaa tggccggata agccatagtt aacatttaga 2714
gaaccattta gaagtgatag aactaatgga atttgcaatg ccttttggac ctctattagt 2774
gatataaata tcaagttatt tctgactttt aaacaaaact cccaaattcc taacttattg 2834
agctatactt aaaaaaaatt acaggtttag agagtttttt gtttttcttt tactgttgga 2894
aaactacttc ccattttggc aggaagttaa cctatttaac aattagagct agcatttcat 2954
gtagtctgaa attctaaatg gttctctgat ttgagggagg ttaaacatca aacaggtttc 3014
ctctattggc cataacatgt ataaaatgtg tgttaaggag gaattacaac gtactttgat 3074
ttgaatacta gtagaaactg gccaggaaaa aggtacattt ttctaaaaat taatggatca 3134
cttgggaatt actgacttga ctagaagtat caaaggatgt ttgcatgtga atgtgggtta 3194
tgttctttcc caccttgtag catattcgat gaaagttgag ttaactgata gctaaaaatc 3254
tgttttaaca gcatgtaaaa agttatttta tctgttaaaa gtcattatac agttttgaat 3314
gttatgtagt ttctttttaa cagtttaggt aataaggtct gttttcattc tggtgctttt 3374
attaattttg atagtatgat gttacttact actgaaatgt aagctagagt gtacactaga 3434
atgtaagctc catgagagca ggtaccttgt ctgtcttctc tgctgtatct attcccaacg 3494
cttgatgatg gtgcctggca catagtaggc actcaataaa tatttgttga atgaatgaa 3553
<210> 4
<211> 694
<212> PRT
<213> 人(Homo sapiens)
<400> 4
Met Pro Ser Ala Thr Ser His Ser Gly Ser Gly Ser Lys Ser Ser Gly
1 5 10 15
Pro Pro Pro Pro Ser Gly Ser Ser Gly Ser Glu Ala Ala Ala Gly Ala
20 25 30
Gly Ala Ala Ala Pro Ala Ser Gln His Pro Ala Thr Gly Thr Gly Ala
35 40 45
Val Gln Thr Glu Ala Met Lys Gln Ile Leu Gly Val Ile Asp Lys Lys
50 55 60
Leu Arg Asn Leu Glu Lys Lys Lys Gly Lys Leu Asp Asp Tyr Gln Glu
65 70 75 80
Arg Met Asn Lys Gly Glu Arg Leu Asn Gln Asp Gln Leu Asp Ala Val
85 90 95
Ser Lys Tyr Gln Glu Val Thr Asn Asn Leu Glu Phe Ala Lys Glu Leu
100 105 110
Gln Arg Ser Phe Met Ala Leu Ser Gln Asp Ile Gln Lys Thr Ile Lys
115 120 125
Lys Thr Ala Arg Arg Glu Gln Leu Met Arg Glu Glu Ala Glu Gln Lys
130 135 140
Arg Leu Lys Thr Val Leu Glu Leu Gln Tyr Val Leu Asp Lys Leu Gly
145 150 155 160
Asp Asp Glu Val Arg Thr Asp Leu Lys Gln Gly Leu Asn Gly Val Pro
165 170 175
Ile Leu Ser Glu Glu Glu Leu Ser Leu Leu Asp Glu Phe Tyr Lys Leu
180 185 190
Val Asp Pro Glu Arg Asp Met Ser Leu Arg Leu Asn Glu Gln Tyr Glu
195 200 205
His Ala Ser Ile His Leu Trp Asp Leu Leu Glu Gly Lys Glu Lys Pro
210 215 220
Val Cys Gly Thr Thr Tyr Lys Val Leu Lys Glu Ile Val Glu Arg Val
225 230 235 240
Phe Gln Ser Asn Tyr Phe Asp Ser Thr His Asn His Gln Asn Gly Leu
245 250 255
Cys Glu Glu Glu Glu Ala Ala Ser Ala Pro Ala Val Glu Asp Gln Val
260 265 270
Pro Glu Ala Glu Pro Glu Pro Ala Glu Glu Tyr Thr Glu Gln Ser Glu
275 280 285
Val Glu Ser Thr Glu Tyr Val Asn Arg Gln Phe Met Ala Glu Thr Gln
290 295 300
Phe Thr Ser Gly Glu Lys Glu Gln Val Asp Glu Trp Thr Val Glu Thr
305 310 315 320
Val Glu Val Val Asn Ser Leu Gln Gln Gln Pro Gln Ala Ala Ser Pro
325 330 335
Ser Val Pro Glu Pro His Ser Leu Thr Pro Val Ala Gln Ala Asp Pro
340 345 350
Leu Val Arg Arg Gln Arg Val Gln Asp Leu Met Ala Gln Met Gln Gly
355 360 365
Pro Tyr Asn Phe Ile Gln Asp Ser Met Leu Asp Phe Glu Asn Gln Thr
370 375 380
Leu Asp Pro Ala Ile Val Ser Ala Gln Pro Met Asn Pro Thr Gln Asn
385 390 395 400
Met Asp Met Pro Gln Leu Val Cys Pro Pro Val His Ser Glu Ser Arg
405 410 415
Leu Ala Gln Pro Asn Gln Val Pro Val Gln Pro Glu Ala Thr Gln Val
420 425 430
Pro Leu Val Ser Ser Thr Ser Glu Gly Tyr Thr Ala Ser Gln Pro Leu
435 440 445
Tyr Gln Pro Ser His Ala Thr Glu Gln Arg Pro Gln Lys Glu Pro Ile
450 455 460
Asp Gln Ile Gln Ala Thr Ile Ser Leu Asn Thr Asp Gln Thr Thr Ala
465 470 475 480
Ser Ser Ser Leu Pro Ala Ala Ser Gln Pro Gln Val Phe Gln Ala Gly
485 490 495
Thr Ser Lys Pro Leu His Ser Ser Gly Ile Asn Val Asn Ala Ala Pro
500 505 510
Phe Gln Ser Met Gln Thr Val Phe Asn Met Asn Ala Pro Val Pro Pro
515 520 525
Val Asn Glu Pro Glu Thr Leu Lys Gln Gln Asn Gln Tyr Gln Ala Ser
530 535 540
Tyr Asn Gln Ser Phe Ser Ser Gln Pro His Gln Val Glu Gln Thr Glu
545 550 555 560
Leu Gln Gln Glu Gln Leu Gln Thr Val Val Gly Thr Tyr His Gly Ser
565 570 575
Pro Asp Gln Ser His Gln Val Thr Gly Asn His Gln Gln Pro Pro Gln
580 585 590
Gln Asn Thr Gly Phe Pro Arg Ser Asn Gln Pro Tyr Tyr Asn Ser Arg
595 600 605
Gly Val Ser Arg Gly Gly Ser Arg Gly Ala Arg Gly Leu Met Asn Gly
610 615 620
Tyr Arg Gly Pro Ala Asn Gly Phe Arg Gly Gly Tyr Asp Gly Tyr Arg
625 630 635 640
Pro Ser Phe Ser Asn Thr Pro Asn Ser Gly Tyr Thr Gln Ser Gln Phe
645 650 655
Ser Ala Pro Arg Asp Tyr Ser Gly Tyr Gln Arg Asp Gly Tyr Gln Gln
660 665 670
Asn Phe Lys Arg Gly Ser Gly Gln Ser Gly Pro Arg Gly Ala Pro Arg
675 680 685
Gly Asn Ile Leu Trp Trp
690
<210> 5
<211> 1605
<212> DNA
<213> 狗(Canis familiaris)
<220>
<221> CDS
<222> (46)..(1392)
<223>
<400> 5
gtcacaaata acttggagtt tgcaaaagaa ttacagagga gtttc atg gca tta agt 57
Met Ala Leu Ser
1
caa gat att cag aaa aca ata aag aag act gca cgt cgg gag cag ctt 105
Gln Asp Ile Gln Lys Thr Ile Lys Lys Thr Ala Arg Arg Glu Gln Leu
5 10 15 20
atg aga gag gaa gcg gaa caa aaa cgt tta aaa act gta ctt gag ctc 153
Met Arg Glu Glu Ala Glu Gln Lys Arg Leu Lys Thr Val Leu Glu Leu
25 30 35
cag tat gtt ttg gac aaa ttg gga gat gat gaa gtg aga act gac ctg 201
Gln Tyr Val Leu Asp Lys Leu Gly Asp Asp Glu Val Arg Thr Asp Leu
40 45 50
aag caa ggt ttg aat gga gtg cca ata ttg tct gaa gaa gaa ttg tcg 249
Lys Gln Gly Leu Asn Gly Val Pro Ile Leu Ser Glu Glu Glu Leu Ser
55 60 65
ttg ttg gat gaa ttc tac aaa tta gca gac cct gaa cgg gac atg agc 297
Leu Leu Asp Glu Phe Tyr Lys Leu Ala Asp Pro Glu Arg Asp Met Ser
70 75 80
ttg agg ttg aat gag cag tat gaa cat gct tcc att cac ctg tgg gac 345
Leu Arg Leu Asn Glu Gln Tyr Glu His Ala Ser Ile His Leu Trp Asp
85 90 95 100
ttg ctg gaa gga aag gaa aag tct gta tgt gga aca acc tat aaa gca 393
Leu Leu Glu Gly Lys Glu Lys Ser Val Cys Gly Thr Thr Tyr Lys Ala
105 110 115
cta aag gaa att gtt gag cgt gtt ttc cag tca aat tac ttt gac agc 441
Leu Lys Glu Ile Val Glu Arg Val Phe Gln Ser Asn Tyr Phe Asp Ser
120 125 130
act cac aac cac cag aat ggg cta tgt gag gaa gaa gag gca gcc tca 489
Thr His Asn His Gln Asn Gly Leu Cys Glu Glu Glu Glu Ala Ala Ser
135 140 145
gca cct aca gtt gaa gac cag gta gct gaa gct gag cct gag cca gca 537
Ala Pro Thr Val Glu Asp Gln Val Ala Glu Ala Glu Pro Glu Pro Ala
150 155 160
gaa gaa tac act gaa caa agt gaa gtt gaa tca aca gag tat gta aat 585
Glu Glu Tyr Thr Glu Gln Ser Glu Val Glu Ser Thr Glu Tyr Val Asn
165 170 175 180
aga caa ttt atg gca gaa aca cag ttc agc agt ggt gaa aag gag cag 633
Arg Gln Phe Met Ala Glu Thr Gln Phe Ser Ser Gly Glu Lys Glu Gln
185 190 195
gta gat gag tgg acg gtc gaa aca gtg gag gtg gtg aat tca ctc cag 681
Val Asp Glu Trp Thr Val Glu Thr Val Glu Val Val Asn Ser Leu Gln
200 205 210
cag caa cct cag gct gcg tct cct tca gta cca gag ccc cac tct ttg 729
Gln Gln Pro Gln Ala Ala Ser Pro Ser Val Pro Glu Pro His Ser Leu
215 220 225
act ccg gtg gct cag gca gat ccc ctt gtg aga aga cag cga gtc cag 777
Thr Pro Val Ala Gln Ala Asp Pro Leu Val Arg Arg Gln Arg Val Gln
230 235 240
gac ctt atg gcg cag atg cag ggg ccc tat aat ttc ata cag gat tca 825
Asp Leu Met Ala Gln Met Gln Gly Pro Tyr Asn Phe Ile Gln Asp Ser
245 250 255 260
atg ctg gat ttt gaa aac cag aca ctc gat cct gcc att gta tct gca 873
Met Leu Asp Phe Glu Asn Gln Thr Leu Asp Pro Ala Ile Val Ser Ala
265 270 275
cag cct atg aat ccg aca caa aac atg gac atg ccc cag ctg gtt tgc 921
Gln Pro Met Asn Pro Thr Gln Asn Met Asp Met Pro Gln Leu Val Cys
280 285 290
cct cca gtt cat tct gaa tct aga ctt gct caa cct aat caa gtt cct 969
Pro Pro Val His Ser Glu Ser Arg Leu Ala Gln Pro Asn Gln Val Pro
295 300 305
gta caa cca gaa gct aca cag gtt cct ttg gtt tca tcc aca agt gag 1017
Val Gln Pro Glu Ala Thr Gln Val Pro Leu Val Ser Ser Thr Ser Glu
310 315 320
ggg tat aca gca tct caa ccc ttg tac cag cct tct cat gct aca gag 1065
Gly Tyr Thr Ala Ser Gln Pro Leu Tyr Gln Pro Ser His Ala Thr Glu
325 330 335 340
caa cga cca caa aag gaa cca att gac cag att cag gca aca atc tct 1113
Gln Arg Pro Gln Lys Glu Pro Ile Asp Gln Ile Gln Ala Thr Ile Ser
345 350 355
tta aat aca gac cag act aca gcg tca tca tcc ctt ccg gct gct tct 1161
Leu Asn Thr Asp Gln Thr Thr Ala Ser Ser Ser Leu Pro Ala Ala Ser
360 365 370
cag cct cag gta ttc cag gct ggg aca agc aaa cca tta cat agc agt 1209
Gln Pro Gln Val Phe Gln Ala Gly Thr Ser Lys Pro Leu His Ser Ser
375 380 385
gga atc aat gta aat gca gct cca ttc caa tcc atg caa acg gtg ttc 1257
Gly Ile Asn Val Asn Ala Ala Pro Phe Gln Ser Met Gln Thr Val Phe
390 395 400
aat atg aat gcc cca gtt cct cct gtt aat gaa cca gaa act ttg aaa 1305
Asn Met Asn Ala Pro Val Pro Pro Val Asn Glu Pro Glu Thr Leu Lys
405 410 415 420
caa caa aat cag tac cag gcc agt tat aac cag agc ttt tct agt cag 1353
Gln Gln Asn Gln Tyr Gln Ala Ser Tyr Asn Gln Ser Phe Ser Ser Gln
425 430 435
cct cac caa gta gaa caa aca gag gga tgc cgc aaa tga acactcagca 1402
Pro His Gln Val Glu Gln Thr Glu Gly Cys Arg Lys
440 445
agtgaattaa tctgattcac aggattatgt ttaaacgcca aaaacacact ggccagtgta 1462
ccataatatg ttaccagaag agttattatc tatttgttct ccctttcagg aaacttattg 1522
taaagggact gttttcatcc cataaagaca ggactacaat tgtcagcttt atattacctg 1582
gaaaaaaaaa aaaaaaaaaa aaa 1605
<210> 6
<211> 448
<212> PRT
<213> 狗(Canis familiaris)
<400> 6
Met Ala Leu Ser Gln Asp Ile Gln Lys Thr Ile Lys Lys Thr Ala Arg
1 5 10 15
Arg Glu Gln Leu Met Arg Glu Glu Ala Glu Gln Lys Arg Leu Lys Thr
20 25 30
Val Leu Glu Leu Gln Tyr Val Leu Asp Lys Leu Gly Asp Asp Glu Val
35 40 45
Arg Thr Asp Leu Lys Gln Gly Leu Asn Gly Val Pro Ile Leu Ser Glu
50 55 60
Glu Glu Leu Ser Leu Leu Asp Glu Phe Tyr Lys Leu Ala Asp Pro Glu
65 70 75 80
Arg Asp Met Ser Leu Arg Leu Asn Glu Gln Tyr Glu His Ala Ser Ile
85 90 95
His Leu Trp Asp Leu Leu Glu Gly Lys Glu Lys Ser Val Cys Gly Thr
100 105 110
Thr Tyr Lys Ala Leu Lys Glu Ile Val Glu Arg Val Phe Gln Ser Asn
115 120 125
Tyr Phe Asp Ser Thr His Asn His Gln Asn Gly Leu Cys Glu Glu Glu
130 135 140
Glu Ala Ala Ser Ala Pro Thr Val Glu Asp Gln Val Ala Glu Ala Glu
145 150 155 160
Pro Glu Pro Ala Glu Glu Tyr Thr Glu Gln Ser Glu Val Glu Ser Thr
165 170 175
Glu Tyr Val Asn Arg Gln Phe Met Ala Glu Thr Gln Phe Ser Ser Gly
180 185 190
Glu Lys Glu Gln Val Asp Glu Trp Thr Val Glu Thr Val Glu Val Val
195 200 205
Asn Ser Leu Gln Gln Gln Pro Gln Ala Ala Ser Pro Ser Val Pro Glu
210 215 220
Pro His Ser Leu Thr Pro Val Ala Gln Ala Asp Pro Leu Val Arg Arg
225 230 235 240
Gln Arg Val Gln Asp Leu Met Ala Gln Met Gln Gly Pro Tyr Asn Phe
245 250 255
Ile Gln Asp Ser Met Leu Asp Phe Glu Asn Gln Thr Leu Asp Pro Ala
260 265 270
Ile Val Ser Ala Gln Pro Met Asn Pro Thr Gln Asn Met Asp Met Pro
275 280 285
Gln Leu Val Cys Pro Pro Val His Ser Glu Ser Arg Leu Ala Gln Pro
290 295 300
Asn Gln Val Pro Val Gln Pro Glu Ala Thr Gln Val Pro Leu Val Ser
305 310 315 320
Ser Thr Ser Glu Gly Tyr Thr Ala Ser Gln Pro Leu Tyr Gln Pro Ser
325 330 335
His Ala Thr Glu Gln Arg Pro Gln Lys Glu Pro Ile Asp Gln Ile Gln
340 345 350
Ala Thr Ile Ser Leu Asn Thr Asp Gln Thr Thr Ala Ser Ser Ser Leu
355 360 365
Pro Ala Ala Ser Gln Pro Gln Val Phe Gln Ala Gly Thr Ser Lys Pro
370 375 380
Leu His Ser Ser Gly Ile Asn Val Asn Ala Ala Pro Phe Gln Ser Met
385 390 395 400
Gln Thr Val Phe Asn Met Asn Ala Pro Val Pro Pro Val Asn Glu Pro
405 410 415
Glu Thr Leu Lys Gln Gln Asn Gln Tyr Gln Ala Ser Tyr Asn Gln Ser
420 425 430
Phe Ser Ser Gln Pro His Gln Val Glu Gln Thr Glu Gly Cys Arg Lys
435 440 445
<210> 7
<211> 4154
<212> DNA
<213> 狗(Canis familiaris)
<220>
<221> CDS
<222> (1)..(2154)
<223>
<400> 7
atg ccg tcg gcc acc agc ctc agc gga agc ggc agc aag tcg tcg ggc 48
Met Pro Ser Ala Thr Ser Leu Ser Gly Ser Gly Ser Lys Ser Ser Gly
1 5 10 15
ccg ccg ccc ccg tcg ggt tcc tcc ggg agc gag gcg gcg gcg gcg gcg 96
Pro Pro Pro Pro Ser Gly Ser Ser Gly Ser Glu Ala Ala Ala Ala Ala
20 25 30
ggg gcg gcg ggg gcg gcg ggg gcc ggg gcg gct gcg ccc gcc tcc cag 144
Gly Ala Ala Gly Ala Ala Gly Ala Gly Ala Ala Ala Pro Ala Ser Gln
35 40 45
cac ccc gcg acc ggc acc ggc gct gtc cag acc gag gcc atg aag cag 192
His Pro Ala Thr Gly Thr Gly Ala Val Gln Thr Glu Ala Met Lys Gln
50 55 60
atc ctc ggg gtg atc gac aag aaa ctc cgg aac ctg gag aag aaa aag 240
Ile Leu Gly Val Ile Asp Lys Lys Leu Arg Asn Leu Glu Lys Lys Lys
65 70 75 80
ggc aag ctt gat gat tac cag gaa cga atg aac aaa ggg gaa agg ctt 288
Gly Lys Leu Asp Asp Tyr Gln Glu Arg Met Asn Lys Gly Glu Arg Leu
85 90 95
aat caa gat cag ctg gat gcc gta tct aag tac cag gaa gtc aca aat 336
Asn Gln Asp Gln Leu Asp Ala Val Ser Lys Tyr Gln Glu Val Thr Asn
100 105 110
aac ttg gag ttt gca aaa gaa tta cag agg agt ttc atg gca tta agt 384
Asn Leu Glu Phe Ala Lys Glu Leu Gln Arg Ser Phe Met Ala Leu Ser
115 120 125
caa gat att cag aaa aca ata aag aag act gca cgt cgg gag cag ctt 432
Gln Asp Ile Gln Lys Thr Ile Lys Lys Thr Ala Arg Arg Glu Gln Leu
130 135 140
atg aga gag gaa gcg gaa caa aaa cgt tta aaa act gta ctt gag ctc 480
Met Arg Glu Glu Ala Glu Gln Lys Arg Leu Lys Thr Val Leu Glu Leu
145 150 155 160
cag tat gtt ttg gac aaa ttg gga gat gat gaa gtg aga act gac ctg 528
Gln Tyr Val Leu Asp Lys Leu Gly Asp Asp Glu Val Arg Thr Asp Leu
165 170 175
aag caa ggt ttg aat gga gtg cca ata ttg tct gaa gaa gaa ttg tcg 576
Lys Gln Gly Leu Asn Gly Val Pro Ile Leu Ser Glu Glu Glu Leu Ser
180 185 190
ttg ttg gat gaa ttc tac aaa tta gca gac cct gaa cgg gac atg agc 624
Leu Leu Asp Glu Phe Tyr Lys Leu Ala Asp Pro Glu Arg Asp Met Ser
195 200 205
ttg agg ttg aat gag cag tat gaa cat gct tcc att cac ctg tgg gac 672
Leu Arg Leu Asn Glu Gln Tyr Glu His Ala Ser Ile His Leu Trp Asp
210 215 220
ttg ctg gaa gga aag gaa aag tct gta tgt gga aca acc tat aaa gca 720
Leu Leu Glu Gly Lys Glu Lys Ser Val Cys Gly Thr Thr Tyr Lys Ala
225 230 235 240
cta aag gaa att gtt gag cgt gtt ttc cag tca aat tac ttt gac agc 768
Leu Lys Glu Ile Val Glu Arg Val Phe Gln Ser Asn Tyr Phe Asp Ser
245 250 255
act cac aac cac cag aat ggg cta tgt gag gaa gaa gag gca gcc tca 816
Thr His Asn His Gln Asn Gly Leu Cys Glu Glu Glu Glu Ala Ala Ser
260 265 270
gca cct aca gtt gaa gac cag gta gct gaa gct gag cct gag cca gca 864
Ala Pro Thr Val Glu Asp Gln Val Ala Glu Ala Glu Pro Glu Pro Ala
275 280 285
gaa gaa tac act gaa caa agt gaa gtt gaa tca aca gag tat gta aat 912
Glu Glu Tyr Thr Glu Gln Ser Glu Val Glu Ser Thr Glu Tyr Val Asn
290 295 300
aga caa ttt atg gca gaa aca cag ttc agc agt ggt gaa aag gag cag 960
Arg Gln Phe Met Ala Glu Thr Gln Phe Ser Ser Gly Glu Lys Glu Gln
305 310 315 320
gta gat gag tgg acg gtc gaa aca gtg gag gtg gtg aat tca ctc cag 1008
Val Asp Glu Trp Thr Val Glu Thr Val Glu Val Val Asn Ser Leu Gln
325 330 335
cag caa cct cag gct gcg tct cct tca gta cca gag ccc cac tct ttg 1056
Gln Gln Pro Gln Ala Ala Ser Pro Ser Val Pro Glu Pro His Ser Leu
340 345 350
act ccg gtg gct cag gca gat ccc ctt gtg aga aga cag cga gtc cag 1104
Thr Pro Val Ala Gln Ala Asp Pro Leu Val Arg Arg Gln Arg Val Gln
355 360 365
gac ctt atg gcg cag atg cag ggg ccc tat aat ttc ata cag gat tca 1152
Asp Leu Met Ala Gln Met Gln Gly Pro Tyr Asn Phe Ile Gln Asp Ser
370 375 380
atg ctg gat ttt gaa aac cag aca ctc gat cct gcc att gta tct gca 1200
Met Leu Asp Phe Glu Asn Gln Thr Leu Asp Pro Ala Ile Val Ser Ala
385 390 395 400
cag cct atg aat ccg aca caa aac atg gac atg ccc cag ctg gtt tgc 1248
Gln Pro Met Asn Pro Thr Gln Asn Met Asp Met Pro Gln Leu Val Cys
405 410 415
cct cca gtt cat tct gaa tct aga ctt gct caa cct aat caa gtt cct 1296
Pro Pro Val His Ser Glu Ser Arg Leu Ala Gln Pro Asn Gln Val Pro
420 425 430
gta caa cca gaa gct aca cag gtt cct ttg gtt tca tcc aca agt gag 1344
Val Gln Pro Glu Ala Thr Gln Val Pro Leu Val Ser Ser Thr Ser Glu
435 440 445
ggg tat aca gca tct caa ccc ttg tac cag cct tct cat gct aca gag 1392
Gly Tyr Thr Ala Ser Gln Pro Leu Tyr Gln Pro Ser His Ala Thr Glu
450 455 460
caa cga cca caa aag gaa cca att gac cag att cag gca aca atc tct 1440
Gln Arg Pro Gln Lys Glu Pro Ile Asp Gln Ile Gln Ala Thr Ile Ser
465 470 475 480
tta aat aca gac cag act aca gcg tca tca tcc ctt ccg gct gct tct 1488
Leu Asn Thr Asp Gln Thr Thr Ala Ser Ser Ser Leu Pro Ala Ala Ser
485 490 495
cag cct cag gta ttc cag gct ggg aca agc aaa cca tta cat agc agt 1536
Gln Pro Gln Val Phe Gln Ala Gly Thr Ser Lys Pro Leu His Ser Ser
500 505 510
gga atc aat gta aat gca gct cca ttc caa tcc atg caa acg gtg ttc 1584
Gly Ile Asn Val Asn Ala Ala Pro Phe Gln Ser Met Gln Thr Val Phe
515 520 525
aat atg aat gcc cca gtt cct cct gtt aat gaa cca gaa act ttg aaa 1632
Asn Met Asn Ala Pro Val Pro Pro Val Asn Glu Pro Glu Thr Leu Lys
530 535 540
caa caa aat cag tac cag gcc agt tat aac cag agc ttt tct agt cag 1680
Gln Gln Asn Gln Tyr Gln Ala Ser Tyr Asn Gln Ser Phe Ser Ser Gln
545 550 555 560
cct cac caa gta gaa caa aca gac ctt cag caa gaa cag ctt caa aca 1728
Pro His Gln Val Glu Gln Thr Asp Leu Gln Gln Glu Gln Leu Gln Thr
565 570 575
gtg gtt ggc act tac cat ggt tcc cag gac cag ccc cac caa gtg act 1776
Val Val Gly Thr Tyr His Gly Ser Gln Asp Gln Pro His Gln Val Thr
580 585 590
ggt aac cat cag cag cct ccc cag cag aac act gga ttt cca cgt agc 1824
Gly Asn His Gln Gln Pro Pro Gln Gln Asn Thr Gly Phe Pro Arg Ser
595 600 605
agt cag ccc tat tac aat agt cgt ggt gtg tct cgt ggt ggt tcc cgt 1872
Ser Gln Pro Tyr Tyr Asn Ser Arg Gly Val Ser Arg Gly Gly Ser Arg
610 615 620
ggt gct aga ggc tta atg aat gga tac agg ggc cct gcc aat gga ttc 1920
Gly Ala Arg Gly Leu Met Asn Gly Tyr Arg Gly Pro Ala Asn Gly Phe
625 630 635 640
aga gga gga tat gat ggt tac cgc cct tca ttc tct aac act cca aac 1968
Arg Gly Gly Tyr Asp Gly Tyr Arg Pro Ser Phe Ser Asn Thr Pro Asn
645 650 655
agt ggt tat aca cag tct cag ttc agt gct ccc cgg gac tac tct ggc 2016
Ser Gly Tyr Thr Gln Ser Gln Phe Ser Ala Pro Arg Asp Tyr Ser Gly
660 665 670
tat cag cgg gat gga tat cag cag aat ttc aag cga ggc tct ggg cag 2064
Tyr Gln Arg Asp Gly Tyr Gln Gln Asn Phe Lys Arg Gly Ser Gly Gln
675 680 685
agt gga cca cgg gga gcc cca cga ggt cgt gga ggg ccc cca aga ccc 2112
Ser Gly Pro Arg Gly Ala Pro Arg Gly Arg Gly Gly Pro Pro Arg Pro
690 695 700
aac aga ggg atg ccg caa atg aac act cag caa gtg aat taa 2154
Asn Arg Gly Met Pro Gln Met Asn Thr Gln Gln Val Asn
705 710 715
tctgattcac aggattatgt ttaaacgcca aaaacacact ggccagtgta ccataatatg 2214
ttaccagaag agttattatc tatttgttct ccctttcagg aaacttattg taaagggact 2274
gttttcatcc cataaagaca ggactacaat tgtcagcttt atattacctg gatatggaag 2334
gaaactattt ttattctgca tgttcttcct aagcgtcatc ttgagccttg cacatgatac 2394
tcagattcct cacccttgct taggagtaaa acataataca ctttacaggg tgatatctcc 2454
atagttattt gaagtggctt ggaaaaagca agattaactt ctgacattgg ataaaaatca 2514
acaaatcagc cctagagtta ttcaaatggt aattgacaaa aactaaaata tttcccttcg 2574
agaaggagtg gaatgtggtt tggcagaaca actgcatttc acagcttttc cggttaaatt 2634
ggagcactaa acgtttagat gcataccaaa ttatgcatgg gcccttaata taaaaggctg 2694
gctaccagct ttgacacagc actattcatc ctctggccaa acaactgtgg ttaaacaaca 2754
catgtaaatt gctttttaac agctgatact ataataagac aaagccaaaa tgcaaaaatt 2814
gggctttgat tggcactttt tgaaaaatat gcaacaaata tgggatgtaa tctggatggc 2874
cgcttctgta cttaatgtga agtatttaga tacctttttg aacacttaac agtttcttct 2934
gacaatgact tttgtaagga ttggtactat ctatcattcc ttataatgta cattgtctgt 2994
cactaatcct cagatcttgc tgtattgtca cctaaattgg tacaggtact gatgaaaata 3054
tctaatggat aatcataaca ctcttggtca catgtttttc ctgcagcctg aaggttttta 3114
aaagaaaaag atatcaaatg cctgctgcta ccaccctttt aaattgctat cttttgaaaa 3174
gcaccagtat gtgttttaga ttgatttccc tattttaggg aaatgacaga cagtagtttc 3234
agttctgatg gtataagcaa aacaaataaa acatgtttat aaaagttgta tcttgaaaca 3294
ctggtgttca acagctagca gcttatgtgg ttcaccccat gcattgttag tgtttcagat 3354
tttatggtta tctccagcag ctgtttctgt agtacttgca tttatctttt gtctaaccct 3414
aatattctca cggaggcatt tatattcaaa gtggtgatcc cttcacttag acgcataggg 3474
agagtcacaa gtttgatgaa gaggacagtg tagtaattta tatgctgttg gaatttgtgc 3534
tagcagtttg agcactagtt ctgtgtgcct atgaacttaa tgctgcttgt catattccac 3594
tttgacttca tggagaatta atcccatcta ctcagcaaag gctatactaa tactaagtta 3654
atggtatttt ctgtgcagaa attgaatttt gttttattag catttagcta aggaattttt 3714
ccagtaggtg ctcagctact aaagaaaaac aaaaacaaga cacaaaacta ttctcaaaca 3774
ttcattgtta gacaactgga gtttttgctg gttttgtaac ctactaaaat ggataggctg 3834
ttgaacattc cacattcaaa agttttttgt agggtggtgg ggaagggggg gtgtcttcaa 3894
tgtttatttt aaaataaaat aagttcttga cttttctcat gtgtggttgt ggtacatcat 3954
attggaaggg ttatctgttt acttttgcaa atgagtattt ctcttgctag cacctcccgt 4014
tgtgcgcttt aaatgacatc tgcctgggat gtaccacaac catatgttag ctgtatttta 4074
tggggaatag ataaaatatt cgtggtttat tgggtaatcc ctagatgtgt atgcttacaa 4134
tcctatatat aaaactaaat 4154
<210> 8
<211> 717
<212> PRT
<213> 狗(Canis familiaris)
<400> 8
Met Pro Ser Ala Thr Ser Leu Ser Gly Ser Gly Ser Lys Ser Ser Gly
1 5 10 15
Pro Pro Pro Pro Ser Gly Ser Ser Gly Ser Glu Ala Ala Ala Ala Ala
20 25 30
Gly Ala Ala Gly Ala Ala Gly Ala Gly Ala Ala Ala Pro Ala Ser Gln
35 40 45
His Pro Ala Thr Gly Thr Gly Ala Val Gln Thr Glu Ala Met Lys Gln
50 55 60
Ile Leu Gly Val Ile Asp Lys Lys Leu Arg Asn Leu Glu Lys Lys Lys
65 70 75 80
Gly Lys Leu Asp Asp Tyr Gln Glu Arg Met Asn Lys Gly Glu Arg Leu
85 90 95
Asn Gln Asp Gln Leu Asp Ala Val Ser Lys Tyr Gln Glu Val Thr Asn
100 105 110
Asn Leu Glu Phe Ala Lys Glu Leu Gln Arg Ser Phe Met Ala Leu Ser
115 120 125
Gln Asp Ile Gln Lys Thr Ile Lys Lys Thr Ala Arg Arg Glu Gln Leu
130 135 140
Met Arg Glu Glu Ala Glu Gln Lys Arg Leu Lys Thr Val Leu Glu Leu
145 150 155 160
Gln Tyr Val Leu Asp Lys Leu Gly Asp Asp Glu Val Arg Thr Asp Leu
165 170 175
Lys Gln Gly Leu Asn Gly Val Pro Ile Leu Ser Glu Glu Glu Leu Ser
180 185 190
Leu Leu Asp Glu Phe Tyr Lys Leu Ala Asp Pro Glu Arg Asp Met Ser
195 200 205
Leu Arg Leu Asn Glu Gln Tyr Glu His Ala Ser Ile His Leu Trp Asp
210 215 220
Leu Leu Glu Gly Lys Glu Lys Ser Val Cys Gly Thr Thr Tyr Lys Ala
225 230 235 240
Leu Lys Glu Ile Val Glu Arg Val Phe Gln Ser Asn Tyr Phe Asp Ser
245 250 255
Thr His Asn His Gln Asn Gly Leu Cys Glu Glu Glu Glu Ala Ala Ser
260 265 270
Ala Pro Thr Val Glu Asp Gln Val Ala Glu Ala Glu Pro Glu Pro Ala
275 280 285
Glu Glu Tyr Thr Glu Gln Ser Glu Val Glu Ser Thr Glu Tyr Val Asn
290 295 300
Arg Gln Phe Met Ala Glu Thr Gln Phe Ser Ser Gly Glu Lys Glu Gln
305 310 315 320
Val Asp Glu Trp Thr Val Glu Thr Val Glu Val Val Asn Ser Leu Gln
325 330 335
Gln Gln Pro Gln Ala Ala Ser Pro Ser Val Pro Glu Pro His Ser Leu
340 345 350
Thr Pro Val Ala Gln Ala Asp Pro Leu Val Arg Arg Gln Arg Val Gln
355 360 365
Asp Leu Met Ala Gln Met Gln Gly Pro Tyr Asn Phe Ile Gln Asp Ser
370 375 380
Met Leu Asp Phe Glu Asn Gln Thr Leu Asp Pro Ala Ile Val Ser Ala
385 390 395 400
Gln Pro Met Asn Pro Thr Gln Asn Met Asp Met Pro Gln Leu Val Cys
405 410 415
Pro Pro Val His Ser Glu Ser Arg Leu Ala Gln Pro Asn Gln Val Pro
420 425 430
Val Gln Pro Glu Ala Thr Gln Val Pro Leu Val Ser Ser Thr Ser Glu
435 440 445
Gly Tyr Thr Ala Ser Gln Pro Leu Tyr Gln Pro Ser His Ala Thr Glu
450 455 460
Gln Arg Pro Gln Lys Glu Pro Ile Asp Gln Ile Gln Ala Thr Ile Ser
465 470 475 480
Leu Asn Thr Asp Gln Thr Thr Ala Ser Ser Ser Leu Pro Ala Ala Ser
485 490 495
Gln Pro Gln Val Phe Gln Ala Gly Thr Ser Lys Pro Leu His Ser Ser
500 505 510
Gly Ile Asn Val Asn Ala Ala Pro Phe Gln Ser Met Gln Thr Val Phe
515 520 525
Asn Met Asn Ala Pro Val Pro Pro Val Asn Glu Pro Glu Thr Leu Lys
530 535 540
Gln Gln Asn Gln Tyr Gln Ala Ser Tyr Asn Gln Ser Phe Ser Ser Gln
545 550 555 560
Pro His Gln Val Glu Gln Thr Asp Leu Gln Gln Glu Gln Leu Gln Thr
565 570 575
Val Val Gly Thr Tyr His Gly Ser Gln Asp Gln Pro His Gln Val Thr
580 585 590
Gly Asn His Gln Gln Pro Pro Gln Gln Asn Thr Gly Phe Pro Arg Ser
595 600 605
Ser Gln Pro Tyr Tyr Asn Ser Arg Gly Val Ser Arg Gly Gly Ser Arg
610 615 620
Gly Ala Arg Gly Leu Met Asn Gly Tyr Arg Gly Pro Ala Asn Gly Phe
625 630 635 640
Arg Gly Gly Tyr Asp Gly Tyr Arg Pro Ser Phe Ser Asn Thr Pro Asn
645 650 655
Ser Gly Tyr Thr Gln Ser Gln Phe Ser Ala Pro Arg Asp Tyr Ser Gly
660 665 670
Tyr Gln Arg Asp Gly Tyr Gln Gln Asn Phe Lys Arg Gly Ser Gly Gln
675 680 685
Ser Gly Pro Arg Gly Ala Pro Arg Gly Arg Gly Gly Pro Pro Arg Pro
690 695 700
Asn Arg Gly Met Pro Gln Met Asn Thr Gln Gln Val Asn
705 710 715
<210> 9
<211> 4939
<212> DNA
<213> 狗(Canis familiaris)
<220>
<221> CDS
<222> (1)..(2109)
<223>
<400> 9
atg ccg tcg gcc acc agc ctc agc gga agc ggc agc aag tcg tcg ggc 48
Met Pro Ser Ala Thr Ser Leu Ser Gly Ser Gly Ser Lys Ser Ser Gly
1 5 10 15
ccg ccg ccc ccg tcg ggt tcc tcc ggg agc gag gcg gcg gcg gcg gcg 96
Pro Pro Pro Pro Ser Gly Ser Ser Gly Ser Glu Ala Ala Ala Ala Ala
20 25 30
ggg gcg gcg ggg gcg gcg ggg gcc ggg gcg gct gcg ccc gcc tcc cag 144
Gly Ala Ala Gly Ala Ala Gly Ala Gly Ala Ala Ala Pro Ala Ser Gln
35 40 45
cac ccc gcg acc ggc acc ggc gct gtc cag acc gag gcc atg aag cag 192
His Pro Ala Thr Gly Thr Gly Ala Val Gln Thr Glu Ala Met Lys Gln
50 55 60
atc ctc ggg gtg atc gac aag aaa ctc cgg aac ctg gag aag aaa aag 240
Ile Leu Gly Val Ile Asp Lys Lys Leu Arg Asn Leu Glu Lys Lys Lys
65 70 75 80
ggc aag ctt gat gat tac cag gaa cga atg aac aaa ggg gaa agg ctt 288
Gly Lys Leu Asp Asp Tyr Gln Glu Arg Met Asn Lys Gly Glu Arg Leu
85 90 95
aat caa gat cag ctg gat gcc gta tct aag tac cag gaa gtc aca aat 336
Asn Gln Asp Gln Leu Asp Ala Val Ser Lys Tyr Gln Glu Val Thr Asn
100 105 110
aac ttg gag ttt gca aaa gaa tta cag agg agt ttc atg gca tta agt 384
Asn Leu Glu Phe Ala Lys Glu Leu Gln Arg Ser Phe Met Ala Leu Ser
115 120 125
caa gat att cag aaa aca ata aag aag act gca cgt cgg gag cag ctt 432
Gln Asp Ile Gln Lys Thr Ile Lys Lys Thr Ala Arg Arg Glu Gln Leu
130 135 140
atg aga gag gaa gcg gaa caa aaa cgt tta aaa act gta ctt gag ctc 480
Met Arg Glu Glu Ala Glu Gln Lys Arg Leu Lys Thr Val Leu Glu Leu
145 150 155 160
cag tat gtt ttg gac aaa ttg gga gat gat gaa gtg aga act gac ctg 528
Gln Tyr Val Leu Asp Lys Leu Gly Asp Asp Glu Val Arg Thr Asp Leu
165 170 175
aag caa ggt ttg aat gga gtg cca ata ttg tct gaa gaa gaa ttg tcg 576
Lys Gln Gly Leu Asn Gly Val Pro Ile Leu Ser Glu Glu Glu Leu Ser
180 185 190
ttg ttg gat gaa ttc tac aaa tta gca gac cct gaa cgg gac atg agc 624
Leu Leu Asp Glu Phe Tyr Lys Leu Ala Asp Pro Glu Arg Asp Met Ser
195 200 205
ttg agg ttg aat gag cag tat gaa cat gct tcc att cac ctg tgg gac 672
Leu Arg Leu Asn Glu Gln Tyr Glu His Ala Ser Ile His Leu Trp Asp
210 215 220
ttg ctg gaa gga aag gaa aag tct gta tgt gga aca acc tat aaa gca 720
Leu Leu Glu Gly Lys Glu Lys Ser Val Cys Gly Thr Thr Tyr Lys Ala
225 230 235 240
cta aag gaa att gtt gag cgt gtt ttc cag tca aat tac ttt gac agc 768
Leu Lys Glu Ile Val Glu Arg Val Phe Gln Ser Asn Tyr Phe Asp Ser
245 250 255
act cac aac cac cag aat ggg cta tgt gag gaa gaa gag gca gcc tca 816
Thr His Asn His Gln Asn Gly Leu Cys Glu Glu Glu Glu Ala Ala Ser
260 265 270
gca cct aca gtt gaa gac cag gta gct gaa gct gag cct gag cca gca 864
Ala Pro Thr Val Glu Asp Gln Val Ala Glu Ala Glu Pro Glu Pro Ala
275 280 285
gaa gaa tac act gaa caa agt gaa gtt gaa tca aca gag tat gta aat 912
Glu Glu Tyr Thr Glu Gln Ser Glu Val Glu Ser Thr Glu Tyr Val Asn
290 295 300
aga caa ttt atg gca gaa aca cag ttc agc agt ggt gaa aag gag cag 960
Arg Gln Phe Met Ala Glu Thr Gln Phe Ser Ser Gly Glu Lys Glu Gln
305 310 315 320
gta gat gag tgg acg gtc gaa aca gtg gag gtg gtg aat tca ctc cag 1008
Val Asp Glu Trp Thr Val Glu Thr Val Glu Val Val Asn Ser Leu Gln
325 330 335
cag caa cct cag gct gcg tct cct tca gta cca gag ccc cac tct ttg 1056
Gln Gln Pro Gln Ala Ala Ser Pro Ser Val Pro Glu Pro His Ser Leu
340 345 350
act ccg gtg gct cag gca gat ccc ctt gtg aga aga cag cga gtc cag 1104
Thr Pro Val Ala Gln Ala Asp Pro Leu Val Arg Arg Gln Arg Val Gln
355 360 365
gac ctt atg gcg cag atg cag ggg ccc tat aat ttc ata cag gat tca 1152
Asp Leu Met Ala Gln Met Gln Gly Pro Tyr Asn Phe Ile Gln Asp Ser
370 375 380
atg ctg gat ttt gaa aac cag aca ctc gat cct gcc att gta tct gca 1200
Met Leu Asp Phe Glu Asn Gln Thr Leu Asp Pro Ala Ile Val Ser Ala
385 390 395 400
cag cct atg aat ccg aca caa aac atg gac atg ccc cag ctg gtt tgc 1248
Gln Pro Met Asn Pro Thr Gln Asn Met Asp Met Pro Gln Leu Val Cys
405 410 415
cct cca gtt cat tct gaa tct aga ctt gct caa cct aat caa gtt cct 1296
Pro Pro Val His Ser Glu Ser Arg Leu Ala Gln Pro Asn Gln Val Pro
420 425 430
gta caa cca gaa gct aca cag gtt cct ttg gtt tca tcc aca agt gag 1344
Val Gln Pro Glu Ala Thr Gln Val Pro Leu Val Ser Ser Thr Ser Glu
435 440 445
ggg tat aca gca tct caa ccc ttg tac cag cct tct cat gct aca gag 1392
Gly Tyr Thr Ala Ser Gln Pro Leu Tyr Gln Pro Ser His Ala Thr Glu
450 455 460
caa cga cca caa aag gaa cca att gac cag att cag gca aca atc tct 1440
Gln Arg Pro Gln Lys Glu Pro Ile Asp Gln Ile Gln Ala Thr Ile Ser
465 470 475 480
tta aat aca gac cag act aca gcg tca tca tcc ctt ccg gct gct tct 1488
Leu Asn Thr Asp Gln Thr Thr Ala Ser Ser Ser Leu Pro Ala Ala Ser
485 490 495
cag cct cag gta ttc cag gct ggg aca agc aaa cca tta cat agc agt 1536
Gln Pro Gln Val Phe Gln Ala Gly Thr Ser Lys Pro Leu His Ser Ser
500 505 510
gga atc aat gta aat gca gct cca ttc caa tcc atg caa acg gtg ttc 1584
Gly Ile Asn Val Asn Ala Ala Pro Phe Gln Ser Met Gln Thr Val Phe
515 520 525
aat atg aat gcc cca gtt cct cct gtt aat gaa cca gaa act ttg aaa 1632
Asn Met Asn Ala Pro Val Pro Pro Val Asn Glu Pro Glu Thr Leu Lys
530 535 540
caa caa aat cag tac cag gcc agt tat aac cag agc ttt tct agt cag 1680
Gln Gln Asn Gln Tyr Gln Ala Ser Tyr Asn Gln Ser Phe Ser Ser Gln
545 550 555 560
cct cac caa gta gaa caa aca gac ctt cag caa gaa cag ctt caa aca 1728
Pro His Gln Val Glu Gln Thr Asp Leu Gln Gln Glu Gln Leu Gln Thr
565 570 575
gtg gtt ggc act tac cat ggt tcc cag gac cag ccc cac caa gtg act 1776
Val Val Gly Thr Tyr His Gly Ser Gln Asp Gln Pro His Gln Val Thr
580 585 590
ggt aac cat cag cag cct ccc cag cag aac act gga ttt cca cgt agc 1824
Gly Asn His Gln Gln Pro Pro Gln Gln Asn Thr Gly Phe Pro Arg Ser
595 600 605
agt cag ccc tat tac aat agt cgt ggt gtg tct cgt ggt ggt tcc cgt 1872
Ser Gln Pro Tyr Tyr Asn Ser Arg Gly Val Ser Arg Gly Gly Ser Arg
610 615 620
ggt gct aga ggc tta atg aat gga tac agg ggc cct gcc aat gga ttc 1920
Gly Ala Arg Gly Leu Met Asn Gly Tyr Arg Gly Pro Ala Asn Gly Phe
625 630 635 640
aga gga gga tat gat ggt tac cgc cct tca ttc tct aac act cca aac 1968
Arg Gly Gly Tyr Asp Gly Tyr Arg Pro Ser Phe Ser Asn Thr Pro Asn
645 650 655
agt ggt tat aca cag tct cag ttc agt gct ccc cgg gac tac tct ggc 2016
Ser Gly Tyr Thr Gln Ser Gln Phe Ser Ala Pro Arg Asp Tyr Ser Gly
660 665 670
tat cag cgg gat gga tat cag cag aat ttc aag cga ggc tct ggg cag 2064
Tyr Gln Arg Asp Gly Tyr Gln Gln Asn Phe Lys Arg Gly Ser Gly Gln
675 680 685
agt gga cca cgg gga gcc cca cga ggt aat att ttg tgg tgg tga 2109
Ser Gly Pro Arg Gly Ala Pro Arg Gly Asn Ile Leu Trp Trp
690 695 700
tcctagctcc taagtggagc ttctgttctg gccttggaag agctgttcca tagtctgcat 2169
gtaggttaca tgttaggaat acatttatca ttaccagact tgttgctagg gattaaatga 2229
aatgctctgt ttctaaaact tctcttgaac ccaaatttaa ttttttgaat gactttccct 2289
gttactatat aaattgtctt gaaaactaga acatttctcc tcctcagaaa aagtgttttt 2349
ccaactgcaa attatttttc aggtcctaaa acctgctaaa tgtttttagg aagtacttac 2409
tgaaacattt ttgtaagaca tttttggaat gagattgaac atttatataa atttattatt 2469
attcctcttt catttttgaa catgcatatt atattttagg gtcagaaatc ctttaatggc 2529
caaataagcc atagttacat ttagagaacc atttagaagt gatagaacta actgaaattt 2589
caatgccttt ggatcattaa tagcgatata aatttcaaat tgtttctgac ttttaaataa 2649
aacatccaaa atcctaacta acttcctgaa ctatatttaa aaattacagg tttaaggagt 2709
ttctggtttt ttttctctta ccataggaaa actgtttcct gtttggccag gaagtcaacc 2769
tgtgtaataa ttagaagtag catttcatat gatctgaagt tctaaatggt tctctgattt 2829
aagggaagtt aaattgaata ggtttcctct agttattggc cataacatgt ataaaatgta 2889
tattaaggag gaatacaaag tactttgatt tcaatgctag tagaaactgg ccagcaaaaa 2949
ggtgcatttt atttttaaat taatggatca cttgggaatt actgacttga agtatcaaag 3009
gatatttgca tgtgaatgtg ggttatgttc tttctcacct tgtagcatat tctatgaaag 3069
ttgagttgac tggtagctaa aaatctgttt taacagcatg taaaaagtta ttttatctgt 3129
tacaagtcat tatacaattt tgaatgttat gtagtttctt tttaacagtt taggtaacaa 3189
ggtctgtttt tcattctggt gcttttatta attttgatag tatgatgtta cttactactg 3249
aaatgtaagc tagagtgtac actagaatgt aagctccatg agagcaggta ccttgtctgt 3309
cttcactgct gtatctattt ccaacgcctg atgacagtgc ctgacacata gtaggcactc 3369
aataaatact tgttgaatga atgaatgaat gagtactggt ggaatactcc attagctcta 3429
ctcttctttt agctagagaa catgagcaaa tttgcgcatg acaacttcca ggacaggtga 3489
acactgaaga attgacctct taaacctaat aatgtggtga caagctgccc acatgcttct 3549
tgacttcaga tgaaaatctg cttgaaggca aagcaaataa tatttgaaag aaaaaccaaa 3609
tgccattttt gtcttctagg tcgtggaggg cccccaagac ccaacagagg gatgccgcaa 3669
atgaacactc agcaagtgaa ttaatctgat tcacaggatt atgtttaaac gccaaaaaca 3729
cactggccag tgtaccataa tatgttacca gaagagttat tatctatttg ttctcccttt 3789
caggaaactt attgtaaagg gactgttttc atcccataaa gacaggacta caattgtcag 3849
ctttatatta cctggatatg gaaggaaact atttttattc tgcatgttct tcctaagcgt 3909
catcttgagc cttgcacatg atactcagat tcctcaccct tgcttaggag taaaacataa 3969
tacactttac agggtgatat ctccatagtt atttgaagtg gcttggaaaa agcaagatta 4029
acttctgaca ttggataaaa atcaacaaat cagccctaga gttattcaaa tggtaattga 4089
caaaaactaa aatatttccc ttcgagaagg agtggaatgt ggtttggcag aacaactgca 4149
tttcacagct tttccggtta aattggagca ctaaacgttt agatgcatac caaattatgc 4209
atgggccctt aatataaaag gctggctacc agctttgaca cagcactatt catcctctgg 4269
ccaaacaact gtggttaaac aacacatgta aattgctttt taacagctga tactataata 4329
agacaaagcc aaaatgcaaa aattgggctt tgattggcac tttttgaaaa atatgcaaca 4389
aatatgggat gtaatctgga tggccgcttc tgtacttaat gtgaagtatt tagatacctt 4449
tttgaacact taacagtttc ttctgacaat gacttttgta aggattggta ctatctatca 4509
ttccttataa tgtacattgt ctgtcactaa tcctcagatc ttgctgtatt gtcacctaaa 4569
ttggtacagg tactgatgaa aatatctaat ggataatcat aacactcttg gtcacatgtt 4629
tttcctgcag cctgaaggtt tttaaaagaa aaagatatca aatgcctgct gctaccaccc 4689
ttttaaattg ctatcttttg aaaagcacca gtatgtgttt tagattgatt tccctatttt 4749
agggaaatga cagacagtag tttcagttct gatggtataa gcaaaacaaa taaaacatgt 4809
ttataaaagt tgtatcttga aacactggtg ttcaacagct agcagcttat gtggttcacc 4869
ccatgcattg ttagtgtttc agattttatg gttatctcca gcagctgttt ctgtagtact 4929
tgcatttatc 4939
<210> 10
<211> 702
<212> PRT
<213> 狗(Canis familiaris)
<400> 10
Met Pro Ser Ala Thr Ser Leu Ser Gly Ser Gly Ser Lys Ser Ser Gly
1 5 10 15
Pro Pro Pro Pro Ser Gly Ser Ser Gly Ser Glu Ala Ala Ala Ala Ala
20 25 30
Gly Ala Ala Gly Ala Ala Gly Ala Gly Ala Ala Ala Pro Ala Ser Gln
35 40 45
His Pro Ala Thr Gly Thr Gly Ala Val Gln Thr Glu Ala Met Lys Gln
50 55 60
Ile Leu Gly Val Ile Asp Lys Lys Leu Arg Asn Leu Glu Lys Lys Lys
65 70 75 80
Gly Lys Leu Asp Asp Tyr Gln Glu Arg Met Asn Lys Gly Glu Arg Leu
85 90 95
Asn Gln Asp Gln Leu Asp Ala Val Ser Lys Tyr Gln Glu Val Thr Asn
100 105 110
Asn Leu Glu Phe Ala Lys Glu Leu Gln Arg Ser Phe Met Ala Leu Ser
115 120 125
Gln Asp Ile Gln Lys Thr Ile Lys Lys Thr Ala Arg Arg Glu Gln Leu
130 135 140
Met Arg Glu Glu Ala Glu Gln Lys Arg Leu Lys Thr Val Leu Glu Leu
145 150 155 160
Gln Tyr Val Leu Asp Lys Leu Gly Asp Asp Glu Val Arg Thr Asp Leu
165 170 175
Lys Gln Gly Leu Asn Gly Val Pro Ile Leu Ser Glu Glu Glu Leu Ser
180 185 190
Leu Leu Asp Glu Phe Tyr Lys Leu Ala Asp Pro Glu Arg Asp Met Ser
195 200 205
Leu Arg Leu Asn Glu Gln Tyr Glu His Ala Ser Ile His Leu Trp Asp
210 215 220
Leu Leu Glu Gly Lys Glu Lys Ser Val Cys Gly Thr Thr Tyr Lys Ala
225 230 235 240
Leu Lys Glu Ile Val Glu Arg Val Phe Gln Ser Asn Tyr Phe Asp Ser
245 250 255
Thr His Asn His Gln Asn Gly Leu Cys Glu Glu Glu Glu Ala Ala Ser
260 265 270
Ala Pro Thr Val Glu Asp Gln Val Ala Glu Ala Glu Pro Glu Pro Ala
275 280 285
Glu Glu Tyr Thr Glu Gln Ser Glu Val Glu Ser Thr Glu Tyr Val Asn
290 295 300
Arg Gln Phe Met Ala Glu Thr Gln Phe Ser Ser Gly Glu Lys Glu Gln
305 310 315 320
Val Asp Glu Trp Thr Val Glu Thr Val Glu Val Val Asn Ser Leu Gln
325 330 335
Gln Gln Pro Gln Ala Ala Ser Pro Ser Val Pro Glu Pro His Ser Leu
340 345 350
Thr Pro Val Ala Gln Ala Asp Pro Leu Val Arg Arg Gln Arg Val Gln
355 360 365
Asp Leu Met Ala Gln Met Gln Gly Pro Tyr Asn Phe Ile Gln Asp Ser
370 375 380
Met Leu Asp Phe Glu Asn Gln Thr Leu Asp Pro Ala Ile Val Ser Ala
385 390 395 400
Gln Pro Met Asn Pro Thr Gln Asn Met Asp Met Pro Gln Leu Val Cys
405 410 415
Pro Pro Val His Ser Glu Ser Arg Leu Ala Gln Pro Asn Gln Val Pro
420 425 430
Val Gln Pro Glu Ala Thr Gln Val Pro Leu Val Ser Ser Thr Ser Glu
435 440 445
Gly Tyr Thr Ala Ser Gln Pro Leu Tyr Gln Pro Ser His Ala Thr Glu
450 455 460
Gln Arg Pro Gln Lys Glu Pro Ile Asp Gln Ile Gln Ala Thr Ile Ser
465 470 475 480
Leu Asn Thr Asp Gln Thr Thr Ala Ser Ser Ser Leu Pro Ala Ala Ser
485 490 495
Gln Pro Gln Val Phe Gln Ala Gly Thr Ser Lys Pro Leu His Ser Ser
500 505 510
Gly Ile Asn Val Asn Ala Ala Pro Phe Gln Ser Met Gln Thr Val Phe
515 520 525
Asn Met Asn Ala Pro Val Pro Pro Val Asn Glu Pro Glu Thr Leu Lys
530 535 540
Gln Gln Asn Gln Tyr Gln Ala Ser Tyr Asn Gln Ser Phe Ser Ser Gln
545 550 555 560
Pro His Gln Val Glu Gln Thr Asp Leu Gln Gln Glu Gln Leu Gln Thr
565 570 575
Val Val Gly Thr Tyr His Gly Ser Gln Asp Gln Pro His Gln Val Thr
580 585 590
Gly Asn His Gln Gln Pro Pro Gln Gln Asn Thr Gly Phe Pro Arg Ser
595 600 605
Ser Gln Pro Tyr Tyr Asn Ser Arg Gly Val Ser Arg Gly Gly Ser Arg
610 615 620
Gly Ala Arg Gly Leu Met Asn Gly Tyr Arg Gly Pro Ala Asn Gly Phe
625 630 635 640
Arg Gly Gly Tyr Asp Gly Tyr Arg Pro Ser Phe Ser Asn Thr Pro Asn
645 650 655
Ser Gly Tyr Thr Gln Ser Gln Phe Ser Ala Pro Arg Asp Tyr Ser Gly
660 665 670
Tyr Gln Arg Asp Gly Tyr Gln Gln Asn Phe Lys Arg Gly Ser Gly Gln
675 680 685
Ser Gly Pro Arg Gly Ala Pro Arg Gly Asn Ile Leu Trp Trp
690 695 700
<210> 11
<211> 3306
<212> DNA
<213> 狗(Canis familiaris)
<220>
<221> CDS
<222> (1)..(2040)
<223>
<400> 11
atg ccg tcg gcc acc agc ctc agc gga agc ggc agc aag tcg tcg ggc 48
Met Pro Ser Ala Thr Ser Leu Ser Gly Ser Gly Ser Lys Ser Ser Gly
1 5 10 15
ccg ccg ccc ccg tcg ggt tcc tcc ggg agc gag gcg gcg gcg gcg gcg 96
Pro Pro Pro Pro Ser Gly Ser Ser Gly Ser Glu Ala Ala Ala Ala Ala
20 25 30
ggg gcg gcg ggg gcg gcg ggg gcc ggg gcg gct gcg ccc gcc tcc cag 144
Gly Ala Ala Gly Ala Ala Gly Ala Gly Ala Ala Ala Pro Ala Ser Gln
35 40 45
cac ccc gcg acc ggc acc ggc gct gtc cag acc gag gcc atg aag cag 192
His Pro Ala Thr Gly Thr Gly Ala Val Gln Thr Glu Ala Met Lys Gln
50 55 60
atc ctc ggg gtg atc gac aag aaa ctc cgg aac ctg gag aag aaa aag 240
Ile Leu Gly Val Ile Asp Lys Lys Leu Arg Asn Leu Glu Lys Lys Lys
65 70 75 80
ggc aag ctt gat gat tac cag gaa cga atg aac aaa ggg gaa agg ctt 288
Gly Lys Leu Asp Asp Tyr Gln Glu Arg Met Asn Lys Gly Glu Arg Leu
85 90 95
aat caa gat cag ctg gat gcc gta tct aag tac cag gaa gtc aca aat 336
Asn Gln Asp Gln Leu Asp Ala Val Ser Lys Tyr Gln Glu Val Thr Asn
100 105 110
aac ttg gag ttt gca aaa gaa tta cag agg agt ttc atg gca tta agt 384
Asn Leu Glu Phe Ala Lys Glu Leu Gln Arg Ser Phe Met Ala Leu Ser
115 120 125
caa gat att cag aaa aca ata aag aag act gca cgt cgg gag cag ctt 432
Gln Asp Ile Gln Lys Thr Ile Lys Lys Thr Ala Arg Arg Glu Gln Leu
130 135 140
atg aga gag gaa gcg gaa caa aaa cgt tta aaa act gta ctt gag ctc 480
Met Arg Glu Glu Ala Glu Gln Lys Arg Leu Lys Thr Val Leu Glu Leu
145 150 155 160
cag tat gtt ttg gac aaa ttg gga gat gat gaa gtg aga act gac ctg 528
Gln Tyr Val Leu Asp Lys Leu Gly Asp Asp Glu Val Arg Thr Asp Leu
165 170 175
aag caa ggt ttg aat gga gtg cca ata ttg tct gaa gaa gaa ttg tcg 576
Lys Gln Gly Leu Asn Gly Val Pro Ile Leu Ser Glu Glu Glu Leu Ser
180 185 190
ttg ttg gat gaa ttc tac aaa tta gca gac cct gaa cgg gac atg agc 624
Leu Leu Asp Glu Phe Tyr Lys Leu Ala Asp Pro Glu Arg Asp Met Ser
195 200 205
ttg agg ttg aat gag cag tat gaa cat gct tcc att cac ctg tgg gac 672
Leu Arg Leu Asn Glu Gln Tyr Glu His Ala Ser Ile His Leu Trp Asp
210 215 220
ttg ctg gaa gga aag gaa aag tct gta tgt gga aca acc tat aaa gca 720
Leu Leu Glu Gly Lys Glu Lys Ser Val Cys Gly Thr Thr Tyr Lys Ala
225 230 235 240
cta aag gaa att gtt gag cgt gtt ttc cag tca aat tac ttt gac agc 768
Leu Lys Glu Ile Val Glu Arg Val Phe Gln Ser Asn Tyr Phe Asp Ser
245 250 255
act cac aac cac cag aat ggg cta tgt gag gaa gaa gag gca gcc tca 816
Thr His Asn His Gln Asn Gly Leu Cys Glu Glu Glu Glu Ala Ala Ser
260 265 270
gca cct aca gtt gaa gac cag gta gct gaa gct gag cct gag cca gca 864
Ala Pro Thr Val Glu Asp Gln Val Ala Glu Ala Glu Pro Glu Pro Ala
275 280 285
gaa gaa tac act gaa caa agt gaa gtt gaa tca aca gag tat gta aat 912
Glu Glu Tyr Thr Glu Gln Ser Glu Val Glu Ser Thr Glu Tyr Val Asn
290 295 300
aga caa ttt atg gca gaa aca cag ttc agc agt ggt gaa aag gag cag 960
Arg Gln Phe Met Ala Glu Thr Gln Phe Ser Ser Gly Glu Lys Glu Gln
305 310 315 320
gta gat gag tgg acg gtc gaa aca gtg gag gtg gtg aat tca ctc cag 1008
Val Asp Glu Trp Thr Val Glu Thr Val Glu Val Val Asn Ser Leu Gln
325 330 335
cag caa cct cag gct gcg tct cct tca gta cca gag ccc cac tct ttg 1056
Gln Gln Pro Gln Ala Ala Ser Pro Ser Val Pro Glu Pro His Ser Leu
340 345 350
act ccg gtg gct cag gca gat ccc ctt gtg aga aga cag cga gtc cag 1104
Thr Pro Val Ala Gln Ala Asp Pro Leu Val Arg Arg Gln Arg Val Gln
355 360 365
gac ctt atg gcg cag atg cag ggg ccc tat aat ttc ata cag gat tca 1152
Asp Leu Met Ala Gln Met Gln Gly Pro Tyr Asn Phe Ile Gln Asp Ser
370 375 380
atg ctg gat ttt gaa aac cag aca ctc gat cct gcc att gta tct gca 1200
Met Leu Asp Phe Glu Asn Gln Thr Leu Asp Pro Ala Ile Val Ser Ala
385 390 395 400
cag cct atg aat ccg aca caa aac atg gac atg ccc cag ctg gtt tgc 1248
Gln Pro Met Asn Pro Thr Gln Asn Met Asp Met Pro Gln Leu Val Cys
405 410 415
cct cca gtt cat tct gaa tct aga ctt gct caa cct aat caa gtt cct 1296
Pro Pro Val His Ser Glu Ser Arg Leu Ala Gln Pro Asn Gln Val Pro
420 425 430
gta caa cca gaa gct aca cag gtt cct ttg gtt tca tcc aca agt gag 1344
Val Gln Pro Glu Ala Thr Gln Val Pro Leu Val Ser Ser Thr Ser Glu
435 440 445
ggg tat aca gca tct caa ccc ttg tac cag cct tct cat gct aca gag 1392
Gly Tyr Thr Ala Ser Gln Pro Leu Tyr Gln Pro Ser His Ala Thr Glu
450 455 460
caa cga cca caa aag gaa cca att gac cag att cag gca aca atc tct 1440
Gln Arg Pro Gln Lys Glu Pro Ile Asp Gln Ile Gln Ala Thr Ile Ser
465 470 475 480
tta aat aca gac cag act aca gcg tca tca tcc ctt ccg gct gct tct 1488
Leu Asn Thr Asp Gln Thr Thr Ala Ser Ser Ser Leu Pro Ala Ala Ser
485 490 495
cag cct cag gta ttc cag gct ggg aca agc aaa cca tta cat agc agt 1536
Gln Pro Gln Val Phe Gln Ala Gly Thr Ser Lys Pro Leu His Ser Ser
500 505 510
gga atc aat gta aat gca gct cca ttc caa tcc atg caa acg gtg ttc 1584
Gly Ile Asn Val Asn Ala Ala Pro Phe Gln Ser Met Gln Thr Val Phe
515 520 525
aat atg aat gcc cca gtt cct cct gtt aat gaa cca gaa act ttg aaa 1632
Asn Met Asn Ala Pro Val Pro Pro Val Asn Glu Pro Glu Thr Leu Lys
530 535 540
caa caa aat cag tac cag gcc agt tat aac cag agc ttt tct agt cag 1680
Gln Gln Asn Gln Tyr Gln Ala Ser Tyr Asn Gln Ser Phe Ser Ser Gln
545 550 555 560
cct cac caa gta gaa caa aca gac ctt cag caa gaa cag ctt caa aca 1728
Pro His Gln Val Glu Gln Thr Asp Leu Gln Gln Glu Gln Leu Gln Thr
565 570 575
gtg gtt ggc act tac cat ggt tcc cag gac cag ccc cac caa gtg act 1776
Val Val Gly Thr Tyr His Gly Ser Gln Asp Gln Pro His Gln Val Thr
580 585 590
ggt aac cat cag cag cct ccc cag cag aac act gga ttt cca cgt agc 1824
Gly Asn His Gln Gln Pro Pro Gln Gln Asn Thr Gly Phe Pro Arg Ser
595 600 605
agt cag ccc tat tac aat agt cgt ggt gtg tct cgt ggt ggt tcc cgt 1872
Ser Gln Pro Tyr Tyr Asn Ser Arg Gly Val Ser Arg Gly Gly Ser Arg
610 615 620
ggt gct aga ggc tta atg aat gga tac agg ggc cct gcc aat gga ttc 1920
Gly Ala Arg Gly Leu Met Asn Gly Tyr Arg Gly Pro Ala Asn Gly Phe
625 630 635 640
aga gga gga tat gat ggt tac cgc cct tca ttc tct aac act cca aac 1968
Arg Gly Gly Tyr Asp Gly Tyr Arg Pro Ser Phe Ser Asn Thr Pro Asn
645 650 655
agt ggt tat aca cag tct cag ttc agt gct ccc cgg gac tac tct ggc 2016
Ser Gly Tyr Thr Gln Ser Gln Phe Ser Ala Pro Arg Asp Tyr Ser Gly
660 665 670
tat cag cgg gga tgc cgc aaa tga acactcagca agtgaattaa tctgattcac 2070
Tyr Gln Arg Gly Cys Arg Lys
675
aggattatgt ttaaacgcca aaaacacact ggccagtgta ccataatatg ttaccagaag 2130
agttattatc tatttgttct ccctttcagg aaacttattg taaagggact gttttcatcc 2190
cataaagaca ggactacaat tgtcagcttt atattacctg gatatggaag gaaactattt 2250
ttattctgca tgttcttcct aagcgtcatc ttgagccttg cacatgatac tcagattcct 2310
cacccttgct taggagtaaa acataataca ctttacaggg tgatatctcc atagttattt 2370
gaagtggctt ggaaaaagca agattaactt ctgacattgg ataaaaatca acaaatcagc 2430
cctagagtta ttcaaatggt aattgacaaa aactaaaata tttcccttcg agaaggagtg 2490
gaatgtggtt tggcagaaca actgcatttc acagcttttc cggttaaatt ggagcactaa 2550
acgtttagat gcataccaaa ttatgcatgg gcccttaata taaaaggctg gctaccagct 2610
ttgacacagc actattcatc ctctggccaa acaactgtgg ttaaacaaca catgtaaatt 2670
gctttttaac agctgatact ataataagac aaagccaaaa tgcaaaaatt gggctttgat 2730
tggcactttt tgaaaaatat gcaacaaata tgggatgtaa tctggatggc cgcttctgta 2790
cttaatgtga agtatttaga tacctttttg aacacttaac agtttcttct gacaatgact 2850
tttgtaagga ttggtactat ctatcattcc ttataatgta cattgtctgt cactaatcct 2910
cagatcttgc tgtattgtca cctaaattgg tacaggtact gatgaaaata tctaatggat 2970
aatcataaca ctcttggtca catgtttttc ctgcagcctg aaggttttta aaagaaaaag 3030
atatcaaatg cctgctgcta ccaccctttt aaattgctat cttttgaaaa gcaccagtat 3090
gtgttttaga ttgatttccc tattttaggg aaatgacaga cagtagtttc agttctgatg 3150
gtataagcaa aacaaataaa acatgtttat aaaagttgta tcttgaaaca ctggtgttca 3210
acagctagca gcttatgtgg ttcaccccat gcattgttag tgtttcagat tttatggtta 3270
tctccagcag ctgtttctgt agtacttgca tttatc 3306
<210> 12
<211> 679
<212> PRT
<213> 狗(Canis familiaris)
<400> 12
Met Pro Ser Ala Thr Ser Leu Ser Gly Ser Gly Ser Lys Ser Ser Gly
1 5 10 15
Pro Pro Pro Pro Ser Gly Ser Ser Gly Ser Glu Ala Ala Ala Ala Ala
20 25 30
Gly Ala Ala Gly Ala Ala Gly Ala Gly Ala Ala Ala Pro Ala Ser Gln
35 40 45
His Pro Ala Thr Gly Thr Gly Ala Val Gln Thr Glu Ala Met Lys Gln
50 55 60
Ile Leu Gly Val Ile Asp Lys Lys Leu Arg Asn Leu Glu Lys Lys Lys
65 70 75 80
Gly Lys Leu Asp Asp Tyr Gln Glu Arg Met Asn Lys Gly Glu Arg Leu
85 90 95
Asn Gln Asp Gln Leu Asp Ala Val Ser Lys Tyr Gln Glu Val Thr Asn
100 105 110
Asn Leu Glu Phe Ala Lys Glu Leu Gln Arg Ser Phe Met Ala Leu Ser
115 120 125
Gln Asp Ile Gln Lys Thr Ile Lys Lys Thr Ala Arg Arg Glu Gln Leu
130 135 140
Met Arg Glu Glu Ala Glu Gln Lys Arg Leu Lys Thr Val Leu Glu Leu
145 150 155 160
Gln Tyr Val Leu Asp Lys Leu Gly Asp Asp Glu Val Arg Thr Asp Leu
165 170 175
Lys Gln Gly Leu Asn Gly Val Pro Ile Leu Ser Glu Glu Glu Leu Ser
180 185 190
Leu Leu Asp Glu Phe Tyr Lys Leu Ala Asp Pro Glu Arg Asp Met Ser
195 200 205
Leu Arg Leu Asn Glu Gln Tyr Glu His Ala Ser Ile His Leu Trp Asp
210 215 220
Leu Leu Glu Gly Lys Glu Lys Ser Val Cys Gly Thr Thr Tyr Lys Ala
225 230 235 240
Leu Lys Glu Ile Val Glu Arg Val Phe Gln Ser Asn Tyr Phe Asp Ser
245 250 255
Thr His Asn His Gln Asn Gly Leu Cys Glu Glu Glu Glu Ala Ala Ser
260 265 270
Ala Pro Thr Val Glu Asp Gln Val Ala Glu Ala Glu Pro Glu Pro Ala
275 280 285
Glu Glu Tyr Thr Glu Gln Ser Glu Val Glu Ser Thr Glu Tyr Val Asn
290 295 300
Arg Gln Phe Met Ala Glu Thr Gln Phe Ser Ser Gly Glu Lys Glu Gln
305 310 315 320
Val Asp Glu Trp Thr Val Glu Thr Val Glu Val Val Asn Ser Leu Gln
325 330 335
Gln Gln Pro Gln Ala Ala Ser Pro Ser Val Pro Glu Pro His Ser Leu
340 345 350
Thr Pro Val Ala Gln Ala Asp Pro Leu Val Arg Arg Gln Arg Val Gln
355 360 365
Asp Leu Met Ala Gln Met Gln Gly Pro Tyr Asn Phe Ile Gln Asp Ser
370 375 380
Met Leu Asp Phe Glu Asn Gln Thr Leu Asp Pro Ala Ile Val Ser Ala
385 390 395 400
Gln Pro Met Asn Pro Thr Gln Asn Met Asp Met Pro Gln Leu Val Cys
405 410 415
Pro Pro Val His Ser Glu Ser Arg Leu Ala Gln Pro Asn Gln Val Pro
420 425 430
Val Gln Pro Glu Ala Thr Gln Val Pro Leu Val Ser Ser Thr Ser Glu
435 440 445
Gly Tyr Thr Ala Ser Gln Pro Leu Tyr Gln Pro Ser His Ala Thr Glu
450 455 460
Gln Arg Pro Gln Lys Glu Pro Ile Asp Gln Ile Gln Ala Thr Ile Ser
465 470 475 480
Leu Asn Thr Asp Gln Thr Thr Ala Ser Ser Ser Leu Pro Ala Ala Ser
485 490 495
Gln Pro Gln Val Phe Gln Ala Gly Thr Ser Lys Pro Leu His Ser Ser
500 505 510
Gly Ile Asn Val Asn Ala Ala Pro Phe Gln Ser Met Gln Thr Val Phe
515 520 525
Asn Met Asn Ala Pro Val Pro Pro Val Asn Glu Pro Glu Thr Leu Lys
530 535 540
Gln Gln Asn Gln Tyr Gln Ala Ser Tyr Asn Gln Ser Phe Ser Ser Gln
545 550 555 560
Pro His Gln Val Glu Gln Thr Asp Leu Gln Gln Glu Gln Leu Gln Thr
565 570 575
Val Val Gly Thr Tyr His Gly Ser Gln Asp Gln Pro His Gln Val Thr
580 585 590
Gly Asn His Gln Gln Pro Pro Gln Gln Asn Thr Gly Phe Pro Arg Ser
595 600 605
Ser Gln Pro Tyr Tyr Asn Ser Arg Gly Val Ser Arg Gly Gly Ser Arg
610 615 620
Gly Ala Arg Gly Leu Met Asn Gly Tyr Arg Gly Pro Ala Asn Gly Phe
625 630 635 640
Arg Gly Gly Tyr Asp Gly Tyr Arg Pro Ser Phe Ser Asn Thr Pro Asn
645 650 655
Ser Gly Tyr Thr Gln Ser Gln Phe Ser Ala Pro Arg Asp Tyr Ser Gly
660 665 670
Tyr Gln Arg Gly Cys Arg Lys
675
<210> 13
<211> 2281
<212> DNA
<213> 狗(Canis familiaris)
<220>
<221> CDS
<222> (1)..(2154)
<223>
<400> 13
atg ccg tcg gcc acc agc ctc agc gga agc ggc agc aag tcg tcg ggc 48
Met Pro Ser Ala Thr Ser Leu Ser Gly Ser Gly Ser Lys Ser Ser Gly
1 5 10 15
ccg ccg ccc ccg tcg ggt tcc tcc ggg agc gag gcg gcg gcg gcg gcg 96
Pro Pro Pro Pro Ser Gly Ser Ser Gly Ser Glu Ala Ala Ala Ala Ala
20 25 30
ggg gcg gcg ggg gcg gcg ggg gcc ggg gcg gct gcg ccc gcc tcc cag 144
Gly Ala Ala Gly Ala Ala Gly Ala Gly Ala Ala Ala Pro Ala Ser Gln
35 40 45
cac ccc gcg acc ggc acc ggc gct gtc cag acc gag gcc atg aag cag 192
His Pro Ala Thr Gly Thr Gly Ala Val Gln Thr Glu Ala Met Lys Gln
50 55 60
atc ctc ggg gtg atc gac aag aaa ctc cgg aac ctg gag aag aaa aag 240
Ile Leu Gly Val Ile Asp Lys Lys Leu Arg Asn Leu Glu Lys Lys Lys
65 70 75 80
ggc aag ctt gat gat tac cag gaa cga atg aac aaa ggg gaa agg ctt 288
Gly Lys Leu Asp Asp Tyr Gln Glu Arg Met Asn Lys Gly Glu Arg Leu
85 90 95
aat caa gat cag ctg gat gcc gta tct aag tac cag gaa gtc aca aat 336
Asn Gln Asp Gln Leu Asp Ala Val Ser Lys Tyr Gln Glu Val Thr Asn
100 105 110
aac ttg gag ttt gca aaa gaa tta cag agg agt ttc atg gca tta agt 384
Asn Leu Glu Phe Ala Lys Glu Leu Gln Arg Ser Phe Met Ala Leu Ser
115 120 125
caa gat att cag aaa aca ata aag aag act gca cgt cgg gag cag ctt 432
Gln Asp Ile Gln Lys Thr Ile Lys Lys Thr Ala Arg Arg Glu Gln Leu
130 135 140
atg aga gag gaa gcg gaa caa aaa cgt tta aaa act gta ctt gag ctc 480
Met Arg Glu Glu Ala Glu Gln Lys Arg Leu Lys Thr Val Leu Glu Leu
145 150 155 160
cag tat gtt ttg gac aaa ttg gga gat gat gaa gtg aga act gac ctg 528
Gln Tyr Val Leu Asp Lys Leu Gly Asp Asp Glu Val Arg Thr Asp Leu
165 170 175
aag caa ggt ttg aat gga gtg cca ata ttg tct gaa gaa gaa ttg tcg 576
Lys Gln Gly Leu Asn Gly Val Pro Ile Leu Ser Glu Glu Glu Leu Ser
180 185 190
ttg ttg gat gaa ttc tac aaa tta gca gac cct gaa cgg gac atg agc 624
Leu Leu Asp Glu Phe Tyr Lys Leu Ala Asp Pro Glu Arg Asp Met Ser
195 200 205
ttg agg ttg aat gag cag tat gaa cat gct tcc att cac ctg tgg gac 672
Leu Arg Leu Asn Glu Gln Tyr Glu His Ala Ser Ile His Leu Trp Asp
210 215 220
ttg ctg gaa gga aag gaa aag tct gta tgt gga aca acc tat aaa gca 720
Leu Leu Glu Gly Lys Glu Lys Ser Val Cys Gly Thr Thr Tyr Lys Ala
225 230 235 240
cta aag gaa att gtt gag cgt gtt ttc cag tca aat tac ttt gac agc 768
Leu Lys Glu Ile Val Glu Arg Val Phe Gln Ser Asn Tyr Phe Asp Ser
245 250 255
act cac aac cac cag aat ggg cta tgt gag gaa gaa gag gca gcc tca 816
Thr His Asn His Gln Asn Gly Leu Cys Glu Glu Glu Glu Ala Ala Ser
260 265 270
gca cct aca gtt gaa gac cag gta gct gaa gct gag cct gag cca gca 864
Ala Pro Thr Val Glu Asp Gln Val Ala Glu Ala Glu Pro Glu Pro Ala
275 280 285
gaa gaa tac act gaa caa agt gaa gtt gaa tca aca gag tat gta aat 912
Glu Glu Tyr Thr Glu Gln Ser Glu Val Glu Ser Thr Glu Tyr Val Asn
290 295 300
aga caa ttt atg gca gaa aca cag ttc agc agt ggt gaa aag gag cag 960
Arg Gln Phe Met Ala Glu Thr Gln Phe Ser Ser Gly Glu Lys Glu Gln
305 310 315 320
gta gat gag tgg acg gtc gaa aca gtg gag gtg gtg aat tca ctc cag 1008
Val Asp Glu Trp Thr Val Glu Thr Val Glu Val Val Asn Ser Leu Gln
325 330 335
cag caa cct cag gct gcg tct cct tca gta cca gag ccc cac tct ttg 1056
Gln Gln Pro Gln Ala Ala Ser Pro Ser Val Pro Glu Pro His Ser Leu
340 345 350
act ccg gtg gct cag gca gat ccc ctt gtg aga aga cag cga gtc cag 1104
Thr Pro Val Ala Gln Ala Asp Pro Leu Val Arg Arg Gln Arg Val Gln
355 360 365
gac ctt atg gcg cag atg cag ggg ccc tat aat ttc ata cag gat tca 1152
Asp Leu Met Ala Gln Met Gln Gly Pro Tyr Asn Phe Ile Gln Asp Ser
370 375 380
atg ctg gat ttt gaa aac cag aca ctc gat cct gcc att gta tct gca 1200
Met Leu Asp Phe Glu Asn Gln Thr Leu Asp Pro Ala Ile Val Ser Ala
385 390 395 400
cag cct atg aat ccg aca caa aac atg gac atg ccc cag ctg gtt tgc 1248
Gln Pro Met Asn Pro Thr Gln Asn Met Asp Met Pro Gln Leu Val Cys
405 410 415
cct cca gtt cat tct gaa tct aga ctt gct caa cct aat caa gtt cct 1296
Pro Pro Val His Ser Glu Ser Arg Leu Ala Gln Pro Asn Gln Val Pro
420 425 430
gta caa cca gaa gct aca cag gtt cct ttg gtt tca tcc aca agt gag 1344
Val Gln Pro Glu Ala Thr Gln Val Pro Leu Val Ser Ser Thr Ser Glu
435 440 445
ggg tat aca gca tct caa ccc ttg tac cag cct tct cat gct aca gag 1392
Gly Tyr Thr Ala Ser Gln Pro Leu Tyr Gln Pro Ser His Ala Thr Glu
450 455 460
caa cga cca caa aag gaa cca att gac cag att cag gca aca atc tct 1440
Gln Arg Pro Gln Lys Glu Pro Ile Asp Gln Ile Gln Ala Thr Ile Ser
465 470 475 480
tta aat aca gac cag act aca gcg tca tca tcc ctt ccg gct gct tct 1488
Leu Asn Thr Asp Gln Thr Thr Ala Ser Ser Ser Leu Pro Ala Ala Ser
485 490 495
cag cct cag gta ttc cag gct ggg aca agc aaa cca tta cat agc agt 1536
Gln Pro Gln Val Phe Gln Ala Gly Thr Ser Lys Pro Leu His Ser Ser
500 505 510
gga atc aat gta aat gca gct cca ttc caa tcc atg caa acg gtg ttc 1584
Gly Ile Asn Val Asn Ala Ala Pro Phe Gln Ser Met Gln Thr Val Phe
515 520 525
aat atg aat gcc cca gtt cct cct gtt aat gaa cca gaa act ttg aaa 1632
Asn Met Asn Ala Pro Val Pro Pro Val Asn Glu Pro Glu Thr Leu Lys
530 535 540
caa caa aat cag tac cag gcc agt tat aac cag agc ttt tct agt cag 1680
Gln Gln Asn Gln Tyr Gln Ala Ser Tyr Asn Gln Ser Phe Ser Ser Gln
545 550 555 560
cct cac caa gta gaa caa aca gac ctt cag caa gaa cag ctt caa aca 1728
Pro His Gln Val Glu Gln Thr Asp Leu Gln Gln Glu Gln Leu Gln Thr
565 570 575
gtg gtt ggc act tac cat ggt tcc cag gac cag ccc cac caa gtg act 1776
Val Val Gly Thr Tyr His Gly Ser Gln Asp Gln Pro His Gln Val Thr
580 585 590
ggt aac cat cag cag cct ccc cag cag aac act gga ttt cca cgt agc 1824
Gly Asn His Gln Gln Pro Pro Gln Gln Asn Thr Gly Phe Pro Arg Ser
595 600 605
agt cag ccc tat tac aat agt cgt ggt gtg tct cgt ggt ggt tcc cgt 1872
Ser Gln Pro Tyr Tyr Asn Ser Arg Gly Val Ser Arg Gly Gly Ser Arg
610 615 620
ggt gct aga ggc tta atg aat gga tac agg ggc cct gcc aat gga ttc 1920
Gly Ala Arg Gly Leu Met Asn Gly Tyr Arg Gly Pro Ala Asn Gly Phe
625 630 635 640
aga gga gga tat gat ggt tac cgc cct tca ttc tct aac act cca aac 1968
Arg Gly Gly Tyr Asp Gly Tyr Arg Pro Ser Phe Ser Asn Thr Pro Asn
645 650 655
agt ggt tat aca cag tct cag ttc agt gct ccc cgg gac tac tct ggc 2016
Ser Gly Tyr Thr Gln Ser Gln Phe Ser Ala Pro Arg Asp Tyr Ser Gly
660 665 670
tat cag cgg gat gga tat cag cag aat ttc aag cga ggc tct ggg cag 2064
Tyr Gln Arg Asp Gly Tyr Gln Gln Asn Phe Lys Arg Gly Ser Gly Gln
675 680 685
agt gga cca cgg gga gcc cca cga ggt cgt gga ggg ccc cca aga ccc 2112
Ser Gly Pro Arg Gly Ala Pro Arg Gly Arg Gly Gly Pro Pro Arg Pro
690 695 700
aac aga ggg atg ccg caa atg aac act cag caa gtg aat taa 2154
Asn Arg Gly Met Pro Gln Met Asn Thr Gln Gln Val Asn
705 710 715
tctgattcac aggattatgt ttaaacgcca aaaacacact ggccagtgta ccataatatg 2214
ttaccagaag agttattatc tatttggact gttttcatcc cataaagaca ggactacaat 2274
tgtcagc 2281
<210> 14
<211> 717
<212> PRT
<213> 狗(Canis familiaris)
<400> 14
Met Pro Ser Ala Thr Ser Leu Ser Gly Ser Gly Ser Lys Ser Ser Gly
1 5 10 15
Pro Pro Pro Pro Ser Gly Ser Ser Gly Ser Glu Ala Ala Ala Ala Ala
20 25 30
Gly Ala Ala Gly Ala Ala Gly Ala Gly Ala Ala Ala Pro Ala Ser Gln
35 40 45
His Pro Ala Thr Gly Thr Gly Ala Val Gln Thr Glu Ala Met Lys Gln
50 55 60
Ile Leu Gly Val Ile Asp Lys Lys Leu Arg Asn Leu Glu Lys Lys Lys
65 70 75 80
Gly Lys Leu Asp Asp Tyr Gln Glu Arg Met Asn Lys Gly Glu Arg Leu
85 90 95
Asn Gln Asp Gln Leu Asp Ala Val Ser Lys Tyr Gln Glu Val Thr Asn
100 105 110
Asn Leu Glu Phe Ala Lys Glu Leu Gln Arg Ser Phe Met Ala Leu Ser
115 120 125
Gln Asp Ile Gln Lys Thr Ile Lys Lys Thr Ala Arg Arg Glu Gln Leu
130 135 140
Met Arg Glu Glu Ala Glu Gln Lys Arg Leu Lys Thr Val Leu Glu Leu
145 150 155 160
Gln Tyr Val Leu Asp Lys Leu Gly Asp Asp Glu Val Arg Thr Asp Leu
165 170 175
Lys Gln Gly Leu Asn Gly Val Pro Ile Leu Ser Glu Glu Glu Leu Ser
180 185 190
Leu Leu Asp Glu Phe Tyr Lys Leu Ala Asp Pro Glu Arg Asp Met Ser
195 200 205
Leu Arg Leu Asn Glu Gln Tyr Glu His Ala Ser Ile His Leu Trp Asp
210 215 220
Leu Leu Glu Gly Lys Glu Lys Ser Val Cys Gly Thr Thr Tyr Lys Ala
225 230 235 240
Leu Lys Glu Ile Val Glu Arg Val Phe Gln Ser Asn Tyr Phe Asp Ser
245 250 255
Thr His Asn His Gln Asn Gly Leu Cys Glu Glu Glu Glu Ala Ala Ser
260 265 270
Ala Pro Thr Val Glu Asp Gln Val Ala Glu Ala Glu Pro Glu Pro Ala
275 280 285
Glu Glu Tyr Thr Glu Gln Ser Glu Val Glu Ser Thr Glu Tyr Val Asn
290 295 300
Arg Gln Phe Met Ala Glu Thr Gln Phe Ser Ser Gly Glu Lys Glu Gln
305 310 315 320
Val Asp Glu Trp Thr Val Glu Thr Val Glu Val Val Asn Ser Leu Gln
325 330 335
Gln Gln Pro Gln Ala Ala Ser Pro Ser Val Pro Glu Pro His Ser Leu
340 345 350
Thr Pro Val Ala Gln Ala Asp Pro Leu Val Arg Arg Gln Arg Val Gln
355 360 365
Asp Leu Met Ala Gln Met Gln Gly Pro Tyr Asn Phe Ile Gln Asp Ser
370 375 380
Met Leu Asp Phe Glu Asn Gln Thr Leu Asp Pro Ala Ile Val Ser Ala
385 390 395 400
Gln Pro Met Asn Pro Thr Gln Asn Met Asp Met Pro Gln Leu Val Cys
405 410 415
Pro Pro Val His Ser Glu Ser Arg Leu Ala Gln Pro Asn Gln Val Pro
420 425 430
Val Gln Pro Glu Ala Thr Gln Val Pro Leu Val Ser Ser Thr Ser Glu
435 440 445
Gly Tyr Thr Ala Ser Gln Pro Leu Tyr Gln Pro Ser His Ala Thr Glu
450 455 460
Gln Arg Pro Gln Lys Glu Pro Ile Asp Gln Ile Gln Ala Thr Ile Ser
465 470 475 480
Leu Asn Thr Asp Gln Thr Thr Ala Ser Ser Ser Leu Pro Ala Ala Ser
485 490 495
Gln Pro Gln Val Phe Gln Ala Gly Thr Ser Lys Pro Leu His Ser Ser
500 505 510
Gly Ile Asn Val Asn Ala Ala Pro Phe Gln Ser Met Gln Thr Val Phe
515 520 525
Asn Met Asn Ala Pro Val Pro Pro Val Asn Glu Pro Glu Thr Leu Lys
530 535 540
Gln Gln Asn Gln Tyr Gln Ala Ser Tyr Asn Gln Ser Phe Ser Ser Gln
545 550 555 560
Pro His Gln Val Glu Gln Thr Asp Leu Gln Gln Glu Gln Leu Gln Thr
565 570 575
Val Val Gly Thr Tyr His Gly Ser Gln Asp Gln Pro His Gln Val Thr
580 585 590
Gly Asn His Gln Gln Pro Pro Gln Gln Asn Thr Gly Phe Pro Arg Ser
595 600 605
Ser Gln Pro Tyr Tyr Asn Ser Arg Gly Val Ser Arg Gly Gly Ser Arg
610 615 620
Gly Ala Arg Gly Leu Met Asn Gly Tyr Arg Gly Pro Ala Asn Gly Phe
625 630 635 640
Arg Gly Gly Tyr Asp Gly Tyr Arg Pro Ser Phe Ser Asn Thr Pro Asn
645 650 655
Ser Gly Tyr Thr Gln Ser Gln Phe Ser Ala Pro Arg Asp Tyr Ser Gly
660 665 670
Tyr Gln Arg Asp Gly Tyr Gln Gln Asn Phe Lys Arg Gly Ser Gly Gln
675 680 685
Ser Gly Pro Arg Gly Ala Pro Arg Gly Arg Gly Gly Pro Pro Arg Pro
690 695 700
Asn Arg Gly Met Pro Gln Met Asn Thr Gln Gln Val Asn
705 710 715
<210> 15
<211> 3386
<212> DNA
<213> 牛(Bos taurus)
<220>
<221> CDS
<222> (82)..(2208)
<223>
<400> 15
cgcgtctcgc cccgtccacc gattgactcg ccgctcttgt ccttcctccc gctctttctt 60
ctctcccctt acggtttcaa g atg cct tcg gcc acc agc cac agc gga agc 111
Met Pro Ser Ala Thr Ser His Ser Gly Ser
1 5 10
ggc agc aag tcg tcc gga ccg cca ccg ccg tcg ggt tcc tcc ggg aat 159
Gly Ser Lys Ser Ser Gly Pro Pro Pro Pro Ser Gly Ser Ser Gly Asn
15 20 25
gag gcg ggg gcc ggg gcc gcc gcg ccg gct tcc caa cac ccc atg acc 207
Glu Ala Gly Ala Gly Ala Ala Ala Pro Ala Ser Gln His Pro Met Thr
30 35 40
ggc acc ggg gct gtc cag acc gag gcc atg aag cag att ctc ggg gtg 255
Gly Thr Gly Ala Val Gln Thr Glu Ala Met Lys Gln Ile Leu Gly Val
45 50 55
atc gac aag aaa ctt cgg aac ctg gag aag aaa aag ggc aag ctt gat 303
Ile Asp Lys Lys Leu Arg Asn Leu Glu Lys Lys Lys Gly Lys Leu Asp
60 65 70
gat tat cag gaa cga atg aac aaa ggg gaa agg ctt aat caa gat cag 351
Asp Tyr Gln Glu Arg Met Asn Lys Gly Glu Arg Leu Asn Gln Asp Gln
75 80 85 90
ctg gat gcc gtg tct aag tac cag gaa gtc aca aat aac ttg gag ttt 399
Leu Asp Ala Val Ser Lys Tyr Gln Glu Val Thr Asn Asn Leu Glu Phe
95 100 105
gca aaa gaa tta cag agg agt ttc atg gca tta agc caa gat att cag 447
Ala Lys Glu Leu Gln Arg Ser Phe Met Ala Leu Ser Gln Asp Ile Gln
110 115 120
aaa aca ata aag aag aca gca cgt cgg gag cag ctt atg aga gag gaa 495
Lys Thr Ile Lys Lys Thr Ala Arg Arg Glu Gln Leu Met Arg Glu Glu
125 130 135
gct gaa cag aaa cgt tta aaa aca gta ctt gag ctg cag tat gtt ttg 543
Ala Glu Gln Lys Arg Leu Lys Thr Val Leu Glu Leu Gln Tyr Val Leu
140 145 150
gac aaa cta gga gat gat gaa gtg aga act gac ctg aag caa ggt ttg 591
Asp Lys Leu Gly Asp Asp Glu Val Arg Thr Asp Leu Lys Gln Gly Leu
155 160 165 170
aat gga gtg cca ata ttg tct gaa gag gag ttg tcg ttg tta gat gag 639
Asn Gly Val Pro Ile Leu Ser Glu Glu Glu Leu Ser Leu Leu Asp Glu
175 180 185
ttc tac aaa tta gca gac cct gaa cga gac atg agc ttg agg ttg aat 687
Phe Tyr Lys Leu Ala Asp Pro Glu Arg Asp Met Ser Leu Arg Leu Asn
190 195 200
gag cag tat gaa cat gcc tcc att cac ctg tgg gac ttg ctg gaa gga 735
Glu Gln Tyr Glu His Ala Ser Ile His Leu Trp Asp Leu Leu Glu Gly
205 210 215
aag gaa aaa cct gta tgt gga aca act tat aaa gct cta aag gaa att 783
Lys Glu Lys Pro Val Cys Gly Thr Thr Tyr Lys Ala Leu Lys Glu Ile
220 225 230
gtt gag cgt gtt ttc cag tca aac tac ttt gac agc acc cac aac cac 831
Val Glu Arg Val Phe Gln Ser Asn Tyr Phe Asp Ser Thr His Asn His
235 240 245 250
cag aat ggt ctg tgt gag gaa gag gag gca gcc tca gca cct aca gtt 879
Gln Asn Gly Leu Cys Glu Glu Glu Glu Ala Ala Ser Ala Pro Thr Val
255 260 265
gaa gac cag gca gct gaa gct gaa cct gag cca gtg gaa gaa tat act 927
Glu Asp Gln Ala Ala Glu Ala Glu Pro Glu Pro Val Glu Glu Tyr Thr
270 275 280
gaa caa aat gag gtt gaa tca aca gag tat gta aat aga caa ttt atg 975
Glu Gln Asn Glu Val Glu Ser Thr Glu Tyr Val Asn Arg Gln Phe Met
285 290 295
gca gaa aca cag ttc agc agt ggt gaa aag gag cag gta gat gat tgg 1023
Ala Glu Thr Gln Phe Ser Ser Gly Glu Lys Glu Gln Val Asp Asp Trp
300 305 310
aca gtt gaa aca gtt gag gtg gta aat tca ctc cag cag caa cct cag 1071
Thr Val Glu Thr Val Glu Val Val Asn Ser Leu Gln Gln Gln Pro Gln
315 320 325 330
gct gca tct cct tca gta cca gaa ccc cac tct ttg acc cca gtg gct 1119
Ala Ala Ser Pro Ser Val Pro Glu Pro His Ser Leu Thr Pro Val Ala
335 340 345
caa gcc gat ccc ctc gtg aga aga cag cga gta cag gac ctt atg gca 1167
Gln Ala Asp Pro Leu Val Arg Arg Gln Arg Val Gln Asp Leu Met Ala
350 355 360
caa atg cag ggg ccc tat aat ttc ata cag gat tca atg ttg gat ttt 1215
Gln Met Gln Gly Pro Tyr Asn Phe Ile Gln Asp Ser Met Leu Asp Phe
365 370 375
gaa aac cag aca ctt gat cct gcc att gta tct gca cag ccg atg aat 1263
Glu Asn Gln Thr Leu Asp Pro Ala Ile Val Ser Ala Gln Pro Met Asn
380 385 390
cca gca cag aac atg gac ata ccc cag ctg gtt tgc cct cca gtt cat 1311
Pro Ala Gln Asn Met Asp Ile Pro Gln Leu Val Cys Pro Pro Val His
395 400 405 410
tct gaa tct aga ctt gct caa cct aat caa gtt tct gta cag cca gaa 1359
Ser Glu Ser Arg Leu Ala Gln Pro Asn Gln Val Ser Val Gln Pro Glu
415 420 425
gct aca cag gtt cct ttg gtt tca tcc aca agt gag gga tat aca gca 1407
Ala Thr Gln Val Pro Leu Val Ser Ser Thr Ser Glu Gly Tyr Thr Ala
430 435 440
tct caa ccc ttg tac caa cct tct cat gct act gac caa cga cca caa 1455
Ser Gln Pro Leu Tyr Gln Pro Ser His Ala Thr Asp Gln Arg Pro Gln
445 450 455
aag gaa ccg att gat cag att cag gcg acg atc tct tta aat aca gac 1503
Lys Glu Pro Ile Asp Gln Ile Gln Ala Thr Ile Ser Leu Asn Thr Asp
460 465 470
cag act aca gca tca tca tcc ctt cct gct gct tct cag cct caa gtg 1551
Gln Thr Thr Ala Ser Ser Ser Leu Pro Ala Ala Ser Gln Pro Gln Val
475 480 485 490
ttc cag gct ggg aca agc aaa cct tta cat agc agt gga atc aat gta 1599
Phe Gln Ala Gly Thr Ser Lys Pro Leu His Ser Ser Gly Ile Asn Val
495 500 505
aat gca gct cca ttc caa tcc atg caa acg gta ttc aat atg aat gcc 1647
Asn Ala Ala Pro Phe Gln Ser Met Gln Thr Val Phe Asn Met Asn Ala
510 515 520
cca gtt cct cct gtt aat gaa cca gaa act tta aaa cag caa aat cag 1695
Pro Val Pro Pro Val Asn Glu Pro Glu Thr Leu Lys Gln Gln Asn Gln
525 530 535
tac cag gcc agt tac aac cag agc ttt tcc agt cag cct cac caa gta 1743
Tyr Gln Ala Ser Tyr Asn Gln Ser Phe Ser Ser Gln Pro His Gln Val
540 545 550
gaa caa aca gag ctt cag caa gaa cag ctt caa aca gtg gtt ggc act 1791
Glu Gln Thr Glu Leu Gln Gln Glu Gln Leu Gln Thr Val Val Gly Thr
555 560 565 570
tat cat ggt tct cag gac cag ccc cat caa gtg act ggt aac cac cag 1839
Tyr His Gly Ser Gln Asp Gln Pro His Gln Val Thr Gly Asn His Gln
575 580 585
cag cct cct cag cag aac act gga ttt cca cgt agc aat cag ccc tat 1887
Gln Pro Pro Gln Gln Asn Thr Gly Phe Pro Arg Ser Asn Gln Pro Tyr
590 595 600
tac aac agt cgt ggt gtg tct cgt gga ggt tcc cgt ggt gct aga ggc 1935
Tyr Asn Ser Arg Gly Val Ser Arg Gly Gly Ser Arg Gly Ala Arg Gly
605 610 615
ttg atg aat gga tac aga gga cct gct aat gga ttc aga gga gga tat 1983
Leu Met Asn Gly Tyr Arg Gly Pro Ala Asn Gly Phe Arg Gly Gly Tyr
620 625 630
gat ggt tac cgc cct tca ttc tct act aac act cca aac agt ggt tat 2031
Asp Gly Tyr Arg Pro Ser Phe Ser Thr Asn Thr Pro Asn Ser Gly Tyr
635 640 645 650
aca caa tct caa ttc agt gct ccc cgg gac tac tct ggc tat cag cgg 2079
Thr Gln Ser Gln Phe Ser Ala Pro Arg Asp Tyr Ser Gly Tyr Gln Arg
655 660 665
gat gga tat cag cag aat ttc aag cga ggc tct ggg cag agt gga cca 2127
Asp Gly Tyr Gln Gln Asn Phe Lys Arg Gly Ser Gly Gln Ser Gly Pro
670 675 680
cgg gga gcc cca cga ggt cgt gga ggg ccc cca aga ccc aac aga ggg 2175
Arg Gly Ala Pro Arg Gly Arg Gly Gly Pro Pro Arg Pro Asn Arg Gly
685 690 695
atg ccg caa atg aac act cag caa gtg aat taa tctgattcac aggattatgt 2228
Met Pro Gln Met Asn Thr Gln Gln Val Asn
700 705
ttaatcgcca aaaacacact ggccagtgta ccataatatg ttaccagaag agttattatc 2288
tatttgttct ccctttcagg aaacttattg taaagggact gttttcatcc cataaagaca 2348
ggactacaat tgtcagcttt atattacctg gatatggaag gaaactattt ttactctgca 2408
tgttctgtcc taagcgtcat cttgagcctt gcacatgata ctcagattcc tcacccttgc 2468
ttaggagtaa aacataatat actttaatgg ggtgatatct ccatagttat ttgaagtggc 2528
ttggataaag caagactgac ttctgacatt ggataaaatc tacaaatcag ccctagagtc 2588
attcagtggt aactgacaaa actaaaatat ttcccttgaa aggaagatgg aaggagtgga 2648
gtgtggtttg gcagaacaac tgcatttcac agcttttcca cttaaattgg agcactgaac 2708
atttagatgc ataccgaatt atgcatgggc cctaatcaca cagacaaggc tggtgccagc 2768
cttaggcttg acacggcagt gttcaccctc tggccagacg actgtggttc aagacacatg 2828
taaattgctt tttaacagct gatactgtat aagacaaagc caaaatgcaa aattaggctt 2888
tgattggcac ttttcgaaaa atatgcaaca attaagggat ataatctgga tggccgcttc 2948
tgtacttaat gtgaaatatt tagatacctt tcaaacactt aacagtttct ttgacaatga 3008
gttttgtaag gattggtagt aaatatcatt ccttatgacg tacattgtct gtcactaatc 3068
cttggatctt gctgtattgt cacctaaatt ggtacaggta ctgatgaaaa tctaatggat 3128
aatcataaca ctcttggtta catgtttttc ctgcagcctg aaagttttta taagaaaaag 3188
acatcaaatg cctgctgctg ccaccctttt aaattgctat cttttgaaaa gcaccagtat 3248
gtgttttaga ttgatttccc tattttaggg aaatgacagt cagtagtttc acttctgatg 3308
gtataagcaa acaaataaaa catgtttata aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 3368
aaaaaaaaaa aaaaaaaa 3386
<210> 16
<211> 708
<212> PRT
<213> 牛(Bos taurus)
<400> 16
Met Pro Ser Ala Thr Ser His Ser Gly Ser Gly Ser Lys Ser Ser Gly
1 5 10 15
Pro Pro Pro Pro Ser Gly Ser Ser Gly Asn Glu Ala Gly Ala Gly Ala
20 25 30
Ala Ala Pro Ala Ser Gln His Pro Met Thr Gly Thr Gly Ala Val Gln
35 40 45
Thr Glu Ala Met Lys Gln Ile Leu Gly Val Ile Asp Lys Lys Leu Arg
50 55 60
Asn Leu Glu Lys Lys Lys Gly Lys Leu Asp Asp Tyr Gln Glu Arg Met
65 70 75 80
Asn Lys Gly Glu Arg Leu Asn Gln Asp Gln Leu Asp Ala Val Ser Lys
85 90 95
Tyr Gln Glu Val Thr Asn Asn Leu Glu Phe Ala Lys Glu Leu Gln Arg
100 105 110
Ser Phe Met Ala Leu Ser Gln Asp Ile Gln Lys Thr Ile Lys Lys Thr
115 120 125
Ala Arg Arg Glu Gln Leu Met Arg Glu Glu Ala Glu Gln Lys Arg Leu
130 135 140
Lys Thr Val Leu Glu Leu Gln Tyr Val Leu Asp Lys Leu Gly Asp Asp
145 150 155 160
Glu Val Arg Thr Asp Leu Lys Gln Gly Leu Asn Gly Val Pro Ile Leu
165 170 175
Ser Glu Glu Glu Leu Ser Leu Leu Asp Glu Phe Tyr Lys Leu Ala Asp
180 185 190
Pro Glu Arg Asp Met Ser Leu Arg Leu Asn Glu Gln Tyr Glu His Ala
195 200 205
Ser Ile His Leu Trp Asp Leu Leu Glu Gly Lys Glu Lys Pro Val Cys
210 215 220
Gly Thr Thr Tyr Lys Ala Leu Lys Glu Ile Val Glu Arg Val Phe Gln
225 230 235 240
Ser Asn Tyr Phe Asp Ser Thr His Asn His Gln Asn Gly Leu Cys Glu
245 250 255
Glu Glu Glu Ala Ala Ser Ala Pro Thr Val Glu Asp Gln Ala Ala Glu
260 265 270
Ala Glu Pro Glu Pro Val Glu Glu Tyr Thr Glu Gln Asn Glu Val Glu
275 280 285
Ser Thr Glu Tyr Val Asn Arg Gln Phe Met Ala Glu Thr Gln Phe Ser
290 295 300
Ser Gly Glu Lys Glu Gln Val Asp Asp Trp Thr Val Glu Thr Val Glu
305 310 315 320
Val Val Asn Ser Leu Gln Gln Gln Pro Gln Ala Ala Ser Pro Ser Val
325 330 335
Pro Glu Pro His Ser Leu Thr Pro Val Ala Gln Ala Asp Pro Leu Val
340 345 350
Arg Arg Gln Arg Val Gln Asp Leu Met Ala Gln Met Gln Gly Pro Tyr
355 360 365
Asn Phe Ile Gln Asp Ser Met Leu Asp Phe Glu Asn Gln Thr Leu Asp
370 375 380
Pro Ala Ile Val Ser Ala Gln Pro Met Asn Pro Ala Gln Asn Met Asp
385 390 395 400
Ile Pro Gln Leu Val Cys Pro Pro Val His Ser Glu Ser Arg Leu Ala
405 410 415
Gln Pro Asn Gln Val Ser Val Gln Pro Glu Ala Thr Gln Val Pro Leu
420 425 430
Val Ser Ser Thr Ser Glu Gly Tyr Thr Ala Ser Gln Pro Leu Tyr Gln
435 440 445
Pro Ser His Ala Thr Asp Gln Arg Pro Gln Lys Glu Pro Ile Asp Gln
450 455 460
Ile Gln Ala Thr Ile Ser Leu Asn Thr Asp Gln Thr Thr Ala Ser Ser
465 470 475 480
Ser Leu Pro Ala Ala Ser Gln Pro Gln Val Phe Gln Ala Gly Thr Ser
485 490 495
Lys Pro Leu His Ser Ser Gly Ile Asn Val Asn Ala Ala Pro Phe Gln
500 505 510
Ser Met Gln Thr Val Phe Asn Met Asn Ala Pro Val Pro Pro Val Asn
515 520 525
Glu Pro Glu Thr Leu Lys Gln Gln Asn Gln Tyr Gln Ala Ser Tyr Asn
530 535 540
Gln Ser Phe Ser Ser Gln Pro His Gln Val Glu Gln Thr Glu Leu Gln
545 550 555 560
Gln Glu Gln Leu Gln Thr Val Val Gly Thr Tyr His Gly Ser Gln Asp
565 570 575
Gln Pro His Gln Val Thr Gly Asn His Gln Gln Pro Pro Gln Gln Asn
580 585 590
Thr Gly Phe Pro Arg Ser Asn Gln Pro Tyr Tyr Asn Ser Arg Gly Val
595 600 605
Ser Arg Gly Gly Ser Arg Gly Ala Arg Gly Leu Met Asn Gly Tyr Arg
610 615 620
Gly Pro Ala Asn Gly Phe Arg Gly Gly Tyr Asp Gly Tyr Arg Pro Ser
625 630 635 640
Phe Ser Thr Asn Thr Pro Asn Ser Gly Tyr Thr Gln Ser Gln Phe Ser
645 650 655
Ala Pro Arg Asp Tyr Ser Gly Tyr Gln Arg Asp Gly Tyr Gln Gln Asn
660 665 670
Phe Lys Arg Gly Ser Gly Gln Ser Gly Pro Arg Gly Ala Pro Arg Gly
675 680 685
Arg Gly Gly Pro Pro Arg Pro Asn Arg Gly Met Pro Gln Met Asn Thr
690 695 700
Gln Gln Val Asn
705
<210> 17
<211> 3150
<212> DNA
<213> 马(equus caballus)
<220>
<221> CDS
<222> (1)..(1917)
<223>
<400> 17
atg gag ggc aag ctc gat gat tac caa gag cga atg aac aaa gga gaa 48
Met Glu Gly Lys Leu Asp Asp Tyr Gln Glu Arg Met Asn Lys Gly Glu
1 5 10 15
agg ctt aat cag gat cag ctg gat gct gtg tct aag tac cag gaa gtc 96
Arg Leu Asn Gln Asp Gln Leu Asp Ala Val Ser Lys Tyr Gln Glu Val
20 25 30
aca aat aac ttg gag ttt gcg aaa gaa ttg cag agg agt ttc atg gcg 144
Thr Asn Asn Leu Glu Phe Ala Lys Glu Leu Gln Arg Ser Phe Met Ala
35 40 45
ttg agt cag gat att cag aaa aca ata aag aag acg gca cgt cgg gag 192
Leu Ser Gln Asp Ile Gln Lys Thr Ile Lys Lys Thr Ala Arg Arg Glu
50 55 60
cag ctt atg aga gaa gaa gct gaa cag aaa cgt tta aaa act gta ctt 240
Gln Leu Met Arg Glu Glu Ala Glu Gln Lys Arg Leu Lys Thr Val Leu
65 70 75 80
gag ctg cag tat gtt ttg gac aaa ttg gga gat gaa gaa gtg cga act 288
Glu Leu Gln Tyr Val Leu Asp Lys Leu Gly Asp Glu Glu Val Arg Thr
85 90 95
gac ctg aaa caa ggt ttg aat gga gtg cca ata ctc tct gaa gaa gag 336
Asp Leu Lys Gln Gly Leu Asn Gly Val Pro Ile Leu Ser Glu Glu Glu
100 105 110
ttg tcg ctg ttg gat gag ttc tac aag tta gca gac cct gta cgg gac 384
Leu Ser Leu Leu Asp Glu Phe Tyr Lys Leu Ala Asp Pro Val Arg Asp
115 120 125
atg agc ttg agg ttg aat gag cag tat gag cat gcc tcc att cac ctg 432
Met Ser Leu Arg Leu Asn Glu Gln Tyr Glu His Ala Ser Ile His Leu
130 135 140
tgg gac ttg ctg gaa ggg aag gaa aaa tct gtc tgt gga aca acc tat 480
Trp Asp Leu Leu Glu Gly Lys Glu Lys Ser Val Cys Gly Thr Thr Tyr
145 150 155 160
aaa gct ctg agg gaa att gtt gag cgt gtt ttc cag tcc aac tac ttt 528
Lys Ala Leu Arg Glu Ile Val Glu Arg Val Phe Gln Ser Asn Tyr Phe
165 170 175
gac agc acc cac aac cac cag aat ggg ctc tgt gag gag gaa gag gct 576
Asp Ser Thr His Asn His Gln Asn Gly Leu Cys Glu Glu Glu Glu Ala
180 185 190
acc tca gct cca aca gct gaa gac cag gga gct gaa gct gaa cct gag 624
Thr Ser Ala Pro Thr Ala Glu Asp Gln Gly Ala Glu Ala Glu Pro Glu
195 200 205
cca gca gaa gaa tac act gaa caa agt gaa gtt gaa tca aca gag tat 672
Pro Ala Glu Glu Tyr Thr Glu Gln Ser Glu Val Glu Ser Thr Glu Tyr
210 215 220
gta aat aga cag ttt atg gca gaa gcg cag ttc agt ggt gag aag gag 720
Val Asn Arg Gln Phe Met Ala Glu Ala Gln Phe Ser Gly Glu Lys Glu
225 230 235 240
cag gtg gat gag tgg aca gtc gag acg gtc gag gtg gta aat tca ctc 768
Gln Val Asp Glu Trp Thr Val Glu Thr Val Glu Val Val Asn Ser Leu
245 250 255
cag cag caa cct cag gct gca tct cct tca gta ccg gag ccc cac tct 816
Gln Gln Gln Pro Gln Ala Ala Ser Pro Ser Val Pro Glu Pro His Ser
260 265 270
ttg act cca gtg gct cag gca gat ccc ctt gtg aga aga cag cga gta 864
Leu Thr Pro Val Ala Gln Ala Asp Pro Leu Val Arg Arg Gln Arg Val
275 280 285
cag gac ctt atg gcg caa atg cag ggg ccc tat aat ttc ata cag gat 912
Gln Asp Leu Met Ala Gln Met Gln Gly Pro Tyr Asn Phe Ile Gln Asp
290 295 300
tca atg ctg gat ttt gaa aac cag aca ctt gat cct gcc att gta tct 960
Ser Met Leu Asp Phe Glu Asn Gln Thr Leu Asp Pro Ala Ile Val Ser
305 310 315 320
gca cag cct atg aat cca gca cag aat atg gac atg ccc cag ctg gtt 1008
Ala Gln Pro Met Asn Pro Ala Gln Asn Met Asp Met Pro Gln Leu Val
325 330 335
tgc cct cca gtt cat gct gaa tct aga ctt gct caa cct aat caa gtt 1056
Cys Pro Pro Val His Ala Glu Ser Arg Leu Ala Gln Pro Asn Gln Val
340 345 350
cct gta caa cca gaa gct aca cag gtt cct ttg gtt tca tcc aca agt 1104
Pro Val Gln Pro Glu Ala Thr Gln Val Pro Leu Val Ser Ser Thr Ser
355 360 365
gag ggg tat aca gca tct cag ccc ttg tac cag cct tct cat gct aca 1152
Glu Gly Tyr Thr Ala Ser Gln Pro Leu Tyr Gln Pro Ser His Ala Thr
370 375 380
gag caa cga ccg caa aag gaa ccg act gac cag atc cag gca aca atc 1200
Glu Gln Arg Pro Gln Lys Glu Pro Thr Asp Gln Ile Gln Ala Thr Ile
385 390 395 400
tct tta aat aca gac cag act aca gca tca tca tcc ctt cct gct gct 1248
Ser Leu Asn Thr Asp Gln Thr Thr Ala Ser Ser Ser Leu Pro Ala Ala
405 410 415
tct cag cct cag gtg ttc cag gct ggg aca agc aaa cct tta cac agc 1296
Ser Gln Pro Gln Val Phe Gln Ala Gly Thr Ser Lys Pro Leu His Ser
420 425 430
agt ggg atc aat gta aat gca gcg cca ttc cag tcc atg caa acg gtg 1344
Ser Gly Ile Asn Val Asn Ala Ala Pro Phe Gln Ser Met Gln Thr Val
435 440 445
ttc aac atg aat gcc ccg gtt cct cct gtt aat gaa cca gaa act tta 1392
Phe Asn Met Asn Ala Pro Val Pro Pro Val Asn Glu Pro Glu Thr Leu
450 455 460
aaa cag caa aat cag tac cag gcc agc tat aac cag agc ttt tcc agt 1440
Lys Gln Gln Asn Gln Tyr Gln Ala Ser Tyr Asn Gln Ser Phe Ser Ser
465 470 475 480
ccg cct cac caa gta gag cag aca gag ctt ccg caa gag cag ctt cag 1488
Pro Pro His Gln Val Glu Gln Thr Glu Leu Pro Gln Glu Gln Leu Gln
485 490 495
acg gtg gtt ggt act tac cat gct tcc caa gac cag ccc cat caa gtg 1536
Thr Val Val Gly Thr Tyr His Ala Ser Gln Asp Gln Pro His Gln Val
500 505 510
acc ggt aac cac cag cag cct ccc cag cag aac act ggg ttt cca cgt 1584
Thr Gly Asn His Gln Gln Pro Pro Gln Gln Asn Thr Gly Phe Pro Arg
515 520 525
agc agt cag ccc tat tac aac agt cgt ggt gtg tct cgt gga ggc tcc 1632
Ser Ser Gln Pro Tyr Tyr Asn Ser Arg Gly Val Ser Arg Gly Gly Ser
530 535 540
cgt ggt gct aga ggc ttg atg aat gga tac agg ggc cct gcc aat gga 1680
Arg Gly Ala Arg Gly Leu Met Asn Gly Tyr Arg Gly Pro Ala Asn Gly
545 550 555 560
ttc aga gga gga tat gat ggt tac cgc cct tcg ttc tct aac act cca 1728
Phe Arg Gly Gly Tyr Asp Gly Tyr Arg Pro Ser Phe Ser Asn Thr Pro
565 570 575
aac agc ggt tac aca cag tct cag ttc agt gct ccc cgg gac tac tct 1776
Asn Ser Gly Tyr Thr Gln Ser Gln Phe Ser Ala Pro Arg Asp Tyr Ser
580 585 590
ggc tat cag cgg gat gga tat cag cag aat ttc aag cga ggc tct ggg 1824
Gly Tyr Gln Arg Asp Gly Tyr Gln Gln Asn Phe Lys Arg Gly Ser Gly
595 600 605
cag agt gga ccc cgg gga gcc cca cga ggt cgt gga ggg ccc cca aga 1872
Gln Ser Gly Pro Arg Gly Ala Pro Arg Gly Arg Gly Gly Pro Pro Arg
610 615 620
ccc aac aga ggg atg ccg caa atg aac act cag caa gtg aat taa 1917
Pro Asn Arg Gly Met Pro Gln Met Asn Thr Gln Gln Val Asn
625 630 635
tctgattcac aggattatct ttaatcgcca aaacacactg gccagtgtac cataatatgt 1977
taccagaaga gttattatct atttgttctc cctttcagga aacttattgt aaagggactg 2037
ttttcatccc ataaagacag gactacagtt gtcagcttta tattacctgg atatggaagg 2097
aaactatttt tactctgcat gttctgtcct aagcgtcatc ttgagccttg cacatgatac 2157
tcagattcct ttcccttgct taggagtaaa acataatata ctttatgggg tgataatatc 2217
tccatagtta tttgaagtgg cttggaaaaa gcaagattga cttttgacat tggataaaat 2277
ctacaaatca gccctagagt ttcatggtca ttcacaaaac taaaatattt cccttgaaag 2337
gaagatggaa ggactggagt gtggtttggc agaacaactg catttcacag cttttcctat 2397
taaattggag cactgaatgt taaatgcata ccaaattatg catgggccct taatcacaca 2457
tacatggcta ccagctttga cacagcacta ttcatcctct ggccaaacga ctgtggttaa 2517
aaacacgtgt aaattgcttt ttaacagctg atactgtaaa agacaaagct aaaatgcaaa 2577
attaggcttt cattggcact tttcgaaaaa tatgcaacaa atttgggatg taatctggat 2637
ggccacttct gtacttaatg tgaagtattt agataccttt ttgaacactt aacagtttct 2697
tcgacaatga cttttgtaag gattggtagt atatatcatt ccttatgaca tacattgtct 2757
gttgctaatc cttggatctt gctgtattgt cacctaaatt ggtacaggta ctgatgaaaa 2817
tctctcatgg ataaacctaa cactcttcgt cacatgtttt tcctgcagcc tgaaggtttt 2877
taaaaggaaa agatatcaaa tgcctgctgc taccaccctt ttaaattgct atcttttgaa 2937
aagcaccagt atgtgttttt agattgattt ccctatttta gggaaatgac agtcagtagt 2997
ttcagttctg atggtataag caaagcaaat aaaacgtgtt tataaaagtt gtatcttgaa 3057
acactggtgt tcaacagcta gcagcttctg tggttcaccc cctgccttgt tagtgttacc 3117
catttatggt tatctccagc agcaatttct cta 3150
<210> 18
<211> 638
<212> PRT
<213> 马(equus caballus)
<400> 18
Met Glu Gly Lys Leu Asp Asp Tyr Gln Glu Arg Met Asn Lys Gly Glu
1 5 10 15
Arg Leu Asn Gln Asp Gln Leu Asp Ala Val Ser Lys Tyr Gln Glu Val
20 25 30
Thr Asn Asn Leu Glu Phe Ala Lys Glu Leu Gln Arg Ser Phe Met Ala
35 40 45
Leu Ser Gln Asp Ile Gln Lys Thr Ile Lys Lys Thr Ala Arg Arg Glu
50 55 60
Gln Leu Met Arg Glu Glu Ala Glu Gln Lys Arg Leu Lys Thr Val Leu
65 70 75 80
Glu Leu Gln Tyr Val Leu Asp Lys Leu Gly Asp Glu Glu Val Arg Thr
85 90 95
Asp Leu Lys Gln Gly Leu Asn Gly Val Pro Ile Leu Ser Glu Glu Glu
100 105 110
Leu Ser Leu Leu Asp Glu Phe Tyr Lys Leu Ala Asp Pro Val Arg Asp
115 120 125
Met Ser Leu Arg Leu Asn Glu Gln Tyr Glu His Ala Ser Ile His Leu
130 135 140
Trp Asp Leu Leu Glu Gly Lys Glu Lys Ser Val Cys Gly Thr Thr Tyr
145 150 155 160
Lys Ala Leu Arg Glu Ile Val Glu Arg Val Phe Gln Ser Asn Tyr Phe
165 170 175
Asp Ser Thr His Asn His Gln Asn Gly Leu Cys Glu Glu Glu Glu Ala
180 185 190
Thr Ser Ala Pro Thr Ala Glu Asp Gln Gly Ala Glu Ala Glu Pro Glu
195 200 205
Pro Ala Glu Glu Tyr Thr Glu Gln Ser Glu Val Glu Ser Thr Glu Tyr
210 215 220
Val Asn Arg Gln Phe Met Ala Glu Ala Gln Phe Ser Gly Glu Lys Glu
225 230 235 240
Gln Val Asp Glu Trp Thr Val Glu Thr Val Glu Val Val Asn Ser Leu
245 250 255
Gln Gln Gln Pro Gln Ala Ala Ser Pro Ser Val Pro Glu Pro His Ser
260 265 270
Leu Thr Pro Val Ala Gln Ala Asp Pro Leu Val Arg Arg Gln Arg Val
275 280 285
Gln Asp Leu Met Ala Gln Met Gln Gly Pro Tyr Asn Phe Ile Gln Asp
290 295 300
Ser Met Leu Asp Phe Glu Asn Gln Thr Leu Asp Pro Ala Ile Val Ser
305 310 315 320
Ala Gln Pro Met Asn Pro Ala Gln Asn Met Asp Met Pro Gln Leu Val
325 330 335
Cys Pro Pro Val His Ala Glu Ser Arg Leu Ala Gln Pro Asn Gln Val
340 345 350
Pro Val Gln Pro Glu Ala Thr Gln Val Pro Leu Val Ser Ser Thr Ser
355 360 365
Glu Gly Tyr Thr Ala Ser Gln Pro Leu Tyr Gln Pro Ser His Ala Thr
370 375 380
Glu Gln Arg Pro Gln Lys Glu Pro Thr Asp Gln Ile Gln Ala Thr Ile
385 390 395 400
Ser Leu Asn Thr Asp Gln Thr Thr Ala Ser Ser Ser Leu Pro Ala Ala
405 410 415
Ser Gln Pro Gln Val Phe Gln Ala Gly Thr Ser Lys Pro Leu His Ser
420 425 430
Ser Gly Ile Asn Val Asn Ala Ala Pro Phe Gln Ser Met Gln Thr Val
435 440 445
Phe Asn Met Asn Ala Pro Val Pro Pro Val Asn Glu Pro Glu Thr Leu
450 455 460
Lys Gln Gln Asn Gln Tyr Gln Ala Ser Tyr Asn Gln Ser Phe Ser Ser
465 470 475 480
Pro Pro His Gln Val Glu Gln Thr Glu Leu Pro Gln Glu Gln Leu Gln
485 490 495
Thr Val Val Gly Thr Tyr His Ala Ser Gln Asp Gln Pro His Gln Val
500 505 510
Thr Gly Asn His Gln Gln Pro Pro Gln Gln Asn Thr Gly Phe Pro Arg
515 520 525
Ser Ser Gln Pro Tyr Tyr Asn Ser Arg Gly Val Ser Arg Gly Gly Ser
530 535 540
Arg Gly Ala Arg Gly Leu Met Asn Gly Tyr Arg Gly Pro Ala Asn Gly
545 550 555 560
Phe Arg Gly Gly Tyr Asp Gly Tyr Arg Pro Ser Phe Ser Asn Thr Pro
565 570 575
Asn Ser Gly Tyr Thr Gln Ser Gln Phe Ser Ala Pro Arg Asp Tyr Ser
580 585 590
Gly Tyr Gln Arg Asp Gly Tyr Gln Gln Asn Phe Lys Arg Gly Ser Gly
595 600 605
Gln Ser Gly Pro Arg Gly Ala Pro Arg Gly Arg Gly Gly Pro Pro Arg
610 615 620
Pro Asn Arg Gly Met Pro Gln Met Asn Thr Gln Gln Val Asn
625 630 635
<210> 19
<211> 6181
<212> DNA
<213> 小鼠(Mus musculus)
<220>
<221> CDS
<222> (179)..(2302)
<223>
<400> 19
gctggctggc taagtccctc ccgcgccggc tcttgtccca ctaggagcag ctcagagccg 60
cggggacagg gcgaagcggc ctgcgcccac ggagcgcacg tctctgttct caacgcagca 120
ccacccttgc ccccctcggc tgcccactcc agacgtccag cggctccgcg cgcgcacg 178
atg ccc tcg gcc acc agc cac agc gga agc ggc agc aaa tcg tcg gga 226
Met Pro Ser Ala Thr Ser His Ser Gly Ser Gly Ser Lys Ser Ser Gly
1 5 10 15
ccg ccg ccg ccg tcc ggt tcc tcc ggg agt gag gcg gcg gcc ggg gca 274
Pro Pro Pro Pro Ser Gly Ser Ser Gly Ser Glu Ala Ala Ala Gly Ala
20 25 30
gct gcg ccg gct tct cag cat ccg gca acc ggc acc ggc gcc gtc cag 322
Ala Ala Pro Ala Ser Gln His Pro Ala Thr Gly Thr Gly Ala Val Gln
35 40 45
acc gag gcc atg aag cag att ctc ggc gta atc gac aag aaa ctt cgg 370
Thr Glu Ala Met Lys Gln Ile Leu Gly Val Ile Asp Lys Lys Leu Arg
50 55 60
aac ctg gag aag aaa aag ggt aaa ctt gat gat tac cag gaa cga atg 418
Asn Leu Glu Lys Lys Lys Gly Lys Leu Asp Asp Tyr Gln Glu Arg Met
65 70 75 80
aat aaa ggg gaa agg ctc aat caa gac cag ctg gat gcc gta tct aag 466
Asn Lys Gly Glu Arg Leu Asn Gln Asp Gln Leu Asp Ala Val Ser Lys
85 90 95
tac cag gaa gtc aca aat aat ttg gag ttt gca aag gaa tta cag agg 514
Tyr Gln Glu Val Thr Asn Asn Leu Glu Phe Ala Lys Glu Leu Gln Arg
100 105 110
agt ttc atg gca tta agt caa gat att cag aaa aca ata aag aag aca 562
Ser Phe Met Ala Leu Ser Gln Asp Ile Gln Lys Thr Ile Lys Lys Thr
115 120 125
gca cgt cgg gaa cag ctt atg aga gaa gaa gca gaa cag aag cgc tta 610
Ala Arg Arg Glu Gln Leu Met Arg Glu Glu Ala Glu Gln Lys Arg Leu
130 135 140
aaa act gta ctt gag tta cag tat gta ttg gat aag ctg gga gat gat 658
Lys Thr Val Leu Glu Leu Gln Tyr Val Leu Asp Lys Leu Gly Asp Asp
145 150 155 160
gat gtg aga aca gat ctg aaa caa ggt ttg agt gga gtg cca ata ttg 706
Asp Val Arg Thr Asp Leu Lys Gln Gly Leu Ser Gly Val Pro Ile Leu
165 170 175
tct gag gag gag ttg tca ttg ctg gat gag ttc tac aag ctc gta gat 754
Ser Glu Glu Glu Leu Ser Leu Leu Asp Glu Phe Tyr Lys Leu Val Asp
180 185 190
cct gag cgt gac atg agt tta agg tta aat gag cag tat gaa cat gcc 802
Pro Glu Arg Asp Met Ser Leu Arg Leu Asn Glu Gln Tyr Glu His Ala
195 200 205
tca att cac ttg tgg gat ttg ctg gaa ggg aaa gaa aag cct gtg tgt 850
Ser Ile His Leu Trp Asp Leu Leu Glu Gly Lys Glu Lys Pro Val Cys
210 215 220
gga aca acc tat aaa gct cta aag gaa att gtt gag cgt gtt ttc cag 898
Gly Thr Thr Tyr Lys Ala Leu Lys Glu Ile Val Glu Arg Val Phe Gln
225 230 235 240
tca aac tac ttt gat agc act cac aat cat caa aat ggg ttg tgt gag 946
Ser Asn Tyr Phe Asp Ser Thr His Asn His Gln Asn Gly Leu Cys Glu
245 250 255
gag gaa gag gcg gct tca gcg ccc aca gtg gag gac cag gta gct gaa 994
Glu Glu Glu Ala Ala Ser Ala Pro Thr Val Glu Asp Gln Val Ala Glu
260 265 270
gct gaa cct gag cca gcg gaa gaa tac aca gag caa agt gag gtt gaa 1042
Ala Glu Pro Glu Pro Ala Glu Glu Tyr Thr Glu Gln Ser Glu Val Glu
275 280 285
tca aca gag tat gtc aat agg cag ttc atg gca gaa aca cag ttc agc 1090
Ser Thr Glu Tyr Val Asn Arg Gln Phe Met Ala Glu Thr Gln Phe Ser
290 295 300
agt ggt gag aag gag caa gtg gat gag tgg aca gtt gaa aca gtt gag 1138
Ser Gly Glu Lys Glu Gln Val Asp Glu Trp Thr Val Glu Thr Val Glu
305 310 315 320
gtt gta aac tca ctc cag cag caa cct cag gct gcg tcc cct tca gtc 1186
Val Val Asn Ser Leu Gln Gln Gln Pro Gln Ala Ala Ser Pro Ser Val
325 330 335
cca gag ccc cac tct ttg act cca gtg gct cag tca gat cca ctt gtg 1234
Pro Glu Pro His Ser Leu Thr Pro Val Ala Gln Ser Asp Pro Leu Val
340 345 350
aga agg cag cgt gta caa gat ctt atg gca caa atg caa ggg ccc tat 1282
Arg Arg Gln Arg Val Gln Asp Leu Met Ala Gln Met Gln Gly Pro Tyr
355 360 365
aat ttc ata cag gat tca atg ttg gat ttt gaa aat cag acg ctt gat 1330
Asn Phe Ile Gln Asp Ser Met Leu Asp Phe Glu Asn Gln Thr Leu Asp
370 375 380
cct gcc att gta tcc gca cag cct atg aac cct acc cag aac atg gat 1378
Pro Ala Ile Val Ser Ala Gln Pro Met Asn Pro Thr Gln Asn Met Asp
385 390 395 400
atg cct cag ctg gtt tgc cct cag gtt cat tct gaa tct aga ctt gcc 1426
Met Pro Gln Leu Val Cys Pro Gln Val His Ser Glu Ser Arg Leu Ala
405 410 415
caa tct aat caa gtt cct gta caa cca gaa gcc aca cag gtt cct ttg 1474
Gln Ser Asn Gln Val Pro Val Gln Pro Glu Ala Thr Gln Val Pro Leu
420 425 430
gtt tca tcc aca agt gag ggg tat aca gca tct cag ccc ttg tac cag 1522
Val Ser Ser Thr Ser Glu Gly Tyr Thr Ala Ser Gln Pro Leu Tyr Gln
435 440 445
cca tct cat gct acg gag cag cgg ccg cag aaa gag cca atg gat cag 1570
Pro Ser His Ala Thr Glu Gln Arg Pro Gln Lys Glu Pro Met Asp Gln
450 455 460
att cag gca aca ata tct ttg aat aca gac cag act aca gca tcc tca 1618
Ile Gln Ala Thr Ile Ser Leu Asn Thr Asp Gln Thr Thr Ala Ser Ser
465 470 475 480
tcc ctt cct gct gct tct cag cct caa gtg ttc cag gct ggg aca agt 1666
Ser Leu Pro Ala Ala Ser Gln Pro Gln Val Phe Gln Ala Gly Thr Ser
485 490 495
aaa cct ttg cac agc agt gga atc aat gta aat gca gct cca ttc cag 1714
Lys Pro Leu His Ser Ser Gly Ile Asn Val Asn Ala Ala Pro Phe Gln
500 505 510
tcc atg caa acg gtg ttc aat atg aat gct cca gtc cct cct gct aat 1762
Ser Met Gln Thr Val Phe Asn Met Asn Ala Pro Val Pro Pro Ala Asn
515 520 525
gaa cca gaa acg tta aaa caa cag agt cag tac cag gcc act tat aac 1810
Glu Pro Glu Thr Leu Lys Gln Gln Ser Gln Tyr Gln Ala Thr Tyr Asn
530 535 540
cag agt ttt tcc agt cag cct cac caa gtg gaa caa aca gag ctt caa 1858
Gln Ser Phe Ser Ser Gln Pro His Gln Val Glu Gln Thr Glu Leu Gln
545 550 555 560
caa gac caa ctg caa acg gtg gtt ggc act tac cat gga tcc cag gac 1906
Gln Asp Gln Leu Gln Thr Val Val Gly Thr Tyr His Gly Ser Gln Asp
565 570 575
cag cct cat caa gtg cct ggt aac cac cag caa ccc cca cag cag aac 1954
Gln Pro His Gln Val Pro Gly Asn His Gln Gln Pro Pro Gln Gln Asn
580 585 590
act ggc ttt cca cgt agc agt cag cct tat tac aac agt cgt ggg gta 2002
Thr Gly Phe Pro Arg Ser Ser Gln Pro Tyr Tyr Asn Ser Arg Gly Val
595 600 605
tct cga gga ggg tct cgt ggt gcc aga ggc ttg atg aat gga tac agg 2050
Ser Arg Gly Gly Ser Arg Gly Ala Arg Gly Leu Met Asn Gly Tyr Arg
610 615 620
ggc cct gcc aat gga ttt aga gga gga tat gat ggt tac cgc cct tca 2098
Gly Pro Ala Asn Gly Phe Arg Gly Gly Tyr Asp Gly Tyr Arg Pro Ser
625 630 635 640
ttc tcg aac act cca aac agt ggt tat tca cag tct cag ttc act gct 2146
Phe Ser Asn Thr Pro Asn Ser Gly Tyr Ser Gln Ser Gln Phe Thr Ala
645 650 655
ccc cgg gac tac tct ggt tac cag cgg gat gga tat cag cag aat ttc 2194
Pro Arg Asp Tyr Ser Gly Tyr Gln Arg Asp Gly Tyr Gln Gln Asn Phe
660 665 670
aag cga ggc tct ggg cag agt gga cca cgg gga gcc cca cga ggt cgt 2242
Lys Arg Gly Ser Gly Gln Ser Gly Pro Arg Gly Ala Pro Arg Gly Arg
675 680 685
gga ggg ccc cca aga ccc aac aga ggg atg ccg caa atg aac act cag 2290
Gly Gly Pro Pro Arg Pro Asn Arg Gly Met Pro Gln Met Asn Thr Gln
690 695 700
caa gtg aat taa tgtgatacac aggattatgt ttaatcgcca aaaacacact 2342
Gln Val Asn
705
ggccagtgta ccataatatg ttaccagaag agttattatc tatttgttct ccctttcagg 2402
aaacttattg taaagggact gttttcatcc cataaagaca ggactgcaat tgtcagcttt 2462
acattacctg gatatggaag gaaactattt ttattctgca tgttctgtcc taagcgtcat 2522
cttgagcctt gcacacaata caatactcag attcctcacc cttgcttagg agtaaaacat 2582
tatatactta tggggtgata atatctccat agttagttga agtggcttgg aaaaaaaatg 2642
caagattgaa tttttgacct tggataaaat ctacaatcag ccctagaact attcagtggt 2702
aattgacaaa gttaaagcat tttctttgaa aggaagatgg aaggagtgga gtgtggttta 2762
gcaaaactgc atttcatagc tttcccatta aattggagca ccgacagatt aaaagcatac 2822
caaattatgc atgggtcctt actcacacaa gtgaggctgg ctaccagcct tgacatagca 2882
ctcactagtc ttctggccaa acgactgtga ttaaaacaca tgtaaattgc tctttagtag 2942
tggatactgt gtaagacaaa gccaaattgc aaatcaggct ttgattggct cttctggaaa 3002
atatgcatca aatatggggg ataatctgga tgggctgctg ctgtgctcaa tgtgaactat 3062
ttagatacct ttggaacact taacagtttc tctgaacaat gacttacatg gggattggtc 3122
ctgtttgtca ttcctcacca taattgcatt gtcatcacta atccttggat cttgctgtat 3182
tgttactcaa attggtaata ggtactgatg gaaatcgcta atggatggat aatcataaca 3242
cttttggtca catgttttct cctgcagcct gaaagttctt aaagaaaaag atatcaaatg 3302
cctgctgcta ccaccctttt aaattgctat ctttagaaaa gcaccggtat gtgttttaga 3362
ttcatttccc tgttttaggg aaatgacagg cagtagtttc agttctgatg gcaaaacaaa 3422
taaaaacatg tttctaaaag ttgtatcttg aaacactggt gttcaacagc tagcagctaa 3482
agtaattcaa cccatgcatt gctagtgtca cagcctttgg ttatgtctag tagctgtttc 3542
tgaagtattt tcatttatct tttgtcaaat ttaaccctgt ttgaattctc tcctttcctc 3602
aaggagacac ttatgttcaa agtgttgatt ctttgcctta ggtgcataga gagtagacag 3662
tttggagatg gaaaggttag cagtgactta gccatatgtt ctgtgttgga atttgtgcta 3722
gcagtttgag cactagctct gcgtgcctat gaactgaatg ctgcttgtcc cattccattt 3782
tatgtcatgg agaaataatt ccacttggta acacaaaggc taagttaatg ttattttctg 3842
tacagaaatt aaattttact tttagccttt tgtaaacttt tttttttttt ttccaagccg 3902
gtatcagcta ctcaaaacaa ttctcagata ttcatcatta gacaactgga gtttttgctg 3962
gttttgtagc ctactaaaac tgctgaggct gttgaacatt ccacattcaa aagttttgta 4022
gggtggtgga taatggggaa gcttcaatgt ttattttaaa ataaataaaa taagttcttg 4082
acttttctca tgtgtggtta tggtacatca tattggaagg gttatctgtt tacttttgcc 4142
aagactattt tgccagcacc tacacttgtg tgctttaaaa gacaactacc tgggatgtac 4202
cacaaccata tgttaattgt attttattgg gatggataaa atgtttgtgg tttattggat 4262
aatccctaga tggtgtgtta cgtgtgtaga atataatttt atgatagtaa gaaagcaaaa 4322
ttgaagaaaa taagtttagt attgaatttg agttctgaag tgaattcagg gaatgtctca 4382
cgtttcgggc ttctacccaa agtgtagggc agaaggtgta aaagttgttt gtagtttgac 4442
ttgtttattt tttaagttgc ttattccttt caacagcaac atatcattag ctgtcattct 4502
accattgcag ttctagtgag ttttaacgtc tgcattcaag actgttttaa aagcaacctc 4562
actggacaga gaactgctaa agtcttttcc ttaagatctg agtctttgtt actcagtatc 4622
ttctataata tgcaaatgct tgtctagagg cagaagacct tttgtttggt caagtgtgta 4682
ttttaccaga gtacagggaa ctgatggtcc tacatgtctc ttagtgtagt aagactataa 4742
aatcttttgt acatgcacaa ttcacagtat gtttagatac cacgtgtata atgccccccc 4802
ctcccccagg tagcatgcca ttgatgactt tttgcttagg gccattttat taccagggcc 4862
ttaatattcc taaaaagatg attttttttc atcctttctc ctcttttgat cattgtatct 4922
tgatattaaa aacatgacct tccaatgatt gtagtaaatt aacttctata gttcttttgt 4982
ctctatatgt attcatatat atgctattgt atagagactt caaggagaca tggagatgca 5042
tgcttattct caggttcatt cactaaggtg cttggcagac aaccagtttc taagtgcaga 5102
atgtagttaa gcagcttcat atatgtgcca ggcaatttgt tttgttaaat tttcatctac 5162
ttaaggaaat agggtattgt agcttaggct gatcataccc ttcatttcaa ccttaagctc 5222
tcaacctgca tccatccgac ttgagctatt aagtacttta gttttatcga gtataagtta 5282
acagaaaaag taaattaagc tttgccttta ctattttgaa tttatataca ttctggaaaa 5342
acttagaaac tgttgtatat ttcattagat taaattatat gaaaatgtga ttgtttatag 5402
caaagcctgt gagttgcata caccctaagg aaaactcctt aagtgctcct tgaagagaga 5462
agaaacaatt ctgggtctgg tctttttaag aacaaagcta gactactgta tgttagcact 5522
gtacattaat agtctgttgt gaagcttgag cagtttcctg catagccttg atccttcacc 5582
gttggcattg aaaatagcag tatccctgat gtacttaaaa cttaaagtca ggttttggta 5642
tatttatttg taagtcttaa tttcctctaa atactatatc tctttagcga gacaacctga 5702
aatttattag cacatttggg tatctcttgc ttggcattat ggccagtgtt aactattcag 5762
tggtgaaaaa attacccctc aagacactgg agtgacccca gatgtgtgta gtaagtggca 5822
tggttcaact gtgtggttaa tgataaatat atgacttagt cggtatgatc tggaaagact 5882
tgattgaaag ataattcagc tgacataagg atgagtgagg agtggcaaac tggataaaag 5942
agtcaagaga cctgtattcc agtgactcct gttttgttta agcattagca agatctgtct 6002
ggggaaactg gatagggcag ttttcttcca tgtttagttt ttgtctcaac atttggaagc 6062
tattgaaggt tttaaaatgg tgtgtattgt ttttttttgg ggggggggtg gccagaatag 6122
tgggtcatct aataaaactg ccatttaaaa gatcaaaaaa aaaaaaaaaa aaaaaaaaa 6181
<210> 20
<211> 707
<212> PRT
<213> 小鼠(Mus musculus)
<400> 20
Met Pro Ser Ala Thr Ser His Ser Gly Ser Gly Ser Lys Ser Ser Gly
1 5 10 15
Pro Pro Pro Pro Ser Gly Ser Ser Gly Ser Glu Ala Ala Ala Gly Ala
20 25 30
Ala Ala Pro Ala Ser Gln His Pro Ala Thr Gly Thr Gly Ala Val Gln
35 40 45
Thr Glu Ala Met Lys Gln Ile Leu Gly Val Ile Asp Lys Lys Leu Arg
50 55 60
Asn Leu Glu Lys Lys Lys Gly Lys Leu Asp Asp Tyr Gln Glu Arg Met
65 70 75 80
Asn Lys Gly Glu Arg Leu Asn Gln Asp Gln Leu Asp Ala Val Ser Lys
85 90 95
Tyr Gln Glu Val Thr Asn Asn Leu Glu Phe Ala Lys Glu Leu Gln Arg
100 105 110
Ser Phe Met Ala Leu Ser Gln Asp Ile Gln Lys Thr Ile Lys Lys Thr
115 120 125
Ala Arg Arg Glu Gln Leu Met Arg Glu Glu Ala Glu Gln Lys Arg Leu
130 135 140
Lys Thr Val Leu Glu Leu Gln Tyr Val Leu Asp Lys Leu Gly Asp Asp
145 150 155 160
Asp Val Arg Thr Asp Leu Lys Gln Gly Leu Ser Gly Val Pro Ile Leu
165 170 175
Ser Glu Glu Glu Leu Ser Leu Leu Asp Glu Phe Tyr Lys Leu Val Asp
180 185 190
Pro Glu Arg Asp Met Ser Leu Arg Leu Asn Glu Gln Tyr Glu His Ala
195 200 205
Ser Ile His Leu Trp Asp Leu Leu Glu Gly Lys Glu Lys Pro Val Cys
210 215 220
Gly Thr Thr Tyr Lys Ala Leu Lys Glu Ile Val Glu Arg Val Phe Gln
225 230 235 240
Ser Asn Tyr Phe Asp Ser Thr His Asn His Gln Asn Gly Leu Cys Glu
245 250 255
Glu Glu Glu Ala Ala Ser Ala Pro Thr Val Glu Asp Gln Val Ala Glu
260 265 270
Ala Glu Pro Glu Pro Ala Glu Glu Tyr Thr Glu Gln Ser Glu Val Glu
275 280 285
Ser Thr Glu Tyr Val Asn Arg Gln Phe Met Ala Glu Thr Gln Phe Ser
290 295 300
Ser Gly Glu Lys Glu Gln Val Asp Glu Trp Thr Val Glu Thr Val Glu
305 310 315 320
Val Val Asn Ser Leu Gln Gln Gln Pro Gln Ala Ala Ser Pro Ser Val
325 330 335
Pro Glu Pro His Ser Leu Thr Pro Val Ala Gln Ser Asp Pro Leu Val
340 345 350
Arg Arg Gln Arg Val Gln Asp Leu Met Ala Gln Met Gln Gly Pro Tyr
355 360 365
Asn Phe Ile Gln Asp Ser Met Leu Asp Phe Glu Asn Gln Thr Leu Asp
370 375 380
Pro Ala Ile Val Ser Ala Gln Pro Met Asn Pro Thr Gln Asn Met Asp
385 390 395 400
Met Pro Gln Leu Val Cys Pro Gln Val His Ser Glu Ser Arg Leu Ala
405 410 415
Gln Ser Asn Gln Val Pro Val Gln Pro Glu Ala Thr Gln Val Pro Leu
420 425 430
Val Ser Ser Thr Ser Glu Gly Tyr Thr Ala Ser Gln Pro Leu Tyr Gln
435 440 445
Pro Ser His Ala Thr Glu Gln Arg Pro Gln Lys Glu Pro Met Asp Gln
450 455 460
Ile Gln Ala Thr Ile Ser Leu Asn Thr Asp Gln Thr Thr Ala Ser Ser
465 470 475 480
Ser Leu Pro Ala Ala Ser Gln Pro Gln Val Phe Gln Ala Gly Thr Ser
485 490 495
Lys Pro Leu His Ser Ser Gly Ile Asn Val Asn Ala Ala Pro Phe Gln
500 505 510
Ser Met Gln Thr Val Phe Asn Met Asn Ala Pro Val Pro Pro Ala Asn
515 520 525
Glu Pro Glu Thr Leu Lys Gln Gln Ser Gln Tyr Gln Ala Thr Tyr Asn
530 535 540
Gln Ser Phe Ser Ser Gln Pro His Gln Val Glu Gln Thr Glu Leu Gln
545 550 555 560
Gln Asp Gln Leu Gln Thr Val Val Gly Thr Tyr His Gly Ser Gln Asp
565 570 575
Gln Pro His Gln Val Pro Gly Asn His Gln Gln Pro Pro Gln Gln Asn
580 585 590
Thr Gly Phe Pro Arg Ser Ser Gln Pro Tyr Tyr Asn Ser Arg Gly Val
595 600 605
Ser Arg Gly Gly Ser Arg Gly Ala Arg Gly Leu Met Asn Gly Tyr Arg
610 615 620
Gly Pro Ala Asn Gly Phe Arg Gly Gly Tyr Asp Gly Tyr Arg Pro Ser
625 630 635 640
Phe Ser Asn Thr Pro Asn Ser Gly Tyr Ser Gln Ser Gln Phe Thr Ala
645 650 655
Pro Arg Asp Tyr Ser Gly Tyr Gln Arg Asp Gly Tyr Gln Gln Asn Phe
660 665 670
Lys Arg Gly Ser Gly Gln Ser Gly Pro Arg Gly Ala Pro Arg Gly Arg
675 680 685
Gly Gly Pro Pro Arg Pro Asn Arg Gly Met Pro Gln Met Asn Thr Gln
690 695 700
Gln Val Asn
705
<210> 21
<211> 6141
<212> DNA
<213> 小鼠(Mus musculus)
<220>
<221> CDS
<222> (139)..(2262)
<223>
<400> 21
cccaccgcgc gcgcgcgtag ccgcctgccc gcccgcccgc tgcgcgtttt gtcccgcgtc 60
tctccccgtc cgtctcctga cttgctggtc ttgtccttcc ctcccgcttt tttcctctcc 120
tctcttctcg gtctaaag atg ccc tcg gcc acc agc cac agc gga agc ggc 171
Met Pro Ser Ala Thr Ser His Ser Gly Ser Gly
1 5 10
agc aaa tcg tcg gga ccg ccg ccg ccg tcc ggt tcc tcc ggg agt gag 219
Ser Lys Ser Ser Gly Pro Pro Pro Pro Ser Gly Ser Ser Gly Ser Glu
15 20 25
gcg gcg gcc ggg gca gct gcg ccg gct tct cag cat ccg gca acc ggc 267
Ala Ala Ala Gly Ala Ala Ala Pro Ala Ser Gln His Pro Ala Thr Gly
30 35 40
acc ggc gcc gtc cag acc gag gcc atg aag cag att ctc ggc gta atc 315
Thr Gly Ala Val Gln Thr Glu Ala Met Lys Gln Ile Leu Gly Val Ile
45 50 55
gac aag aaa ctt cgg aac ctg gag aag aaa aag ggt aaa ctt gat gat 363
Asp Lys Lys Leu Arg Asn Leu Glu Lys Lys Lys Gly Lys Leu Asp Asp
60 65 70 75
tac cag gaa cga atg aat aaa ggg gaa agg ctc aat caa gac cag ctg 411
Tyr Gln Glu Arg Met Asn Lys Gly Glu Arg Leu Asn Gln Asp Gln Leu
80 85 90
gat gcc gta tct aag tac cag gaa gtc aca aat aat ttg gag ttt gca 459
Asp Ala Val Ser Lys Tyr Gln Glu Val Thr Asn Asn Leu Glu Phe Ala
95 100 105
aag gaa tta cag agg agt ttc atg gca tta agt caa gat att cag aaa 507
Lys Glu Leu Gln Arg Ser Phe Met Ala Leu Ser Gln Asp Ile Gln Lys
110 115 120
aca ata aag aag aca gca cgt cgg gaa cag ctt atg aga gaa gaa gca 555
Thr Ile Lys Lys Thr Ala Arg Arg Glu Gln Leu Met Arg Glu Glu Ala
125 130 135
gaa cag aag cgc tta aaa act gta ctt gag tta cag tat gta ttg gat 603
Glu Gln Lys Arg Leu Lys Thr Val Leu Glu Leu Gln Tyr Val Leu Asp
140 145 150 155
aag ctg gga gat gat gat gtg aga aca gat ctg aaa caa ggt ttg agt 651
Lys Leu Gly Asp Asp Asp Val Arg Thr Asp Leu Lys Gln Gly Leu Ser
160 165 170
gga gtg cca ata ttg tct gag gag gag ttg tca ttg ctg gat gag ttc 699
Gly Val Pro Ile Leu Ser Glu Glu Glu Leu Ser Leu Leu Asp Glu Phe
175 180 185
tac aag ctc gta gat cct gag cgt gac atg agt tta agg tta aat gag 747
Tyr Lys Leu Val Asp Pro Glu Arg Asp Met Ser Leu Arg Leu Asn Glu
190 195 200
cag tat gaa cat gcc tca att cac ttg tgg gat ttg ctg gaa ggg aaa 795
Gln Tyr Glu His Ala Ser Ile His Leu Trp Asp Leu Leu Glu Gly Lys
205 210 215
gaa aag cct gtg tgt gga aca acc tat aaa gct cta aag gaa att gtt 843
Glu Lys Pro Val Cys Gly Thr Thr Tyr Lys Ala Leu Lys Glu Ile Val
220 225 230 235
gag cgt gtt ttc cag tca aac tac ttt gat agc act cac aat cat caa 891
Glu Arg Val Phe Gln Ser Asn Tyr Phe Asp Ser Thr His Asn His Gln
240 245 250
aat ggg ttg tgt gag gag gaa gag gcg gct tca gcg ccc aca gtg gag 939
Asn Gly Leu Cys Glu Glu Glu Glu Ala Ala Ser Ala Pro Thr Val Glu
255 260 265
gac cag gta gct gaa gct gaa cct gag cca gcg gaa gaa tac aca gag 987
Asp Gln Val Ala Glu Ala Glu Pro Glu Pro Ala Glu Glu Tyr Thr Glu
270 275 280
caa agt gag gtt gaa tca aca gag tat gtc aat agg cag ttc atg gca 1035
Gln Ser Glu Val Glu Ser Thr Glu Tyr Val Asn Arg Gln Phe Met Ala
285 290 295
gaa aca cag ttc agc agt ggt gag aag gag caa gtg gat gag tgg aca 1083
Glu Thr Gln Phe Ser Ser Gly Glu Lys Glu Gln Val Asp Glu Trp Thr
300 305 310 315
gtt gaa aca gtt gag gtt gta aac tca ctc cag cag caa cct cag gct 1131
Val Glu Thr Val Glu Val Val Asn Ser Leu Gln Gln Gln Pro Gln Ala
320 325 330
gcg tcc cct tca gtc cca gag ccc cac tct ttg act cca gtg gct cag 1179
Ala Ser Pro Ser Val Pro Glu Pro His Ser Leu Thr Pro Val Ala Gln
335 340 345
tca gat cca ctt gtg aga agg cag cgt gta caa gat ctt atg gca caa 1227
Ser Asp Pro Leu Val Arg Arg Gln Arg Val Gln Asp Leu Met Ala Gln
350 355 360
atg caa ggg ccc tat aat ttc ata cag gat tca atg ttg gat ttt gaa 1275
Met Gln Gly Pro Tyr Asn Phe Ile Gln Asp Ser Met Leu Asp Phe Glu
365 370 375
aat cag acg ctt gat cct gcc att gta tcc gca cag cct atg aac cct 1323
Asn Gln Thr Leu Asp Pro Ala Ile Val Ser Ala Gln Pro Met Asn Pro
380 385 390 395
acc cag aac atg gat atg cct cag ctg gtt tgc cct cag gtt cat tct 1371
Thr Gln Asn Met Asp Met Pro Gln Leu Val Cys Pro Gln Val His Ser
400 405 410
gaa tct aga ctt gcc caa tct aat caa gtt cct gta caa cca gaa gcc 1419
Glu Ser Arg Leu Ala Gln Ser Asn Gln Val Pro Val Gln Pro Glu Ala
415 420 425
aca cag gtt cct ttg gtt tca tcc aca agt gag ggg tat aca gca tct 1467
Thr Gln Val Pro Leu Val Ser Ser Thr Ser Glu Gly Tyr Thr Ala Ser
430 435 440
cag ccc ttg tac cag cca tct cat gct acg gag cag cgg ccg cag aaa 1515
Gln Pro Leu Tyr Gln Pro Ser His Ala Thr Glu Gln Arg Pro Gln Lys
445 450 455
gag cca atg gat cag att cag gca aca ata tct ttg aat aca gac cag 1563
Glu Pro Met Asp Gln Ile Gln Ala Thr Ile Ser Leu Asn Thr Asp Gln
460 465 470 475
act aca gca tcc tca tcc ctt cct gct gct tct cag cct caa gtg ttc 1611
Thr Thr Ala Ser Ser Ser Leu Pro Ala Ala Ser Gln Pro Gln Val Phe
480 485 490
cag gct ggg aca agt aaa cct ttg cac agc agt gga atc aat gta aat 1659
Gln Ala Gly Thr Ser Lys Pro Leu His Ser Ser Gly Ile Asn Val Asn
495 500 505
gca gct cca ttc cag tcc atg caa acg gtg ttc aat atg aat gct cca 1707
Ala Ala Pro Phe Gln Ser Met Gln Thr Val Phe Asn Met Asn Ala Pro
510 515 520
gtc cct cct gct aat gaa cca gaa acg tta aaa caa cag agt cag tac 1755
Val Pro Pro Ala Asn Glu Pro Glu Thr Leu Lys Gln Gln Ser Gln Tyr
525 530 535
cag gcc act tat aac cag agt ttt tcc agt cag cct cac caa gtg gaa 1803
Gln Ala Thr Tyr Asn Gln Ser Phe Ser Ser Gln Pro His Gln Val Glu
540 545 550 555
caa aca gag ctt caa caa gac caa ctg caa acg gtg gtt ggc act tac 1851
Gln Thr Glu Leu Gln Gln Asp Gln Leu Gln Thr Val Val Gly Thr Tyr
560 565 570
cat gga tcc cag gac cag cct cat caa gtg cct ggt aac cac cag caa 1899
His Gly Ser Gln Asp Gln Pro His Gln Val Pro Gly Asn His Gln Gln
575 580 585
ccc cca cag cag aac act ggc ttt cca cgt agc agt cag cct tat tac 1947
Pro Pro Gln Gln Asn Thr Gly Phe Pro Arg Ser Ser Gln Pro Tyr Tyr
590 595 600
aac agt cgt ggg gta tct cga gga ggg tct cgt ggt gcc aga ggc ttg 1995
Asn Ser Arg Gly Val Ser Arg Gly Gly Ser Arg Gly Ala Arg Gly Leu
605 610 615
atg aat gga tac agg ggc cct gcc aat gga ttt aga gga gga tat gat 2043
Met Asn Gly Tyr Arg Gly Pro Ala Asn Gly Phe Arg Gly Gly Tyr Asp
620 625 630 635
ggt tac cgc cct tca ttc tcg aac act cca aac agt ggt tat tca cag 2091
Gly Tyr Arg Pro Ser Phe Ser Asn Thr Pro Asn Ser Gly Tyr Ser Gln
640 645 650
tct cag ttc act gct ccc cgg gac tac tct ggt tac cag cgg gat gga 2139
Ser Gln Phe Thr Ala Pro Arg Asp Tyr Ser Gly Tyr Gln Arg Asp Gly
655 660 665
tat cag cag aat ttc aag cga ggc tct ggg cag agt gga cca cgg gga 2187
Tyr Gln Gln Asn Phe Lys Arg Gly Ser Gly Gln Ser Gly Pro Arg Gly
670 675 680
gcc cca cga ggt cgt gga ggg ccc cca aga ccc aac aga ggg atg ccg 2235
Ala Pro Arg Gly Arg Gly Gly Pro Pro Arg Pro Asn Arg Gly Met Pro
685 690 695
caa atg aac act cag caa gtg aat taa tgtgatacac aggattatgt 2282
Gln Met Asn Thr Gln Gln Val Asn
700 705
ttaatcgcca aaaacacact ggccagtgta ccataatatg ttaccagaag agttattatc 2342
tatttgttct ccctttcagg aaacttattg taaagggact gttttcatcc cataaagaca 2402
ggactgcaat tgtcagcttt acattacctg gatatggaag gaaactattt ttattctgca 2462
tgttctgtcc taagcgtcat cttgagcctt gcacacaata caatactcag attcctcacc 2522
cttgcttagg agtaaaacat tatatactta tggggtgata atatctccat agttagttga 2582
agtggcttgg aaaaaaaatg caagattgaa tttttgacct tggataaaat ctacaatcag 2642
ccctagaact attcagtggt aattgacaaa gttaaagcat tttctttgaa aggaagatgg 2702
aaggagtgga gtgtggttta gcaaaactgc atttcatagc tttcccatta aattggagca 2762
ccgacagatt aaaagcatac caaattatgc atgggtcctt actcacacaa gtgaggctgg 2822
ctaccagcct tgacatagca ctcactagtc ttctggccaa acgactgtga ttaaaacaca 2882
tgtaaattgc tctttagtag tggatactgt gtaagacaaa gccaaattgc aaatcaggct 2942
ttgattggct cttctggaaa atatgcatca aatatggggg ataatctgga tgggctgctg 3002
ctgtgctcaa tgtgaactat ttagatacct ttggaacact taacagtttc tctgaacaat 3062
gacttacatg gggattggtc ctgtttgtca ttcctcacca taattgcatt gtcatcacta 3122
atccttggat cttgctgtat tgttactcaa attggtaata ggtactgatg gaaatcgcta 3182
atggatggat aatcataaca cttttggtca catgttttct cctgcagcct gaaagttctt 3242
aaagaaaaag atatcaaatg cctgctgcta ccaccctttt aaattgctat ctttagaaaa 3302
gcaccggtat gtgttttaga ttcatttccc tgttttaggg aaatgacagg cagtagtttc 3362
agttctgatg gcaaaacaaa taaaaacatg tttctaaaag ttgtatcttg aaacactggt 3422
gttcaacagc tagcagctaa agtaattcaa cccatgcatt gctagtgtca cagcctttgg 3482
ttatgtctag tagctgtttc tgaagtattt tcatttatct tttgtcaaat ttaaccctgt 3542
ttgaattctc tcctttcctc aaggagacac ttatgttcaa agtgttgatt ctttgcctta 3602
ggtgcataga gagtagacag tttggagatg gaaaggttag cagtgactta gccatatgtt 3662
ctgtgttgga atttgtgcta gcagtttgag cactagctct gcgtgcctat gaactgaatg 3722
ctgcttgtcc cattccattt tatgtcatgg agaaataatt ccacttggta acacaaaggc 3782
taagttaatg ttattttctg tacagaaatt aaattttact tttagccttt tgtaaacttt 3842
tttttttttt ttccaagccg gtatcagcta ctcaaaacaa ttctcagata ttcatcatta 3902
gacaactgga gtttttgctg gttttgtagc ctactaaaac tgctgaggct gttgaacatt 3962
ccacattcaa aagttttgta gggtggtgga taatggggaa gcttcaatgt ttattttaaa 4022
ataaataaaa taagttcttg acttttctca tgtgtggtta tggtacatca tattggaagg 4082
gttatctgtt tacttttgcc aagactattt tgccagcacc tacacttgtg tgctttaaaa 4142
gacaactacc tgggatgtac cacaaccata tgttaattgt attttattgg gatggataaa 4202
atgtttgtgg tttattggat aatccctaga tggtgtgtta cgtgtgtaga atataatttt 4262
atgatagtaa gaaagcaaaa ttgaagaaaa taagtttagt attgaatttg agttctgaag 4322
tgaattcagg gaatgtctca cgtttcgggc ttctacccaa agtgtagggc agaaggtgta 4382
aaagttgttt gtagtttgac ttgtttattt tttaagttgc ttattccttt caacagcaac 4442
atatcattag ctgtcattct accattgcag ttctagtgag ttttaacgtc tgcattcaag 4502
actgttttaa aagcaacctc actggacaga gaactgctaa agtcttttcc ttaagatctg 4562
agtctttgtt actcagtatc ttctataata tgcaaatgct tgtctagagg cagaagacct 4622
tttgtttggt caagtgtgta ttttaccaga gtacagggaa ctgatggtcc tacatgtctc 4682
ttagtgtagt aagactataa aatcttttgt acatgcacaa ttcacagtat gtttagatac 4742
cacgtgtata atgccccccc ctcccccagg tagcatgcca ttgatgactt tttgcttagg 4802
gccattttat taccagggcc ttaatattcc taaaaagatg attttttttc atcctttctc 4862
ctcttttgat cattgtatct tgatattaaa aacatgacct tccaatgatt gtagtaaatt 4922
aacttctata gttcttttgt ctctatatgt attcatatat atgctattgt atagagactt 4982
caaggagaca tggagatgca tgcttattct caggttcatt cactaaggtg cttggcagac 5042
aaccagtttc taagtgcaga atgtagttaa gcagcttcat atatgtgcca ggcaatttgt 5102
tttgttaaat tttcatctac ttaaggaaat agggtattgt agcttaggct gatcataccc 5162
ttcatttcaa ccttaagctc tcaacctgca tccatccgac ttgagctatt aagtacttta 5222
gttttatcga gtataagtta acagaaaaag taaattaagc tttgccttta ctattttgaa 5282
tttatataca ttctggaaaa acttagaaac tgttgtatat ttcattagat taaattatat 5342
gaaaatgtga ttgtttatag caaagcctgt gagttgcata caccctaagg aaaactcctt 5402
aagtgctcct tgaagagaga agaaacaatt ctgggtctgg tctttttaag aacaaagcta 5462
gactactgta tgttagcact gtacattaat agtctgttgt gaagcttgag cagtttcctg 5522
catagccttg atccttcacc gttggcattg aaaatagcag tatccctgat gtacttaaaa 5582
cttaaagtca ggttttggta tatttatttg taagtcttaa tttcctctaa atactatatc 5642
tctttagcga gacaacctga aatttattag cacatttggg tatctcttgc ttggcattat 5702
ggccagtgtt aactattcag tggtgaaaaa attacccctc aagacactgg agtgacccca 5762
gatgtgtgta gtaagtggca tggttcaact gtgtggttaa tgataaatat atgacttagt 5822
cggtatgatc tggaaagact tgattgaaag ataattcagc tgacataagg atgagtgagg 5882
agtggcaaac tggataaaag agtcaagaga cctgtattcc agtgactcct gttttgttta 5942
agcattagca agatctgtct ggggaaactg gatagggcag ttttcttcca tgtttagttt 6002
ttgtctcaac atttggaagc tattgaaggt tttaaaatgg tgtgtattgt ttttttttgg 6062
ggggggggtg gccagaatag tgggtcatct aataaaactg ccatttaaaa gatcaaaaaa 6122
aaaaaaaaaa aaaaaaaaa 6141
<210> 22
<211> 707
<212> PRT
<213> 小鼠(Mus musculus)
<400> 22
Met Pro Ser Ala Thr Ser His Ser Gly Ser Gly Ser Lys Ser Ser Gly
1 5 10 15
Pro Pro Pro Pro Ser Gly Ser Ser Gly Ser Glu Ala Ala Ala Gly Ala
20 25 30
Ala Ala Pro Ala Ser Gln His Pro Ala Thr Gly Thr Gly Ala Val Gln
35 40 45
Thr Glu Ala Met Lys Gln Ile Leu Gly Val Ile Asp Lys Lys Leu Arg
50 55 60
Asn Leu Glu Lys Lys Lys Gly Lys Leu Asp Asp Tyr Gln Glu Arg Met
65 70 75 80
Asn Lys Gly Glu Arg Leu Asn Gln Asp Gln Leu Asp Ala Val Ser Lys
85 90 95
Tyr Gln Glu Val Thr Asn Asn Leu Glu Phe Ala Lys Glu Leu Gln Arg
100 105 110
Ser Phe Met Ala Leu Ser Gln Asp Ile Gln Lys Thr Ile Lys Lys Thr
115 120 125
Ala Arg Arg Glu Gln Leu Met Arg Glu Glu Ala Glu Gln Lys Arg Leu
130 135 140
Lys Thr Val Leu Glu Leu Gln Tyr Val Leu Asp Lys Leu Gly Asp Asp
145 150 155 160
Asp Val Arg Thr Asp Leu Lys Gln Gly Leu Ser Gly Val Pro Ile Leu
165 170 175
Ser Glu Glu Glu Leu Ser Leu Leu Asp Glu Phe Tyr Lys Leu Val Asp
180 185 190
Pro Glu Arg Asp Met Ser Leu Arg Leu Asn Glu Gln Tyr Glu His Ala
195 200 205
Ser Ile His Leu Trp Asp Leu Leu Glu Gly Lys Glu Lys Pro Val Cys
210 215 220
Gly Thr Thr Tyr Lys Ala Leu Lys Glu Ile Val Glu Arg Val Phe Gln
225 230 235 240
Ser Asn Tyr Phe Asp Ser Thr His Asn His Gln Asn Gly Leu Cys Glu
245 250 255
Glu Glu Glu Ala Ala Ser Ala Pro Thr Val Glu Asp Gln Val Ala Glu
260 265 270
Ala Glu Pro Glu Pro Ala Glu Glu Tyr Thr Glu Gln Ser Glu Val Glu
275 280 285
Ser Thr Glu Tyr Val Asn Arg Gln Phe Met Ala Glu Thr Gln Phe Ser
290 295 300
Ser Gly Glu Lys Glu Gln Val Asp Glu Trp Thr Val Glu Thr Val Glu
305 310 315 320
Val Val Asn Ser Leu Gln Gln Gln Pro Gln Ala Ala Ser Pro Ser Val
325 330 335
Pro Glu Pro His Ser Leu Thr Pro Val Ala Gln Ser Asp Pro Leu Val
340 345 350
Arg Arg Gln Arg Val Gln Asp Leu Met Ala Gln Met Gln Gly Pro Tyr
355 360 365
Asn Phe Ile Gln Asp Ser Met Leu Asp Phe Glu Asn Gln Thr Leu Asp
370 375 380
Pro Ala Ile Val Ser Ala Gln Pro Met Asn Pro Thr Gln Asn Met Asp
385 390 395 400
Met Pro Gln Leu Val Cys Pro Gln Val His Ser Glu Ser Arg Leu Ala
405 410 415
Gln Ser Asn Gln Val Pro Val Gln Pro Glu Ala Thr Gln Val Pro Leu
420 425 430
Val Ser Ser Thr Ser Glu Gly Tyr Thr Ala Ser Gln Pro Leu Tyr Gln
435 440 445
Pro Ser His Ala Thr Glu Gln Arg Pro Gln Lys Glu Pro Met Asp Gln
450 455 460
Ile Gln Ala Thr Ile Ser Leu Asn Thr Asp Gln Thr Thr Ala Ser Ser
465 470 475 480
Ser Leu Pro Ala Ala Ser Gln Pro Gln Val Phe Gln Ala Gly Thr Ser
485 490 495
Lys Pro Leu His Ser Ser Gly Ile Asn Val Asn Ala Ala Pro Phe Gln
500 505 510
Ser Met Gln Thr Val Phe Asn Met Asn Ala Pro Val Pro Pro Ala Asn
515 520 525
Glu Pro Glu Thr Leu Lys Gln Gln Ser Gln Tyr Gln Ala Thr Tyr Asn
530 535 540
Gln Ser Phe Ser Ser Gln Pro His Gln Val Glu Gln Thr Glu Leu Gln
545 550 555 560
Gln Asp Gln Leu Gln Thr Val Val Gly Thr Tyr His Gly Ser Gln Asp
565 570 575
Gln Pro His Gln Val Pro Gly Asn His Gln Gln Pro Pro Gln Gln Asn
580 585 590
Thr Gly Phe Pro Arg Ser Ser Gln Pro Tyr Tyr Asn Ser Arg Gly Val
595 600 605
Ser Arg Gly Gly Ser Arg Gly Ala Arg Gly Leu Met Asn Gly Tyr Arg
610 615 620
Gly Pro Ala Asn Gly Phe Arg Gly Gly Tyr Asp Gly Tyr Arg Pro Ser
625 630 635 640
Phe Ser Asn Thr Pro Asn Ser Gly Tyr Ser Gln Ser Gln Phe Thr Ala
645 650 655
Pro Arg Asp Tyr Ser Gly Tyr Gln Arg Asp Gly Tyr Gln Gln Asn Phe
660 665 670
Lys Arg Gly Ser Gly Gln Ser Gly Pro Arg Gly Ala Pro Arg Gly Arg
675 680 685
Gly Gly Pro Pro Arg Pro Asn Arg Gly Met Pro Gln Met Asn Thr Gln
690 695 700
Gln Val Asn
705
<210> 23
<211> 6114
<212> DNA
<213> 小鼠(Mus musculus)
<220>
<221> CDS
<222> (139)..(2235)
<223>
<400> 23
cccaccgcgc gcgcgcgtag ccgcctgccc gcccgcccgc tgcgcgtttt gtcccgcgtc 60
tctccccgtc cgtctcctga cttgctggtc ttgtccttcc ctcccgcttt tttcctctcc 120
tctcttctcg gtctaaag atg ccc tcg gcc acc agc cac agc gga agc ggc 171
Met Pro Ser Ala Thr Ser His Ser Gly Ser Gly
1 5 10
agc aaa tcg tcg gga ccg ccg ccg ccg tcc ggt tcc tcc ggg agt gag 219
Ser Lys Ser Ser Gly Pro Pro Pro Pro Ser Gly Ser Ser Gly Ser Glu
15 20 25
gcg gcg gcc ggg gca gct gcg ccg gct tct cag cat ccg gca acc ggc 267
Ala Ala Ala Gly Ala Ala Ala Pro Ala Ser Gln His Pro Ala Thr Gly
30 35 40
acc ggc gcc gtc cag acc gag gcc atg aag cag att ctc ggc gta atc 315
Thr Gly Ala Val Gln Thr Glu Ala Met Lys Gln Ile Leu Gly Val Ile
45 50 55
gac aag aaa ctt cgg aac ctg gag aag aaa aag ggt aaa ctt gat gat 363
Asp Lys Lys Leu Arg Asn Leu Glu Lys Lys Lys Gly Lys Leu Asp Asp
60 65 70 75
tac cag gaa cga atg aat aaa ggg gaa agg ctc aat caa gac cag ctg 411
Tyr Gln Glu Arg Met Asn Lys Gly Glu Arg Leu Asn Gln Asp Gln Leu
80 85 90
gat gcc gta tct aag tac cag gaa gtc aca aat aat ttg gag ttt gca 459
Asp Ala Val Ser Lys Tyr Gln Glu Val Thr Asn Asn Leu Glu Phe Ala
95 100 105
aag gaa tta cag agg agt ttc atg gca tta agt caa gat att cag aaa 507
Lys Glu Leu Gln Arg Ser Phe Met Ala Leu Ser Gln Asp Ile Gln Lys
110 115 120
aca ata aag aag aca gca cgt cgg gaa cag ctt atg aga gaa gaa gca 555
Thr Ile Lys Lys Thr Ala Arg Arg Glu Gln Leu Met Arg Glu Glu Ala
125 130 135
gaa cag aag cgc tta aaa act gta ctt gag tta cag tat gta ttg gat 603
Glu Gln Lys Arg Leu Lys Thr Val Leu Glu Leu Gln Tyr Val Leu Asp
140 145 150 155
aag ctg gga gat gat gat gtg aga aca gat ctg aaa caa ggt ttg agt 651
Lys Leu Gly Asp Asp Asp Val Arg Thr Asp Leu Lys Gln Gly Leu Ser
160 165 170
gga gtg cca ata ttg tct gag gag gag ttg tca ttg ctg gat gag ttc 699
Gly Val Pro Ile Leu Ser Glu Glu Glu Leu Ser Leu Leu Asp Glu Phe
175 180 185
tac aag ctc gta gat cct gag cgt gac atg agt tta agg tta aat gag 747
Tyr Lys Leu Val Asp Pro Glu Arg Asp Met Ser Leu Arg Leu Asn Glu
190 195 200
cag tat gaa cat gcc tca att cac ttg tgg gat ttg ctg gaa ggg aaa 795
Gln Tyr Glu His Ala Ser Ile His Leu Trp Asp Leu Leu Glu Gly Lys
205 210 215
gaa aag cct gtg tgt gga aca acc tat aaa gct cta aag gaa att gtt 843
Glu Lys Pro Val Cys Gly Thr Thr Tyr Lys Ala Leu Lys Glu Ile Val
220 225 230 235
gag cgt gtt ttc cag tca aac tac ttt gat agc act cac aat cat caa 891
Glu Arg Val Phe Gln Ser Asn Tyr Phe Asp Ser Thr His Asn His Gln
240 245 250
aat ggg ttg tgt gag gag gaa gag gcg gct tca gcg ccc aca gtg gag 939
Asn Gly Leu Cys Glu Glu Glu Glu Ala Ala Ser Ala Pro Thr Val Glu
255 260 265
gac cag gta gct gaa gct gaa cct gag cca gcg gaa gaa tac aca gag 987
Asp Gln Val Ala Glu Ala Glu Pro Glu Pro Ala Glu Glu Tyr Thr Glu
270 275 280
caa agt gag gtt gaa tca aca gag tat gtc aat agg cag ttc atg gca 1035
Gln Ser Glu Val Glu Ser Thr Glu Tyr Val Asn Arg Gln Phe Met Ala
285 290 295
gaa aca cag ttc agc agt ggt gag aag gag caa gtg gat gag tgg aca 1083
Glu Thr Gln Phe Ser Ser Gly Glu Lys Glu Gln Val Asp Glu Trp Thr
300 305 310 315
gtt gaa aca gtt gag gtt gta aac tca ctc cag cag caa cct cag gct 1131
Val Glu Thr Val Glu Val Val Asn Ser Leu Gln Gln Gln Pro Gln Ala
320 325 330
gcg tcc cct tca gtc cca gag ccc cac tct ttg act cca gtg gct cag 1179
Ala Ser Pro Ser Val Pro Glu Pro His Ser Leu Thr Pro Val Ala Gln
335 340 345
tca gat cca ctt gtg aga agg cag cgt gta caa gat ctt atg gca caa 1227
Ser Asp Pro Leu Val Arg Arg Gln Arg Val Gln Asp Leu Met Ala Gln
350 355 360
atg caa ggg ccc tat aat ttc ata cag acg ctt gat cct gcc att gta 1275
Met Gln Gly Pro Tyr Asn Phe Ile Gln Thr Leu Asp Pro Ala Ile Val
365 370 375
tcc gca cag cct atg aac cct acc cag aac atg gat atg cct cag ctg 1323
Ser Ala Gln Pro Met Asn Pro Thr Gln Asn Met Asp Met Pro Gln Leu
380 385 390 395
gtt tgc cct cag gtt cat tct gaa tct aga ctt gcc caa tct aat caa 1371
Val Cys Pro Gln Val His Ser Glu Ser Arg Leu Ala Gln Ser Asn Gln
400 405 410
gtt cct gta caa cca gaa gcc aca cag gtt cct ttg gtt tca tcc aca 1419
Val Pro Val Gln Pro Glu Ala Thr Gln Val Pro Leu Val Ser Ser Thr
415 420 425
agt gag ggg tat aca gca tct cag ccc ttg tac cag cca tct cat gct 1467
Ser Glu Gly Tyr Thr Ala Ser Gln Pro Leu Tyr Gln Pro Ser His Ala
430 435 440
acg gag cag cgg ccg cag aaa gag cca atg gat cag att cag gca aca 1515
Thr Glu Gln Arg Pro Gln Lys Glu Pro Met Asp Gln Ile Gln Ala Thr
445 450 455
ata tct ttg aat aca gac cag act aca gca tcc tca tcc ctt cct gct 1563
Ile Ser Leu Asn Thr Asp Gln Thr Thr Ala Ser Ser Ser Leu Pro Ala
460 465 470 475
gct tct cag cct caa gtg ttc cag gct ggg aca agt aaa cct ttg cac 1611
Ala Ser Gln Pro Gln Val Phe Gln Ala Gly Thr Ser Lys Pro Leu His
480 485 490
agc agt gga atc aat gta aat gca gct cca ttc cag tcc atg caa acg 1659
Ser Ser Gly Ile Asn Val Asn Ala Ala Pro Phe Gln Ser Met Gln Thr
495 500 505
gtg ttc aat atg aat gct cca gtc cct cct gct aat gaa cca gaa acg 1707
Val Phe Asn Met Asn Ala Pro Val Pro Pro Ala Asn Glu Pro Glu Thr
510 515 520
tta aaa caa cag agt cag tac cag gcc act tat aac cag agt ttt tcc 1755
Leu Lys Gln Gln Ser Gln Tyr Gln Ala Thr Tyr Asn Gln Ser Phe Ser
525 530 535
agt cag cct cac caa gtg gaa caa aca gag ctt caa caa gac caa ctg 1803
Ser Gln Pro His Gln Val Glu Gln Thr Glu Leu Gln Gln Asp Gln Leu
540 545 550 555
caa acg gtg gtt ggc act tac cat gga tcc cag gac cag cct cat caa 1851
Gln Thr Val Val Gly Thr Tyr His Gly Ser Gln Asp Gln Pro His Gln
560 565 570
gtg cct ggt aac cac cag caa ccc cca cag cag aac act ggc ttt cca 1899
Val Pro Gly Asn His Gln Gln Pro Pro Gln Gln Asn Thr Gly Phe Pro
575 580 585
cgt agc agt cag cct tat tac aac agt cgt ggg gta tct cga gga ggg 1947
Arg Ser Ser Gln Pro Tyr Tyr Asn Ser Arg Gly Val Ser Arg Gly Gly
590 595 600
tct cgt ggt gcc aga ggc ttg atg aat gga tac agg ggc cct gcc aat 1995
Ser Arg Gly Ala Arg Gly Leu Met Asn Gly Tyr Arg Gly Pro Ala Asn
605 610 615
gga ttt aga gga gga tat gat ggt tac cgc cct tca ttc tcg aac act 2043
Gly Phe Arg Gly Gly Tyr Asp Gly Tyr Arg Pro Ser Phe Ser Asn Thr
620 625 630 635
cca aac agt ggt tat tca cag tct cag ttc act gct ccc cgg gac tac 2091
Pro Asn Ser Gly Tyr Ser Gln Ser Gln Phe Thr Ala Pro Arg Asp Tyr
640 645 650
tct ggt tac cag cgg gat gga tat cag cag aat ttc aag cga ggc tct 2139
Ser Gly Tyr Gln Arg Asp Gly Tyr Gln Gln Asn Phe Lys Arg Gly Ser
655 660 665
ggg cag agt gga cca cgg gga gcc cca cga ggt cgt gga ggg ccc cca 2187
Gly Gln Ser Gly Pro Arg Gly Ala Pro Arg Gly Arg Gly Gly Pro Pro
670 675 680
aga ccc aac aga ggg atg ccg caa atg aac act cag caa gtg aat taa 2235
Arg Pro Asn Arg Gly Met Pro Gln Met Asn Thr Gln Gln Val Asn
685 690 695
tgtgatacac aggattatgt ttaatcgcca aaaacacact ggccagtgta ccataatatg 2295
ttaccagaag agttattatc tatttgttct ccctttcagg aaacttattg taaagggact 2355
gttttcatcc cataaagaca ggactgcaat tgtcagcttt acattacctg gatatggaag 2415
gaaactattt ttattctgca tgttctgtcc taagcgtcat cttgagcctt gcacacaata 2475
caatactcag attcctcacc cttgcttagg agtaaaacat tatatactta tggggtgata 2535
atatctccat agttagttga agtggcttgg aaaaaaaatg caagattgaa tttttgacct 2595
tggataaaat ctacaatcag ccctagaact attcagtggt aattgacaaa gttaaagcat 2655
tttctttgaa aggaagatgg aaggagtgga gtgtggttta gcaaaactgc atttcatagc 2715
tttcccatta aattggagca ccgacagatt aaaagcatac caaattatgc atgggtcctt 2775
actcacacaa gtgaggctgg ctaccagcct tgacatagca ctcactagtc ttctggccaa 2835
acgactgtga ttaaaacaca tgtaaattgc tctttagtag tggatactgt gtaagacaaa 2895
gccaaattgc aaatcaggct ttgattggct cttctggaaa atatgcatca aatatggggg 2955
ataatctgga tgggctgctg ctgtgctcaa tgtgaactat ttagatacct ttggaacact 3015
taacagtttc tctgaacaat gacttacatg gggattggtc ctgtttgtca ttcctcacca 3075
taattgcatt gtcatcacta atccttggat cttgctgtat tgttactcaa attggtaata 3135
ggtactgatg gaaatcgcta atggatggat aatcataaca cttttggtca catgttttct 3195
cctgcagcct gaaagttctt aaagaaaaag atatcaaatg cctgctgcta ccaccctttt 3255
aaattgctat ctttagaaaa gcaccggtat gtgttttaga ttcatttccc tgttttaggg 3315
aaatgacagg cagtagtttc agttctgatg gcaaaacaaa taaaaacatg tttctaaaag 3375
ttgtatcttg aaacactggt gttcaacagc tagcagctaa agtaattcaa cccatgcatt 3435
gctagtgtca cagcctttgg ttatgtctag tagctgtttc tgaagtattt tcatttatct 3495
tttgtcaaat ttaaccctgt ttgaattctc tcctttcctc aaggagacac ttatgttcaa 3555
agtgttgatt ctttgcctta ggtgcataga gagtagacag tttggagatg gaaaggttag 3615
cagtgactta gccatatgtt ctgtgttgga atttgtgcta gcagtttgag cactagctct 3675
gcgtgcctat gaactgaatg ctgcttgtcc cattccattt tatgtcatgg agaaataatt 3735
ccacttggta acacaaaggc taagttaatg ttattttctg tacagaaatt aaattttact 3795
tttagccttt tgtaaacttt tttttttttt ttccaagccg gtatcagcta ctcaaaacaa 3855
ttctcagata ttcatcatta gacaactgga gtttttgctg gttttgtagc ctactaaaac 3915
tgctgaggct gttgaacatt ccacattcaa aagttttgta gggtggtgga taatggggaa 3975
gcttcaatgt ttattttaaa ataaataaaa taagttcttg acttttctca tgtgtggtta 4035
tggtacatca tattggaagg gttatctgtt tacttttgcc aagactattt tgccagcacc 4095
tacacttgtg tgctttaaaa gacaactacc tgggatgtac cacaaccata tgttaattgt 4155
attttattgg gatggataaa atgtttgtgg tttattggat aatccctaga tggtgtgtta 4215
cgtgtgtaga atataatttt atgatagtaa gaaagcaaaa ttgaagaaaa taagtttagt 4275
attgaatttg agttctgaag tgaattcagg gaatgtctca cgtttcgggc ttctacccaa 4335
agtgtagggc agaaggtgta aaagttgttt gtagtttgac ttgtttattt tttaagttgc 4395
ttattccttt caacagcaac atatcattag ctgtcattct accattgcag ttctagtgag 4455
ttttaacgtc tgcattcaag actgttttaa aagcaacctc actggacaga gaactgctaa 4515
agtcttttcc ttaagatctg agtctttgtt actcagtatc ttctataata tgcaaatgct 4575
tgtctagagg cagaagacct tttgtttggt caagtgtgta ttttaccaga gtacagggaa 4635
ctgatggtcc tacatgtctc ttagtgtagt aagactataa aatcttttgt acatgcacaa 4695
ttcacagtat gtttagatac cacgtgtata atgccccccc ctcccccagg tagcatgcca 4755
ttgatgactt tttgcttagg gccattttat taccagggcc ttaatattcc taaaaagatg 4815
attttttttc atcctttctc ctcttttgat cattgtatct tgatattaaa aacatgacct 4875
tccaatgatt gtagtaaatt aacttctata gttcttttgt ctctatatgt attcatatat 4935
atgctattgt atagagactt caaggagaca tggagatgca tgcttattct caggttcatt 4995
cactaaggtg cttggcagac aaccagtttc taagtgcaga atgtagttaa gcagcttcat 5055
atatgtgcca ggcaatttgt tttgttaaat tttcatctac ttaaggaaat agggtattgt 5115
agcttaggct gatcataccc ttcatttcaa ccttaagctc tcaacctgca tccatccgac 5175
ttgagctatt aagtacttta gttttatcga gtataagtta acagaaaaag taaattaagc 5235
tttgccttta ctattttgaa tttatataca ttctggaaaa acttagaaac tgttgtatat 5295
ttcattagat taaattatat gaaaatgtga ttgtttatag caaagcctgt gagttgcata 5355
caccctaagg aaaactcctt aagtgctcct tgaagagaga agaaacaatt ctgggtctgg 5415
tctttttaag aacaaagcta gactactgta tgttagcact gtacattaat agtctgttgt 5475
gaagcttgag cagtttcctg catagccttg atccttcacc gttggcattg aaaatagcag 5535
tatccctgat gtacttaaaa cttaaagtca ggttttggta tatttatttg taagtcttaa 5595
tttcctctaa atactatatc tctttagcga gacaacctga aatttattag cacatttggg 5655
tatctcttgc ttggcattat ggccagtgtt aactattcag tggtgaaaaa attacccctc 5715
aagacactgg agtgacccca gatgtgtgta gtaagtggca tggttcaact gtgtggttaa 5775
tgataaatat atgacttagt cggtatgatc tggaaagact tgattgaaag ataattcagc 5835
tgacataagg atgagtgagg agtggcaaac tggataaaag agtcaagaga cctgtattcc 5895
agtgactcct gttttgttta agcattagca agatctgtct ggggaaactg gatagggcag 5955
ttttcttcca tgtttagttt ttgtctcaac atttggaagc tattgaaggt tttaaaatgg 6015
tgtgtattgt ttttttttgg ggggggggtg gccagaatag tgggtcatct aataaaactg 6075
ccatttaaaa gatcaaaaaa aaaaaaaaaa aaaaaaaaa 6114
<210> 24
<211> 698
<212> PRT
<213> 小鼠(Mus musculus)
<400> 24
Met Pro Ser Ala Thr Ser His Ser Gly Ser Gly Ser Lys Ser Ser Gly
1 5 10 15
Pro Pro Pro Pro Ser Gly Ser Ser Gly Ser Glu Ala Ala Ala Gly Ala
20 25 30
Ala Ala Pro Ala Ser Gln His Pro Ala Thr Gly Thr Gly Ala Val Gln
35 40 45
Thr Glu Ala Met Lys Gln Ile Leu Gly Val Ile Asp Lys Lys Leu Arg
50 55 60
Asn Leu Glu Lys Lys Lys Gly Lys Leu Asp Asp Tyr Gln Glu Arg Met
65 70 75 80
Asn Lys Gly Glu Arg Leu Asn Gln Asp Gln Leu Asp Ala Val Ser Lys
85 90 95
Tyr Gln Glu Val Thr Asn Asn Leu Glu Phe Ala Lys Glu Leu Gln Arg
100 105 110
Ser Phe Met Ala Leu Ser Gln Asp Ile Gln Lys Thr Ile Lys Lys Thr
115 120 125
Ala Arg Arg Glu Gln Leu Met Arg Glu Glu Ala Glu Gln Lys Arg Leu
130 135 140
Lys Thr Val Leu Glu Leu Gln Tyr Val Leu Asp Lys Leu Gly Asp Asp
145 150 155 160
Asp Val Arg Thr Asp Leu Lys Gln Gly Leu Ser Gly Val Pro Ile Leu
165 170 175
Ser Glu Glu Glu Leu Ser Leu Leu Asp Glu Phe Tyr Lys Leu Val Asp
180 185 190
Pro Glu Arg Asp Met Ser Leu Arg Leu Asn Glu Gln Tyr Glu His Ala
195 200 205
Ser Ile His Leu Trp Asp Leu Leu Glu Gly Lys Glu Lys Pro Val Cys
210 215 220
Gly Thr Thr Tyr Lys Ala Leu Lys Glu Ile Val Glu Arg Val Phe Gln
225 230 235 240
Ser Asn Tyr Phe Asp Ser Thr His Asn His Gln Asn Gly Leu Cys Glu
245 250 255
Glu Glu Glu Ala Ala Ser Ala Pro Thr Val Glu Asp Gln Val Ala Glu
260 265 270
Ala Glu Pro Glu Pro Ala Glu Glu Tyr Thr Glu Gln Ser Glu Val Glu
275 280 285
Ser Thr Glu Tyr Val Asn Arg Gln Phe Met Ala Glu Thr Gln Phe Ser
290 295 300
Ser Gly Glu Lys Glu Gln Val Asp Glu Trp Thr Val Glu Thr Val Glu
305 310 315 320
Val Val Asn Ser Leu Gln Gln Gln Pro Gln Ala Ala Ser Pro Ser Val
325 330 335
Pro Glu Pro His Ser Leu Thr Pro Val Ala Gln Ser Asp Pro Leu Val
340 345 350
Arg Arg Gln Arg Val Gln Asp Leu Met Ala Gln Met Gln Gly Pro Tyr
355 360 365
Asn Phe Ile Gln Thr Leu Asp Pro Ala Ile Val Ser Ala Gln Pro Met
370 375 380
Asn Pro Thr Gln Asn Met Asp Met Pro Gln Leu Val Cys Pro Gln Val
385 390 395 400
His Ser Glu Ser Arg Leu Ala Gln Ser Asn Gln Val Pro Val Gln Pro
405 410 415
Glu Ala Thr Gln Val Pro Leu Val Ser Ser Thr Ser Glu Gly Tyr Thr
420 425 430
Ala Ser Gln Pro Leu Tyr Gln Pro Ser His Ala Thr Glu Gln Arg Pro
435 440 445
Gln Lys Glu Pro Met Asp Gln Ile Gln Ala Thr Ile Ser Leu Asn Thr
450 455 460
Asp Gln Thr Thr Ala Ser Ser Ser Leu Pro Ala Ala Ser Gln Pro Gln
465 470 475 480
Val Phe Gln Ala Gly Thr Ser Lys Pro Leu His Ser Ser Gly Ile Asn
485 490 495
Val Asn Ala Ala Pro Phe Gln Ser Met Gln Thr Val Phe Asn Met Asn
500 505 510
Ala Pro Val Pro Pro Ala Asn Glu Pro Glu Thr Leu Lys Gln Gln Ser
515 520 525
Gln Tyr Gln Ala Thr Tyr Asn Gln Ser Phe Ser Ser Gln Pro His Gln
530 535 540
Val Glu Gln Thr Glu Leu Gln Gln Asp Gln Leu Gln Thr Val Val Gly
545 550 555 560
Thr Tyr His Gly Ser Gln Asp Gln Pro His Gln Val Pro Gly Asn His
565 570 575
Gln Gln Pro Pro Gln Gln Asn Thr Gly Phe Pro Arg Ser Ser Gln Pro
580 585 590
Tyr Tyr Asn Ser Arg Gly Val Ser Arg Gly Gly Ser Arg Gly Ala Arg
595 600 605
Gly Leu Met Asn Gly Tyr Arg Gly Pro Ala Asn Gly Phe Arg Gly Gly
610 615 620
Tyr Asp Gly Tyr Arg Pro Ser Phe Ser Asn Thr Pro Asn Ser Gly Tyr
625 630 635 640
Ser Gln Ser Gln Phe Thr Ala Pro Arg Asp Tyr Ser Gly Tyr Gln Arg
645 650 655
Asp Gly Tyr Gln Gln Asn Phe Lys Arg Gly Ser Gly Gln Ser Gly Pro
660 665 670
Arg Gly Ala Pro Arg Gly Arg Gly Gly Pro Pro Arg Pro Asn Arg Gly
675 680 685
Met Pro Gln Met Asn Thr Gln Gln Val Asn
690 695
<210> 25
<211> 3548
<212> DNA
<213> 小鼠(Mus musculus)
<220>
<221> CDS
<222> (179)..(2257)
<223>
<400> 25
gctggctggc taagtccctc ccgcgccggc tcttgtccca ctaggagcag ctcagagccg 60
cggggacagg gcgaagcggc ctgcgcccac ggagcgcacg tctctgttct caacgcagca 120
ccacccttgc ccccctcggc tgcccactcc agacgtccag cggctccgcg cgcgcacg 178
atg ccc tcg gcc acc agc cac agc gga agc ggc agc aaa tcg tcg gga 226
Met Pro Ser Ala Thr Ser His Ser Gly Ser Gly Ser Lys Ser Ser Gly
1 5 10 15
ccg ccg ccg ccg tcc ggt tcc tcc ggg agt gag gcg gcg gcc ggg gca 274
Pro Pro Pro Pro Ser Gly Ser Ser Gly Ser Glu Ala Ala Ala Gly Ala
20 25 30
gct gcg ccg gct tct cag cat ccg gca acc ggc acc ggc gcc gtc cag 322
Ala Ala Pro Ala Ser Gln His Pro Ala Thr Gly Thr Gly Ala Val Gln
35 40 45
acc gag gcc atg aag cag att ctc ggc gta atc gac aag aaa ctt cgg 370
Thr Glu Ala Met Lys Gln Ile Leu Gly Val Ile Asp Lys Lys Leu Arg
50 55 60
aac ctg gag aag aaa aag ggt aaa ctt gat gat tac cag gaa cga atg 418
Asn Leu Glu Lys Lys Lys Gly Lys Leu Asp Asp Tyr Gln Glu Arg Met
65 70 75 80
aat aaa ggg gaa agg ctc aat caa gac cag ctg gat gcc gta tct aag 466
Asn Lys Gly Glu Arg Leu Asn Gln Asp Gln Leu Asp Ala Val Ser Lys
85 90 95
tac cag gaa gtc aca aat aat ttg gag ttt gca aag gaa tta cag agg 514
Tyr Gln Glu Val Thr Asn Asn Leu Glu Phe Ala Lys Glu Leu Gln Arg
100 105 110
agt ttc atg gca tta agt caa gat att cag aaa aca ata aag aag aca 562
Ser Phe Met Ala Leu Ser Gln Asp Ile Gln Lys Thr Ile Lys Lys Thr
115 120 125
gca cgt cgg gaa cag ctt atg aga gaa gaa gca gaa cag aag cgc tta 610
Ala Arg Arg Glu Gln Leu Met Arg Glu Glu Ala Glu Gln Lys Arg Leu
130 135 140
aaa act gta ctt gag tta cag tat gta ttg gat aag ctg gga gat gat 658
Lys Thr Val Leu Glu Leu Gln Tyr Val Leu Asp Lys Leu Gly Asp Asp
145 150 155 160
gat gtg aga aca gat ctg aaa caa ggt ttg agt gga gtg cca ata ttg 706
Asp Val Arg Thr Asp Leu Lys Gln Gly Leu Ser Gly Val Pro Ile Leu
165 170 175
tct gag gag gag ttg tca ttg ctg gat gag ttc tac aag ctc gta gat 754
Ser Glu Glu Glu Leu Ser Leu Leu Asp Glu Phe Tyr Lys Leu Val Asp
180 185 190
cct gag cgt gac atg agt tta agg tta aat gag cag tat gaa cat gcc 802
Pro Glu Arg Asp Met Ser Leu Arg Leu Asn Glu Gln Tyr Glu His Ala
195 200 205
tca att cac ttg tgg gat ttg ctg gaa ggg aaa gaa aag cct gtg tgt 850
Ser Ile His Leu Trp Asp Leu Leu Glu Gly Lys Glu Lys Pro Val Cys
210 215 220
gga aca acc tat aaa gct cta aag gaa att gtt gag cgt gtt ttc cag 898
Gly Thr Thr Tyr Lys Ala Leu Lys Glu Ile Val Glu Arg Val Phe Gln
225 230 235 240
tca aac tac ttt gat agc act cac aat cat caa aat ggg ttg tgt gag 946
Ser Asn Tyr Phe Asp Ser Thr His Asn His Gln Asn Gly Leu Cys Glu
245 250 255
gag gaa gag gcg gct tca gcg ccc aca gtg gag gac cag gta gct gaa 994
Glu Glu Glu Ala Ala Ser Ala Pro Thr Val Glu Asp Gln Val Ala Glu
260 265 270
gct gaa cct gag cca gcg gaa gaa tac aca gag caa agt gag gtt gaa 1042
Ala Glu Pro Glu Pro Ala Glu Glu Tyr Thr Glu Gln Ser Glu Val Glu
275 280 285
tca aca gag tat gtc aat agg cag ttc atg gca gaa aca cag ttc agc 1090
Ser Thr Glu Tyr Val Asn Arg Gln Phe Met Ala Glu Thr Gln Phe Ser
290 295 300
agt ggt gag aag gag caa gtg gat gag tgg aca gtt gaa aca gtt gag 1138
Ser Gly Glu Lys Glu Gln Val Asp Glu Trp Thr Val Glu Thr Val Glu
305 310 315 320
gtt gta aac tca ctc cag cag caa cct cag gct gcg tcc cct tca gtc 1186
Val Val Asn Ser Leu Gln Gln Gln Pro Gln Ala Ala Ser Pro Ser Val
325 330 335
cca gag ccc cac tct ttg act cca gtg gct cag tca gat cca ctt gtg 1234
Pro Glu Pro His Ser Leu Thr Pro Val Ala Gln Ser Asp Pro Leu Val
340 345 350
aga agg cag cgt gta caa gat ctt atg gca caa atg caa ggg ccc tat 1282
Arg Arg Gln Arg Val Gln Asp Leu Met Ala Gln Met Gln Gly Pro Tyr
355 360 365
aat ttc ata cag gat tca atg ttg gat ttt gaa aat cag acg ctt gat 1330
Asn Phe Ile Gln Asp Ser Met Leu Asp Phe Glu Asn Gln Thr Leu Asp
370 375 380
cct gcc att gta tcc gca cag cct atg aac cct acc cag aac atg gat 1378
Pro Ala Ile Val Ser Ala Gln Pro Met Asn Pro Thr Gln Asn Met Asp
385 390 395 400
atg cct cag ctg gtt tgc cct cag gtt cat tct gaa tct aga ctt gcc 1426
Met Pro Gln Leu Val Cys Pro Gln Val His Ser Glu Ser Arg Leu Ala
405 410 415
caa tct aat caa gtt cct gta caa cca gaa gcc aca cag gtt cct ttg 1474
Gln Ser Asn Gln Val Pro Val Gln Pro Glu Ala Thr Gln Val Pro Leu
420 425 430
gtt tca tcc aca agt gag ggg tat aca gca tct cag ccc ttg tac cag 1522
Val Ser Ser Thr Ser Glu Gly Tyr Thr Ala Ser Gln Pro Leu Tyr Gln
435 440 445
cca tct cat gct acg gag cag cgg ccg cag aaa gag cca atg gat cag 1570
Pro Ser His Ala Thr Glu Gln Arg Pro Gln Lys Glu Pro Met Asp Gln
450 455 460
att cag gca aca ata tct ttg aat aca gac cag act aca gca tcc tca 1618
Ile Gln Ala Thr Ile Ser Leu Asn Thr Asp Gln Thr Thr Ala Ser Ser
465 470 475 480
tcc ctt cct gct gct tct cag cct caa gtg ttc cag gct ggg aca agt 1666
Ser Leu Pro Ala Ala Ser Gln Pro Gln Val Phe Gln Ala Gly Thr Ser
485 490 495
aaa cct ttg cac agc agt gga atc aat gta aat gca gct cca ttc cag 1714
Lys Pro Leu His Ser Ser Gly Ile Asn Val Asn Ala Ala Pro Phe Gln
500 505 510
tcc atg caa acg gtg ttc aat atg aat gct cca gtc cct cct gct aat 1762
Ser Met Gln Thr Val Phe Asn Met Asn Ala Pro Val Pro Pro Ala Asn
515 520 525
gaa cca gaa acg tta aaa caa cag agt cag tac cag gcc act tat aac 1810
Glu Pro Glu Thr Leu Lys Gln Gln Ser Gln Tyr Gln Ala Thr Tyr Asn
530 535 540
cag agt ttt tcc agt cag cct cac caa gtg gaa caa aca gag ctt caa 1858
Gln Ser Phe Ser Ser Gln Pro His Gln Val Glu Gln Thr Glu Leu Gln
545 550 555 560
caa gac caa ctg caa acg gtg gtt ggc act tac cat gga tcc cag gac 1906
Gln Asp Gln Leu Gln Thr Val Val Gly Thr Tyr His Gly Ser Gln Asp
565 570 575
cag cct cat caa gtg cct ggt aac cac cag caa ccc cca cag cag aac 1954
Gln Pro His Gln Val Pro Gly Asn His Gln Gln Pro Pro Gln Gln Asn
580 585 590
act ggc ttt cca cgt agc agt cag cct tat tac aac agt cgt ggg gta 2002
Thr Gly Phe Pro Arg Ser Ser Gln Pro Tyr Tyr Asn Ser Arg Gly Val
595 600 605
tct cga gga ggg tct cgt ggt gcc aga ggc ttg atg aat gga tac agg 2050
Ser Arg Gly Gly Ser Arg Gly Ala Arg Gly Leu Met Asn Gly Tyr Arg
610 615 620
ggc cct gcc aat gga ttt aga gga gga tat gat ggt tac cgc cct tca 2098
Gly Pro Ala Asn Gly Phe Arg Gly Gly Tyr Asp Gly Tyr Arg Pro Ser
625 630 635 640
ttc tcg aac act cca aac agt ggt tat tca cag tct cag ttc act gct 2146
Phe Ser Asn Thr Pro Asn Ser Gly Tyr Ser Gln Ser Gln Phe Thr Ala
645 650 655
ccc cgg gac tac tct ggt tac cag cgg gat gga tat cag cag aat ttc 2194
Pro Arg Asp Tyr Ser Gly Tyr Gln Arg Asp Gly Tyr Gln Gln Asn Phe
660 665 670
aag cga ggc tct ggg cag agt gga cca cgg gga gcc cca cga ggt aat 2242
Lys Arg Gly Ser Gly Gln Ser Gly Pro Arg Gly Ala Pro Arg Gly Asn
675 680 685
ata ttg tgg tgg tga tcctagctcc tatgtggagc ttctgttctg gccttggaag 2297
Ile Leu Trp Trp
690
aactgttcat agtccgcatg taggttacat gttaggaata catttatctt ttccagactt 2357
gttgctaaag attaaatgaa atgctctgtt tctaaaattt catcttgaat ccaaatttta 2417
atttttgaat gactttccct gctgttgtct tcaaaatcag aacattttct ctgcctcaga 2477
aaagcgtttt tccaactgga aatttatttt tcaggtctta aaacctgcta aatgttttta 2537
ggaagtacct actgaaactt tttgtaagac atttttggaa cgagcttgaa catttatata 2597
aatttattac cctctttgat ttttgaaaca tgcatattat atttaggctg agaagccctt 2657
caaatggcca gataagccac agttttagct agagaaccat ttagaattga cataactaat 2717
ctaaacttga acacttttag gaccaatgtt agtgttctaa ataccaacat atttctgatg 2777
tttaaacaga tctcccaaat tcttaggacc ttgatgtcat taaaatttag aatgacaagc 2837
ttaagaggct ttagtttcat ttgtttttca agtaatgaaa aataatttct tacatgggca 2897
gatagttaat ttgttgaaca attacaggta gcatttcatg taatctgatg ttctaaatgg 2957
ttctcttatt gaaggaggtt aaagaattag gtttcttaca gtttttggct ggccatgaca 3017
tgtataaaat gtatattaag gaggaattat aaagtacttt aatttgaatg ctagtggcaa 3077
ttgatcatta agaaagtact ttaaagcaaa aggttaatgg gtcatctggg aaaaatactg 3137
aagtatcaaa ggtatttgca tgtgaatgtg ggttatgttc ttctatccca ccttgtagca 3197
tattctatga aagttgagtt aaatgatagc taaaatatct gtttcaacag catgtaaaaa 3257
gttattttaa ctgttacaag tcattataca attttgaatg ttctgtagtt tctttttaac 3317
agtttaggta caaaggtctg ttttcattct ggtgcttttt attaattttg atagtatgat 3377
gtcacttcct attgaaatgt aagctagcgt gtaccttaga atgtgagctc catgagagca 3437
ggtaccttgt ttgtcttcac tgctgtatct attcccaacg cctcatgaca gtgcctggca 3497
catagtaggc actcaataaa tacttgttga atgaatgaaa aaaaaaaaaa a 3548
<210> 26
<211> 692
<212> PRT
<213> 小鼠(Mus musculus)
<400> 26
Met Pro Ser Ala Thr Ser His Ser Gly Ser Gly Ser Lys Ser Ser Gly
1 5 10 15
Pro Pro Pro Pro Ser Gly Ser Ser Gly Ser Glu Ala Ala Ala Gly Ala
20 25 30
Ala Ala Pro Ala Ser Gln His Pro Ala Thr Gly Thr Gly Ala Val Gln
35 40 45
Thr Glu Ala Met Lys Gln Ile Leu Gly Val Ile Asp Lys Lys Leu Arg
50 55 60
Asn Leu Glu Lys Lys Lys Gly Lys Leu Asp Asp Tyr Gln Glu Arg Met
65 70 75 80
Asn Lys Gly Glu Arg Leu Asn Gln Asp Gln Leu Asp Ala Val Ser Lys
85 90 95
Tyr Gln Glu Val Thr Asn Asn Leu Glu Phe Ala Lys Glu Leu Gln Arg
100 105 110
Ser Phe Met Ala Leu Ser Gln Asp Ile Gln Lys Thr Ile Lys Lys Thr
115 120 125
Ala Arg Arg Glu Gln Leu Met Arg Glu Glu Ala Glu Gln Lys Arg Leu
130 135 140
Lys Thr Val Leu Glu Leu Gln Tyr Val Leu Asp Lys Leu Gly Asp Asp
145 150 155 160
Asp Val Arg Thr Asp Leu Lys Gln Gly Leu Ser Gly Val Pro Ile Leu
165 170 175
Ser Glu Glu Glu Leu Ser Leu Leu Asp Glu Phe Tyr Lys Leu Val Asp
180 185 190
Pro Glu Arg Asp Met Ser Leu Arg Leu Asn Glu Gln Tyr Glu His Ala
195 200 205
Ser Ile His Leu Trp Asp Leu Leu Glu Gly Lys Glu Lys Pro Val Cys
210 215 220
Gly Thr Thr Tyr Lys Ala Leu Lys Glu Ile Val Glu Arg Val Phe Gln
225 230 235 240
Ser Asn Tyr Phe Asp Ser Thr His Asn His Gln Asn Gly Leu Cys Glu
245 250 255
Glu Glu Glu Ala Ala Ser Ala Pro Thr Val Glu Asp Gln Val Ala Glu
260 265 270
Ala Glu Pro Glu Pro Ala Glu Glu Tyr Thr Glu Gln Ser Glu Val Glu
275 280 285
Ser Thr Glu Tyr Val Asn Arg Gln Phe Met Ala Glu Thr Gln Phe Ser
290 295 300
Ser Gly Glu Lys Glu Gln Val Asp Glu Trp Thr Val Glu Thr Val Glu
305 310 315 320
Val Val Asn Ser Leu Gln Gln Gln Pro Gln Ala Ala Ser Pro Ser Val
325 330 335
Pro Glu Pro His Ser Leu Thr Pro Val Ala Gln Ser Asp Pro Leu Val
340 345 350
Arg Arg Gln Arg Val Gln Asp Leu Met Ala Gln Met Gln Gly Pro Tyr
355 360 365
Asn Phe Ile Gln Asp Ser Met Leu Asp Phe Glu Asn Gln Thr Leu Asp
370 375 380
Pro Ala Ile Val Ser Ala Gln Pro Met Asn Pro Thr Gln Asn Met Asp
385 390 395 400
Met Pro Gln Leu Val Cys Pro Gln Val His Ser Glu Ser Arg Leu Ala
405 410 415
Gln Ser Asn Gln Val Pro Val Gln Pro Glu Ala Thr Gln Val Pro Leu
420 425 430
Val Ser Ser Thr Ser Glu Gly Tyr Thr Ala Ser Gln Pro Leu Tyr Gln
435 440 445
Pro Ser His Ala Thr Glu Gln Arg Pro Gln Lys Glu Pro Met Asp Gln
450 455 460
Ile Gln Ala Thr Ile Ser Leu Asn Thr Asp Gln Thr Thr Ala Ser Ser
465 470 475 480
Ser Leu Pro Ala Ala Ser Gln Pro Gln Val Phe Gln Ala Gly Thr Ser
485 490 495
Lys Pro Leu His Ser Ser Gly Ile Asn Val Asn Ala Ala Pro Phe Gln
500 505 510
Ser Met Gln Thr Val Phe Asn Met Asn Ala Pro Val Pro Pro Ala Asn
515 520 525
Glu Pro Glu Thr Leu Lys Gln Gln Ser Gln Tyr Gln Ala Thr Tyr Asn
530 535 540
Gln Ser Phe Ser Ser Gln Pro His Gln Val Glu Gln Thr Glu Leu Gln
545 550 555 560
Gln Asp Gln Leu Gln Thr Val Val Gly Thr Tyr His Gly Ser Gln Asp
565 570 575
Gln Pro His Gln Val Pro Gly Asn His Gln Gln Pro Pro Gln Gln Asn
580 585 590
Thr Gly Phe Pro Arg Ser Ser Gln Pro Tyr Tyr Asn Ser Arg Gly Val
595 600 605
Ser Arg Gly Gly Ser Arg Gly Ala Arg Gly Leu Met Asn Gly Tyr Arg
610 615 620
Gly Pro Ala Asn Gly Phe Arg Gly Gly Tyr Asp Gly Tyr Arg Pro Ser
625 630 635 640
Phe Ser Asn Thr Pro Asn Ser Gly Tyr Ser Gln Ser Gln Phe Thr Ala
645 650 655
Pro Arg Asp Tyr Ser Gly Tyr Gln Arg Asp Gly Tyr Gln Gln Asn Phe
660 665 670
Lys Arg Gly Ser Gly Gln Ser Gly Pro Arg Gly Ala Pro Arg Gly Asn
675 680 685
Ile Leu Trp Trp
690
<210> 27
<211> 3508
<212> DNA
<213> 小鼠(Mus musculus)
<220>
<221> CDS
<222> (139)..(2217)
<223>
<400> 27
cccaccgcgc gcgcgcgtag ccgcctgccc gcccgcccgc tgcgcgtttt gtcccgcgtc 60
tctccccgtc cgtctcctga cttgctggtc ttgtccttcc ctcccgcttt tttcctctcc 120
tctcttctcg gtctaaag atg ccc tcg gcc acc agc cac agc gga agc ggc 171
Met Pro Ser Ala Thr Ser His Ser Gly Ser Gly
1 5 10
agc aaa tcg tcg gga ccg ccg ccg ccg tcc ggt tcc tcc ggg agt gag 219
Ser Lys Ser Ser Gly Pro Pro Pro Pro Ser Gly Ser Ser Gly Ser Glu
15 20 25
gcg gcg gcc ggg gca gct gcg ccg gct tct cag cat ccg gca acc ggc 267
Ala Ala Ala Gly Ala Ala Ala Pro Ala Ser Gln His Pro Ala Thr Gly
30 35 40
acc ggc gcc gtc cag acc gag gcc atg aag cag att ctc ggc gta atc 315
Thr Gly Ala Val Gln Thr Glu Ala Met Lys Gln Ile Leu Gly Val Ile
45 50 55
gac aag aaa ctt cgg aac ctg gag aag aaa aag ggt aaa ctt gat gat 363
Asp Lys Lys Leu Arg Asn Leu Glu Lys Lys Lys Gly Lys Leu Asp Asp
60 65 70 75
tac cag gaa cga atg aat aaa ggg gaa agg ctc aat caa gac cag ctg 411
Tyr Gln Glu Arg Met Asn Lys Gly Glu Arg Leu Asn Gln Asp Gln Leu
80 85 90
gat gcc gta tct aag tac cag gaa gtc aca aat aat ttg gag ttt gca 459
Asp Ala Val Ser Lys Tyr Gln Glu Val Thr Asn Asn Leu Glu Phe Ala
95 100 105
aag gaa tta cag agg agt ttc atg gca tta agt caa gat att cag aaa 507
Lys Glu Leu Gln Arg Ser Phe Met Ala Leu Ser Gln Asp Ile Gln Lys
110 115 120
aca ata aag aag aca gca cgt cgg gaa cag ctt atg aga gaa gaa gca 555
Thr Ile Lys Lys Thr Ala Arg Arg Glu Gln Leu Met Arg Glu Glu Ala
125 130 135
gaa cag aag cgc tta aaa act gta ctt gag tta cag tat gta ttg gat 603
Glu Gln Lys Arg Leu Lys Thr Val Leu Glu Leu Gln Tyr Val Leu Asp
140 145 150 155
aag ctg gga gat gat gat gtg aga aca gat ctg aaa caa ggt ttg agt 651
Lys Leu Gly Asp Asp Asp Val Arg Thr Asp Leu Lys Gln Gly Leu Ser
160 165 170
gga gtg cca ata ttg tct gag gag gag ttg tca ttg ctg gat gag ttc 699
Gly Val Pro Ile Leu Ser Glu Glu Glu Leu Ser Leu Leu Asp Glu Phe
175 180 185
tac aag ctc gta gat cct gag cgt gac atg agt tta agg tta aat gag 747
Tyr Lys Leu Val Asp Pro Glu Arg Asp Met Ser Leu Arg Leu Asn Glu
190 195 200
cag tat gaa cat gcc tca att cac ttg tgg gat ttg ctg gaa ggg aaa 795
Gln Tyr Glu His Ala Ser Ile His Leu Trp Asp Leu Leu Glu Gly Lys
205 210 215
gaa aag cct gtg tgt gga aca acc tat aaa gct cta aag gaa att gtt 843
Glu Lys Pro Val Cys Gly Thr Thr Tyr Lys Ala Leu Lys Glu Ile Val
220 225 230 235
gag cgt gtt ttc cag tca aac tac ttt gat agc act cac aat cat caa 891
Glu Arg Val Phe Gln Ser Asn Tyr Phe Asp Ser Thr His Asn His Gln
240 245 250
aat ggg ttg tgt gag gag gaa gag gcg gct tca gcg ccc aca gtg gag 939
Asn Gly Leu Cys Glu Glu Glu Glu Ala Ala Ser Ala Pro Thr Val Glu
255 260 265
gac cag gta gct gaa gct gaa cct gag cca gcg gaa gaa tac aca gag 987
Asp Gln Val Ala Glu Ala Glu Pro Glu Pro Ala Glu Glu Tyr Thr Glu
270 275 280
caa agt gag gtt gaa tca aca gag tat gtc aat agg cag ttc atg gca 1035
Gln Ser Glu Val Glu Ser Thr Glu Tyr Val Asn Arg Gln Phe Met Ala
285 290 295
gaa aca cag ttc agc agt ggt gag aag gag caa gtg gat gag tgg aca 1083
Glu Thr Gln Phe Ser Ser Gly Glu Lys Glu Gln Val Asp Glu Trp Thr
300 305 310 315
gtt gaa aca gtt gag gtt gta aac tca ctc cag cag caa cct cag gct 1131
Val Glu Thr Val Glu Val Val Asn Ser Leu Gln Gln Gln Pro Gln Ala
320 325 330
gcg tcc cct tca gtc cca gag ccc cac tct ttg act cca gtg gct cag 1179
Ala Ser Pro Ser Val Pro Glu Pro His Ser Leu Thr Pro Val Ala Gln
335 340 345
tca gat cca ctt gtg aga agg cag cgt gta caa gat ctt atg gca caa 1227
Ser Asp Pro Leu Val Arg Arg Gln Arg Val Gln Asp Leu Met Ala Gln
350 355 360
atg caa ggg ccc tat aat ttc ata cag gat tca atg ttg gat ttt gaa 1275
Met Gln Gly Pro Tyr Asn Phe Ile Gln Asp Ser Met Leu Asp Phe Glu
365 370 375
aat cag acg ctt gat cct gcc att gta tcc gca cag cct atg aac cct 1323
Asn Gln Thr Leu Asp Pro Ala Ile Val Ser Ala Gln Pro Met Asn Pro
380 385 390 395
acc cag aac atg gat atg cct cag ctg gtt tgc cct cag gtt cat tct 1371
Thr Gln Asn Met Asp Met Pro Gln Leu Val Cys Pro Gln Val His Ser
400 405 410
gaa tct aga ctt gcc caa tct aat caa gtt cct gta caa cca gaa gcc 1419
Glu Ser Arg Leu Ala Gln Ser Asn Gln Val Pro Val Gln Pro Glu Ala
415 420 425
aca cag gtt cct ttg gtt tca tcc aca agt gag ggg tat aca gca tct 1467
Thr Gln Val Pro Leu Val Ser Ser Thr Ser Glu Gly Tyr Thr Ala Ser
430 435 440
cag ccc ttg tac cag cca tct cat gct acg gag cag cgg ccg cag aaa 1515
Gln Pro Leu Tyr Gln Pro Ser His Ala Thr Glu Gln Arg Pro Gln Lys
445 450 455
gag cca atg gat cag att cag gca aca ata tct ttg aat aca gac cag 1563
Glu Pro Met Asp Gln Ile Gln Ala Thr Ile Ser Leu Asn Thr Asp Gln
460 465 470 475
act aca gca tcc tca tcc ctt cct gct gct tct cag cct caa gtg ttc 1611
Thr Thr Ala Ser Ser Ser Leu Pro Ala Ala Ser Gln Pro Gln Val Phe
480 485 490
cag gct ggg aca agt aaa cct ttg cac agc agt gga atc aat gta aat 1659
Gln Ala Gly Thr Ser Lys Pro Leu His Ser Ser Gly Ile Asn Val Asn
495 500 505
gca gct cca ttc cag tcc atg caa acg gtg ttc aat atg aat gct cca 1707
Ala Ala Pro Phe Gln Ser Met Gln Thr Val Phe Asn Met Asn Ala Pro
510 515 520
gtc cct cct gct aat gaa cca gaa acg tta aaa caa cag agt cag tac 1755
Val Pro Pro Ala Asn Glu Pro Glu Thr Leu Lys Gln Gln Ser Gln Tyr
525 530 535
cag gcc act tat aac cag agt ttt tcc agt cag cct cac caa gtg gaa 1803
Gln Ala Thr Tyr Asn Gln Ser Phe Ser Ser Gln Pro His Gln Val Glu
540 545 550 555
caa aca gag ctt caa caa gac caa ctg caa acg gtg gtt ggc act tac 1851
Gln Thr Glu Leu Gln Gln Asp Gln Leu Gln Thr Val Val Gly Thr Tyr
560 565 570
cat gga tcc cag gac cag cct cat caa gtg cct ggt aac cac cag caa 1899
His Gly Ser Gln Asp Gln Pro His Gln Val Pro Gly Asn His Gln Gln
575 580 585
ccc cca cag cag aac act ggc ttt cca cgt agc agt cag cct tat tac 1947
Pro Pro Gln Gln Asn Thr Gly Phe Pro Arg Ser Ser Gln Pro Tyr Tyr
590 595 600
aac agt cgt ggg gta tct cga gga ggg tct cgt ggt gcc aga ggc ttg 1995
Asn Ser Arg Gly Val Ser Arg Gly Gly Ser Arg Gly Ala Arg Gly Leu
605 610 615
atg aat gga tac agg ggc cct gcc aat gga ttt aga gga gga tat gat 2043
Met Asn Gly Tyr Arg Gly Pro Ala Asn Gly Phe Arg Gly Gly Tyr Asp
620 625 630 635
ggt tac cgc cct tca ttc tcg aac act cca aac agt ggt tat tca cag 2091
Gly Tyr Arg Pro Ser Phe Ser Asn Thr Pro Asn Ser Gly Tyr Ser Gln
640 645 650
tct cag ttc act gct ccc cgg gac tac tct ggt tac cag cgg gat gga 2139
Ser Gln Phe Thr Ala Pro Arg Asp Tyr Ser Gly Tyr Gln Arg Asp Gly
655 660 665
tat cag cag aat ttc aag cga ggc tct ggg cag agt gga cca cgg gga 2187
Tyr Gln Gln Asn Phe Lys Arg Gly Ser Gly Gln Ser Gly Pro Arg Gly
670 675 680
gcc cca cga ggt aat ata ttg tgg tgg tga tcctagctcc tatgtggagc 2237
Ala Pro Arg Gly Asn Ile Leu Trp Trp
685 690
ttctgttctg gccttggaag aactgttcat agtccgcatg taggttacat gttaggaata 2297
catttatctt ttccagactt gttgctaaag attaaatgaa atgctctgtt tctaaaattt 2357
catcttgaat ccaaatttta atttttgaat gactttccct gctgttgtct tcaaaatcag 2417
aacattttct ctgcctcaga aaagcgtttt tccaactgga aatttatttt tcaggtctta 2477
aaacctgcta aatgttttta ggaagtacct actgaaactt tttgtaagac atttttggaa 2537
cgagcttgaa catttatata aatttattac cctctttgat ttttgaaaca tgcatattat 2597
atttaggctg agaagccctt caaatggcca gataagccac agttttagct agagaaccat 2657
ttagaattga cataactaat ctaaacttga acacttttag gaccaatgtt agtgttctaa 2717
ataccaacat atttctgatg tttaaacaga tctcccaaat tcttaggacc ttgatgtcat 2777
taaaatttag aatgacaagc ttaagaggct ttagtttcat ttgtttttca agtaatgaaa 2837
aataatttct tacatgggca gatagttaat ttgttgaaca attacaggta gcatttcatg 2897
taatctgatg ttctaaatgg ttctcttatt gaaggaggtt aaagaattag gtttcttaca 2957
gtttttggct ggccatgaca tgtataaaat gtatattaag gaggaattat aaagtacttt 3017
aatttgaatg ctagtggcaa ttgatcatta agaaagtact ttaaagcaaa aggttaatgg 3077
gtcatctggg aaaaatactg aagtatcaaa ggtatttgca tgtgaatgtg ggttatgttc 3137
ttctatccca ccttgtagca tattctatga aagttgagtt aaatgatagc taaaatatct 3197
gtttcaacag catgtaaaaa gttattttaa ctgttacaag tcattataca attttgaatg 3257
ttctgtagtt tctttttaac agtttaggta caaaggtctg ttttcattct ggtgcttttt 3317
attaattttg atagtatgat gtcacttcct attgaaatgt aagctagcgt gtaccttaga 3377
atgtgagctc catgagagca ggtaccttgt ttgtcttcac tgctgtatct attcccaacg 3437
cctcatgaca gtgcctggca catagtaggc actcaataaa tacttgttga atgaatgaaa 3497
aaaaaaaaaa a 3508
<210> 28
<211> 692
<212> PRT
<213> 小鼠(Mus musculus)
<400> 28
Met Pro Ser Ala Thr Ser His Ser Gly Ser Gly Ser Lys Ser Ser Gly
1 5 10 15
Pro Pro Pro Pro Ser Gly Ser Ser Gly Ser Glu Ala Ala Ala Gly Ala
20 25 30
Ala Ala Pro Ala Ser Gln His Pro Ala Thr Gly Thr Gly Ala Val Gln
35 40 45
Thr Glu Ala Met Lys Gln Ile Leu Gly Val Ile Asp Lys Lys Leu Arg
50 55 60
Asn Leu Glu Lys Lys Lys Gly Lys Leu Asp Asp Tyr Gln Glu Arg Met
65 70 75 80
Asn Lys Gly Glu Arg Leu Asn Gln Asp Gln Leu Asp Ala Val Ser Lys
85 90 95
Tyr Gln Glu Val Thr Asn Asn Leu Glu Phe Ala Lys Glu Leu Gln Arg
100 105 110
Ser Phe Met Ala Leu Ser Gln Asp Ile Gln Lys Thr Ile Lys Lys Thr
115 120 125
Ala Arg Arg Glu Gln Leu Met Arg Glu Glu Ala Glu Gln Lys Arg Leu
130 135 140
Lys Thr Val Leu Glu Leu Gln Tyr Val Leu Asp Lys Leu Gly Asp Asp
145 150 155 160
Asp Val Arg Thr Asp Leu Lys Gln Gly Leu Ser Gly Val Pro Ile Leu
165 170 175
Ser Glu Glu Glu Leu Ser Leu Leu Asp Glu Phe Tyr Lys Leu Val Asp
180 185 190
Pro Glu Arg Asp Met Ser Leu Arg Leu Asn Glu Gln Tyr Glu His Ala
195 200 205
Ser Ile His Leu Trp Asp Leu Leu Glu Gly Lys Glu Lys Pro Val Cys
210 215 220
Gly Thr Thr Tyr Lys Ala Leu Lys Glu Ile Val Glu Arg Val Phe Gln
225 230 235 240
Ser Asn Tyr Phe Asp Ser Thr His Asn His Gln Asn Gly Leu Cys Glu
245 250 255
Glu Glu Glu Ala Ala Ser Ala Pro Thr Val Glu Asp Gln Val Ala Glu
260 265 270
Ala Glu Pro Glu Pro Ala Glu Glu Tyr Thr Glu Gln Ser Glu Val Glu
275 280 285
Ser Thr Glu Tyr Val Asn Arg Gln Phe Met Ala Glu Thr Gln Phe Ser
290 295 300
Ser Gly Glu Lys Glu Gln Val Asp Glu Trp Thr Val Glu Thr Val Glu
305 310 315 320
Val Val Asn Ser Leu Gln Gln Gln Pro Gln Ala Ala Ser Pro Ser Val
325 330 335
Pro Glu Pro His Ser Leu Thr Pro Val Ala Gln Ser Asp Pro Leu Val
340 345 350
Arg Arg Gln Arg Val Gln Asp Leu Met Ala Gln Met Gln Gly Pro Tyr
355 360 365
Asn Phe Ile Gln Asp Ser Met Leu Asp Phe Glu Asn Gln Thr Leu Asp
370 375 380
Pro Ala Ile Val Ser Ala Gln Pro Met Asn Pro Thr Gln Asn Met Asp
385 390 395 400
Met Pro Gln Leu Val Cys Pro Gln Val His Ser Glu Ser Arg Leu Ala
405 410 415
Gln Ser Asn Gln Val Pro Val Gln Pro Glu Ala Thr Gln Val Pro Leu
420 425 430
Val Ser Ser Thr Ser Glu Gly Tyr Thr Ala Ser Gln Pro Leu Tyr Gln
435 440 445
Pro Ser His Ala Thr Glu Gln Arg Pro Gln Lys Glu Pro Met Asp Gln
450 455 460
Ile Gln Ala Thr Ile Ser Leu Asn Thr Asp Gln Thr Thr Ala Ser Ser
465 470 475 480
Ser Leu Pro Ala Ala Ser Gln Pro Gln Val Phe Gln Ala Gly Thr Ser
485 490 495
Lys Pro Leu His Ser Ser Gly Ile Asn Val Asn Ala Ala Pro Phe Gln
500 505 510
Ser Met Gln Thr Val Phe Asn Met Asn Ala Pro Val Pro Pro Ala Asn
515 520 525
Glu Pro Glu Thr Leu Lys Gln Gln Ser Gln Tyr Gln Ala Thr Tyr Asn
530 535 540
Gln Ser Phe Ser Ser Gln Pro His Gln Val Glu Gln Thr Glu Leu Gln
545 550 555 560
Gln Asp Gln Leu Gln Thr Val Val Gly Thr Tyr His Gly Ser Gln Asp
565 570 575
Gln Pro His Gln Val Pro Gly Asn His Gln Gln Pro Pro Gln Gln Asn
580 585 590
Thr Gly Phe Pro Arg Ser Ser Gln Pro Tyr Tyr Asn Ser Arg Gly Val
595 600 605
Ser Arg Gly Gly Ser Arg Gly Ala Arg Gly Leu Met Asn Gly Tyr Arg
610 615 620
Gly Pro Ala Asn Gly Phe Arg Gly Gly Tyr Asp Gly Tyr Arg Pro Ser
625 630 635 640
Phe Ser Asn Thr Pro Asn Ser Gly Tyr Ser Gln Ser Gln Phe Thr Ala
645 650 655
Pro Arg Asp Tyr Ser Gly Tyr Gln Arg Asp Gly Tyr Gln Gln Asn Phe
660 665 670
Lys Arg Gly Ser Gly Gln Ser Gly Pro Arg Gly Ala Pro Arg Gly Asn
675 680 685
Ile Leu Trp Trp
690
<210> 29
<211> 2109
<212> DNA
<213> 鸡(Gallus gallus)
<220>
<221> CDS
<222> (1)..(2109)
<223>
<400> 29
atg ccc tcg gct acc aac ggc acc atg gcg agc agc agc ggg aag gcg 48
Met Pro Ser Ala Thr Asn Gly Thr Met Ala Ser Ser Ser Gly Lys Ala
1 5 10 15
ggc ccg ggc ggc aac gag cag gcc ccg gcg gcg gca gcg gcg gcc ccg 96
Gly Pro Gly Gly Asn Glu Gln Ala Pro Ala Ala Ala Ala Ala Ala Pro
20 25 30
cag gcg tcg ggc ggc agc atc acc tcg gtt cag acc gag gcc atg aag 144
Gln Ala Ser Gly Gly Ser Ile Thr Ser Val Gln Thr Glu Ala Met Lys
35 40 45
cag atc ttg gga gtg atc gac aaa aag ctc cgc aac ctc gag aag aaa 192
Gln Ile Leu Gly Val Ile Asp Lys Lys Leu Arg Asn Leu Glu Lys Lys
50 55 60
aag agc aaa ctt gac gat tac cag gaa cga atg aac aag ggg gaa cgt 240
Lys Ser Lys Leu Asp Asp Tyr Gln Glu Arg Met Asn Lys Gly Glu Arg
65 70 75 80
cta aat caa gat caa ctg gat gca gtg tca aaa tac cag gaa gtg aca 288
Leu Asn Gln Asp Gln Leu Asp Ala Val Ser Lys Tyr Gln Glu Val Thr
85 90 95
aat aac ctg gaa ttc gct aaa gaa ctg cag agg agc ttt atg gca ctg 336
Asn Asn Leu Glu Phe Ala Lys Glu Leu Gln Arg Ser Phe Met Ala Leu
100 105 110
agc caa gat atc cag aaa aca ata aaa aag acg gct cgc agg gag cag 384
Ser Gln Asp Ile Gln Lys Thr Ile Lys Lys Thr Ala Arg Arg Glu Gln
115 120 125
ctg atg aga gaa gag gct gag cag aag cgt tta aag act gtg cta gag 432
Leu Met Arg Glu Glu Ala Glu Gln Lys Arg Leu Lys Thr Val Leu Glu
130 135 140
ctg cag ttc att ttg gac aag ttg ggt gac gat gaa gtg cgc agt gac 480
Leu Gln Phe Ile Leu Asp Lys Leu Gly Asp Asp Glu Val Arg Ser Asp
145 150 155 160
ttg aaa caa gga tca aat gga gta ccg gta ctg aca gag gag gaa ctg 528
Leu Lys Gln Gly Ser Asn Gly Val Pro Val Leu Thr Glu Glu Glu Leu
165 170 175
aca atg ctg gat gaa ttt tac aag cta gtt tac cct gaa agg gac atg 576
Thr Met Leu Asp Glu Phe Tyr Lys Leu Val Tyr Pro Glu Arg Asp Met
180 185 190
aac atg agg ttg aat gag cag tat gag caa gca tct gtt cac ctg tgg 624
Asn Met Arg Leu Asn Glu Gln Tyr Glu Gln Ala Ser Val His Leu Trp
195 200 205
gac tta ctg gaa ggg aag gaa aaa ccc gtt tgt gga aca acc tat aaa 672
Asp Leu Leu Glu Gly Lys Glu Lys Pro Val Cys Gly Thr Thr Tyr Lys
210 215 220
gcc ctg aag gag gtt gtt gaa cgt att ctt caa act agt tac ttt gat 720
Ala Leu Lys Glu Val Val Glu Arg Ile Leu Gln Thr Ser Tyr Phe Asp
225 230 235 240
agc acc cat aac cat cag aac ggg tta tgt gag gaa gaa gag gca gca 768
Ser Thr His Asn His Gln Asn Gly Leu Cys Glu Glu Glu Glu Ala Ala
245 250 255
ccc aca cct gca gta gaa gac act gta gca gaa gct gag cct gat cca 816
Pro Thr Pro Ala Val Glu Asp Thr Val Ala Glu Ala Glu Pro Asp Pro
260 265 270
gca gaa gaa ttt act gaa cct act gaa gtt gaa tcg act gag tat gta 864
Ala Glu Glu Phe Thr Glu Pro Thr Glu Val Glu Ser Thr Glu Tyr Val
275 280 285
aac aga caa ttc atg gca gag act cag ttc agc agt agt gag aag gaa 912
Asn Arg Gln Phe Met Ala Glu Thr Gln Phe Ser Ser Ser Glu Lys Glu
290 295 300
cag gta gat gag tgg aca gtt gaa acg gtt gag gtt gta aat tca ctg 960
Gln Val Asp Glu Trp Thr Val Glu Thr Val Glu Val Val Asn Ser Leu
305 310 315 320
cag caa caa aca caa gct aca tct cct cca gtt cct gaa cct cat aca 1008
Gln Gln Gln Thr Gln Ala Thr Ser Pro Pro Val Pro Glu Pro His Thr
325 330 335
ctc act act gtg gct caa gca gat cct ctt gtt aga aga cag aga gta 1056
Leu Thr Thr Val Ala Gln Ala Asp Pro Leu Val Arg Arg Gln Arg Val
340 345 350
cag gac ctt atg gcc cag atg cag ggt cca tat aac ttc atg cag gac 1104
Gln Asp Leu Met Ala Gln Met Gln Gly Pro Tyr Asn Phe Met Gln Asp
355 360 365
tct atg ctg gag ttt gag aac cag aca ctt gat cct gcc att gta tct 1152
Ser Met Leu Glu Phe Glu Asn Gln Thr Leu Asp Pro Ala Ile Val Ser
370 375 380
gca cag ccc atg aat cca gca cag aat ttg gac atg ccg caa atg gtc 1200
Ala Gln Pro Met Asn Pro Ala Gln Asn Leu Asp Met Pro Gln Met Val
385 390 395 400
tgc cct cca gtt cat act gag tca aga ctt gcc cag cct aat caa gtt 1248
Cys Pro Pro Val His Thr Glu Ser Arg Leu Ala Gln Pro Asn Gln Val
405 410 415
cct gtg caa cca gaa gct acg cag gtt ccc ttg gtt tca tct aca agt 1296
Pro Val Gln Pro Glu Ala Thr Gln Val Pro Leu Val Ser Ser Thr Ser
420 425 430
gag gga tat aca gcc tcc cag ccc atg tat cag cct tct cat acc aca 1344
Glu Gly Tyr Thr Ala Ser Gln Pro Met Tyr Gln Pro Ser His Thr Thr
435 440 445
gag caa cgg cca cag aag gaa tcc att gac cag att cag gct tca atg 1392
Glu Gln Arg Pro Gln Lys Glu Ser Ile Asp Gln Ile Gln Ala Ser Met
450 455 460
tca ctg aat gca gac cag acc ccg tca tca tca tca ctt ccc act gca 1440
Ser Leu Asn Ala Asp Gln Thr Pro Ser Ser Ser Ser Leu Pro Thr Ala
465 470 475 480
tcc cag ccg caa gtt ttc caa gct gga tct agc aaa cct ttg cat agc 1488
Ser Gln Pro Gln Val Phe Gln Ala Gly Ser Ser Lys Pro Leu His Ser
485 490 495
agc gga atc aat gtt aat gca gct cca ttc caa tcc atg caa aca gta 1536
Ser Gly Ile Asn Val Asn Ala Ala Pro Phe Gln Ser Met Gln Thr Val
500 505 510
ttc aac atg aat gca cct gtt cct cct gtt aat gag cca gaa gcc ctt 1584
Phe Asn Met Asn Ala Pro Val Pro Pro Val Asn Glu Pro Glu Ala Leu
515 520 525
aag caa caa aat cag tac cag gcc agt tac aac cag agt ttc tcc aat 1632
Lys Gln Gln Asn Gln Tyr Gln Ala Ser Tyr Asn Gln Ser Phe Ser Asn
530 535 540
cag cca cac caa gta gaa caa tca gat ctt cag caa gaa cag ctc cag 1680
Gln Pro His Gln Val Glu Gln Ser Asp Leu Gln Gln Glu Gln Leu Gln
545 550 555 560
aca gtg gtt ggt act tac cat ggt tct ccg gac cag acc cat caa gtg 1728
Thr Val Val Gly Thr Tyr His Gly Ser Pro Asp Gln Thr His Gln Val
565 570 575
gca gga aac cac cag caa cct ccc cag cag aat act gga ttt cca cgc 1776
Ala Gly Asn His Gln Gln Pro Pro Gln Gln Asn Thr Gly Phe Pro Arg
580 585 590
aac agt cag cct tat tac aac agt cgg gga gtg tct cgt ggt gga tca 1824
Asn Ser Gln Pro Tyr Tyr Asn Ser Arg Gly Val Ser Arg Gly Gly Ser
595 600 605
cgt ggg act cgt gga ttg atg aat ggt tac agg gga cct gca aat gga 1872
Arg Gly Thr Arg Gly Leu Met Asn Gly Tyr Arg Gly Pro Ala Asn Gly
610 615 620
ttt aga gga gga tat gat ggc tac cgt cct tca ttt tcc aac act ccg 1920
Phe Arg Gly Gly Tyr Asp Gly Tyr Arg Pro Ser Phe Ser Asn Thr Pro
625 630 635 640
aac agt ggt tac acg cag ccc caa ttt aat gct cct cga gat tat tca 1968
Asn Ser Gly Tyr Thr Gln Pro Gln Phe Asn Ala Pro Arg Asp Tyr Ser
645 650 655
aac tac cag cgg gat gga tat cag cag aac ttc aaa cgt ggt tct gga 2016
Asn Tyr Gln Arg Asp Gly Tyr Gln Gln Asn Phe Lys Arg Gly Ser Gly
660 665 670
caa agt ggg cct cgg gga gct cct cga ggt cgt gga ggg ccc cca aga 2064
Gln Ser Gly Pro Arg Gly Ala Pro Arg Gly Arg Gly Gly Pro Pro Arg
675 680 685
cca aac aga ggg atg cct caa atg aac gct cag caa gtg aat taa 2109
Pro Asn Arg Gly Met Pro Gln Met Asn Ala Gln Gln Val Asn
690 695 700
<210> 30
<211> 702
<212> PRT
<213> 鸡(Gallus gallus)
<400> 30
Met Pro Ser Ala Thr Asn Gly Thr Met Ala Ser Ser Ser Gly Lys Ala
1 5 10 15
Gly Pro Gly Gly Asn Glu Gln Ala Pro Ala Ala Ala Ala Ala Ala Pro
20 25 30
Gln Ala Ser Gly Gly Ser Ile Thr Ser Val Gln Thr Glu Ala Met Lys
35 40 45
Gln Ile Leu Gly Val Ile Asp Lys Lys Leu Arg Asn Leu Glu Lys Lys
50 55 60
Lys Ser Lys Leu Asp Asp Tyr Gln Glu Arg Met Asn Lys Gly Glu Arg
65 70 75 80
Leu Asn Gln Asp Gln Leu Asp Ala Val Ser Lys Tyr Gln Glu Val Thr
85 90 95
Asn Asn Leu Glu Phe Ala Lys Glu Leu Gln Arg Ser Phe Met Ala Leu
100 105 110
Ser Gln Asp Ile Gln Lys Thr Ile Lys Lys Thr Ala Arg Arg Glu Gln
115 120 125
Leu Met Arg Glu Glu Ala Glu Gln Lys Arg Leu Lys Thr Val Leu Glu
130 135 140
Leu Gln Phe Ile Leu Asp Lys Leu Gly Asp Asp Glu Val Arg Ser Asp
145 150 155 160
Leu Lys Gln Gly Ser Asn Gly Val Pro Val Leu Thr Glu Glu Glu Leu
165 170 175
Thr Met Leu Asp Glu Phe Tyr Lys Leu Val Tyr Pro Glu Arg Asp Met
180 185 190
Asn Met Arg Leu Asn Glu Gln Tyr Glu Gln Ala Ser Val His Leu Trp
195 200 205
Asp Leu Leu Glu Gly Lys Glu Lys Pro Val Cys Gly Thr Thr Tyr Lys
210 215 220
Ala Leu Lys Glu Val Val Glu Arg Ile Leu Gln Thr Ser Tyr Phe Asp
225 230 235 240
Ser Thr His Asn His Gln Asn Gly Leu Cys Glu Glu Glu Glu Ala Ala
245 250 255
Pro Thr Pro Ala Val Glu Asp Thr Val Ala Glu Ala Glu Pro Asp Pro
260 265 270
Ala Glu Glu Phe Thr Glu Pro Thr Glu Val Glu Ser Thr Glu Tyr Val
275 280 285
Asn Arg Gln Phe Met Ala Glu Thr Gln Phe Ser Ser Ser Glu Lys Glu
290 295 300
Gln Val Asp Glu Trp Thr Val Glu Thr Val Glu Val Val Asn Ser Leu
305 310 315 320
Gln Gln Gln Thr Gln Ala Thr Ser Pro Pro Val Pro Glu Pro His Thr
325 330 335
Leu Thr Thr Val Ala Gln Ala Asp Pro Leu Val Arg Arg Gln Arg Val
340 345 350
Gln Asp Leu Met Ala Gln Met Gln Gly Pro Tyr Asn Phe Met Gln Asp
355 360 365
Ser Met Leu Glu Phe Glu Asn Gln Thr Leu Asp Pro Ala Ile Val Ser
370 375 380
Ala Gln Pro Met Asn Pro Ala Gln Asn Leu Asp Met Pro Gln Met Val
385 390 395 400
Cys Pro Pro Val His Thr Glu Ser Arg Leu Ala Gln Pro Asn Gln Val
405 410 415
Pro Val Gln Pro Glu Ala Thr Gln Val Pro Leu Val Ser Ser Thr Ser
420 425 430
Glu Gly Tyr Thr Ala Ser Gln Pro Met Tyr Gln Pro Ser His Thr Thr
435 440 445
Glu Gln Arg Pro Gln Lys Glu Ser Ile Asp Gln Ile Gln Ala Ser Met
450 455 460
Ser Leu Asn Ala Asp Gln Thr Pro Ser Ser Ser Ser Leu Pro Thr Ala
465 470 475 480
Ser Gln Pro Gln Val Phe Gln Ala Gly Ser Ser Lys Pro Leu His Ser
485 490 495
Ser Gly Ile Asn Val Asn Ala Ala Pro Phe Gln Ser Met Gln Thr Val
500 505 510
Phe Asn Met Asn Ala Pro Val Pro Pro Val Asn Glu Pro Glu Ala Leu
515 520 525
Lys Gln Gln Asn Gln Tyr Gln Ala Ser Tyr Asn Gln Ser Phe Ser Asn
530 535 540
Gln Pro His Gln Val Glu Gln Ser Asp Leu Gln Gln Glu Gln Leu Gln
545 550 555 560
Thr Val Val Gly Thr Tyr His Gly Ser Pro Asp Gln Thr His Gln Val
565 570 575
Ala Gly Asn His Gln Gln Pro Pro Gln Gln Asn Thr Gly Phe Pro Arg
580 585 590
Asn Ser Gln Pro Tyr Tyr Asn Ser Arg Gly Val Ser Arg Gly Gly Ser
595 600 605
Arg Gly Thr Arg Gly Leu Met Asn Gly Tyr Arg Gly Pro Ala Asn Gly
610 615 620
Phe Arg Gly Gly Tyr Asp Gly Tyr Arg Pro Ser Phe Ser Asn Thr Pro
625 630 635 640
Asn Ser Gly Tyr Thr Gln Pro Gln Phe Asn Ala Pro Arg Asp Tyr Ser
645 650 655
Asn Tyr Gln Arg Asp Gly Tyr Gln Gln Asn Phe Lys Arg Gly Ser Gly
660 665 670
Gln Ser Gly Pro Arg Gly Ala Pro Arg Gly Arg Gly Gly Pro Pro Arg
675 680 685
Pro Asn Arg Gly Met Pro Gln Met Asn Ala Gln Gln Val Asn
690 695 700
<210> 31
<211> 20
<212> DNA
<213> 人工序列
<220>
<223> T3 引物
<400> 31
aattaaccct cactaaaggg 20
<210> 32
<211> 19
<212> DNA
<213> 人工序列
<220>
<223> T7 引物
<400> 32
taatacgact cactatagg 19
<210> 33
<211> 18
<212> DNA
<213> 人工序列
<220>
<223> 引物
<400> 33
aaggtttgaa tggagtgc 18
<210> 34
<211> 18
<212> DNA
<213> 人工序列
<220>
<223> 引物
<400> 34
tgctcctttt caccactg 18
<210> 35
<211> 18
<212> DNA
<213> 人工序列
<220>
<223> GAPDH 引物
<400> 35
gggctgcttt taactctg 18
<210> 36
<211> 18
<212> DNA
<213> 人工序列
<220>
<223> GAPDH 引物
<400> 36
ccaggaaatg agcttgac 18
<210> 37
<211> 58
<212> PRT
<213> 人(Homo sapiens)
<400> 37
Val Phe Gln Ser Asn Tyr Phe Asp Ser Thr His Asn His Gln Asn Gly
1 5 10 15
Leu Cys Glu Glu Glu Glu Ala Ala Ser Ala Pro Ala Val Glu Asp Gln
20 25 30
Val Pro Glu Ala Glu Pro Glu Pro Ala Glu Glu Tyr Thr Glu Gln Ser
35 40 45
Glu Val Glu Ser Thr Glu Tyr Val Asn Arg
50 55
<210> 38
<211> 22
<212> DNA
<213> 人工序列
<220>
<223> 引物
<400> 38
aggtsharct gcagsagtcw gg 22
<210> 39
<211> 23
<212> DNA
<213> 人工序列
<220>
<223> 引物
<400> 39
ctcgagttaa ttcacttgct gag 23
<210> 40
<211> 5
<212> PRT
<213> 小鼠(Mus musculus)
<400> 40
Asp Tyr Asn Met Asp
1 5
<210> 41
<211> 17
<212> PRT
<213> 小鼠(Mus musculus)
<400> 41
Asp Ile Asn Pro Asn Tyr Asp Ser Thr Ser Tyr Asn Gln Lys Phe Lys
1 5 10 15
Gly
<210> 42
<211> 11
<212> PRT
<213> 小鼠(Mus musculus)
<400> 42
Ser Arg Ser Tyr Asp Tyr Glu Gly Phe Ala Tyr
1 5 10
<210> 43
<211> 148
<212> PRT
<213> 小鼠(Mus musculus)
<400> 43
Met Glu Trp Ser Gly Val Phe Ile Phe Leu Leu Ser Gly Thr Ala Gly
1 5 10 15
Val Leu Ser Glu Val Gln Leu His Gln Phe Gly Ala Glu Leu Val Lys
20 25 30
Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe
35 40 45
Thr Asp Tyr Asn Met Asp Trp Val Lys Gln Ser His Gly Lys Ser Leu
50 55 60
Glu Trp Ile Gly Asp Ile Asn Pro Asn Tyr Asp Ser Thr Ser Tyr Asn
65 70 75 80
Gln Lys Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser
85 90 95
Thr Ala Tyr Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Thr Ala Val
100 105 110
Tyr Tyr Cys Ala Arg Ser Arg Ser Tyr Asp Tyr Glu Gly Phe Ala Tyr
115 120 125
Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala Ala Lys Thr Thr Pro
130 135 140
Pro Ser Val Tyr
145
<210> 44
<211> 11
<212> PRT
<213> 小鼠(Mus musculus)
<400> 44
Arg Ala Ser Gly Asn Ile His Asn Tyr Leu Ala
1 5 10
<210> 45
<211> 7
<212> PRT
<213> 小鼠(Mus musculus)
<400> 45
Asn Ala Lys Thr Leu Ala Asp
1 5
<210> 46
<211> 8
<212> PRT
<213> 小鼠(Mus musculus)
<400> 46
Gln His Phe Trp Ser Thr Leu Thr
1 5
<210> 47
<211> 139
<212> PRT
<213> 小鼠(Mus musculus)
<400> 47
Met Ser Val Leu Thr Gln Val Leu Gly Leu Leu Leu Leu Trp Leu Thr
1 5 10 15
Gly Ala Arg Cys Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser
20 25 30
Ala Ser Val Gly Glu Thr Val Thr Ile Thr Cys Arg Ala Ser Gly Asn
35 40 45
Ile His Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Gln Gly Lys Ser Pro
50 55 60
Gln Leu Leu Val Tyr Asn Ala Lys Thr Leu Ala Asp Gly Val Pro Ser
65 70 75 80
Arg Phe Ser Gly Ser Gly Ser Gly Thr Gln Tyr Ser Leu Lys Ile Asn
85 90 95
Ser Leu Gln Pro Glu Asp Phe Gly Ser Tyr Tyr Cys Gln His Phe Trp
100 105 110
Ser Thr Leu Thr Phe Gly Ala Gly Thr Lys Leu Glu Leu Lys Arg Ala
115 120 125
Asp Ala Ala Pro Thr Val Ser Asn Pro Tyr Asp
130 135
<210> 48
<211> 444
<212> DNA
<213> 小鼠(Mus musculus)
<400> 48
atggaatgga gcggggtctt tatctttctc ctgtcaggaa ctgcaggtgt cctctctgag 60
gtccagctgc atcagtttgg agctgagctg gtgaagcctg gggcttcagt gaagatatcc 120
tgcaaggctt ctggctacac attcactgac tacaacatgg actgggtgaa gcagagccat 180
ggaaagagcc ttgagtggat tggagatatt aatcctaact atgatagtac tagctacaac 240
cagaagttca agggaaaggc cacattgact gtagacaagt cctccagcac agcctacatg 300
gagctccgca gcctgacatc tgaggacact gcagtctatt actgtgcaag atcgaggagc 360
tatgattacg aaggatttgc ttactggggc caagggactc tggtcactgt ctctgcagcc 420
aaaacaacac ccccatcagt ctat 444
<210> 49
<211> 444
<212> DNA
<213> 小鼠(Mus musculus)
<400> 49
atggaatgga gcggggtctt tatctttctc ctgtcaggaa ctgcaggtgt cctctctgag 60
gtccagctgc atcagtttgg agctgagctg gtgaagcctg gggcttcagt gaagatatcc 120
tgcaaggctt ctggctacac attcactgac tacaacatgg actgggtgaa gcagagccat 180
ggaaagagcc ttgagtggat tggagatatt aatcctaact atgatagtac tagctacaac 240
cagaagttca agggaaaggc cacattgact gtagacaagt cctccagcac agcctacatg 300
gagctccgca gcctgacatc tgaggacact gcagtctatt actgtgcaag atcgaggagc 360
tatgattacg aaggatttgc ttactggggc caagggactc tggtcactgt ctctgcagcc 420
aaaacaacac ccccatcagt ctat 444
<210> 50
<211> 11
<212> PRT
<213> 小鼠(Mus musculus)
<400> 50
Leu Trp Ser Val Asn Gln Lys Asn Tyr Leu Ser
1 5 10
<210> 51
<211> 7
<212> PRT
<213> 小鼠(Mus musculus)
<400> 51
Gly Ala Ser Ile Arg Glu Ser
1 5
<210> 52
<211> 9
<212> PRT
<213> 小鼠(Mus musculus)
<400> 52
Gln His Asn His Gly Ser Phe Leu Pro
1 5
<210> 53
<211> 132
<212> PRT
<213> 小鼠(Mus musculus)
<400> 53
Ala Val Leu Arg Cys Ser Arg Gly Leu Leu Val Ile Trp Ile Ser Asp
1 5 10 15
Ile Gln Leu Thr Gln Ser Pro Ser Ser Leu Ala Val Thr Ala Gly Glu
20 25 30
Lys Val Thr Met Ser Cys Lys Ser Ser Gln Ser Leu Leu Trp Ser Val
35 40 45
Asn Gln Lys Asn Tyr Leu Ser Trp Tyr Gln Gln Lys Gln Arg Gln Pro
50 55 60
Pro Lys Leu Leu Ile Tyr Gly Ala Ser Ile Arg Glu Ser Trp Val Pro
65 70 75 80
Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile
85 90 95
Ser Asn Val His Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gln His Asn
100 105 110
His Gly Ser Phe Leu Pro Ser Arg Ser Glu Gln Val Pro Ser Trp Arg
115 120 125
Ser Asn Asn Arg
130
<210> 54
<211> 398
<212> DNA
<213> 小鼠(Mus musculus)
<400> 54
gcggtcctgc ggtgctctag aggactacta gtcatatgga tttccgatat ccagctgacc 60
cagtctccat cctccctggc tgtgacagca ggagagaagg tcactatgag ctgcaagtcc 120
agtcagagtc ttttgtggag tgtaaaccag aagaactact tgtcctggta ccagcagaaa 180
caaaggcagc ctcctaaact gcttatctat ggggcatcca ttagagaatc ttgggtccct 240
gatcggttca caggaagtgg atctgggaca gacttcactc tcaccattag caatgtgcat 300
gctgaagacc tagcagttta ttactgtcaa cacaatcatg gcagctttct cccctcacgt 360
tcggagcagg taccaagctg gagatcaaac aatcggat 398
<210> 55
<211> 11
<212> PRT
<213> 小鼠(Mus musculus)
<400> 55
Arg Ala Ser Gly Asn Ile His Asn Tyr Leu Ala
1 5 10
<210> 56
<211> 7
<212> PRT
<213> 小鼠(Mus musculus)
<400> 56
Asn Ala Lys Thr Leu Ala Asp
1 5
<210> 57
<211> 9
<212> PRT
<213> 小鼠(Mus musculus)
<400> 57
Gln His Phe Trp Ser Thr Leu Thr Phe
1 5
<210> 58
<211> 117
<212> PRT
<213> 小鼠(Mus musculus)
<400> 58
Arg Thr Thr Ser His Met Asp Ser Asp Ile Gln Leu Thr Gln Ser Pro
1 5 10 15
Ala Ser Leu Ser Ala Ser Val Gly Glu Thr Val Thr Ile Thr Cys Arg
20 25 30
Ala Ser Gly Asn Ile His Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Gln
35 40 45
Gly Lys Ser Pro Gln Leu Leu Val Tyr Asn Ala Lys Thr Leu Ala Asp
50 55 60
Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Gln Tyr Ser
65 70 75 80
Leu Lys Ile Asn Ser Leu Gln Pro Glu Asp Phe Gly Ser Tyr Tyr Cys
85 90 95
Gln His Phe Trp Ser Thr Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu
100 105 110
Ile Lys Gln Ser Asp
115
<210> 59
<211> 353
<212> DNA
<213> 小鼠(Mus musculus)
<400> 59
gaggactact agtcatatgg attccgatat ccagctgacc cagtctccag cctccctatc 60
tgcatctgtg ggagaaactg tcaccatcac atgtcgagca agtgggaata ttcacaatta 120
tttagcatgg tatcagcaga aacagggaaa atctcctcag ctcctggtct ataatgcaaa 180
aaccttagca gatggtgtgc catcaaggtt cagtggcagt ggatcaggaa cacaatattc 240
tctcaagatc aacagcctgc agcctgaaga ttttgggagt tattactgtc aacatttttg 300
gagtacgctc acgttcggag gtggtaccaa gctggagatc aaacaatcgg atc 353
<210> 60
<211> 11
<212> PRT
<213> 小鼠(Mus musculus)
<400> 60
Arg Ala Ser Gln Ser Ile Ser Asn Tyr Leu His
1 5 10
<210> 61
<211> 7
<212> PRT
<213> 小鼠(Mus musculus)
<400> 61
Tyr Ala Ser Gln Ser Ile Ser
1 5
<210> 62
<211> 9
<212> PRT
<213> 小鼠(Mus musculus)
<400> 62
Gln Gln Ser Asn Ser Trp Pro Tyr Thr
1 5
<210> 63
<211> 94
<212> PRT
<213> 小鼠(Mus musculus)
<400> 63
Ser Gly Asp Arg Val Ser Leu Ser Cys Arg Ala Ser Gln Ser Ile Ser
1 5 10 15
Asn Tyr Leu His Trp Tyr Gln Gln Lys Ser His Glu Ser Pro Arg Leu
20 25 30
Leu Ile Lys Tyr Ala Ser Gln Ser Ile Ser Gly Ile Pro Ser Arg Phe
35 40 45
Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Ser Ile Asn Ser Val
50 55 60
Glu Thr Glu Asp Phe Gly Met Tyr Phe Cys Gln Gln Ser Asn Ser Trp
65 70 75 80
Pro Tyr Thr Phe Gly Ala Gly Thr Lys Leu Glu Ile Lys Gln
85 90
<210> 64
<211> 283
<212> DNA
<213> 小鼠(Mus musculus)
<400> 64
tcaggagata gagtcagtct ttcctgcagg gccagtcaaa gtattagcaa ctacctacac 60
tggtatcaac aaaaatcaca tgagtctcca aggcttctca tcaagtatgc ttcccagtcc 120
atctctggga tcccctccag gttcagtggc agtggatcag ggacagattt cactctcagt 180
atcaacagtg tggagactga agattttgga atgtatttct gtcaacagag taacagctgg 240
ccgtacacgt tcggtgcagg taccaagctg gagatcaaac aga 283
<210> 65
<211> 11
<212> PRT
<213> 小鼠(Mus musculus)
<400> 65
Leu Ser Ile Val Asn Arg Tyr His Tyr Met Ser
1 5 10
<210> 66
<211> 6
<212> PRT
<213> 小鼠(Mus musculus)
<400> 66
Glu Ala Ser Ile Thr Lys
1 5
<210> 67
<211> 9
<212> PRT
<213> 小鼠(Mus musculus)
<400> 67
Gln His Asn Arg Gly Ser Phe Leu Pro
1 5
<210> 68
<211> 105
<212> PRT
<213> 小鼠(Mus musculus)
<400> 68
Gly Leu Phe Cys Ser Val Glu Arg Cys His Tyr Gln Leu Gln Ser Ser
1 5 10 15
Gln Asn Leu Leu Ser Ile Val Asn Arg Tyr His Tyr Met Ser Gly Asn
20 25 30
Pro Pro Lys Leu Leu Val Tyr Pro Ala Leu Leu Ile Tyr Glu Ala Ser
35 40 45
Ile Thr Lys Ser Cys Val Pro Asp Arg Phe Thr Arg Ser Gly Ser Gly
50 55 60
Thr Asn Phe Thr Leu Thr Ile Asn Phe Val His Ala Asp Asp Leu Ile
65 70 75 80
Phe Tyr Tyr Cys Gln His Asn Arg Gly Ser Phe Leu Pro Ser Ser Ser
85 90 95
Val Gln Val Pro Arg Arg Arg Ser Asn
100 105
<210> 69
<211> 317
<212> DNA
<213> 小鼠(Mus musculus)
<400> 69
ggactcttct gctctgtgga gagatgtcac tatcaactgc aatccagtca gaatcttttg 60
agtattgtaa accggtatca ctacatgtcc ggaaaccctc ctaaactcct ggtctatcct 120
gcactgctta tctatgaggc atccattaca aaatcctgtg tccctgatcg gttcacacga 180
agtggatctg ggacaaactt cactctcacc attaattttg tgcatgctga tgacctaatt 240
ttttattact gtcaacacaa tcgtggcagc tttctcccct caagttcggt gcaggtacca 300
agaaggagat caaacaa 317
<210> 70
<211> 5
<212> PRT
<213> 小鼠(Mus musculus)
<400> 70
Gly Tyr Thr Met Asn
1 5
<210> 71
<211> 16
<212> PRT
<213> 小鼠(Mus musculus)
<400> 71
Asn Pro Tyr Asn Gly Gly Thr Ser Tyr Asn Gln Lys Phe Lys Gly Lys
1 5 10 15
<210> 72
<211> 9
<212> PRT
<213> 小鼠(Mus musculus)
<400> 72
Trp Gly Val Trp Ser Ala Met Asp Tyr
1 5
<210> 73
<211> 100
<212> PRT
<213> 小鼠(Mus musculus)
<400> 73
Asp Ile Leu Gln Ala Ser Gly Tyr Ser Phe Thr Gly Tyr Thr Met Asn
1 5 10 15
Trp Val Lys Gln Ser His Gly Lys Asn Leu Glu Trp Ile Gly Leu Ile
20 25 30
Asn Pro Tyr Asn Gly Gly Thr Ser Tyr Asn Gln Lys Phe Lys Gly Lys
35 40 45
Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu
50 55 60
Leu Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Trp
65 70 75 80
Gly Val Trp Ser Ala Met Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr
85 90 95
Val Ser Ser Lys
100
<210> 74
<211> 11
<212> PRT
<213> 小鼠(Mus musculus)
<400> 74
Lys Ala Ser Gln Asn Val Arg Thr Ala Val Ala
1 5 10
<210> 75
<211> 7
<212> PRT
<213> 小鼠(Mus musculus)
<400> 75
Leu Ala Ser Asn Arg Asp Thr
1 5
<210> 76
<211> 9
<212> PRT
<213> 小鼠(Mus musculus)
<400> 76
Leu Gln His Cys Asn Tyr Pro Asn Glu
1 5
<210> 77
<211> 90
<212> PRT
<213> 小鼠(Mus musculus)
<400> 77
Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asn Val Arg Thr Ala
1 5 10 15
Val Ala Trp Tyr Gln Gln Lys Pro Arg Gln Ser Pro Lys Ala Leu Ile
20 25 30
Tyr Leu Ala Ser Asn Arg Asp Thr Gly Leu Pro Asp Arg Phe Pro Gly
35 40 45
Arg Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile Thr Asn Val Gln Ser
50 55 60
Glu Asp Leu Glu Asp Tyr Phe Cys Leu Gln His Cys Asn Tyr Pro Asn
65 70 75 80
Glu Phe Arg Gly Cys Thr Lys Val Pro Ile
85 90
<210> 78
<211> 301
<212> DNA
<213> 小鼠(Mus musculus)
<400> 78
gatatcctgc aggcttctgg ttactcattc actggctaca ccatgaactg ggtgaagcag 60
agccatggaa agaaccttga gtggattgga cttattaatc cttacaatgg tggtactagc 120
tacaaccaga agttcaaggg caaggccaca ttaactgtag acaagtcatc cagcacagcc 180
tacatggagc tcctcagtct gacatctgag gactctgcag tctattactg tgcaagatgg 240
ggggtatggt cggctatgga ctactggggc caagggacca cggtcaccgt ctcctcaaaa 300
a 301
<210> 79
<211> 290
<212> DNA
<213> 小鼠(Mus musculus)
<400> 79
gacagggtca gcatcacctg caaggccagt caaaatgttc gtactgctgt agcctggtat 60
caacagaaac cacggcagtc tcctaaagca ctgatttact tggcatccaa ccgggacact 120
ggactccctg atcgcttccc aggcagggga tctgggacag atttcactct caacattacc 180
aatgtgcaat ctgaagacct ggaagattat ttctgtctgc aacattgtaa ttatcctaac 240
gagttcagag gttgtaccaa ggtgccaatc taaagaacaa acaccccctg 290
<210> 80
<211> 5
<212> PRT
<213> 小鼠(Mus musculus)
<400> 80
Ser Tyr Trp Met Gln
1 5
<210> 81
<211> 17
<212> PRT
<213> 小鼠(Mus musculus)
<400> 81
Ala Ile Tyr Pro Gly Asp Gly Asp Thr Arg Tyr Thr Gln Lys Phe Lys
1 5 10 15
Gly
<210> 82
<211> 11
<212> PRT
<213> 小鼠(Mus musculus)
<400> 82
Ala Arg Gly Glu Tyr Gly Asn Tyr Phe Ala Tyr
1 5 10
<210> 83
<211> 116
<212> PRT
<213> 小鼠(Mus musculus)
<400> 83
Leu Gln Glu Ser Gly Ala Glu Leu Ala Arg Pro Gly Ala Ser Val Lys
1 5 10 15
Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Trp Met Gln
20 25 30
Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly Ala Ile
35 40 45
Tyr Pro Gly Asp Gly Asp Thr Arg Tyr Thr Gln Lys Phe Lys Gly Lys
50 55 60
Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr Met Gln Leu
65 70 75 80
Ser Ser Leu Ala Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Gly
85 90 95
Glu Tyr Gly Asn Tyr Phe Ala Tyr Trp Gly Gln Gly Thr Thr Val Thr
100 105 110
Val Ser Ser Asn
115
<210> 84
<211> 11
<212> PRT
<213> 小鼠(Mus musculus)
<400> 84
Lys Ala Ser Gln Asp Ile Asn Ser Tyr Leu Ser
1 5 10
<210> 85
<211> 7
<212> PRT
<213> 小鼠(Mus musculus)
<400> 85
Arg Ala Asn Arg Leu Val Asp
1 5
<210> 86
<211> 9
<212> PRT
<213> 小鼠(Mus musculus)
<400> 86
Leu Gln Tyr Asp Glu Phe Pro Leu Thr
1 5
<210> 87
<211> 100
<212> PRT
<213> 小鼠(Mus musculus)
<400> 87
Thr Ser Asp Ala Ser Leu Gly Glu Arg Val Thr Ile Thr Cys Lys Ala
1 5 10 15
Ser Gln Asp Ile Asn Ser Tyr Leu Ser Trp Phe Gln Gln Lys Pro Gly
20 25 30
Lys Ser Pro Lys Thr Leu Ile Tyr Arg Ala Asn Arg Leu Val Asp Gly
35 40 45
Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Gln Asp Tyr Ser Leu
50 55 60
Thr Ile Ser Ser Leu Glu Tyr Glu Asp Met Gly Ile Tyr Tyr Cys Leu
65 70 75 80
Gln Tyr Asp Glu Phe Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu
85 90 95
Ile Lys Gln Lys
100
<210> 88
<211> 352
<212> DNA
<213> 小鼠(Mus musculus)
<400> 88
aactgcagga gtctggggct gagctggcaa gacctggggc ttcagtgaag ttgtcctgca 60
aggcttctgg ctacaccttt actagctact ggatgcagtg ggtaaaacag aggcctggac 120
agggtctgga atggattggg gctatttatc ctggagatgg tgatactagg tacactcaga 180
agttcaaggg caaggccaca ttgactgcag ataaatcctc cagcacagcc tacatgcaac 240
tcagcagctt ggcatctgag gactctgcgg tctattactg tgcaagaggg gagtatggta 300
actattttgc ttactggggc caagggacca cggtcaccgt ctcctcaaat cg 352
<210> 89
<211> 302
<212> DNA
<213> 小鼠(Mus musculus)
<400> 89
ggacatcgga tgcatctcta ggagagagag tcactatcac ttgcaaggcg agtcaggaca 60
ttaatagcta tttaagctgg ttccagcaga aaccagggaa atctcctaag accctgatct 120
atcgtgcaaa cagattggta gatggggtcc catcaaggtt cagtggcagt ggatctgggc 180
aagattattc tctcaccatc agcagcctgg agtatgaaga tatgggaatt tattattgtc 240
tacagtatga tgagtttccg ctcacgttcg gaggaggtac caagctggag atcaaacaaa 300
aa 302
<210> 90
<211> 5
<212> PRT
<213> 小鼠(Mus musculus)
<400> 90
Asp Thr Tyr Met His
1 5
<210> 91
<211> 17
<212> PRT
<213> 小鼠(Mus musculus)
<400> 91
Arg Ile Asp Pro Ala Asn Gly Asn Thr Lys Tyr Asp Pro Lys Phe Gln
1 5 10 15
Gly
<210> 92
<211> 14
<212> PRT
<213> 小鼠(Mus musculus)
<400> 92
Ala Arg Pro Ile His Tyr Tyr Tyr Gly Ser Ser Leu Ala Tyr
1 5 10
<210> 93
<211> 108
<212> PRT
<213> 小鼠(Mus musculus)
<400> 93
Ala Trp Leu Ser Gln Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys
1 5 10 15
Asp Thr Tyr Met His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu
20 25 30
Trp Ile Gly Arg Ile Asp Pro Ala Asn Gly Asn Thr Lys Tyr Asp Pro
35 40 45
Lys Phe Gln Gly Lys Ala Thr Ile Thr Ala Asp Thr Ser Ser Asn Thr
50 55 60
Ala Tyr Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr
65 70 75 80
Tyr Cys Ala Arg Pro Ile His Tyr Tyr Tyr Gly Ser Ser Leu Ala Tyr
85 90 95
Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Lys
100 105
<210> 94
<211> 11
<212> PRT
<213> 小鼠(Mus musculus)
<400> 94
Ser Val Asp Ser Tyr Gly Asn Ser Phe Met His
1 5 10
<210> 95
<211> 7
<212> PRT
<213> 小鼠(Mus musculus)
<400> 95
Arg Ala Ser Asn Leu Glu Ser
1 5
<210> 96
<211> 9
<212> PRT
<213> 小鼠(Mus musculus)
<400> 96
Gln Gln Ser Asn Glu Asp Pro Gly Arg
1 5
<210> 97
<211> 104
<212> PRT
<213> 小鼠(Mus musculus)
<400> 97
Glu Phe His Ala Val Ser Leu Gly Gln Arg Ala Thr Ile Ser Cys Arg
1 5 10 15
Ala Ser Glu Ser Val Asp Ser Tyr Gly Asn Ser Phe Met His Trp Tyr
20 25 30
Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Arg Ala Ser
35 40 45
Asn Leu Glu Ser Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser Arg
50 55 60
Thr Asp Phe Thr Leu Thr Ile Asn Pro Val Glu Ala Asp Asp Val Ala
65 70 75 80
Thr Tyr Tyr Cys Gln Gln Ser Asn Glu Asp Pro Gly Arg Ser Glu Val
85 90 95
Val Pro Ser Trp Arg Ser Asn Lys
100
<210> 98
<211> 326
<212> DNA
<213> 小鼠(Mus musculus)
<400> 98
gcatggctca gtcagttgtc ctgcacagct tctggcttca acattaaaga cacctatatg 60
cactgggtga agcagaggcc tgaacagggc ctggagtgga ttggaaggat tgatcctgcg 120
aatggtaata ctaaatatga cccgaagttc cagggcaagg ccactataac agcagacaca 180
tcctccaaca cagcctacct gcagctcagc agcctgacat ctgaggacac tgccgtctat 240
tactgtgcta gaccgattca ttattactac ggtagtagcc ttgcttactg gggccaaggg 300
accacggtca ccgtctcctc aaaaaa 326
<210> 99
<211> 313
<212> DNA
<213> 小鼠(Mus musculus)
<400> 99
gagtttcatg ctgtgtctct agggcagagg gccaccatat cctgcagagc cagtgaaagt 60
gttgatagtt atggcaatag ttttatgcac tggtaccagc agaaaccagg acagccaccc 120
aaactcctca tctatcgtgc atccaaccta gaatctggga tccctgccag gttcagtggc 180
agtgggtcta ggacagactt caccctcacc attaatcctg tggaggctga tgatgttgca 240
acctattact gtcagcaaag taatgaggat cctggacgtt cggaggtggt accaagctgg 300
agatcaaaca aaa 313
<210> 100
<211> 5
<212> PRT
<213> 小鼠(Mus musculus)
<400> 100
Asp Tyr Tyr Met Ser
1 5
<210> 101
<211> 17
<212> PRT
<213> 小鼠(Mus musculus)
<400> 101
Arg Asn Lys Ala Asn Gly Tyr Thr Thr Glu Tyr Ser Ala Ser Val Lys
1 5 10 15
Gly
<210> 102
<211> 9
<212> PRT
<213> 小鼠(Mus musculus)
<400> 102
Ala Arg Ala Asn Trp Ala Phe Asp Tyr
1 5
<210> 103
<211> 109
<212> PRT
<213> 小鼠(Mus musculus)
<400> 103
Pro Arg Ala Ser Leu Gly Val Ser Glu Thr Leu Leu Cys Thr Ser Gly
1 5 10 15
Phe Thr Phe Thr Asp Tyr Tyr Met Ser Trp Val Arg Gln Pro Pro Gly
20 25 30
Lys Ala Leu Glu Trp Leu Gly Phe Ile Arg Asn Lys Ala Asn Gly Tyr
35 40 45
Thr Thr Glu Tyr Ser Ala Ser Val Lys Gly Arg Phe Thr Ile Ser Arg
50 55 60
Asp Asn Ser Gln Ser Ile Leu Tyr Leu Gln Met Asn Thr Leu Arg Ala
65 70 75 80
Glu Asp Ser Ala Thr Tyr Tyr Cys Ala Arg Ala Asn Trp Ala Phe Asp
85 90 95
Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Lys
100 105
<210> 104
<211> 11
<212> PRT
<213> 小鼠(Mus musculus)
<400> 104
Arg Ala Ser Gln Ser Ile Ser Asn Tyr Leu His
1 5 10
<210> 105
<211> 7
<212> PRT
<213> 小鼠(Mus musculus)
<400> 105
Tyr Ala Ser Gln Ser Ile Ser
1 5
<210> 106
<211> 9
<212> PRT
<213> 小鼠(Mus musculus)
<400> 106
Gln Gln Ser Asn Ser Trp Pro Tyr Thr
1 5
<210> 107
<211> 94
<212> PRT
<213> 小鼠(Mus musculus)
<400> 107
Ser Gly Asp Arg Val Ser Leu Ser Cys Arg Ala Ser Gln Ser Ile Ser
1 5 10 15
Asn Tyr Leu His Trp Tyr Gln Gln Lys Ser His Glu Ser Pro Arg Leu
20 25 30
Leu Ile Lys Tyr Ala Ser Gln Ser Ile Ser Gly Ile Pro Ser Arg Phe
35 40 45
Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Ser Ile Asn Ser Val
50 55 60
Glu Thr Glu Asp Phe Gly Met Tyr Phe Cys Gln Gln Ser Asn Ser Trp
65 70 75 80
Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Gln
85 90
<210> 108
<211> 329
<212> DNA
<213> 小鼠(Mus musculus)
<400> 108
ggccgcgtgc tagcctgggg gtctctgaga ctctcctgtg cacttctggg ttcaccttca 60
ctgattacta catgagctgg gtccgccagc ctccaggaaa ggcacttgag tggttgggtt 120
ttattagaaa caaagctaat ggttacacaa cagagtacag tgcatctgtg aagggtcggt 180
tcaccatctc cagagataat tcccaaagca tcctctatct tcaaatgaac accctgagag 240
ctgaggacag tgccacttat tactgtgcaa gggctaactg ggcctttgac tactggggcc 300
aagggaccac ggtcaccgtc tcctcaaaa 329
<210> 109
<211> 284
<212> DNA
<213> 小鼠(Mus musculus)
<400> 109
tcaggagata gagtcagtct ttcctgcagg gccagtcaaa gtattagcaa ctacctacac 60
tggtatcaac aaaaatcaca tgagtctcca aggcttctca tcaagtatgc ttcccagtcc 120
atctctggga tcccctccag gttcagtggc agtggatcag ggacagattt cactctcagt 180
atcaacagtg tggagactga agattttgga atgtatttct gtcaacagag taacagctgg 240
ccgtacacgt tcggaggagg taccaagctg gagatcaaac agaa 284
<210> 110
<211> 5
<212> PRT
<213> 小鼠(Mus musculus)
<400> 110
Asp Tyr Tyr Met Ser
1 5
<210> 111
<211> 17
<212> PRT
<213> 小鼠(Mus musculus)
<400> 111
Arg Asn Lys Ala Asn Gly Tyr Thr Thr Glu Tyr Ser Ala Ser Val Lys
1 5 10 15
Gly
<210> 112
<211> 12
<212> PRT
<213> 小鼠(Mus musculus)
<400> 112
Ala Arg Ala Pro Leu Leu Tyr Tyr Ala Met Asp Tyr
1 5 10
<210> 113
<211> 111
<212> PRT
<213> 小鼠(Mus musculus)
<400> 113
Pro Ala Cys Leu Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Thr Ser
1 5 10 15
Gly Phe Thr Phe Thr Asp Tyr Tyr Met Ser Trp Val Arg Gln Pro Pro
20 25 30
Gly Lys Ala Leu Glu Trp Leu Gly Phe Ile Arg Asn Lys Ala Asn Gly
35 40 45
Tyr Thr Thr Glu Tyr Ser Ala Ser Val Lys Gly Arg Phe Thr Ile Ser
50 55 60
Arg Asp Asn Ser Gln Ser Ile Leu Tyr Leu Gln Met Asn Thr Leu Arg
65 70 75 80
Ala Glu Asp Ser Ala Thr Tyr Tyr Cys Ala Arg Ala Pro Leu Leu Tyr
85 90 95
Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser
100 105 110
<210> 114
<211> 11
<212> PRT
<213> 小鼠(Mus musculus)
<400> 114
Asn Val Ser Thr Ser Gly Tyr Ser Tyr Met His
1 5 10
<210> 115
<211> 7
<212> PRT
<213> 小鼠(Mus musculus)
<400> 115
Leu Val Ser Asn Leu Glu Ser
1 5
<210> 116
<211> 8
<212> PRT
<213> 小鼠(Mus musculus)
<400> 116
Gln His Ile Arg Glu Leu Thr Arg
1 5
<210> 117
<211> 102
<212> PRT
<213> 小鼠(Mus musculus)
<400> 117
Arg Leu Pro Phe Tyr Ser Leu Glu Gln Arg Ala Thr Ile Ser Tyr Arg
1 5 10 15
Ala Ser Lys Asn Val Ser Thr Ser Gly Tyr Ser Tyr Met His Trp Asn
20 25 30
Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Leu Val Ser
35 40 45
Asn Leu Glu Ser Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly
50 55 60
Thr Asp Phe Thr Leu Asn Ile His Pro Val Glu Glu Glu Asp Ala Ala
65 70 75 80
Thr Tyr Tyr Cys Gln His Ile Arg Glu Leu Thr Arg Ser Glu Leu Val
85 90 95
Pro Ser Trp Lys Ser Asn
100
<210> 118
<211> 340
<212> DNA
<213> 小鼠(Mus musculus)
<400> 118
ccggcctgct tgcctggtgg ttctctgaga ctctcctgtg caacttctgg gttcaccttc 60
actgattact acatgagctg ggtccgccag cctccaggaa aggcacttga gtggttgggt 120
tttattagaa acaaagctaa tggttacaca acagagtaca gtgcatctgt gaagggtcgg 180
ttcaccatct ccagagataa ttcccaaagc atcctctatc ttcaaatgaa caccctgaga 240
gctgaggaca gtgccactta ttactgtgca agagcccctc tactttacta tgctatggac 300
tactggggcc aagggaccac ggtcaccgtc tcctaaatta 340
<210> 119
<211> 306
<212> DNA
<213> 小鼠(Mus musculus)
<400> 119
cgccttcctt tctattctct ggagcagagg gccaccatct catacagggc cagcaaaaat 60
gtcagtacat ctggctatag ttatatgcac tggaaccaac agaaaccagg acagccaccc 120
aaactcctca tctatcttgt atccaaccta gaatctgggg tccctgccag gttcagtggc 180
agtgggtctg ggacagactt caccctcaac atccatcctg tggaggagga ggatgctgca 240
acctattact gtcagcacat tagggagctt acacgttcgg agctggtacc aagctggaaa 300
tcaaac 306
<210> 120
<211> 5
<212> PRT
<213> 小鼠(Mus musculus)
<400> 120
Ser Tyr Trp Met His
1 5
<210> 121
<211> 17
<212> PRT
<213> 小鼠(Mus musculus)
<400> 121
Met Ile Asp Pro Ser Asn Ser Glu Thr Arg Leu Asn Gln Lys Phe Lys
1 5 10 15
Asp
<210> 122
<211> 12
<212> PRT
<213> 小鼠(Mus musculus)
<400> 122
Ala Arg Gly Leu Arg His Tyr Trp Tyr Phe Asp Val
1 5 10
<210> 123
<211> 101
<212> PRT
<213> 小鼠(Mus musculus)
<400> 123
Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ser Tyr Trp Met His
1 5 10 15
Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile Gly Met Ile
20 25 30
Asp Pro Ser Asn Ser Glu Thr Arg Leu Asn Gln Lys Phe Lys Asp Lys
35 40 45
Ala Thr Leu Asn Val Asp Lys Ser Ser Asn Thr Ala Tyr Met Gln Leu
50 55 60
Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Arg Gly
65 70 75 80
Leu Arg His Tyr Trp Tyr Phe Asp Val Trp Gly Gln Gly Thr Thr Val
85 90 95
Thr Val Ser Ser Lys
100
<210> 124
<211> 11
<212> PRT
<213> 小鼠(Mus musculus)
<400> 124
Ser Val Ser Thr Ser Gly Tyr Ser Tyr Met His
1 5 10
<210> 125
<211> 7
<212> PRT
<213> 小鼠(Mus musculus)
<400> 125
Leu Val Ser Asn Leu Glu Ser
1 5
<210> 126
<211> 9
<212> PRT
<213> 小鼠(Mus musculus)
<400> 126
Gln His Ile Arg Glu Leu Thr Arg Ser
1 5
<210> 127
<211> 99
<212> PRT
<213> 小鼠(Mus musculus)
<400> 127
Thr Ile Leu Trp Arg Glu Gly Pro Phe Ser Tyr Arg Ala Ser Lys Ser
1 5 10 15
Val Ser Thr Ser Gly Tyr Ser Tyr Met His Trp Asn Gln Gln Lys Pro
20 25 30
Gly Gln Pro Pro Arg Leu Leu Ile Tyr Leu Val Ser Asn Leu Glu Ser
35 40 45
Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr
50 55 60
Leu Asn Ile His Pro Val Glu Glu Glu Asp Ala Ala Thr Tyr Tyr Cys
65 70 75 80
Gln His Ile Arg Glu Leu Thr Arg Ser Glu Glu Val Pro Ser Trp Arg
85 90 95
Ser Asn Lys
<210> 128
<211> 304
<212> DNA
<213> 小鼠(Mus musculus)
<400> 128
gtgtcctgca aggcttcagg ctataccttc accagctact ggatgcactg ggtgaaacag 60
aggcctggac aaggccttga gtggattggc atgattgatc cttccaatag tgaaactagg 120
ttaaatcaga agttcaagga caaggccaca ttgaatgtag acaaatcctc caacacagcc 180
tacatgcagc tcagcagcct gacatctgag gactctgcag tctattactg tgcaagaggg 240
ttacgccact actggtactt cgatgtctgg ggccaaggga ccacggtcac cgtctcctca 300
aaaa 304
<210> 129
<211> 298
<212> DNA
<213> 小鼠(Mus musculus)
<400> 129
actattctct ggagagaggg ccccttctca tacagggcca gcaaaagtgt cagtacatct 60
ggctatagtt atatgcactg gaaccaacag aaaccaggac agccacccag actcctcatc 120
tatcttgtat ccaacctaga atctggggtc cctgccaggt tcagtggcag tgggtctggg 180
acagacttca ccctcaacat ccatcctgtg gaggaggagg atgctgcaac ctattactgt 240
cagcacatta gggagcttac acgttcggag gaggtaccaa gctggagatc aaacaaaa 298
<210> 130
<211> 22
<212> DNA
<213> 人工序列
<220>
<223> 引物
<400> 130
aggtsharct gcagsagtcw gg 22
<210> 131
<211> 34
<212> DNA
<213> 人工序列
<220>
<223> 引物
<400> 131
tgaggagacg gtgaccgtgg tcccttggcc ccag 34
<210> 132
<211> 27
<212> DNA
<213> 人工序列
<220>
<223> 引物
<400> 132
tccgatatcc agctgaccca gtctcca 27
<210> 133
<211> 31
<212> DNA
<213> 人工序列
<220>
<223> 引物
<400> 133
gtttgatctc cagcttggta cchscdccga a 31
<210> 134
<211> 15
<212> DNA
<213> 人工序列
<220>
<223> 引物
<400> 134
agtcacgacg ttgta 15
<210> 135
<211> 17
<212> DNA
<213> 人工序列
<220>
<223> 引物
<400> 135
caggaaacag ctatgac 17

Claims (14)

1.用于表达CAPRIN-1的癌的治疗的药物,其特征在于,一起组合含有或者分别组合含有:
与在癌细胞表面上存在的CAPRIN-1蛋白质的细胞外区域特异性地结合且对癌细胞具有细胞毒性的抗体、和
1种以上的其它抗肿瘤剂。
2.根据权利要求1所述的药物,其特征在于,上述抗体是与在癌细胞表面上存在的CAPRIN-1蛋白质的细胞外区域中的下述多肽特异性地结合的抗体,所述多肽是序列编号37所示的氨基酸序列。
3.根据权利要求1所述的药物,其中所述CAPRIN-1蛋白质来源于人。
4.权利要求1所述的药物,其中,所述抗肿瘤剂选自环磷酰胺、紫杉醇、多西紫杉醇、长春瑞滨以及它们的药学上可接受的盐和环磷酰胺衍生物、紫杉醇衍生物、多西紫杉醇衍生物、长春瑞滨衍生物。
5.根据权利要求1所述的药物,其中,所述癌是乳癌、脑瘤、白血病、淋巴瘤、肺癌、肥大细胞瘤、肾癌、宫颈癌、膀胱癌、食道癌、胃癌或大肠癌。
6.根据权利要求1所述的药物,其中,所述抗体为单克隆抗体、多克隆抗体或重组抗体。
7.根据权利要求1~6中任一项所述的药物,其中,所述抗体为人抗体、人源化抗体、嵌合抗体、单链抗体、或双特异性抗体。
8.与在癌细胞表面上存在的CAPRIN-1蛋白质的细胞外区域特异性地结合且对癌细胞具有细胞毒性的抗体的用途,用于与1种以上的其它抗肿瘤剂一起组合来制备表达CAPRIN-1的癌的治疗的药物或者分别组合来制备表达CAPRIN-1的癌的治疗的药物。
9.根据权利要求8所述的用途,其特征在于,上述抗体是与在癌细胞表面上存在的CAPRIN-1蛋白质的细胞外区域中的下述多肽特异性地结合的抗体,所述多肽具有序列编号37所示的氨基酸序列。
10.根据权利要求8所述的用途,其中所述CAPRIN-1蛋白质来源于人。
11.权利要求8所述的用途,其中,所述抗肿瘤剂选自环磷酰胺、紫杉醇、多西紫杉醇、长春瑞滨以及它们的药学上可接受的盐和环磷酰胺衍生物、紫杉醇衍生物、多西紫杉醇衍生物、长春瑞滨衍生物。
12.根据权利要求8所述的用途,其中,所述癌是乳癌、脑瘤、白血病、淋巴瘤、肺癌、肥大细胞瘤、肾癌、宫颈癌、膀胱癌、食道癌、胃癌或大肠癌。
13.根据权利要求8所述的用途,其中,所述抗体为单克隆抗体、多克隆抗体或重组抗体。
14.根据权利要求8~13中任一项所述的用途,其中,所述抗体为人抗体、人源化抗体、嵌合抗体、单链抗体、或双特异性抗体。
CN201910271408.5A 2010-02-04 2011-02-04 用于癌的治疗和/或预防的药物 Active CN109925511B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910271408.5A CN109925511B (zh) 2010-02-04 2011-02-04 用于癌的治疗和/或预防的药物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2010023455 2010-02-04
JP2010-023455 2010-02-04
CN2011800172337A CN102844048A (zh) 2010-02-04 2011-02-04 用于癌的治疗和/或预防的药物
PCT/JP2011/052414 WO2011096535A1 (ja) 2010-02-04 2011-02-04 癌の治療及び/又は予防のための医薬品
CN201910271408.5A CN109925511B (zh) 2010-02-04 2011-02-04 用于癌的治疗和/或预防的药物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN2011800172337A Division CN102844048A (zh) 2010-02-04 2011-02-04 用于癌的治疗和/或预防的药物

Publications (2)

Publication Number Publication Date
CN109925511A true CN109925511A (zh) 2019-06-25
CN109925511B CN109925511B (zh) 2024-03-19

Family

ID=44355529

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201910271408.5A Active CN109925511B (zh) 2010-02-04 2011-02-04 用于癌的治疗和/或预防的药物
CN2011800172337A Pending CN102844048A (zh) 2010-02-04 2011-02-04 用于癌的治疗和/或预防的药物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN2011800172337A Pending CN102844048A (zh) 2010-02-04 2011-02-04 用于癌的治疗和/或预防的药物

Country Status (16)

Country Link
US (1) US9180187B2 (zh)
EP (1) EP2532367B1 (zh)
JP (1) JP5923984B2 (zh)
KR (1) KR101843807B1 (zh)
CN (2) CN109925511B (zh)
AU (1) AU2011211700B2 (zh)
BR (1) BR112012018943A8 (zh)
CA (1) CA2788720C (zh)
DK (1) DK2532367T3 (zh)
ES (1) ES2691738T3 (zh)
HU (1) HUE040012T2 (zh)
MX (1) MX2012008991A (zh)
PL (1) PL2532367T3 (zh)
PT (1) PT2532367T (zh)
RU (1) RU2624029C2 (zh)
WO (1) WO2011096535A1 (zh)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106039307A (zh) * 2008-08-05 2016-10-26 东丽株式会社 用于治疗和预防癌症的药物组合物
HUE027332T2 (en) 2008-08-05 2016-09-28 Toray Industries Cancer Detection Method
AU2011211700B2 (en) 2010-02-04 2015-06-11 Toray Industries, Inc. Medicament for treating and/or preventing cancer
DK2532366T3 (da) 2010-02-04 2017-01-02 Toray Industries Farmaceutisk sammensætning til behandling og/eller forebyggelse af cancer
WO2011096528A1 (ja) 2010-02-04 2011-08-11 東レ株式会社 癌の治療及び/又は予防用医薬組成物
PL2532680T3 (pl) 2010-02-04 2015-10-30 Toray Industries Kompozycja medyczna do leczenia raka i/lub zapobiegania
RU2598258C2 (ru) 2010-02-04 2016-09-20 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики рака
KR101805520B1 (ko) 2010-02-04 2017-12-07 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
US9181348B2 (en) 2011-08-04 2015-11-10 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prophylaxis of cancer
PL3351630T3 (pl) 2011-08-04 2020-05-18 Toray Industries, Inc. Kompozycja farmaceutyczna zawierająca przeciwciała przeciwko CAPRIN-1 do leczenia nowotworu i/lub zapobiegania nowotworowi
JP6065592B2 (ja) 2011-08-04 2017-01-25 東レ株式会社 癌の治療及び/又は予防用医薬組成物
US9796775B2 (en) 2011-08-04 2017-10-24 Toray Industries, Inc. Method for detecting pancreatic cancer
KR101968498B1 (ko) 2011-08-04 2019-04-12 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
RU2610428C2 (ru) 2011-08-04 2017-02-10 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли
PL2740489T3 (pl) 2011-08-04 2017-06-30 Toray Industries, Inc. Kompozycja farmaceutyczna do leczenia i/lub zapobiegania raka trzustki
PT2824114T (pt) * 2012-02-21 2019-08-05 Toray Industries Composição farmacêutica para o tratamento do cancro
IN2014KN01715A (zh) 2012-02-21 2015-10-23 Toray Industries
WO2013125636A1 (ja) * 2012-02-21 2013-08-29 東レ株式会社 癌の治療及び/又は予防用医薬組成物
AU2013223137B2 (en) * 2012-02-21 2017-10-19 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
HUE036425T2 (hu) 2012-03-30 2018-07-30 Toray Industries Gyógyászati készítmény epehólyagrák kezelésére és/vagy megelõzésére
MX358224B (es) * 2012-03-30 2018-08-10 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion de cancer de higado.
RU2646464C2 (ru) 2012-07-19 2018-03-05 Торэй Индастриз, Инк. Метод детекции рака
EP2876446B1 (en) 2012-07-19 2018-12-26 Toray Industries, Inc. Method for detecting cancer
RU2678138C2 (ru) 2013-08-09 2019-01-23 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики рака
AU2017348734A1 (en) 2016-10-28 2019-05-16 Toray Industries, Inc. Pharmaceutical composition for cancer treatment and/or prevention
CA3095719A1 (en) 2018-03-30 2019-10-03 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
US20230129035A1 (en) 2020-03-12 2023-04-27 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
WO2021182574A1 (ja) 2020-03-12 2021-09-16 東レ株式会社 癌の治療及び/又は予防のための医薬品
WO2021182570A1 (ja) 2020-03-12 2021-09-16 東レ株式会社 癌の治療及び/又は予防のための医薬品
BR112022018166A2 (pt) 2020-03-12 2022-10-25 Toray Industries Medicamento para tratamento e/ou prevenção de câncer, agentes que aumentam a eficácia de droga de uma composição farmacêutica e método para tratar e/ou prevenir câncer
JPWO2021182572A1 (zh) 2020-03-12 2021-09-16
WO2022270523A1 (ja) 2021-06-23 2022-12-29 東レ株式会社 癌の治療及び/又は予防のための医薬品
CA3225422A1 (en) 2021-06-23 2022-12-29 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
EP4378476A1 (en) 2021-07-27 2024-06-05 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
CN117677398A (zh) 2021-07-27 2024-03-08 东丽株式会社 用于癌的治疗和/或预防的药品
AU2022316644A1 (en) 2021-07-27 2024-02-29 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
AU2022338463A1 (en) 2021-09-03 2024-03-21 Toray Industries, Inc. Pharmaceutical composition for cancer treatment and/or prevention
WO2024048542A1 (ja) * 2022-08-30 2024-03-07 東レ株式会社 癌の治療及び/又は予防のための医薬品
WO2024048541A1 (ja) * 2022-08-30 2024-03-07 東レ株式会社 癌の治療及び/又は予防のための医薬品

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002078524A2 (en) * 2001-03-28 2002-10-10 Zycos Inc. Translational profiling
WO2005100998A2 (en) * 2004-04-16 2005-10-27 Europroteome Ag Membrane markers for use in cancer diagnosis and therapy
US20080075722A1 (en) * 2006-02-14 2008-03-27 Depinho Ronald A Compostions, kits, and methods for identification, assessment, prevention, and therapy of cancer

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE449342T1 (de) * 1994-09-19 2009-12-15 Ricardo J Moro Nachweis von krebs
US5698396A (en) 1995-06-07 1997-12-16 Ludwig Institute For Cancer Research Method for identifying auto-immunoreactive substances from a subject
US20030118599A1 (en) 1999-04-02 2003-06-26 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
EP1870466A3 (en) 1998-07-14 2008-03-19 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
RU2234942C2 (ru) 1998-07-14 2004-08-27 Корикса Корпорейшн Выделенный опухолевый полипептид предстательной железы и кодирующий его полинуклеотид
US6969518B2 (en) 1998-12-28 2005-11-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
WO2000052204A2 (en) 1999-02-22 2000-09-08 Orntoft Torben F Gene expression in bladder tumors
US6444425B1 (en) 1999-04-02 2002-09-03 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
JP2002540790A (ja) 1999-04-02 2002-12-03 コリクサ コーポレイション 肺癌の治療および診断のための化合物ならびにその使用のための方法
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
EP1224285A4 (en) 1999-10-29 2004-12-08 Human Genome Sciences Inc 27 HUMAN SECRETED PROTEINS
US20020006404A1 (en) 1999-11-08 2002-01-17 Idec Pharmaceuticals Corporation Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
JP2004526401A (ja) 2000-03-29 2004-09-02 コリクサ コーポレイション 肺癌の治療および診断のための組成物および方法
US7919467B2 (en) * 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US7408041B2 (en) * 2000-12-08 2008-08-05 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US20040029114A1 (en) 2001-01-24 2004-02-12 Eos Technology, Inc. Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
RU2306952C2 (ru) 2001-01-31 2007-09-27 Байоджен Айдек Инк. Лечение в-клеточных злокачественных опухолей с использованием комбинации применений, связанных с антителами, уменьшающими количество b-клеток, и с иммуномодулирующими антителами
WO2002083070A2 (en) 2001-04-10 2002-10-24 Corixa Corporation Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
WO2002092001A2 (en) 2001-05-11 2002-11-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US20030190640A1 (en) 2001-05-31 2003-10-09 Mary Faris Genes expressed in prostate cancer
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
CA2476518A1 (en) 2002-02-22 2003-09-04 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US20050003390A1 (en) * 2002-05-17 2005-01-06 Axenovich Sergey A. Targets for controlling cellular growth and for diagnostic methods
US20040126379A1 (en) * 2002-08-21 2004-07-01 Boehringer Ingelheim International Gmbh Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents
US20060121029A1 (en) 2002-08-30 2006-06-08 Hiroshi Shiku Method and composition for regulating the activity of regulatory t cells
EP2311870A1 (en) 2002-11-26 2011-04-20 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2004076682A2 (en) 2003-02-26 2004-09-10 Surromed, Inc. Targets for controlling cellular growth and for diagnostic methods
US20050202451A1 (en) 2003-04-29 2005-09-15 Burczynski Michael E. Methods and apparatuses for diagnosing AML and MDS
AU2004256425A1 (en) 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
WO2005007830A2 (en) 2003-07-14 2005-01-27 Mayo Foundation For Medical Education And Research Methods and compositions for diagnosis, staging and prognosis of prostate cancer
US20050032113A1 (en) 2003-07-17 2005-02-10 Mitsubishi Pharma Corporation Membrane protein library for proteome analysis and method for preparing same
CA2553826A1 (en) 2004-01-26 2005-12-08 Debiovision Inc. Neoplasm-specific polypeptides and their uses
EP1735348B1 (en) 2004-03-19 2012-06-20 Imclone LLC Human anti-epidermal growth factor receptor antibody
DE102004026135A1 (de) 2004-05-25 2006-01-05 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
WO2006002378A2 (en) 2004-06-23 2006-01-05 Avalon Pharmaceuticals Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods
ZA200706017B (en) 2005-01-21 2008-12-31 Genentech Inc Fixed dosing of her antibodies
AU2006214105A1 (en) 2005-02-18 2006-08-24 Children's Medical Center Corporation Cyr61 as a biomarker for diagnosis and prognosis of cancers of epithelial origin
AU2006223374B2 (en) 2005-03-11 2011-07-21 Aspira Women’s Health Inc. Biomarkers for ovarian cancer and endometrial cancer: hepcidin
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Herceptin(登録商標)補助療法
US8014957B2 (en) 2005-12-15 2011-09-06 Fred Hutchinson Cancer Research Center Genes associated with progression and response in chronic myeloid leukemia and uses thereof
US20100015724A1 (en) 2006-08-17 2010-01-21 Peter Hornbeck Lysine acetylation sites
US20080107668A1 (en) 2006-08-30 2008-05-08 Immunotope, Inc. Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US7615349B2 (en) 2006-09-07 2009-11-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. Melanoma gene signature
WO2008059252A2 (en) 2006-11-15 2008-05-22 Oxford Biomedica (Uk) Limited Methods and composition fro t cell receptors which recognize 5t4 antigen
JP5663834B2 (ja) 2008-03-14 2015-02-04 東ソー株式会社 遺伝子組換え抗体の製造方法
AU2009278385B2 (en) 2008-08-05 2015-06-11 Toray Industries, Inc. Immunity-inducing agent
HUE027332T2 (en) 2008-08-05 2016-09-28 Toray Industries Cancer Detection Method
CN106039307A (zh) 2008-08-05 2016-10-26 东丽株式会社 用于治疗和预防癌症的药物组合物
WO2011020529A2 (en) 2009-08-19 2011-02-24 Merck Patent Gmbh Antibodies for the detection of integrin complexes in ffpe material
MY160680A (en) 2009-09-22 2017-03-15 Probiogen Ag Process for producing molecules containing specialized glycan structures
PL2532680T3 (pl) * 2010-02-04 2015-10-30 Toray Industries Kompozycja medyczna do leczenia raka i/lub zapobiegania
WO2011096528A1 (ja) 2010-02-04 2011-08-11 東レ株式会社 癌の治療及び/又は予防用医薬組成物
AU2011211700B2 (en) 2010-02-04 2015-06-11 Toray Industries, Inc. Medicament for treating and/or preventing cancer
DK2532366T3 (da) 2010-02-04 2017-01-02 Toray Industries Farmaceutisk sammensætning til behandling og/eller forebyggelse af cancer
RU2598258C2 (ru) 2010-02-04 2016-09-20 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или профилактики рака
KR101805520B1 (ko) 2010-02-04 2017-12-07 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
US9796775B2 (en) 2011-08-04 2017-10-24 Toray Industries, Inc. Method for detecting pancreatic cancer
PL2740489T3 (pl) 2011-08-04 2017-06-30 Toray Industries, Inc. Kompozycja farmaceutyczna do leczenia i/lub zapobiegania raka trzustki
PL3351630T3 (pl) 2011-08-04 2020-05-18 Toray Industries, Inc. Kompozycja farmaceutyczna zawierająca przeciwciała przeciwko CAPRIN-1 do leczenia nowotworu i/lub zapobiegania nowotworowi
MX358224B (es) 2012-03-30 2018-08-10 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion de cancer de higado.
HUE036425T2 (hu) 2012-03-30 2018-07-30 Toray Industries Gyógyászati készítmény epehólyagrák kezelésére és/vagy megelõzésére

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002078524A2 (en) * 2001-03-28 2002-10-10 Zycos Inc. Translational profiling
WO2005100998A2 (en) * 2004-04-16 2005-10-27 Europroteome Ag Membrane markers for use in cancer diagnosis and therapy
US20080075722A1 (en) * 2006-02-14 2008-03-27 Depinho Ronald A Compostions, kits, and methods for identification, assessment, prevention, and therapy of cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GRILL ET AL.: "Activation/Division of Lymphocytes Results in Increased Levels of Cytoplasmic Activation/Proliferation-Associated Protein-1:Prototype of a New Family of Proteins", 《THE JOURNAL OF IMMUNOLOGY》 *
KATSAFANAS ET AL.: "Vaccinia Virus Intermediate Stage Transcription Is Complemented by Ras-GTPase-activating Protein SH3 Domain-binding Protein (G3BP) and Cytoplasmic Activation/Proliferation-associated Protein(p137) Individually or as a Heterodimer", 《THE JOURNAL OF BIOLOGICAL CHEMISTRY》 *

Also Published As

Publication number Publication date
AU2011211700A1 (en) 2012-08-23
CA2788720A1 (en) 2011-08-11
AU2011211700B2 (en) 2015-06-11
US20120294860A1 (en) 2012-11-22
RU2624029C2 (ru) 2017-06-30
RU2012137503A (ru) 2014-03-10
CN109925511B (zh) 2024-03-19
PL2532367T3 (pl) 2019-02-28
CN102844048A (zh) 2012-12-26
ES2691738T3 (es) 2018-11-28
EP2532367A4 (en) 2014-05-28
CA2788720C (en) 2019-08-20
US9180187B2 (en) 2015-11-10
DK2532367T3 (en) 2018-11-19
BR112012018943A8 (pt) 2017-12-19
EP2532367B1 (en) 2018-08-29
PT2532367T (pt) 2018-11-09
EP2532367A1 (en) 2012-12-12
JP5923984B2 (ja) 2016-05-25
KR20120139720A (ko) 2012-12-27
JPWO2011096535A1 (ja) 2013-06-13
MX2012008991A (es) 2012-09-07
KR101843807B1 (ko) 2018-03-30
WO2011096535A1 (ja) 2011-08-11
HUE040012T2 (hu) 2019-02-28

Similar Documents

Publication Publication Date Title
CN109925511A (zh) 用于癌的治疗和/或预防的药物
KR101667319B1 (ko) 암의 치료 및 예방용 의약 조성물
CA2844037C (en) Pharmaceutical composition for treatment and/or prevention of pancreatic cancer
KR102052400B1 (ko) 담낭암의 치료 및/또는 예방용 의약 조성물
CA2788716C (en) Pharmaceutical composition for treating and/or preventing cancer
KR101805520B1 (ko) 암의 치료 및/또는 예방용 의약 조성물
KR102155531B1 (ko) 간암의 치료 및/또는 예방용 의약 조성물
CN102821788B (zh) 癌的治疗和/或预防用药物组合物
CA2844042C (en) Pharmaceutical composition for treatment and/or prophylaxis of cancer
CA2788545C (en) Pharmaceutical composition for treating and/or preventing cancer
CA2788547C (en) Pharmaceutical composition for treating and/or preventing cancer
CN104114583B (zh) 癌的治疗和/或预防用药物组合物
CA2864999C (en) Pharmaceutical composition for treatment and/or prevention of cancer
CN107530426A (zh) 癌的治疗和/或预防用药物组合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant